No., subject, TM-score, RMSD, Sequence Identity, Subject length, Aligned length, Description
1, d3nyxA1, 1.0000, 0.00, 1.000, 285, 285, NON-PHOSPHORYLATED TYK2 JH1 DOMAIN WITH QUINOLINE-THIADIAZOLE- THIOPHENE INHIBITOR
2, d4bbeC_, 0.9220, 2.05, 0.509, 288, 281, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
3, d4bbeB_, 0.9218, 2.05, 0.509, 288, 281, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
4, d5cf5B1, 0.9211, 1.93, 0.464, 292, 280, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 7-[(DIMETHYL-13-THIAZOL-2-YL)AMINO]-10-ETHYL-3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.026] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
5, d4zimB1, 0.9210, 2.06, 0.480, 292, 281, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH A 9H-CARBAZOLE-1- CARBOXAMIDE INHIBITOR
6, d5l3aA_, 0.9207, 2.18, 0.491, 290, 283, FRAGMENT-BASED DISCOVERY OF 6-ARYLINDAZOLE JAK INHIBITORS
7, d5f1zA1, 0.9203, 1.56, 0.974, 280, 274, STRUCTURE OF TYK2 WITH INHIBITOR 16: 3-AZANYL-5-[(2~{S})-3- METHYLBUTAN-2-YL]-7-[1-METHYL-5-(2-OXIDANYLPROPAN-2-YL)PYRAZOL-3-YL]- 1~{H}-PYRAZOLO[43-C]PYRIDIN-4-ONE
8, d4bbfA_, 0.9196, 2.19, 0.507, 288, 282, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
9, d4e4mD_, 0.9195, 1.98, 0.482, 296, 280, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
10, d4e4mB_, 0.9194, 1.99, 0.482, 296, 280, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
11, d4bbfD_, 0.9194, 2.19, 0.507, 288, 282, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
12, d4bbeD_, 0.9193, 2.11, 0.509, 288, 281, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
13, d5tq5A_, 0.9189, 2.31, 0.484, 291, 283, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
14, d5cf4B_, 0.9184, 2.10, 0.480, 291, 281, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
15, d4bbeA_, 0.9181, 2.13, 0.505, 288, 281, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
16, d5tq8A_, 0.9178, 2.30, 0.491, 291, 283, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
17, d4e4mE_, 0.9175, 2.08, 0.484, 296, 281, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
18, d4e4mA_, 0.9175, 2.08, 0.484, 296, 281, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
19, d4gihA1, 0.9172, 2.12, 0.943, 287, 281, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-N-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}BENZAMIDE
20, d3q32A_, 0.9172, 1.99, 0.468, 291, 280, STRUCTURE OF JANUS KINASE 2 WITH A PYRROLOTRIAZINE INHIBITOR
21, d4gmyA_, 0.9170, 2.21, 0.489, 298, 282, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH 26-DICHLORO-N-{2- [(CYCLOPROPYLCARBONYL)AMINO]PYRIDIN-4-YL}BENZAMIDE
22, d4gj2A1, 0.9170, 2.12, 0.943, 287, 281, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-N-[2-({[(1R2R)-2- FLUOROCYCLOPROPYL]CARBONYL}AMINO)PYRIDIN-4-YL]BENZAMIDE
23, d4gvjA1, 0.9169, 2.47, 0.968, 288, 285, TYK2 (JH1) IN COMPLEX WITH ADENOSINE DI-PHOSPHATE
24, d4bbfC_, 0.9168, 2.26, 0.500, 288, 282, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
25, d4gj3A1, 0.9167, 2.13, 0.943, 287, 281, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-4-CYANO-N-[2-({[(1R2R)-2- FLUOROCYCLOPROPYL]CARBONYL}AMINO)PYRIDIN-4-YL]BENZAMIDE
26, d4d0xA_, 0.9167, 1.97, 0.486, 291, 280, PYRROLE-3-CARBOXAMIDES AS POTENT AND SELECTIVE JAK2 INHIBITORS
27, d3e63A_, 0.9167, 2.05, 0.484, 290, 281, FRAGMENT BASED DISCOVERY OF JAK-2 INHIBITORS
28, d3e62A_, 0.9164, 2.05, 0.484, 291, 281, FRAGMENT BASED DISCOVERY OF JAK-2 INHIBITORS
29, d4d0wA_, 0.9163, 2.06, 0.488, 289, 281, PYRROLE-3-CARBOXAMIDES AS POTENT AND SELECTIVE JAK2 INHIBITORS
30, d4bbfB_, 0.9162, 2.26, 0.504, 288, 282, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
31, d4gfmA_, 0.9161, 2.06, 0.484, 289, 281, JAK2 KINASE (JH1 DOMAIN) WITH 26-DICHLORO-N-(2-OXO-25- DIHYDROPYRIDIN-4-YL)BENZAMIDE
32, d3iokA_, 0.9161, 1.86, 0.489, 285, 278, 2-AMINOPYRAZOLO[15-A]PYRIMIDINES AS POTENT AND SELECTIVE INHIBITORS OF JAK2
33, d3e64A_, 0.9161, 2.07, 0.484, 291, 281, FRAGMENT BASED DISCOVERY OF JAK-2 INHIBITORS
34, d3krrA1, 0.9160, 2.05, 0.484, 290, 281, CRYSTAL STRUCTURE OF JAK2 COMPLEXED WITH A POTENT QUINOXALINE ATP SITE INHIBITOR
35, d3pjcA_, 0.9157, 2.07, 0.487, 286, 279, CRYSTAL STRUCTURE OF JAK3 COMPLEXED WITH A POTENT ATP SITE INHIBITOR SHOWING HIGH SELECTIVITY WITHIN THE JANUS KINASE FAMILY
36, d4py1A_, 0.9156, 2.32, 0.965, 289, 283, CRYSTAL STRUCTURE OF TYK2 IN COMPLEX WITH COMPOUND 15 6-((25- DIMETHOXYPHENYL)THIO)-3-(1-METHYL-1H-PYRAZOL-4-YL)-[124]TRIAZOLO[4 3-B]PYRIDAZINE
37, d3nz0A1, 0.9156, 1.85, 0.957, 283, 276, NON-PHOSPHORYLATED TYK2 KINASE WITH CMP6
38, d4aqcB_, 0.9155, 2.16, 0.480, 295, 281, TRIAZOLOPYRIDINE-BASED INHIBITOR OF JANUS KINASE 2
39, d4giiA1, 0.9154, 2.15, 0.943, 287, 281, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-4-CYANO-N-{2- [(CYCLOPROPYLCARBONYL)AMINO]PYRIDIN-4-YL}BENZAMIDE
40, d4jiaA_, 0.9150, 2.12, 0.480, 298, 281, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 9
41, d4e6qA_, 0.9147, 2.03, 0.461, 296, 280, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 12
42, d5wevA_, 0.9143, 2.01, 0.484, 293, 279, IDENTIFICATION OF AN IMIDAZOPYRIDINE SCAFFOLD TO GENERATE POTENT AND SELECTIVE TYK2 INHIBITORS THAT DEMONSTRATE ACTIVITY IN AN IN VIVO PSORIASIS MODEL
43, d3q32B1, 0.9143, 2.16, 0.480, 293, 281, STRUCTURE OF JANUS KINASE 2 WITH A PYRROLOTRIAZINE INHIBITOR
44, d4ythA_, 0.9142, 2.02, 0.470, 287, 279, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASES
45, d4ivaA_, 0.9142, 2.04, 0.471, 290, 280, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR TRANS-4-[(8AS)- 2-[(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(8AH)- YL]CYCLOHEXANECARBONITRILE
46, d5cf6A_, 0.9140, 1.97, 0.478, 285, 278, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-[(2S)-23-DIHYDROXYPROPYL]-3-METHYL-7-(METHYLAMINO)-35810- TETRAAZATRICYCLO [7.3.0.026]DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
47, d4aqcA_, 0.9137, 2.06, 0.486, 289, 280, TRIAZOLOPYRIDINE-BASED INHIBITOR OF JANUS KINASE 2
48, d4zimA_, 0.9131, 1.96, 0.489, 285, 278, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH A 9H-CARBAZOLE-1- CARBOXAMIDE INHIBITOR
49, d3tjcB_, 0.9131, 1.96, 0.486, 287, 278, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 8
50, d5cf6B1, 0.9126, 1.85, 0.469, 288, 277, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-[(2S)-23-DIHYDROXYPROPYL]-3-METHYL-7-(METHYLAMINO)-35810- TETRAAZATRICYCLO [7.3.0.026]DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
51, d3kckA_, 0.9125, 2.04, 0.487, 285, 279, A NOVEL CHEMOTYPE OF KINASE INHIBITORS
52, d5aepA_, 0.9124, 1.98, 0.487, 287, 279, NOVEL PYRROLE CARBOXAMIDE INHIBITORS OF JAK2 AS POTENTIAL TREATMENT OF MYELOPROLIFERATIVE DISORDERS
53, d5cf5A1, 0.9122, 1.86, 0.477, 286, 277, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 7-[(DIMETHYL-13-THIAZOL-2-YL)AMINO]-10-ETHYL-3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.026] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
54, d4e1zA_, 0.9122, 2.15, 0.868, 288, 280, STRUCTURE OF MOUSE TYK-2 COMPLEXED TO A 3-AMINOINDAZOLE INHIBITOR
55, d4ytfA_, 0.9120, 1.84, 0.473, 283, 277, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASES
56, d4e6qB_, 0.9120, 2.07, 0.461, 296, 280, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 12
57, d3io7A_, 0.9120, 1.86, 0.491, 282, 277, 2-AMINOPYRAZOLO[15-A]PYRIMIDINES AS POTENT AND SELECTIVE INHIBITORS OF JAK2
58, d2b7aB_, 0.9119, 1.86, 0.469, 287, 277, THE STRUCTURAL BASIS OF JANUS KINASE 2 INHIBITION BY A POTENT AND SPECIFIC PAN-JANUS KINASE INHIBITOR
59, d5cf8B1, 0.9118, 1.94, 0.487, 287, 277, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
60, d4ytcA_, 0.9115, 1.98, 0.471, 284, 278, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASE
61, d3tjdB_, 0.9109, 2.00, 0.486, 287, 278, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 19
62, d4ytiA_, 0.9102, 1.90, 0.473, 284, 277, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASE
63, d4hgeB_, 0.9102, 2.02, 0.486, 288, 278, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 8
64, d3jy9A_, 0.9101, 1.81, 0.475, 282, 276, JANUS KINASE 2 INHIBITORS
65, d5usyB_, 0.9097, 2.21, 0.498, 287, 279, JAK2 JH1 IN COMPLEX WITH JNJ-7706621
66, d4ji9B_, 0.9094, 2.05, 0.486, 288, 278, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH TG101209
67, d5tq3B_, 0.9093, 2.23, 0.504, 285, 278, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
68, d5f20A_, 0.9091, 1.51, 0.981, 274, 270, STRUCTURE OF TYK2 WITH INHIBITOR 4: 3-AZANYL-5-(2-METHYLPHENYL)-7-(1- METHYLPYRAZOL-3-YL)-1~{H}-PYRAZOLO[43-C]PYRIDIN-4-ONE
69, d5usyA_, 0.9087, 2.27, 0.496, 287, 280, JAK2 JH1 IN COMPLEX WITH JNJ-7706621
70, d3lxpA_, 0.9084, 2.08, 0.938, 285, 276, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
71, d4p7eB_, 0.9083, 1.89, 0.475, 285, 276, TRIAZOLOPYRIDINE COMPOUNDS AS SELECTIVE JAK1 INHIBITORS: FROM HIT IDENTIFICATION TO GLPG0634
72, d3fupB_, 0.9082, 2.03, 0.486, 287, 278, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
73, d4f08A_, 0.9079, 2.10, 0.484, 288, 279, DISCOVERY AND OPTIMIZATION OF C-2 METHYL IMIDAZO-PYRROLOPYRIDINES AS POTENT AND ORALLY BIOAVAILABLE JAK1 INHIBITORS WITH SELECTIVITY OVER JAK2
74, d5lwnA_, 0.9078, 2.25, 0.475, 290, 282, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 5 (FM409)
75, d4f08B_, 0.9076, 2.12, 0.484, 288, 279, DISCOVERY AND OPTIMIZATION OF C-2 METHYL IMIDAZO-PYRROLOPYRIDINES AS POTENT AND ORALLY BIOAVAILABLE JAK1 INHIBITORS WITH SELECTIVITY OVER JAK2
76, d5lwmA_, 0.9075, 2.26, 0.475, 290, 282, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 4 (FM381)
77, d3lxnA_, 0.9075, 2.18, 0.946, 287, 279, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
78, d2w1iB_, 0.9073, 1.85, 0.491, 284, 275, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
79, d5walA1, 0.9072, 2.34, 0.964, 285, 281, IDENTIFICATION OF AN IMIDAZOPYRIDINE SCAFFOLD TO GENERATE POTENT AND SELECTIVE TYK2 INHIBITORS THAT DEMONSTRATE ACTIVITY IN AN IN VIVO PSORIASIS MODEL
80, d4f09A_, 0.9071, 2.19, 0.477, 288, 279, DISCOVERY AND OPTIMIZATION OF C-2 METHYL IMIDAZO-PYRROLOPYRIDINES AS POTENT AND ORALLY BIOAVAILABLE JAK1 INHIBITORS WITH SELECTIVITY OVER JAK2
81, d2w1iA_, 0.9068, 1.87, 0.491, 284, 275, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
82, d5cf8A1, 0.9066, 1.94, 0.493, 284, 276, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
83, d4gfoA1, 0.9064, 1.29, 0.989, 270, 267, TYK2 KINASE (JH1 DOMAIN) WITH 26-DICHLORO-N-(2-OXO-25- DIHYDROPYRIDIN-4-YL)BENZAMIDE
84, d4ji9A_, 0.9062, 1.83, 0.476, 284, 275, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH TG101209
85, d4e6dB_, 0.9060, 1.92, 0.467, 286, 276, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 7
86, d4e6dA_, 0.9058, 1.89, 0.475, 286, 276, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 7
87, d5cf4A_, 0.9053, 1.86, 0.473, 283, 275, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
88, d4e20A_, 0.9053, 2.01, 0.891, 282, 276, STRUCTURE OF MOUSE TYK-2 COMPLEXED TO A 3-AMINOINDAZOLE INHIBITOR
89, d3rvgA_, 0.9049, 1.97, 0.489, 285, 276, CRYSTALS STRUCTURE OF JAK2 WITH A 1-AMINO-5H-PYRIDO[43-B]INDOL-4- CARBOXAMIDE INHIBITOR
90, d4hgeA_, 0.9044, 1.89, 0.491, 284, 275, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 8
91, d2b7aA_, 0.9037, 1.88, 0.473, 284, 275, THE STRUCTURAL BASIS OF JANUS KINASE 2 INHIBITION BY A POTENT AND SPECIFIC PAN-JANUS KINASE INHIBITOR
92, d3tjcA_, 0.9029, 2.00, 0.489, 284, 276, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 8
93, d3eyhA_, 0.9028, 2.21, 0.574, 285, 277, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
94, d3lpbB1, 0.9027, 1.91, 0.485, 283, 274, CRYSTAL STRUCTURE OF JAK2 COMPLEXED WITH A POTENT 28-DIARYL- QUINOXALINE INHIBITOR
95, d5tq3A_, 0.9020, 2.13, 0.502, 282, 275, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
96, d3fupA_, 0.9015, 1.94, 0.476, 284, 275, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
97, d1yvjA_, 0.9013, 2.40, 0.475, 288, 280, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN IN COMPLEX WITH A STAUROSPORINE ANALOGUE
98, d3tjdA_, 0.9005, 2.04, 0.489, 284, 276, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 19
99, d5tq4A_, 0.9004, 2.44, 0.495, 290, 281, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
100, d4hvgA_, 0.8985, 1.95, 0.482, 281, 274, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((S)-2-HYDROXY-12-DIMETHYL-PROPYL)- AMIDE
101, d4rioA_, 0.8978, 2.27, 0.484, 285, 277, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRIDAZINE CARBOXAMIDE INHIBITOR
102, d4p7eA_, 0.8977, 2.01, 0.500, 281, 274, TRIAZOLOPYRIDINE COMPOUNDS AS SELECTIVE JAK1 INHIBITORS: FROM HIT IDENTIFICATION TO GLPG0634
103, d3lpbA_, 0.8967, 1.77, 0.487, 278, 271, CRYSTAL STRUCTURE OF JAK2 COMPLEXED WITH A POTENT 28-DIARYL- QUINOXALINE INHIBITOR
104, d2xa4A_, 0.8967, 1.86, 0.494, 276, 271, INHIBITORS OF JAK2 KINASE DOMAIN
105, d4d1sA_, 0.8959, 2.10, 0.496, 280, 274, PYRROLE-3-CARBOXAMIDES AS POTENT AND SELECTIVE JAK2 INHIBITORS
106, d3eygA_, 0.8954, 2.04, 0.579, 280, 273, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
107, d4hvhA_, 0.8951, 1.88, 0.485, 278, 272, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((R)-2-HYDROXY-12-DIMETHYL-PROPYL
108, d2xa4B_, 0.8923, 1.70, 0.504, 275, 268, INHIBITORS OF JAK2 KINASE DOMAIN
109, d4qt1A_, 0.8920, 1.89, 0.487, 277, 271, JAK3 KINASE DOMAIN IN COMPLEX WITH 1-[(3S)-1-ISOBUTYLSULFONYL-3- PIPERIDYL]-3-(5H-PYRROLO[23-B]PYRAZIN-2-YL)UREA
110, d3zepC_, 0.8920, 2.02, 0.493, 276, 272, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
111, d5khwA_, 0.8916, 2.06, 0.596, 276, 272, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH ADP
112, d4i6qA_, 0.8910, 1.90, 0.483, 277, 271, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-PHENOXY-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((S)-1-CYCLOPROPYL-ETHYL)-AMIDE
113, d5hx8A_, 0.8906, 2.07, 0.573, 291, 274, JAK1 COMPLEX WITH 4-[(4-AMINOCYCLOHEXYL)AMINO]-3-(1H-BENZIMIDAZOL-2- YL)-1H-PYRIDIN-2-ONE
114, d4k77A_, 0.8905, 2.08, 0.573, 282, 274, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 6
115, d3lxlA_, 0.8900, 2.11, 0.491, 281, 273, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
116, d5e1eA_, 0.8899, 1.98, 0.574, 279, 272, HUMAN JAK1 KINASE IN COMPLEX WITH COMPOUND 30 AT 2.30 ANGSTROMS RESOLUTION
117, d4c61B_, 0.8899, 1.69, 0.509, 274, 267, INHIBITORS OF JAK2 KINASE DOMAIN
118, d3zmmB_, 0.8897, 1.70, 0.509, 274, 267, INHIBITORS OF JAK2 KINASE DOMAIN
119, d4z16B_, 0.8895, 2.13, 0.502, 276, 271, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
120, d3zmmA_, 0.8891, 1.79, 0.500, 273, 268, INHIBITORS OF JAK2 KINASE DOMAIN
121, d4c62A_, 0.8890, 1.80, 0.500, 273, 268, INHIBITORS OF JAK2 KINASE DOMAIN
122, d4hvdA_, 0.8889, 1.88, 0.485, 276, 270, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((S)-122-TRIMETHYL-PROPYL)-AMIDE
123, d5tozA_, 0.8888, 2.07, 0.485, 278, 272, JAK3 WITH COVALENT INHIBITOR PF-06651600
124, d4k77B_, 0.8883, 2.05, 0.571, 280, 273, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 6
125, d4e4nB_, 0.8880, 2.07, 0.568, 280, 273, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 49
126, d4c61A_, 0.8878, 1.62, 0.481, 272, 266, INHIBITORS OF JAK2 KINASE DOMAIN
127, d4fk6B_, 0.8877, 2.22, 0.535, 284, 275, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 72
128, d5e1eB_, 0.8875, 2.07, 0.571, 280, 273, HUMAN JAK1 KINASE IN COMPLEX WITH COMPOUND 30 AT 2.30 ANGSTROMS RESOLUTION
129, d5wo4A_, 0.8874, 2.14, 0.573, 292, 274, JAK1 COMPLEXED WITH COMPOUND 28
130, d4fk6A_, 0.8874, 2.29, 0.542, 285, 275, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 72
131, d4c62B_, 0.8874, 1.57, 0.506, 271, 265, INHIBITORS OF JAK2 KINASE DOMAIN
132, d4ivdB_, 0.8869, 2.09, 0.575, 280, 273, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 34
133, d4ivbB_, 0.8865, 2.00, 0.562, 280, 272, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXANECARBONITRILE
134, d3zepA_, 0.8855, 1.96, 0.500, 274, 268, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
135, d4qpsC_, 0.8853, 1.99, 0.496, 276, 270, CRYSTAL STRUCTURE OF JAK3 COMPLEXED TO N-[3-(6-PHENYLAMINO-PYRAZIN-2- YL)-3H-BENZOIMIDAZOL-5-YL]-ACRYLAMIDE
136, d4e5wA1, 0.8853, 2.02, 0.562, 291, 272, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 26
137, d5khwB_, 0.8852, 2.14, 0.592, 276, 272, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH ADP
138, d4e4nA1, 0.8851, 2.07, 0.570, 290, 272, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 49
139, d5hx8B_, 0.8850, 2.12, 0.575, 279, 273, JAK1 COMPLEX WITH 4-[(4-AMINOCYCLOHEXYL)AMINO]-3-(1H-BENZIMIDAZOL-2- YL)-1H-PYRIDIN-2-ONE
140, d4ei4B_, 0.8848, 2.12, 0.553, 280, 273, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 20
141, d4hviA_, 0.8845, 1.81, 0.489, 274, 268, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((R)-1-METHYL-2-OXO-2-PIPERIDIN-1-YL- ETHYL)-AMIDE
142, d4ivcB_, 0.8843, 2.13, 0.553, 280, 273, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR (TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXYL)ACETONITRILE
143, d5ttvA_, 0.8840, 2.22, 0.489, 280, 272, JAK3 WITH COVALENT INHIBITOR 6
144, d4ivbA1, 0.8840, 2.07, 0.574, 290, 272, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXANECARBONITRILE
145, d4k6zA_, 0.8838, 2.04, 0.574, 279, 272, THE JAK1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 37
146, d5wo4B_, 0.8836, 2.06, 0.562, 280, 272, JAK1 COMPLEXED WITH COMPOUND 28
147, d4ehzA_, 0.8832, 2.32, 0.549, 290, 275, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
148, d5khxA_, 0.8830, 2.11, 0.533, 276, 272, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH PF-4950736
149, d4i5cB1, 0.8830, 2.09, 0.574, 290, 272, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
150, d4i5cA_, 0.8830, 2.10, 0.577, 279, 272, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
151, d4qpsA_, 0.8828, 1.64, 0.494, 270, 265, CRYSTAL STRUCTURE OF JAK3 COMPLEXED TO N-[3-(6-PHENYLAMINO-PYRAZIN-2- YL)-3H-BENZOIMIDAZOL-5-YL]-ACRYLAMIDE
152, d4ehzB_, 0.8828, 2.14, 0.557, 280, 273, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
153, d5ttuA_, 0.8826, 1.71, 0.496, 271, 266, JAK3 WITH COVALENT INHIBITOR 7
154, d4ivdA1, 0.8825, 2.05, 0.576, 289, 271, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 34
155, d3lxkA_, 0.8825, 2.12, 0.487, 279, 271, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
156, d4ivcA1, 0.8819, 2.12, 0.574, 290, 272, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR (TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXYL)ACETONITRILE
157, d5ttsA_, 0.8810, 1.91, 0.493, 274, 268, JAK3 WITH COVALENT INHIBITOR 4
158, d4e4lD_, 0.8806, 2.25, 0.553, 281, 273, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
159, d4e4lE_, 0.8803, 2.15, 0.559, 280, 272, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
160, d5tq7A_, 0.8800, 1.93, 0.491, 275, 267, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
161, d5w86D_, 0.8793, 2.15, 0.500, 272, 268, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
162, d3zepD_, 0.8791, 1.93, 0.500, 272, 266, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
163, d4ehzC_, 0.8790, 2.14, 0.555, 278, 272, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
164, d4ehzD_, 0.8789, 2.22, 0.557, 280, 273, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
165, d4e5wB_, 0.8786, 2.03, 0.567, 278, 270, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 26
166, d4ei4A1, 0.8784, 2.05, 0.578, 288, 270, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 20
167, d2jiuA_, 0.8784, 1.96, 0.347, 303, 268, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION IN COMPLEX WITH AEE788
168, d5tq6A_, 0.8774, 1.81, 0.474, 274, 266, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
169, d4e4lB_, 0.8773, 2.12, 0.557, 279, 271, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
170, d3ikaA_, 0.8766, 1.97, 0.341, 310, 267, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M MUTANT COVALENTLY BINDING TO WZ4002
171, d4z16A_, 0.8750, 1.99, 0.491, 271, 265, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
172, d4z16D_, 0.8745, 2.13, 0.500, 271, 266, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
173, d4z16C_, 0.8743, 2.12, 0.500, 271, 266, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
174, d5tq6B_, 0.8740, 1.81, 0.475, 271, 265, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
175, d5w86C_, 0.8739, 2.43, 0.494, 273, 269, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
176, d4e4lA_, 0.8736, 2.03, 0.565, 277, 269, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
177, d4v0gB_, 0.8732, 2.32, 0.489, 272, 268, JAK3 IN COMPLEX WITH A COVALENT EGFR INHIBITOR
178, d5xgnA_, 0.8721, 2.05, 0.345, 302, 267, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/C797S IN COMPLEX WITH GO6976
179, d4riyD_, 0.8719, 2.14, 0.343, 297, 268, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
180, d3zepB_, 0.8716, 1.71, 0.498, 268, 263, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
181, d5w86A_, 0.8715, 1.99, 0.500, 269, 264, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
182, d4g5pA_, 0.8715, 2.08, 0.341, 299, 267, CRYSTAL STRUCTURE OF EGFR KINASE T790M IN COMPLEX WITH BIBW2992
183, d5tq7B_, 0.8712, 1.77, 0.494, 269, 263, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
184, d4riwD_, 0.8707, 2.14, 0.343, 297, 268, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
185, d5vo6A_, 0.8704, 1.95, 0.491, 271, 265, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRIDAZINE INHIBITOR
186, d5hg5A_, 0.8693, 2.11, 0.347, 302, 268, EGFR (L858R T790M V948R) IN COMPLEX WITH N-{3-[(2-{[4-(4- METHYLPIPERAZIN-1-YL)PHENYL]AMINO}-7H-PYRROLO[23-D]PYRIMIDIN-4-YL) OXY]PHENYL}PROP-2-ENAMIDE
187, d4rixD_, 0.8676, 2.21, 0.345, 297, 267, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
188, d5hg8A_, 0.8670, 2.15, 0.347, 300, 268, EGFR (L858R T790M V948R) IN COMPLEX WITH N-[3-({2-[(1-METHYL-1H- PYRAZOL-4-YL)AMINO]-7H-PYRROLO[23-D]PYRIMIDIN-4-YL}OXY)PHENYL]PROP- 2-ENAMIDE
189, d2jitA_, 0.8663, 2.05, 0.316, 299, 266, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION
190, d4li5A1, 0.8645, 2.26, 0.345, 303, 267, EGFR-K IN COMPLEX WITH N-[3-[[5-CHLORO-4-(1H-INDOL-3-YL)PYRIMIDIN-2- YL]AMINO]-4-METHOXY-PHENYL] PROP-2-ENAMIDE
191, d5w86B_, 0.8641, 2.17, 0.494, 267, 263, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
192, d4v0gA_, 0.8604, 2.13, 0.504, 267, 262, JAK3 IN COMPLEX WITH A COVALENT EGFR INHIBITOR
193, d4jq8A_, 0.8593, 2.25, 0.342, 303, 266, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 4B
194, d4riyB_, 0.8584, 2.16, 0.348, 293, 264, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
195, d5wfjA_, 0.8581, 1.87, 0.492, 265, 260, THE JAK3 KINASE DOMAIN IN COMPLEX WITH A COVALENT INHIBITOR
196, d5ugbA_, 0.8577, 2.27, 0.346, 307, 266, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN IN COMPLEX WITH 4-(4-{[2- {[(3S)-1-ACETYLPYRROLIDIN-3-YL]AMINO}-9-(PROPAN-2-YL)-9H-PURIN-6- YL]AMINO}PHENYL)-1-METHYLPIPERAZIN-1-IUM
197, d4ewhA_, 0.8576, 2.33, 0.383, 274, 266, CO-CRYSTAL STRUCTURE OF ACK1 WITH INHIBITOR
198, d4jr3A_, 0.8571, 2.31, 0.342, 303, 266, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 3G
199, d4jq7A_, 0.8570, 2.31, 0.342, 303, 266, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 2A
200, d3pp0A_, 0.8568, 1.99, 0.318, 286, 264, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN HER2 (ERBB2).
201, d2j6mA_, 0.8568, 2.33, 0.342, 306, 266, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AEE788
202, d5cy3A1, 0.8567, 2.28, 0.352, 274, 267, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT AND ORALLY BIOAVAILABLE BENZISOTHIAZOLE INHIBITOR
203, d4jrvA_, 0.8566, 2.24, 0.343, 300, 265, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 4C
204, d2itpA_, 0.8563, 2.32, 0.346, 305, 266, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH AEE788
205, d2gs6A2, 0.8561, 2.25, 0.347, 308, 265, CRYSTAL STRUCTURE OF THE ACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AN ATP ANALOG-PEPTIDE CONJUGATE
206, d1m17A_, 0.8555, 2.33, 0.342, 312, 266, EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE DOMAIN WITH 4-ANILINOQUINAZOLINE INHIBITOR ERLOTINIB
207, d4riwB_, 0.8553, 2.20, 0.345, 293, 264, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
208, d2itqA_, 0.8553, 2.31, 0.346, 300, 266, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH AFN941
209, d5cavA_, 0.8550, 2.35, 0.342, 306, 266, EGFR KINASE DOMAIN WITH COMPOUND 41A
210, d5eg3A_, 0.8548, 2.47, 0.352, 301, 267, CRYSTAL STRUCTURE OF THE ACTIVATED FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN IN COMPLEX WITH THE CSH2 DOMAIN OF PHOSPHOLIPASE C GAMMA (PLCGAMMA)
211, d4k33A_, 0.8548, 2.47, 0.365, 293, 266, CRYSTAL STRUCTURE OF FGF RECEPTOR 3 (FGFR3) KINASE DOMAIN HARBORING THE K650E MUTATION A GAIN-OF-FUNCTION MUTATION RESPONSIBLE FOR THANATOPHORIC DYSPLASIA TYPE II AND SPERMATOCYTIC SEMINOMA
212, d4rixB_, 0.8547, 2.22, 0.346, 293, 263, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
213, d4zogA_, 0.8542, 2.13, 0.326, 269, 264, VX-680/MK-0457 BINDS TO HUMAN ABL1 ALSO IN INACTIVE DFG CONFORMATIONS.
214, d3pp0B_, 0.8542, 2.19, 0.321, 296, 265, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN HER2 (ERBB2).
215, d4ewhB_, 0.8538, 2.34, 0.381, 273, 265, CO-CRYSTAL STRUCTURE OF ACK1 WITH INHIBITOR
216, d1m14A_, 0.8535, 2.33, 0.346, 307, 266, TYROSINE KINASE DOMAIN FROM EPIDERMAL GROWTH FACTOR RECEPTOR
217, d2g2hB_, 0.8526, 2.08, 0.326, 272, 264, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
218, d3eqpB_, 0.8525, 2.30, 0.381, 270, 265, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T95
219, d2j5eA_, 0.8520, 2.32, 0.340, 309, 265, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR 13-JAB
220, d2itwA_, 0.8518, 2.39, 0.346, 300, 266, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AFN941
221, d4i23A_, 0.8510, 2.21, 0.335, 304, 263, CRYSTAL STRUCTURE OF THE WILD-TYPE EGFR KINASE DOMAIN IN COMPLEX WITH DACOMITINIB (SOAKED)
222, d3vjnA_, 0.8509, 2.18, 0.342, 297, 263, CRYSTAL STRUCTURE OF THE MUTATED EGFR KINASE DOMAIN (G719S/T790M) IN COMPLEX WITH AMPPNP.
223, d3bceC_, 0.8505, 2.24, 0.356, 286, 264, CRYSTAL STRUCTURE OF THE ERBB4 KINASE
224, d3eqpA_, 0.8504, 2.24, 0.384, 268, 263, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T95
225, d2ivuA1, 0.8504, 2.50, 0.374, 283, 265, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN COMPLEXED WITH THE INHIBITOR ZD6474
226, d5xdkA_, 0.8503, 2.48, 0.346, 307, 266, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH CO-1686
227, d3r7oA1, 0.8503, 2.31, 0.325, 295, 265, STRUCTURE OF DUALLY PHOSPHORYLATED C-MET RECEPTOR KINASE IN COMPLEX WITH AN MK-2461 ANALOG
228, d2f4jA_, 0.8502, 2.23, 0.330, 287, 264, STRUCTURE OF THE KINASE DOMAIN OF AN IMATINIB-RESISTANT ABL MUTANT IN COMPLEX WITH THE AURORA KINASE INHIBITOR VX-680
229, d2qohA2, 0.8501, 1.99, 0.330, 270, 261, CRYSTAL STRUCTURE OF ABL KINASE BOUND WITH PPY-A
230, d3gqiA_, 0.8498, 2.40, 0.370, 304, 265, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
231, d2ivsA_, 0.8497, 2.58, 0.372, 284, 266, CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED RET TYROSINE KINASE DOMAIN
232, d2ivtA1, 0.8496, 2.51, 0.374, 283, 265, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN
233, d4zogB_, 0.8495, 2.03, 0.332, 268, 262, VX-680/MK-0457 BINDS TO HUMAN ABL1 ALSO IN INACTIVE DFG CONFORMATIONS.
234, d2x2kA1, 0.8495, 2.51, 0.374, 284, 265, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
235, d2qohB2, 0.8494, 1.98, 0.330, 280, 261, CRYSTAL STRUCTURE OF ABL KINASE BOUND WITH PPY-A
236, d4gfgA1, 0.8491, 2.54, 0.363, 273, 267, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH R9021
237, d3eqrA_, 0.8491, 2.30, 0.379, 270, 264, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T74
238, d3bceB_, 0.8490, 2.23, 0.357, 286, 263, CRYSTAL STRUCTURE OF THE ERBB4 KINASE
239, d5flfD_, 0.8489, 2.56, 0.375, 290, 267, DISEASE LINKED MUTATION IN FGFR
240, d3ugcA_, 0.8488, 2.58, 0.494, 274, 265, STRUCTURAL BASIS OF JAK2 INHIBITION BY THE TYPE II INHIBTOR NVP-BBT594
241, d5cxhA1, 0.8487, 2.52, 0.348, 273, 267, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT ORALLY BIOAVAILABLE THIAZOLE INHIBITOR
242, d3q6wA1, 0.8486, 2.36, 0.325, 293, 265, STRUCTURE OF DUALLY-PHOSPHORYLATED MET RECEPTOR KINASE IN COMPLEX WITH AN MK-2461 ANALOG WITH SPECIFICITY FOR THE ACTIVATED RECEPTOR
243, d2z60A1, 0.8485, 2.02, 0.330, 280, 261, CRYSTAL STRUCTURE OF THE T315I MUTANT OF ABL KINASE BOUND WITH PPY-A
244, d5flfA_, 0.8484, 2.60, 0.375, 296, 267, DISEASE LINKED MUTATION IN FGFR
245, d4id7A_, 0.8483, 2.24, 0.388, 268, 263, ACK1 KINASE IN COMPLEX WITH THE INHIBITOR CIS-3-[8-AMINO-1-(4- PHENOXYPHENYL)IMIDAZO[15-A]PYRAZIN-3-YL]CYCLOBUTANOL
246, d3clyA_, 0.8483, 2.33, 0.358, 289, 265, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAINS TRAPPED IN TRANS-PHOSPHORYLATION REACTION
247, d2gs2A_, 0.8477, 2.41, 0.343, 305, 265, CRYSTAL STRUCTURE OF THE ACTIVE EGFR KINASE DOMAIN
248, d4twpB_, 0.8474, 2.14, 0.327, 271, 263, THE CRYSTAL STRUCTURE OF HUMAN ABL1 T315I GATEKEEPER MUTANT KINASE DOMAIN IN COMPLEX WITH AXITINIB
249, d3bceA_, 0.8474, 2.33, 0.356, 285, 264, CRYSTAL STRUCTURE OF THE ERBB4 KINASE
250, d4wnmA1, 0.8472, 2.44, 0.351, 269, 265, SYK CATALYTIC DOMAIN IN COMPLEX WITH A POTENT TRIAZOLOPYRIDINE INHIBITOR
251, d4iwdA1, 0.8472, 2.36, 0.326, 295, 264, STRUCTURE OF DUALLY PHOSPHORYLATED C-MET RECEPTOR KINASE IN COMPLEX WITH AN MK-8033 ANALOG
252, d2x2mA1, 0.8471, 2.50, 0.379, 281, 264, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
253, d4ckiA1, 0.8470, 2.52, 0.375, 288, 264, CRYSTAL STRUCTURE OF ONCOGENIC RET TYROSINE KINASE M918T BOUND TO ADENOSINE
254, d3eqrB_, 0.8468, 2.27, 0.376, 271, 263, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T74
255, d5tr6A1, 0.8466, 2.36, 0.352, 268, 264, DISCOVERY OF TAK-659 AN ORALLY AVAILABLE INVESTIGATIONAL INHIBITOR OF SPLEEN TYROSINE KINASE (SYK)
256, d4ckjA1, 0.8466, 2.50, 0.386, 287, 264, CRYSTAL STRUCTURE OF RET TYROSINE KINASE DOMAIN BOUND TO ADENOSINE
257, d3ug1A_, 0.8465, 2.12, 0.342, 296, 260, CRYSTAL STRUCTURE OF THE MUTATED EGFR KINASE DOMAIN (G719S/T790M) IN THE APO FORM
258, d1m52A_, 0.8465, 2.19, 0.318, 271, 264, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH PD173955
259, d1m52B_, 0.8462, 2.14, 0.312, 272, 263, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH PD173955
260, d5em8A_, 0.8461, 2.33, 0.346, 303, 263, EGFR KINASE DOMAIN WITH PYRIDONE COMPOUND 13: 4-[(2-METHOXYPHENYL) AMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-2-OXIDANYLIDENE-1~{H}- PYRIDINE-3-CARBOXAMIDE
261, d5j9yA_, 0.8460, 2.30, 0.354, 300, 263, EGFR-T790M IN COMPLEX WITH PYRAZOLOPYRIMIDINE INHIBITOR 1B
262, d4wkqA1, 0.8460, 2.06, 0.340, 294, 259, 1.85 ANGSTROM STRUCTURE OF EGFR KINASE DOMAIN WITH GEFITINIB
263, d4rx7A1, 0.8460, 2.53, 0.353, 270, 266, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT TRIAZINE INHIBITOR
264, d5ui0B_, 0.8459, 2.64, 0.360, 304, 267, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING AN E565A/K659M DOUBLE GAIN-OF-FUNCTION MUTATION
265, d3nsvA_, 0.8457, 2.10, 0.322, 264, 261,  
266, d2xynA_, 0.8457, 2.10, 0.322, 264, 261, HUMAN ABL2 IN COMPLEX WITH AURORA KINASE INHIBITOR VX-680
267, d2jiuB_, 0.8457, 2.24, 0.307, 309, 264, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION IN COMPLEX WITH AEE788
268, d3vjoA_, 0.8456, 2.29, 0.335, 298, 263, CRYSTAL STRUCTURE OF THE WILD-TYPE EGFR KINASE DOMAIN IN COMPLEX WITH AMPPNP.
269, d5u6bD1, 0.8455, 2.33, 0.284, 289, 264, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
270, d4j96B_, 0.8453, 2.64, 0.363, 305, 267, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659M MUTATION IDENTIFIED IN CERVICAL CANCER.
271, d3w2qA1, 0.8452, 2.50, 0.342, 306, 266, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH HKI-272
272, d5flfB_, 0.8450, 2.63, 0.375, 292, 267, DISEASE LINKED MUTATION IN FGFR
273, d4j98B_, 0.8450, 2.64, 0.363, 304, 267, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659Q MUTATION.
274, d2ivvA1, 0.8450, 2.54, 0.375, 277, 264, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN COMPLEXED WITH THE INHIBITOR PP1
275, d5u6bB1, 0.8448, 2.32, 0.284, 289, 264, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
276, d5tt7A1, 0.8445, 2.33, 0.357, 270, 263, DISCOVERY OF TAK-659 AN ORALLY AVAILABLE INVESTIGATIONAL INHIBITOR OF SPLEEN TYROSINE KINASE (SYK)
277, d3kulB_, 0.8445, 2.40, 0.302, 271, 265, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 8 (EPHA8)
278, d4xg3A_, 0.8442, 2.09, 0.358, 262, 260, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
279, d5ui0A_, 0.8438, 2.68, 0.360, 301, 267, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING AN E565A/K659M DOUBLE GAIN-OF-FUNCTION MUTATION
280, d2eb2A_, 0.8437, 2.22, 0.344, 305, 262, CRYSTAL STRUCTURE OF MUTATED EGFR KINASE DOMAIN (G719S)
281, d2x2lA1, 0.8436, 2.53, 0.373, 282, 263, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
282, d5cxzA1, 0.8434, 2.40, 0.354, 267, 263, SYK CATALYTIC DOMAIN COMPLEXED WITH NAPHTHYRIDINE INHIBITOR
283, d5hibA_, 0.8433, 2.23, 0.352, 314, 261, EGFR KINASE DOMAIN MUTANT TMLR WITH A PYRAZOLOPYRIMIDINE INHIBITOR
284, d1xbcA1, 0.8431, 2.37, 0.350, 267, 263, CRYSTAL STRUCTURE OF THE SYK TYROSINE KINASE DOMAIN WITH STAUROSPORIN
285, d2g2hA_, 0.8430, 2.34, 0.330, 272, 264, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
286, d4j98A_, 0.8429, 2.69, 0.363, 304, 267, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659Q MUTATION.
287, d2jitB_, 0.8428, 2.31, 0.307, 312, 264, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION
288, d4j96A_, 0.8427, 2.70, 0.363, 302, 267, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659M MUTATION IDENTIFIED IN CERVICAL CANCER.
289, d3w2oA1, 0.8427, 2.50, 0.346, 304, 266, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH TAK-285
290, d4pv0A1, 0.8423, 2.37, 0.357, 266, 263, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH AN IMIDAZOPYRAZINE INHIBITOR
291, d4twpA_, 0.8422, 2.00, 0.328, 266, 259, THE CRYSTAL STRUCTURE OF HUMAN ABL1 T315I GATEKEEPER MUTANT KINASE DOMAIN IN COMPLEX WITH AXITINIB
292, d3vf8A_, 0.8422, 2.24, 0.356, 265, 261, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE SYK CATALYTIC DOMAIN WITH PYRAZOLYLBENZIMIDAZOLE INHIBITOR 416
293, d4xg6A1, 0.8421, 2.41, 0.348, 270, 264, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
294, d3kf4B_, 0.8419, 2.12, 0.326, 270, 261, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
295, d2hziB_, 0.8418, 2.02, 0.323, 264, 260, ABL KINASE DOMAIN IN COMPLEX WITH PD180970
296, d4dfnA1, 0.8417, 2.52, 0.366, 268, 265, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH AN ADAMANTYLPYRAZINE INHIBITOR
297, d3kf4A_, 0.8415, 2.02, 0.332, 281, 259, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
298, d2fo0A3, 0.8413, 2.25, 0.330, 291, 264, ORGANIZATION OF THE SH3-SH2 UNIT IN ACTIVE AND INACTIVE FORMS OF THE C-ABL TYROSINE KINASE
299, d4rssA_, 0.8412, 2.45, 0.351, 269, 265, CRYSTAL STRUCTURE OF TYROSINE-PROTEIN KINASE SYK WITH AN INHIBITOR
300, d1xbaA1, 0.8412, 2.26, 0.356, 265, 261, CRYSTAL STRUCTURE OF APO SYK TYROSINE KINASE DOMAIN
301, d3ue4A_, 0.8411, 2.37, 0.323, 270, 263, STRUCTURAL AND SPECTROSCOPIC ANALYSIS OF THE KINASE INHIBITOR BOSUTINIB BINDING TO THE ABL TYROSINE KINASE DOMAIN
302, d3dk3B_, 0.8407, 2.06, 0.323, 269, 260, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
303, d1u59A1, 0.8407, 2.35, 0.333, 276, 264, CRYSTAL STRUCTURE OF THE ZAP-70 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
304, d3dk7B_, 0.8405, 1.99, 0.324, 268, 259, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
305, d3ug2A_, 0.8403, 2.20, 0.342, 299, 260, CRYSTAL STRUCTURE OF THE MUTATED EGFR KINASE DOMAIN (G719S/T790M) IN COMPLEX WITH GEFITINIB
306, d3fqhA_, 0.8402, 2.19, 0.358, 262, 260, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH A 2-SUBSTITUTED 7-AZAINDOLE
307, d2gqgA1, 0.8402, 2.36, 0.327, 271, 263, X-RAY CRYSTAL STRUCTURE OF DASATINIB (BMS-354825) BOUND TO ACTIVATED ABL KINASE DOMAIN
308, d4xg9B_, 0.8401, 2.32, 0.359, 265, 262, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
309, d2x2mB1, 0.8401, 2.45, 0.375, 274, 261, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
310, d5lmbA_, 0.8400, 2.28, 0.352, 264, 261, HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR
311, d3srvB_, 0.8400, 2.26, 0.356, 263, 261, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH A DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITOR
312, d1oplB2, 0.8399, 2.32, 0.331, 267, 263, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
313, d1opkA3, 0.8398, 2.39, 0.330, 291, 264, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
314, d3hmiA_, 0.8394, 2.29, 0.322, 268, 264, THE CRYSTAL STRUCTURE OF HUMAN ABL2 IN COMPLEX WITH 5-AMINO-3-{[4- (AMINOSULFONYL)PHENYL]AMINO}-N-(26-DIFLUOROPHENYL)-1H-124- TRIAZOLE-1-CARBOTHIOAMIDE
315, d3dqwC_, 0.8394, 2.32, 0.333, 275, 261, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
316, d3dqwD_, 0.8392, 2.32, 0.333, 276, 261, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
317, d5flfC_, 0.8391, 2.54, 0.364, 283, 264, DISEASE LINKED MUTATION IN FGFR
318, d3vf9A_, 0.8390, 2.31, 0.356, 265, 261, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE SYK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 027
319, d1qpjA_, 0.8390, 2.30, 0.349, 265, 261, CRYSTAL STRUCTURE OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH STAUROSPORINE.
320, d1oplA3, 0.8390, 2.40, 0.330, 291, 264, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
321, d5c26A1, 0.8389, 2.66, 0.358, 271, 265, CRYSTAL STRUCTURE OF SYK IN COMPLEX WITH COMPOUND 1
322, d2of4A_, 0.8389, 2.39, 0.351, 271, 262, CRYSTAL STRUCTURE OF FURANOPYRIMIDINE 1 BOUND TO LCK
323, d3w2pA1, 0.8388, 2.55, 0.342, 307, 266, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH COMPOUND 2
324, d4rx8A1, 0.8384, 2.41, 0.359, 266, 262, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT TRIAZINE INHIBITOR2
325, d4j99C_, 0.8384, 2.67, 0.353, 291, 266, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
326, d4xg3B_, 0.8383, 2.53, 0.356, 267, 264, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
327, d2xynC_, 0.8383, 2.10, 0.328, 262, 259, HUMAN ABL2 IN COMPLEX WITH AURORA KINASE INHIBITOR VX-680
328, d4xliB_, 0.8382, 2.19, 0.327, 264, 260, CRYSTAL STRUCTURE OF ABL2/ARG KINASE IN COMPLEX WITH DASATINIB
329, d4j97A_, 0.8382, 2.56, 0.352, 282, 264, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
330, d4j95B_, 0.8381, 2.72, 0.363, 282, 267, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
331, d2itxA_, 0.8381, 2.40, 0.347, 307, 262, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AMP- PNP
332, d3srvA_, 0.8380, 2.26, 0.362, 262, 260, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH A DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITOR
333, d2gqgB1, 0.8380, 2.31, 0.328, 270, 262, X-RAY CRYSTAL STRUCTURE OF DASATINIB (BMS-354825) BOUND TO ACTIVATED ABL KINASE DOMAIN
334, d1u4dB_, 0.8374, 2.09, 0.391, 262, 258, STRUCTURE OF THE ACK1 KINASE DOMAIN BOUND TO DEBROMOHYMENIALDISINE
335, d2of2A_, 0.8373, 2.41, 0.351, 271, 262, CRYSTAL STRUCTURE OF FURANOPYRIMIDINE 8 BOUND TO LCK
336, d3nsvC_, 0.8372, 2.12, 0.328, 262, 259,  
337, d5ugxA_, 0.8371, 2.72, 0.350, 297, 266, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A E565A/D650V DOUBLE GAIN-OF-FUNCTION MUTATION
338, d2pvfA_, 0.8371, 2.63, 0.360, 285, 264, CRYSTAL STRUCTURE OF TYROSINE PHOSPHORYLATED ACTIVATED FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN IN COMPLEX WITH ATP ANALOG AND SUBSTRATE PEPTIDE
339, d1pkgA_, 0.8370, 2.41, 0.347, 290, 262, STRUCTURE OF A C-KIT KINASE PRODUCT COMPLEX
340, d2xynB_, 0.8369, 2.25, 0.322, 264, 261, HUMAN ABL2 IN COMPLEX WITH AURORA KINASE INHIBITOR VX-680
341, d3nsvB_, 0.8368, 2.25, 0.322, 264, 261,  
342, d4j99B_, 0.8367, 2.74, 0.363, 291, 267, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
343, d2v7aA_, 0.8367, 2.36, 0.324, 269, 262, CRYSTAL STRUCTURE OF THE T315I ABL MUTANT IN COMPLEX WITH THE INHIBITOR PHA-739358
344, d2j0lA_, 0.8364, 2.44, 0.348, 274, 264, CRYSTAL STRUCTURE OF A THE ACTIVE CONFORMATION OF THE KINASE DOMAIN OF FOCAL ADHESION KINASE WITH A PHOSPHORYLATED ACTIVATION LOOP.
345, d5lmaA_, 0.8363, 2.55, 0.357, 267, 263, HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR
346, d3kxzA_, 0.8363, 2.28, 0.350, 263, 260, THE COMPLEX CRYSTAL STRUCTURE OF LCK WITH A PROBE MOLECULE W259
347, d5amnA1, 0.8362, 2.49, 0.387, 282, 261, THE DISCOVERY OF 2-SUBSTITUTED PHENOL QUINAZOLINES AS POTENT AND SELECTIVE RET KINASE INHIBITORS
348, d4j95C_, 0.8362, 2.62, 0.355, 281, 265, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
349, d1qpdA_, 0.8362, 2.37, 0.345, 270, 261, STRUCTURAL ANALYSIS OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH NON-SELECTIVE AND SRC FAMILY SELECTIVE KINASE INHIBITORS
350, d5c27A1, 0.8361, 2.66, 0.347, 271, 265, CRYSTAL STRUCTURE OF SYK IN COMPLEX WITH COMPOUND 2
351, d4xg7A1, 0.8361, 2.32, 0.356, 265, 261, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
352, d2ofuA_, 0.8361, 2.40, 0.349, 272, 261, X-RAY CRYSTAL STRUCTURE OF 2-AMINOPYRIMIDINE CARBAMATE 43 BOUND TO LCK
353, d4j97C_, 0.8360, 2.58, 0.357, 283, 263, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
354, d4puzB_, 0.8358, 2.39, 0.352, 265, 261, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH GS- 9973
355, d4dflA1, 0.8358, 2.18, 0.355, 262, 259, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH A SULFONAMIDOPYRAZINE PIPERIDINE INHIBITOR
356, d4j97B_, 0.8357, 2.58, 0.354, 283, 263, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
357, d3bymA_, 0.8357, 2.40, 0.349, 271, 261, X-RAY CO-CRYSTAL STRUCTURE AMINOBENZIMIDAZOLE TRIAZINE 1 BOUND TO LCK
358, d3fqeA1, 0.8355, 2.40, 0.352, 265, 261, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH YM193306
359, d1qpcA_, 0.8355, 2.41, 0.349, 270, 261, STRUCTURAL ANALYSIS OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH NON-SELECTIVE AND SRC FAMILY SELECTIVE KINASE INHIBITORS
360, d4g5jA_, 0.8352, 1.87, 0.343, 307, 254, CRYSTAL STRUCTURE OF EGFR KINASE IN COMPLEX WITH BIBW2992
361, d4rx9A1, 0.8350, 2.43, 0.364, 264, 261, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT PYRIMIDINE INHIBITOR
362, d3kmmA_, 0.8349, 2.42, 0.349, 270, 261, STRUCTURE OF HUMAN LCK KINASE WITH A SMALL MOLECULE INHIBITOR
363, d4j97D_, 0.8346, 2.52, 0.355, 285, 262, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
364, d3ac1A_, 0.8346, 2.42, 0.349, 270, 261, CRYSTAL STRUCTURE OF PYRAZIN DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
365, d5uhnA_, 0.8343, 2.76, 0.350, 282, 266, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A N549H/E565A DOUBLE GAIN-OF-FUNCTION MUTATION
366, d5fedA_, 0.8340, 2.05, 0.344, 288, 256, EGFR KINASE DOMAIN IN COMPLEX WITH A COVALENT AMINOBENZIMIDAZOLE INHIBITOR.
367, d4xeyA_, 0.8340, 2.17, 0.315, 269, 260, CRYSTAL STRUCTURE OF AN SH2-KINASE DOMAIN CONSTRUCT OF C-ABL TYROSINE KINASE
368, d4puzA_, 0.8337, 2.42, 0.352, 263, 261, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH GS- 9973
369, d3kulA_, 0.8337, 2.48, 0.313, 267, 262, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 8 (EPHA8)
370, d3dqwA_, 0.8337, 2.41, 0.333, 278, 261, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
371, d5tiuA1, 0.8335, 2.29, 0.363, 262, 259, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH INHIBITOR
372, d5hezD_, 0.8334, 2.53, 0.460, 289, 263, JAK2 KINASE (JH1 DOMAIN) MUTANT P1057A IN COMPLEX WITH TG101209
373, d1u54B_, 0.8334, 2.11, 0.391, 261, 256, CRYSTAL STRUCTURES OF THE PHOSPHORYLATED AND UNPHOSPHORYLATED KINASE DOMAINS OF THE CDC42-ASSOCIATED TYROSINE KINASE ACK1 BOUND TO AMP-PCP
374, d4j99D_, 0.8333, 2.65, 0.364, 281, 264, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
375, d3ad6A_, 0.8333, 2.44, 0.349, 272, 261, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
376, d3ac5A_, 0.8333, 2.42, 0.349, 270, 261, CRYSTAL STRUCTURE OF TRIAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
377, d4xliA_, 0.8332, 2.33, 0.327, 264, 260, CRYSTAL STRUCTURE OF ABL2/ARG KINASE IN COMPLEX WITH DASATINIB
378, d3ue4B_, 0.8332, 2.33, 0.324, 268, 262, STRUCTURAL AND SPECTROSCOPIC ANALYSIS OF THE KINASE INHIBITOR BOSUTINIB BINDING TO THE ABL TYROSINE KINASE DOMAIN
379, d3ac2A_, 0.8331, 2.44, 0.352, 270, 261, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
380, d3lckA_, 0.8329, 2.45, 0.349, 270, 261, THE KINASE DOMAIN OF HUMAN LYMPHOCYTE KINASE (LCK) ACTIVATED FORM (AUTO-PHOSPHORYLATED ON TYR394)
381, d3lcdA_, 0.8329, 2.58, 0.340, 290, 262, INHIBITOR BOUND TO A DFG-IN STRUCTURE OF THE KINASE DOMAIN OF CSF-1R
382, d3acjA_, 0.8329, 2.44, 0.352, 270, 261, CRYSTAL STRUCTURE OF IMIDAZO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
383, d2zm4A_, 0.8329, 2.44, 0.352, 270, 261, CRYSTAL STRUCTURE OF IMIDAZO QUINOXALINE 1 BOUND TO THE KINASE DOMAIN OF HUMAN LCK ACTIVATED FORM (AUTO- PHOSPHORYLATED ON TYR394)
384, d2zm1A_, 0.8329, 2.44, 0.349, 270, 261, CRYSTAL STRUCTURE OF IMIDAZO PYRAZIN 1 BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
385, d2hziA_, 0.8329, 2.50, 0.326, 268, 264, ABL KINASE DOMAIN IN COMPLEX WITH PD180970
386, d3ikaB_, 0.8328, 2.27, 0.299, 310, 261, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M MUTANT COVALENTLY BINDING TO WZ4002
387, d3dqwB_, 0.8328, 2.42, 0.333, 278, 261, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
388, d3ad4A_, 0.8328, 2.45, 0.352, 270, 261, CRYSTAL STRUCTURE OF METHOXY BENZOFURAN DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
389, d3ac4A_, 0.8328, 2.45, 0.352, 270, 261, CRYSTAL STRUCTURE OF TRIAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
390, d2v7aB_, 0.8328, 2.33, 0.322, 268, 261, CRYSTAL STRUCTURE OF THE T315I ABL MUTANT IN COMPLEX WITH THE INHIBITOR PHA-739358
391, d5hezB_, 0.8325, 2.59, 0.460, 289, 263, JAK2 KINASE (JH1 DOMAIN) MUTANT P1057A IN COMPLEX WITH TG101209
392, d3ac3A_, 0.8325, 2.45, 0.349, 270, 261, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
393, d5ghvB_, 0.8324, 2.41, 0.356, 265, 261, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
394, d4xg5B_, 0.8324, 2.41, 0.356, 265, 261,  
395, d3w2sA_, 0.8324, 2.11, 0.352, 307, 256, EGFR KINASE DOMAIN WITH COMPOUND4
396, d3ackA_, 0.8324, 2.45, 0.349, 270, 261, CRYSTAL STRUCTURE OF PYRROLO PYRAZINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
397, d3byoA_, 0.8323, 2.47, 0.349, 270, 261, X-RAY CO-CRYSTAL STRUCTURE OF 2-AMINO-6-PHENYLPYRIMIDO[5  4 :56]PYRIMIDO[12-A]BENZIMIDAZOL-5(6H)-ONE 25 BOUND TO LCK
398, d1qpeA_, 0.8322, 2.45, 0.349, 270, 261, STRUCTURAL ANALYSIS OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH NON-SELECTIVE AND SRC FAMILY SELECTIVE KINASE INHIBITORS
399, d3ad5A_, 0.8321, 2.46, 0.349, 270, 261, CRYSTAL STRUCTURE OF TRIAZOLONE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
400, d5ghvA_, 0.8320, 2.42, 0.356, 265, 261, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
401, d4xg5A_, 0.8320, 2.42, 0.356, 265, 261,  
402, d2zybA_, 0.8319, 2.44, 0.349, 270, 261, CRYSTAL STRUCTURE OF PHENYLIMIDAZO PYRAZIN 2 BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
403, d2pvyA_, 0.8319, 2.51, 0.352, 288, 261, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
404, d4i0tA1, 0.8318, 2.27, 0.368, 262, 258, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 2-(5678- TETRAHYDRO-IMIDAZO[15-A]PYRIDIN-1-YL)-5H-PYRROLO[23-B]PYRAZINE-7- CARBOXYLIC ACID TERT-BUTYLAMIDE
405, d2pvyD_, 0.8318, 2.52, 0.352, 283, 261, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
406, d2dq7X_, 0.8317, 2.07, 0.332, 262, 256, CRYSTAL STRUCTURE OF FYN KINASE DOMAIN COMPLEXED WITH STAUROSPORINE
407, d5hezC_, 0.8315, 2.59, 0.456, 289, 263, JAK2 KINASE (JH1 DOMAIN) MUTANT P1057A IN COMPLEX WITH TG101209
408, d3ac8A_, 0.8315, 2.45, 0.352, 270, 261, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
409, d4fl1A_, 0.8314, 2.84, 0.366, 268, 265, STRUCTURAL AND BIOPHYSICAL CHARACTERIZATION OF THE SYK ACTIVATION SWITCH
410, d1y57A3, 0.8313, 2.47, 0.337, 285, 261, STRUCTURE OF UNPHOSPHORYLATED C-SRC IN COMPLEX WITH AN INHIBITOR
411, d4hzrA_, 0.8312, 2.11, 0.383, 261, 256, CRYSTAL STRUCTURE OF ACK1 KINASE DOMAIN
412, d4xg4A_, 0.8310, 2.39, 0.358, 264, 260, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
413, d2psqA_, 0.8308, 2.67, 0.348, 287, 264, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED UNACTIVATED WILD TYPE FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN
414, d3fqhB_, 0.8307, 2.20, 0.358, 258, 257, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH A 2-SUBSTITUTED 7-AZAINDOLE
415, d4hzrB_, 0.8306, 2.10, 0.382, 258, 254, CRYSTAL STRUCTURE OF ACK1 KINASE DOMAIN
416, d3dk7A_, 0.8306, 2.16, 0.324, 265, 259, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
417, d3dk3A_, 0.8304, 2.23, 0.323, 266, 260, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
418, d1u54A_, 0.8304, 2.07, 0.384, 262, 255, CRYSTAL STRUCTURES OF THE PHOSPHORYLATED AND UNPHOSPHORYLATED KINASE DOMAINS OF THE CDC42-ASSOCIATED TYROSINE KINASE ACK1 BOUND TO AMP-PCP
419, d1oecA_, 0.8304, 2.85, 0.342, 280, 266, FGFR2 KINASE DOMAIN
420, d4fyoA1, 0.8303, 2.38, 0.351, 263, 259, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH N-{(S)-1- [7-(34-DIMETHOXY-PHENYLAMINO)-THIAZOLO[54-D]PYRIMIDIN-5-YL]- PYRROLIDIN-3-YL}-TEREPHTHALAMIC ACID
421, d4zseC_, 0.8302, 1.89, 0.340, 301, 253, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
422, d4fynA1, 0.8302, 2.48, 0.358, 263, 260, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 3-(8-{4- [ETHYL-(2-HYDROXY-ETHYL)-AMINO]-PHENYLAMINO}-IMIDAZO[12-A]PYRAZIN-5- YL)-PHENOL
423, d3b2tA_, 0.8301, 2.92, 0.352, 288, 267, STRUCTURE OF PHOSPHOTRANSFERASE
424, d4i0sA1, 0.8300, 2.36, 0.351, 263, 259, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 2-(6- CHLORO-1-METHYL-1H-INDAZOL-3-YL)-5H-PYRROLO[23-B]PYRAZINE-7- CARBOXYLIC ACID ISOPROPYLAMIDE
425, d1k2pA_, 0.8298, 2.09, 0.324, 258, 256, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE DOMAIN
426, d1gjoA_, 0.8297, 2.86, 0.342, 280, 266, THE FGFR2 TYROSINE KINASE DOMAIN
427, d1xbbA1, 0.8293, 2.48, 0.358, 266, 260, CRYSTAL STRUCTURE OF THE SYK TYROSINE KINASE DOMAIN WITH GLEEVEC
428, d4zseA_, 0.8292, 2.06, 0.349, 297, 255, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
429, d5uglA_, 0.8291, 2.81, 0.353, 285, 266, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 TYROSINE KINASE DOMAIN HARBORING THE D650V ACTIVATING MUTATION
430, d4i0rA1, 0.8290, 2.27, 0.362, 260, 257, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 2-(345- TRIMETHOXY-PHENYL)-5H-PYRROLO[23-B]PYRAZINE-7-CARBOXYLIC ACID ISOPROPYLAMIDE
431, d3zzeA_, 0.8285, 2.47, 0.328, 286, 259, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH N - ((3Z)-4-CHLORO-7-METHYL-2-OXO-12-DIHYDRO-3H-INDOL-3- YLIDENE)-2-(4-HYDROXYPHENYL)PROPANOHYDRAZIDE
432, d5hezA_, 0.8282, 2.57, 0.458, 287, 262, JAK2 KINASE (JH1 DOMAIN) MUTANT P1057A IN COMPLEX WITH TG101209
433, d4px6A1, 0.8282, 2.24, 0.362, 261, 257, SYK CATALYTIC DOMAIN IN COMPLEX WITH A POTENT PYRIDOPYRIMIDINONE INHIBITOR
434, d4hjoA_, 0.8282, 2.44, 0.336, 278, 259, CRYSTAL STRUCTURE OF THE INACTIVE EGFR TYROSINE KINASE DOMAIN WITH ERLOTINIB
435, d3rhkA_, 0.8282, 2.44, 0.338, 298, 260, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF C-MET KINASE IN COMPLEX WITH ARQ 197
436, d2hz4A_, 0.8279, 2.27, 0.328, 262, 259, ABL KINASE DOMAIN UNLIGATED AND IN COMPLEX WITH TETRAHYDROSTAUROSPORINE
437, d2psqB_, 0.8278, 2.95, 0.357, 286, 266, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED UNACTIVATED WILD TYPE FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN
438, d4fz6A1, 0.8274, 2.38, 0.364, 262, 258, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH [6-((S)-2- METHYL-PYRROLIDIN-1-YL)-PYRIDIN-2-YL]-(6-PHENYL-IMIDAZO[12- B]PYRIDAZIN-8-YL)-AMINE
439, d4lqmA_, 0.8273, 2.38, 0.345, 305, 258, EGFR L858R IN COMPLEX WITH PD168393
440, d4yjoA_, 0.8272, 2.68, 0.361, 267, 263, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000222
441, d3fqsA1, 0.8271, 2.69, 0.368, 264, 261, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH R406
442, d1u46B_, 0.8271, 1.95, 0.387, 257, 253, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED KINASE DOMAIN OF THE TYROSINE KINASE ACK1
443, d2gs7A_, 0.8270, 2.52, 0.337, 281, 261, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
444, d5gtzA_, 0.8269, 2.63, 0.350, 317, 260, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH JTS-1-39
445, d2gs7B_, 0.8269, 2.44, 0.323, 288, 260, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
446, d3w2rA_, 0.8266, 1.93, 0.316, 297, 253, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH COMPOUND 4
447, d4j99A_, 0.8265, 2.67, 0.363, 280, 262, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
448, d2py3B_, 0.8265, 2.82, 0.354, 284, 263, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565G MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
449, d4xeyB2, 0.8262, 2.06, 0.306, 264, 255, CRYSTAL STRUCTURE OF AN SH2-KINASE DOMAIN CONSTRUCT OF C-ABL TYROSINE KINASE
450, d4fz7A1, 0.8262, 2.41, 0.357, 261, 258, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 6-((1R2S)- 2-AMINO-CYCLOHEXYLAMINO)-4-(6-ETHYL-PYRIDIN-2-YLAMINO)-PYRIDAZINE-3- CARBOXYLIC ACID AMIDE
451, d5cnnB_, 0.8261, 2.17, 0.344, 304, 256, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN MUTANT I682Q
452, d3ri1A_, 0.8260, 2.96, 0.367, 285, 267, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR2 KINASE IN COMPLEX WITH ARQ 069
453, d5feeA_, 0.8259, 2.09, 0.346, 287, 254, EGFR KINASE DOMAIN T790M MUTANT IN COMPLEX WITH A COVALENT AMINOBENZIMIDAZOLE INHIBITOR.
454, d4wrgA1, 0.8258, 2.02, 0.340, 287, 253, 1.9 ANGSTROM STRUCTURE OF EGFR KINASE DOMAIN
455, d2j5fA_, 0.8257, 2.40, 0.345, 308, 258, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR 34-JAB
456, d3rhkB_, 0.8256, 2.49, 0.342, 299, 260, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF C-MET KINASE IN COMPLEX WITH ARQ 197
457, d3plsA_, 0.8255, 2.51, 0.344, 298, 262, RON IN COMPLEX WITH LIGAND AMP-PNP
458, d2pwlA_, 0.8255, 2.78, 0.345, 284, 264, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549H MUTATION RESPONSIBLE FOR CROUZON SYNDROME.
459, d4aoiA_, 0.8254, 2.35, 0.332, 289, 256, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH 4-( 3-((1H- PYRROLO(23-B)PYRIDIN-3-YL)METHYL)-(124)TRIAZOLO( 43-B)(124) TRIAZIN-6-YL)BENZONITRILE
460, d3sxsA1, 0.8254, 2.21, 0.318, 261, 258, CRYSTAL STRUCTURE OF BMX NON-RECEPTOR TYROSINE KINASE COMPLEXED WITH PP2
461, d4yc8B_, 0.8253, 2.20, 0.322, 264, 258, C-HELIX-OUT BINDING OF DASATINIB ANALOG TO C-ABL KINASE
462, d2pwlB_, 0.8251, 2.91, 0.355, 286, 265, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549H MUTATION RESPONSIBLE FOR CROUZON SYNDROME.
463, d4r1vA_, 0.8248, 2.60, 0.332, 289, 259, IDENTIFICATION AND OPTIMIZATION OF PYRIDAZINONES AS POTENT AND SELECTIVE C-MET KINASE INHIBITORS
464, d3zclA_, 0.8247, 2.38, 0.332, 289, 256, X-RAY STRUCTURE OF C-MET KINASE IN COMPLEX WITH INHIBITOR ( S)-3-(1-(1H-PYRROLO(23-B)PYRIDIN-3-YL)ETHYL)-N-ISOPROPYL-( 124)TRIAZOLO(43-B)PYRIDAZIN-6-AMINE
465, d4f4pA1, 0.8246, 2.22, 0.363, 260, 256, SYK IN COMPLEX WITH LIGAND LASW836
466, d4yc8A_, 0.8245, 2.01, 0.319, 259, 254, C-HELIX-OUT BINDING OF DASATINIB ANALOG TO C-ABL KINASE
467, d3zbxA_, 0.8245, 2.36, 0.332, 282, 256, X-RAY STRUCTURE OF C-MET KINASE IN COMPLEX WITH INHIBITOR 6- ((6-(4-FLUOROPHENYL)-(124)TRIAZOLO(43-B)(124)TRIAZIN- 3-YL)METHYL)QUINOLINE.
468, d2g15A_, 0.8245, 2.65, 0.324, 301, 262, STRUCTURAL CHARACTERIZATION OF AUTOINHIBITED C-MET KINASE
469, d3ri1B_, 0.8244, 2.99, 0.353, 283, 266, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR2 KINASE IN COMPLEX WITH ARQ 069
470, d5d41B_, 0.8241, 2.13, 0.353, 302, 255, EGFR KINASE DOMAIN IN COMPLEX WITH MUTANT SELECTIVE ALLOSTERIC INHIBITOR
471, d4i24B_, 0.8240, 2.43, 0.362, 304, 257, STRUCTURE OF T790M EGFR KINASE DOMAIN CO-CRYSTALLIZED WITH DACOMITINIB
472, d3dk6A_, 0.8240, 2.11, 0.324, 262, 256, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
473, d2wd1A_, 0.8240, 2.56, 0.333, 289, 258, HUMAN C-MET KINASE IN COMPLEX WITH AZAINDOLE INHIBITOR
474, d4xg8A_, 0.8238, 2.16, 0.361, 258, 255, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
475, d3zc5A_, 0.8238, 2.49, 0.339, 289, 257, X-RAY STRUCTURE OF C-MET KINASE IN COMPLEX WITH INHIBITOR ( S)-6-(1-(6-(1-METHYL-1H-PYRAZOL-4-YL)-(124)TRIAZOLO(43- B)PYRIDAZIN-3-YL)ETHYL)QUINOLINE.
476, d4ap7A_, 0.8237, 2.42, 0.327, 289, 257, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH 4-( (6-(4- FLUOROPHENYL)-(124)TRIAZOLO(43-B)(124)TRIAZIN-3-YL)METHYL) PHENOL
477, d4xg9A_, 0.8236, 2.35, 0.362, 259, 257, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
478, d4j95A_, 0.8236, 2.72, 0.359, 279, 262, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
479, d4zseB_, 0.8235, 2.36, 0.359, 313, 256, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
480, d3b2tB_, 0.8234, 2.76, 0.346, 287, 263, STRUCTURE OF PHOSPHOTRANSFERASE
481, d2r4bA_, 0.8234, 2.00, 0.350, 292, 254, ERBB4 KINASE DOMAIN COMPLEXED WITH A THIENOPYRIMIDINE INHIBITOR
482, d3zxzA_, 0.8233, 2.48, 0.342, 289, 257, X-RAY STRUCTURE OF PF-04217903 BOUND TO THE KINASE DOMAIN OF C-MET
483, d4zauA_, 0.8232, 2.18, 0.350, 283, 254, AZD9291 COMPLEX WITH WILD TYPE EGFR
484, d2hz4C_, 0.8232, 2.14, 0.328, 259, 256, ABL KINASE DOMAIN UNLIGATED AND IN COMPLEX WITH TETRAHYDROSTAUROSPORINE
485, d5gtyH_, 0.8231, 2.07, 0.361, 300, 252, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
486, d2rfeD_, 0.8229, 2.23, 0.354, 278, 254, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE EGFR KINASE DOMAIN AND A MIG6 PEPTIDE
487, d5lmbB_, 0.8228, 2.48, 0.360, 261, 258, HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR
488, d1u4dA_, 0.8228, 2.08, 0.385, 258, 252, STRUCTURE OF THE ACK1 KINASE DOMAIN BOUND TO DEBROMOHYMENIALDISINE
489, d3w32A_, 0.8226, 2.51, 0.330, 317, 261, EGFR KINASE DOMAIN COMPLEXED WITH COMPOUND 20A
490, d3u6iA_, 0.8223, 1.96, 0.333, 281, 252, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH PYRAZOLONE INHIBITOR 58A
491, d5xgnB_, 0.8217, 2.32, 0.306, 308, 258, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/C797S IN COMPLEX WITH GO6976
492, d3lctA_, 0.8213, 2.77, 0.307, 308, 264, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
493, d2q0bB_, 0.8212, 2.84, 0.351, 282, 262, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565A MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
494, d4xg2A1, 0.8211, 2.25, 0.365, 258, 255, CRYSTAL STRUCTURE OF LIGAND-FREE SYK
495, d2wgjA_, 0.8209, 2.49, 0.327, 289, 257, X-RAY STRUCTURE OF PF-02341066 BOUND TO THE KINASE DOMAIN OF C-MET
496, d2r4bB_, 0.8208, 2.09, 0.354, 291, 254, ERBB4 KINASE DOMAIN COMPLEXED WITH A THIENOPYRIMIDINE INHIBITOR
497, d3kcfE_, 0.8207, 2.88, 0.230, 330, 269, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
498, d2r2pA1, 0.8206, 2.85, 0.297, 276, 266, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 5 (EPHA5)
499, d3lcsA_, 0.8204, 2.78, 0.303, 304, 264, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
500, d5eobA_, 0.8201, 2.64, 0.336, 288, 259, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
501, d2ittA_, 0.8201, 2.44, 0.346, 302, 257, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH AEE788
502, d2pz5B_, 0.8200, 2.83, 0.352, 280, 261, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549T MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
503, d2py3A_, 0.8200, 2.83, 0.355, 282, 262, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565G MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
504, d2pzpB_, 0.8198, 2.84, 0.352, 282, 261, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K526E MUTATION RESPONSIBLE FOR CROUZON SYNDROME
505, d5t68B_, 0.8197, 2.61, 0.358, 264, 260, CRYSTAL STRUCTURE OF SYK CATALYTIC DOMAIN IN COMPLEX WITH A FURO[32- D]PYRIMIDINE
506, d5mjbA_, 0.8197, 2.70, 0.281, 276, 263, KINASE DOMAIN OF HUMAN EPHB1 G703C MUTANT COVALENTLY BOUND TO A QUINAZOLINE-BASED INHIBITOR
507, d2rgpA_, 0.8197, 2.05, 0.347, 284, 251, STRUCTURE OF EGFR IN COMPLEX WITH HYDRAZONE A POTENT DUAL INHIBITOR
508, d2itzA_, 0.8196, 2.40, 0.344, 302, 256, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH IRESSA
509, d2q0bA_, 0.8194, 2.85, 0.351, 280, 262, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565A MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
510, d2itnA_, 0.8194, 2.47, 0.342, 304, 257, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH AMP-PNP
511, d1xkkA_, 0.8194, 2.10, 0.345, 289, 252, EGFR KINASE DOMAIN COMPLEXED WITH A QUINAZOLINE INHIBITOR- GW572016
512, d4g5pB_, 0.8193, 2.18, 0.298, 303, 255, CRYSTAL STRUCTURE OF EGFR KINASE T790M IN COMPLEX WITH BIBW2992
513, d1k2pB_, 0.8193, 2.11, 0.322, 258, 255, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE DOMAIN
514, d1iasD_, 0.8191, 2.92, 0.238, 330, 269, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
515, d1iasE_, 0.8189, 2.91, 0.238, 330, 269, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
516, d5t68A1, 0.8188, 2.63, 0.358, 264, 260, CRYSTAL STRUCTURE OF SYK CATALYTIC DOMAIN IN COMPLEX WITH A FURO[32- D]PYRIMIDINE
517, d4yjtA_, 0.8186, 2.85, 0.364, 268, 261, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000233
518, d4yjpA_, 0.8186, 2.88, 0.374, 263, 262, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000223
519, d2wkmA_, 0.8186, 2.83, 0.335, 286, 260, X-RAY STRUCTURE OF PHA-00665752 BOUND TO THE KINASE DOMAIN OF C-MET
520, d1k9aA3, 0.8185, 2.04, 0.377, 267, 252, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
521, d4trlA_, 0.8184, 2.55, 0.313, 268, 259, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
522, d2z8cA1, 0.8184, 2.89, 0.316, 297, 263, PHOSPHORYLATED INSULIN RECEPTOR TYROSINE KINASE IN COMPLEX WITH (4-{[5-CARBAMOYL-4-(3-METHYLANILINO)PYRIMIDIN-2- YL]AMINO}PHENYL)ACETIC ACID
523, d2pzrB_, 0.8183, 2.84, 0.349, 282, 261, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K641R MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
524, d5gtyD_, 0.8182, 1.93, 0.348, 297, 250, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
525, d2ityA1, 0.8182, 2.39, 0.352, 299, 256, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH IRESSA
526, d1u46A_, 0.8182, 2.07, 0.392, 255, 250, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED KINASE DOMAIN OF THE TYROSINE KINASE ACK1
527, d1b6cD_, 0.8181, 3.19, 0.234, 326, 273, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
528, d5gtyE_, 0.8180, 1.92, 0.348, 297, 250, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
529, d1iasC_, 0.8180, 2.93, 0.238, 330, 269, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
530, d1b6cB_, 0.8180, 3.21, 0.234, 326, 273, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
531, d4yjuA_, 0.8179, 2.65, 0.368, 262, 258, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000249
532, d3u6hA_, 0.8179, 1.99, 0.335, 280, 251, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH PYRAZOLONE INHIBITOR 26
533, d5gtyG_, 0.8178, 2.01, 0.356, 299, 250, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
534, d5d41A_, 0.8178, 1.83, 0.344, 300, 250, EGFR KINASE DOMAIN IN COMPLEX WITH MUTANT SELECTIVE ALLOSTERIC INHIBITOR
535, d3lzbA_, 0.8178, 2.09, 0.353, 265, 252, EGFR KINASE DOMAIN COMPLEXED WITH AN IMIDAZO[21-B]THIAZOLE INHIBITOR
536, d2pvyC_, 0.8177, 2.51, 0.359, 285, 256, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
537, d2hk5A2, 0.8176, 2.50, 0.349, 268, 258, HCK KINASE IN COMPLEX WITH LCK TARGETTED INHIBITOR PG-1009247
538, d1b6cF_, 0.8176, 3.16, 0.234, 326, 273, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
539, d5gtyA_, 0.8175, 2.11, 0.357, 300, 252, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
540, d3belA_, 0.8175, 2.03, 0.348, 280, 250, X-RAY STRUCTURE OF EGFR IN COMPLEX WITH OXIME INHIBITOR
541, d2pzrA_, 0.8175, 2.64, 0.344, 280, 259, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K641R MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
542, d2itvA_, 0.8175, 2.46, 0.346, 303, 257, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH AMP-PNP
543, d1k9aE3, 0.8175, 2.07, 0.377, 268, 252, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
544, d1iasA_, 0.8175, 2.94, 0.238, 330, 269, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
545, d3pozA_, 0.8174, 2.11, 0.359, 293, 251, EGFR KINASE DOMAIN COMPLEXED WITH TAK-285
546, d3dk6B_, 0.8173, 1.94, 0.319, 259, 251, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
547, d1k9aB3, 0.8173, 2.10, 0.377, 267, 252, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
548, d3kcfD_, 0.8171, 2.95, 0.238, 330, 269, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
549, d5hcyA_, 0.8169, 2.24, 0.356, 302, 253, EGFR KINASE DOMAIN MUTANT TMLR WITH 3-CARBOXAMIDE AZAINDOLE COMPOUND 13
550, d2pzpA_, 0.8169, 2.68, 0.347, 280, 259, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K526E MUTATION RESPONSIBLE FOR CROUZON SYNDROME
551, d2pz5A_, 0.8169, 2.69, 0.347, 280, 259, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549T MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
552, d3zewA_, 0.8168, 2.46, 0.275, 269, 258, CRYSTAL STRUCTURE OF EPHB4 IN COMPLEX WITH STAUROSPORINE
553, d3zfxA_, 0.8167, 2.40, 0.293, 267, 256, CRYSTAL STRUCTURE OF EPHB1
554, d3lzbB_, 0.8167, 2.09, 0.353, 265, 252, EGFR KINASE DOMAIN COMPLEXED WITH AN IMIDAZO[21-B]THIAZOLE INHIBITOR
555, d5mjbB_, 0.8166, 2.86, 0.278, 278, 266, KINASE DOMAIN OF HUMAN EPHB1 G703C MUTANT COVALENTLY BOUND TO A QUINAZOLINE-BASED INHIBITOR
556, d3dkcA1, 0.8166, 2.66, 0.313, 310, 262, STRUCTURE OF MET RECEPTOR TYROSINE KINASE IN COMPLEX WITH ATP
557, d3sxrA1, 0.8162, 2.23, 0.322, 257, 255, CRYSTAL STRUCTURE OF BMX NON-RECEPTOR TYROSINE KINASE COMPLEX WITH DASATINIB
558, d2b4sB_, 0.8162, 2.81, 0.318, 294, 261, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN PTP1B AND THE INSULIN RECEPTOR TYROSINE KINASE
559, d1b6cH_, 0.8162, 3.23, 0.234, 326, 273, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
560, d4hctA_, 0.8160, 2.37, 0.299, 265, 254, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 52
561, d3ppzB_, 0.8158, 2.09, 0.289, 264, 253, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
562, d5gtyB_, 0.8157, 2.08, 0.355, 299, 251, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
563, d4yhfB_, 0.8157, 2.20, 0.304, 269, 253, BRUTON S TYROSINE KINASE IN COMPLEX WITH A T-BUTYL CYANOACRYLAMIDE INHIBITOR
564, d5cnnA_, 0.8155, 2.05, 0.355, 300, 251, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN MUTANT I682Q
565, d4uxlA_, 0.8155, 2.55, 0.332, 288, 259, STRUCTURE OF HUMAN ROS1 KINASE DOMAIN IN COMPLEX WITH PF-06463922
566, d3kcfA_, 0.8154, 2.91, 0.231, 328, 268, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
567, d3zfxH_, 0.8153, 2.46, 0.293, 266, 256, CRYSTAL STRUCTURE OF EPHB1
568, d2pvyB_, 0.8151, 2.48, 0.357, 286, 255, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
569, d3a4pA_, 0.8150, 2.37, 0.325, 285, 255, HUMAN C-MET KINASE DOMAIN COMPLEXED WITH 6-BENZYLOXYQUINOLINE INHIBITOR
570, d3zfxD_, 0.8148, 2.36, 0.294, 265, 255, CRYSTAL STRUCTURE OF EPHB1
571, d3l8vA_, 0.8148, 2.51, 0.329, 293, 258, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A BIARYLAMINE BASED INHIBITOR
572, d3kcfC_, 0.8148, 2.97, 0.238, 330, 269, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
573, d2b4sD_, 0.8148, 2.81, 0.318, 294, 261, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN PTP1B AND THE INSULIN RECEPTOR TYROSINE KINASE
574, d4cnhB_, 0.8147, 2.32, 0.306, 293, 255, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 3-((1R)-1-(5-FLUORO-2- METHOXYPHENYL)ETHOXY)-5-(1-METHYL-1H-123-TRIAZOL-5-YL) PYRIDIN-2-AMINE
575, d3d7uC1, 0.8146, 2.06, 0.375, 255, 251, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
576, d3d7uA1, 0.8146, 2.06, 0.375, 255, 251, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
577, d2ivsB1, 0.8146, 2.61, 0.373, 272, 255, CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED RET TYROSINE KINASE DOMAIN
578, d3gt8A_, 0.8145, 2.08, 0.353, 300, 252, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
579, d5p9gA_, 0.8143, 2.38, 0.307, 265, 254, STRUCTURE OF BTK WITH RN486
580, d5gtyF_, 0.8143, 2.08, 0.363, 297, 251, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
581, d5hcxA_, 0.8142, 2.15, 0.359, 298, 251, EGFR KINASE DOMAIN MUTANT TMLR WITH AZABENZIMIDAZOLE COMPOUND 7
582, d3efjA_, 0.8142, 2.10, 0.332, 276, 250, STRUCTURE OF C-MET WITH PYRIMIDONE INHIBITOR 7
583, d3gt8B_, 0.8141, 2.09, 0.349, 292, 252, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
584, d4yhfA_, 0.8140, 2.41, 0.314, 268, 255, BRUTON S TYROSINE KINASE IN COMPLEX WITH A T-BUTYL CYANOACRYLAMIDE INHIBITOR
585, d4zseD_, 0.8139, 2.26, 0.352, 297, 253, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
586, d3lzbD_, 0.8138, 1.79, 0.355, 261, 248, EGFR KINASE DOMAIN COMPLEXED WITH AN IMIDAZO[21-B]THIAZOLE INHIBITOR
587, d5hicA_, 0.8137, 2.24, 0.357, 302, 252, EGFR KINASE DOMAIN MUTANT TMLR WITH A IMIDAZOPYRIDINYL- AMINOPYRIMIDINE INHIBITOR
588, d1rqqA_, 0.8137, 2.87, 0.326, 294, 261, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH THE SH2 DOMAIN OF APS
589, d5eycA_, 0.8133, 2.47, 0.345, 288, 255, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH NAPHTHYRIDINONE INHIBITOR 5
590, d4yjsA_, 0.8133, 2.48, 0.365, 257, 255, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000226
591, d4zlzA_, 0.8132, 2.44, 0.325, 270, 255, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE IN COMPLEX WITH A SUBSTITUTED CINNOLINE
592, d4z3vA_, 0.8132, 2.44, 0.325, 271, 255, FRAGMENT-BASED DISCOVERY OF A SMALL MOLECULE REVERSIBLE INHIBITOR OF BRUTON S TYROSINE KINASE
593, d4xg8C_, 0.8131, 2.30, 0.364, 254, 253, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
594, d2ituA_, 0.8131, 2.45, 0.348, 304, 256, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH AFN941
595, d5p9fA_, 0.8130, 2.25, 0.316, 266, 253, BTK IN COMPLEX WITH GDC-0834
596, d1rqqB_, 0.8130, 2.83, 0.326, 294, 261, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH THE SH2 DOMAIN OF APS
597, d5vloB_, 0.8129, 2.58, 0.211, 293, 261, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
598, d3gt8C_, 0.8129, 2.39, 0.350, 296, 254, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
599, d3c0gB_, 0.8129, 2.45, 0.225, 320, 258, CASK CAM-KINASE DOMAIN- 3 -AMP COMPLEX P1 FORM
600, d3w33A_, 0.8127, 2.08, 0.348, 297, 250, EGFR KINASE DOMAIN COMPLEXED WITH COMPOUND 19B
601, d5gmpA_, 0.8126, 2.53, 0.357, 305, 255, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH XTF-262
602, d3ppzA_, 0.8126, 2.35, 0.298, 264, 255, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
603, d3efjB_, 0.8126, 2.10, 0.333, 275, 249, STRUCTURE OF C-MET WITH PYRIMIDONE INHIBITOR 7
604, d3c0hA_, 0.8126, 2.45, 0.225, 300, 258, CASK CAM-KINASE DOMAIN- AMPPNP COMPLEX P1 FORM
605, d6aywB_, 0.8124, 2.59, 0.211, 293, 261, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
606, d4xyfA_, 0.8124, 2.59, 0.344, 290, 256, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH (S)-5-(8-FLUORO-3-(1-(3-(2- METHOXYETHOXY)QUINOLIN-6-YL)ETHYL)-[124]TRIAZOLO[43-A]PYRIDIN-6- YL)-3-METHYLISOXAZOLE
607, d4u5jB_, 0.8124, 2.36, 0.339, 267, 254, C-SRC IN COMPLEX WITH RUXOLITINIB
608, d4i22A_, 0.8124, 2.04, 0.357, 297, 249, STRUCTURE OF THE MONOMERIC (V948R)GEFITINIB/ERLOTINIB RESISTANT DOUBLE MUTANT (L858R+T790M) EGFR KINASE DOMAIN CO-CRYSTALLIZED WITH GEFITINIB
609, d3emgA_, 0.8124, 2.29, 0.372, 255, 253, DISCOVERY AND SAR OF NOVEL 4-THIAZOLYL-2- PHENYLAMINOPYRIMIDINES AS POTENT INHIBITORS OF SPLEEN TYROSINE KINASE (SYK)
610, d5hczA_, 0.8122, 2.19, 0.359, 300, 251, EGFR KINASE DOMAIN MUTANT TMLR WITH 3-AZETIDINYL AZAINDAZOLE COMPOUND 21
611, d1iasB_, 0.8122, 2.89, 0.240, 324, 267, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
612, d4mkcA_, 0.8121, 2.72, 0.292, 303, 260, CRYSTAL STRUCTURE OF ANAPLASTIC LYMPHOMA KINASE COMPLEXED WITH LDK378
613, d3c0hB_, 0.8120, 2.58, 0.232, 300, 259, CASK CAM-KINASE DOMAIN- AMPPNP COMPLEX P1 FORM
614, d5p9kA_, 0.8119, 2.45, 0.318, 271, 255, CRYSTAL STRUCTURE OF BTK WITH CNX 774
615, d3kexA_, 0.8119, 2.40, 0.354, 292, 257, CRYSTAL STRUCTURE OF THE CATALYTICALLY INACTIVE KINASE DOMAIN OF THE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3)
616, d3efkA_, 0.8119, 2.13, 0.340, 276, 250, STRUCTURE OF C-MET WITH PYRIMIDONE INHIBITOR 50
617, d5p9iA_, 0.8118, 2.32, 0.315, 271, 254, BTK1 SOAKED WITH IBRUTINIB-REV
618, d5iuiA_, 0.8118, 2.67, 0.300, 303, 260, CRYSTAL STRUCTURE OF ANAPLASTIC LYPHOMA KINASE (ALK) IN COMPLEX WITH 4
619, d3kexB_, 0.8118, 2.40, 0.354, 283, 257, CRYSTAL STRUCTURE OF THE CATALYTICALLY INACTIVE KINASE DOMAIN OF THE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3)
620, d3zfxI_, 0.8117, 2.33, 0.292, 263, 253, CRYSTAL STRUCTURE OF EPHB1
621, d3l9pA_, 0.8117, 2.81, 0.302, 303, 262, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
622, d3bu6A_, 0.8117, 2.82, 0.314, 294, 261, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH IRS2 KRLB PHOSPHOPEPTIDE
623, d3bu3A_, 0.8116, 2.74, 0.315, 294, 260, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH IRS2 KRLB PEPTIDE
624, d1yi6A_, 0.8116, 2.80, 0.342, 274, 260, C-TERM TAIL SEGMENT OF HUMAN TYROSINE KINASE (258-533)
625, d4deiA_, 0.8115, 2.47, 0.343, 287, 254, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH TRIAZOLOPYRIDINONE INHIBITOR 24
626, d4ot6A_, 0.8114, 2.30, 0.308, 265, 253, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 4- METHANESULFONYL-N-(3-{8-[4-(MORPHOLINE-4-CARBONYL)-PHENYLAMINO]- IMIDAZO[12-A]PYRAZIN-6-YL}-PHENYL)-BENZAMIDE
627, d3kcfB_, 0.8114, 2.92, 0.236, 324, 267, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
628, d1yi6B_, 0.8114, 2.63, 0.340, 274, 259, C-TERM TAIL SEGMENT OF HUMAN TYROSINE KINASE (258-533)
629, d5ugxB_, 0.8113, 2.67, 0.352, 282, 256, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A E565A/D650V DOUBLE GAIN-OF-FUNCTION MUTATION
630, d4zlyA_, 0.8112, 2.45, 0.318, 270, 255, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE BOUND TO A CINNOLINE FRAGMENT
631, d4y95B1, 0.8112, 2.22, 0.313, 265, 252, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
632, d4knbA_, 0.8112, 2.35, 0.333, 273, 252, C-MET IN COMPLEX WITH OSI LIGAND
633, d5canA_, 0.8111, 2.27, 0.357, 301, 252, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 27
634, d4y95C1, 0.8111, 2.23, 0.313, 265, 252, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
635, d3dqxB_, 0.8111, 2.50, 0.337, 268, 255, CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH ATPGS
636, d3c0gA_, 0.8111, 2.41, 0.222, 309, 257, CASK CAM-KINASE DOMAIN- 3 -AMP COMPLEX P1 FORM
637, d5cnoB_, 0.8110, 2.07, 0.356, 302, 250, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN MUTANT V924R
638, d4hcuA_, 0.8110, 2.33, 0.312, 263, 253, CRYSTAL STRUCTURE OF ITK IN COMPLEXT WITH COMPOUND 40
639, d3mfsA_, 0.8110, 2.46, 0.236, 303, 258, CASK-4M CAM KINASE DOMAIN AMPPNP
640, d4u5jA_, 0.8109, 2.40, 0.339, 267, 254, C-SRC IN COMPLEX WITH RUXOLITINIB
641, d1qcfA3, 0.8109, 2.50, 0.341, 281, 255, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH A SRC FAMILY- SELECTIVE TYROSINE KINASE INHIBITOR
642, d5u6bA_, 0.8107, 2.21, 0.302, 270, 252, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
643, d4rwjA1, 0.8107, 2.61, 0.375, 306, 259, CRYSTAL STRUCTURE OF FGFR1 (C488A C584S) IN COMPLEX WITH AZD4547 (N- {3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE)
644, d3mfuA_, 0.8107, 2.72, 0.238, 302, 260, CASK-4M CAM KINASE DOMAIN AMPPNP-MN2+
645, d3c4fB_, 0.8106, 2.65, 0.369, 290, 260, FGFR TYROSINE KINASE DOMAIN IN COMPLEX WITH 3-(3- METHOXYBENZYL)-7-AZAINDOLE
646, d3c4fA_, 0.8106, 2.66, 0.369, 290, 260, FGFR TYROSINE KINASE DOMAIN IN COMPLEX WITH 3-(3- METHOXYBENZYL)-7-AZAINDOLE
647, d6eixA_, 0.8105, 3.36, 0.243, 312, 272, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF THE Q207E MUTANT OF ACVR1 (ALK2) IN COMPLEX WITH A 2-AMINOPYRIDINE INHIBITOR K02288
648, d5fm3A_, 0.8105, 2.95, 0.392, 276, 260, CRYSTAL STRUCTURE OF HYPER-PHOSPHORYLATED RET KINASE DOMAIN WITH (PROXIMAL) JUXTAMEMBRANE SEGMENT
649, d3lzbC_, 0.8104, 1.81, 0.356, 259, 247, EGFR KINASE DOMAIN COMPLEXED WITH AN IMIDAZO[21-B]THIAZOLE INHIBITOR
650, d5cnoA_, 0.8103, 2.18, 0.347, 300, 251, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN MUTANT V924R
651, d4xmoA_, 0.8103, 2.57, 0.345, 289, 255, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH (R)-5-(8-FLUORO-3-(1- FLUORO-1-(3-METHOXYQUINOLIN-6-YL)ETHYL)-[124]TRIAZOLO[43- A]PYRIDIN-6-YL)-3-METHYLISOXAZOLE
652, d5gnkA_, 0.8102, 2.48, 0.346, 277, 254, CRYSTAL STRUCTURE OF EGFR 696-988 T790M IN COMPLEX WITH LXX-6-34
653, d5p9jA_, 0.8099, 2.43, 0.323, 263, 254, BTK1 COCRYSTALLIZED WITH IBRUTINIB
654, d3bbtB_, 0.8099, 2.23, 0.359, 274, 251, CRYSTAL STRUCTURE OF THE ERBB4 KINASE IN COMPLEX WITH LAPATINIB
655, d5p9hA_, 0.8098, 2.38, 0.308, 264, 253, BTK1 COCRYSTALLIZED WITH RN983
656, d3c0iA_, 0.8098, 2.78, 0.231, 298, 260, CASK CAM-KINASE DOMAIN- 3 -AMP COMPLEX P212121 FORM
657, d5e8uA1, 0.8097, 2.89, 0.233, 303, 266, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204DI211VY249FS280T Y282FS287NA350CL352F)
658, d4gg7A_, 0.8096, 2.63, 0.331, 278, 257, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
659, d6babA_, 0.8094, 2.39, 0.218, 290, 257, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
660, d4yjqA_, 0.8093, 2.83, 0.360, 264, 258, SYK KINASE DOMAIN IN COMPLEX WITH INHIBITOR GTC000224
661, d3bu5A_, 0.8093, 2.79, 0.320, 291, 259, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH IRS2 KRLB PEPTIDE AND ATP
662, d4at3A1, 0.8092, 2.45, 0.390, 286, 254, CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH CPD5N
663, d3zfxE_, 0.8092, 2.28, 0.294, 262, 252, CRYSTAL STRUCTURE OF EPHB1
664, d5j87B_, 0.8091, 2.40, 0.315, 274, 254, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
665, d5e90A1, 0.8090, 3.02, 0.224, 300, 268, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204DI211VY249F S280T Y282FS287NA350CL352F) IN COMPLEX WITH 3-AMINO-6- [4-(2- HYDROXYETHYL)PHENYL]-N-[4-(MORPHOLIN-4-YL)PYRIDIN-3-YL]PYRAZINE-2- CARBOXAMIDE
666, d4z55A_, 0.8090, 2.71, 0.290, 294, 259, ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN COMPLEXED WITH PYRAZOLOPYRIMIDINE DERIVATIVE OF LDK378
667, d4j95D_, 0.8090, 2.66, 0.367, 271, 256, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
668, d5u6bC_, 0.8089, 2.23, 0.302, 270, 252, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
669, d3l8pA_, 0.8089, 2.03, 0.337, 292, 249, CRYSTAL STRUCTURE OF CYTOPLASMIC KINASE DOMAIN OF TIE2 COMPLEXED WITH INHIBITOR CEP11207
670, d2wotA_, 0.8089, 3.04, 0.231, 303, 268, ALK5 IN COMPLEX WITH 4-((56-DIMETHYL-2-(2-PYRIDYL)-3- PYRIDYL)OXY)-N-(345-TRIMETHOXYPHENYL)PYRIDIN-2-AMINE
671, d1fvrB_, 0.8089, 2.54, 0.329, 300, 258, TIE2 KINASE DOMAIN
672, d4y95A1, 0.8087, 2.28, 0.313, 265, 252, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
673, d4xlvA_, 0.8087, 2.89, 0.330, 307, 261, CRYSTAL STRUCTURE OF THE ACTIVATED INSULIN RECEPTOR TYROSINE KINASE DIMER
674, d4i24A_, 0.8087, 2.07, 0.367, 295, 248, STRUCTURE OF T790M EGFR KINASE DOMAIN CO-CRYSTALLIZED WITH DACOMITINIB
675, d5t3qA1, 0.8086, 1.99, 0.327, 277, 248, CRYSTAL STRUCTURE OF THE C-MET KINASE DOMAIN IN COMPLEX WITH A PYRAZOLONE INHIBITOR
676, d4y95D_, 0.8086, 2.28, 0.313, 265, 252, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
677, d2zvaA1, 0.8086, 2.70, 0.350, 260, 257, LYN TYROSINE KINASE DOMAIN-DASATINIB COMPLEX
678, d3sxrB1, 0.8085, 2.25, 0.320, 255, 253, CRYSTAL STRUCTURE OF BMX NON-RECEPTOR TYROSINE KINASE COMPLEX WITH DASATINIB
679, d1py5A_, 0.8085, 3.16, 0.230, 301, 270, CRYSTAL STRUCTURE OF TGF-BETA RECEPTOR I KINASE WITH INHIBITOR
680, d5u9dA_, 0.8084, 2.50, 0.318, 271, 255, DISCOVERY OF A POTENT BTK INHIBITOR WITH A NOVEL BINDING MODE USING PARALLEL SELECTIONS WITH A DNA-ENCODED CHEMICAL LIBRARY
681, d5gtyC_, 0.8084, 2.04, 0.365, 295, 249, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
682, d5calA_, 0.8084, 2.25, 0.359, 300, 251, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 24
683, d3vrzB3, 0.8084, 2.12, 0.339, 269, 248, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-BENZYLUREA
684, d5fbnC_, 0.8083, 2.44, 0.316, 256, 253, BTK KINASE DOMAIN WITH INHIBITOR 1
685, d4yjvA_, 0.8083, 2.77, 0.358, 263, 257, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000250
686, d4xi2A2, 0.8083, 2.38, 0.315, 274, 254, CRYSTAL STRUCTURE OF AN AUTO-INHIBITED FORM OF BRUTON S TRYROSINE KINASE
687, d4bcgA_, 0.8083, 2.80, 0.201, 312, 264, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
688, d4p2wB_, 0.8082, 2.20, 0.319, 253, 251,  
689, d4bcjA_, 0.8082, 2.74, 0.202, 309, 263, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
690, d3gt8D_, 0.8082, 2.31, 0.349, 295, 252, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
691, d5e8zA1, 0.8081, 3.03, 0.228, 300, 268, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH 3- AMINO-6-[4-(2-HYDROXYETHYL)PHENYL]-N-[4-(MORPHOLIN-4-YL)PYRIDIN-3- YL]PYRAZINE-2-CARBOXAMIDE
692, d5casA_, 0.8081, 2.32, 0.359, 299, 251, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 41A
693, d4hcvA_, 0.8081, 2.40, 0.312, 263, 253, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 53
694, d6babD_, 0.8080, 2.52, 0.216, 291, 259, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
695, d5em7A_, 0.8079, 2.29, 0.355, 300, 251, EGFR KINASE DOMAIN MUTANT TMLR WITH PYRIDONE COMPOUND 13: 4-[(2- METHOXYPHENYL)AMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-2- OXIDANYLIDENE-1~{H}-PYRIDINE-3-CARBOXAMIDE
696, d5em6A_, 0.8079, 2.28, 0.359, 301, 251, EGFR KINASE DOMAIN MUTANT TMLR WITH PYRIDONE COMPOUND 19: 4-[(2- AZANYLPYRIMIDIN-4-YL)AMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]- 2-OXIDANYLIDENE-1~{H}-PYRIDINE-3-CARBOXAMIDE
697, d3vs3B3, 0.8079, 2.38, 0.347, 271, 251, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[TRANS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)- 7H-PYRROLO[23-D]PYRIMIDIN-4-AMINE
698, d5e8tA1, 0.8078, 2.98, 0.228, 300, 268, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D)
699, d4otrA_, 0.8078, 2.25, 0.315, 263, 251, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6-CYCLOPROPYL-2- [3-[5-[[5-(4-ETHYLPIPERAZIN-1-YL)-2-PYRIDYL]AMINO]-1-METHYL-6-OXO-3- PYRIDYL]-2-(HYDROXYMETHYL)PHENYL]-8-FLUORO-ISOQUINOLIN-1-ONE
700, d5caqA_, 0.8077, 2.38, 0.357, 301, 252, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 33
701, d4wa9B1, 0.8077, 2.08, 0.331, 263, 251, THE CRYSTAL STRUCTURE OF HUMAN ABL1 WILD TYPE KINASE DOMAIN IN COMPLEX WITH AXITINIB
702, d4rfyA_, 0.8077, 2.25, 0.315, 263, 251, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6- (DIMETHYLAMINO)-2-[2-(HYDROXYMETHYL)-3-[1-METHYL-5-[[5-(MORPHOLINE-4- CARBONYL)-2-PYRIDYL]AMINO]-6-OXO-3-PYRIDYL]PHENYL]-34- DIHYDROISOQUINOLIN-1-ONE
703, d2h8hA3, 0.8077, 2.35, 0.328, 280, 253, SRC KINASE IN COMPLEX WITH A QUINAZOLINE INHIBITOR
704, d5fbnD_, 0.8075, 2.39, 0.313, 255, 252, BTK KINASE DOMAIN WITH INHIBITOR 1
705, d5eydA_, 0.8075, 2.54, 0.344, 289, 253, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH AMG 337
706, d4or5A_, 0.8074, 2.89, 0.201, 319, 264, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB AND AFF4
707, d5j87A_, 0.8073, 2.33, 0.317, 263, 252, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
708, d6aywA_, 0.8071, 2.72, 0.218, 293, 262, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
709, d5p9mA_, 0.8071, 2.46, 0.312, 271, 253, BTK1 BINDS COVALENTLY TO HY-15771 ONO-4059
710, d3mfrA_, 0.8071, 2.69, 0.228, 302, 259, CASK-4M CAM KINASE DOMAIN NATIVE
711, d1fgiA_, 0.8071, 2.63, 0.375, 283, 259, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU5402 INHIBITOR
712, d4cd0A_, 0.8070, 2.75, 0.306, 295, 258, STRUCTURE OF L1196M MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 2-(5-(6-AMINO-5-((R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)PYRIDIN-3-YL)-4-METHYLTHIAZOL-2-YL)PROPANE-12-DIOL
713, d3my1A_, 0.8070, 2.83, 0.201, 314, 264, STRUCTURE OF CDK9/CYCLINT1 IN COMPLEX WITH DRB
714, d5bpyA1, 0.8069, 2.29, 0.319, 262, 251, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-824171 AKA 6-[(3R)-3-(4-TERT-BU TYLBENZAMIDO) PIPERIDIN-1-YL]-2-{[4-(MORPHOLINE-4-CARBONYL) PHENYL]AMINO}PYRIDINE- 3-CARBOXAMIDE
715, d4x2nA1, 0.8069, 2.99, 0.224, 302, 268, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
716, d3genA_, 0.8069, 2.34, 0.321, 264, 252, THE 1.6 A CRYSTAL STRUCTURE OF HUMAN BRUTON S TYROSINE KINASE BOUND TO A PYRROLOPYRIMIDINE-CONTAINING COMPOUND
717, d5e8sA1, 0.8068, 2.96, 0.221, 299, 267, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (WT)
718, d3mdyC_, 0.8068, 2.88, 0.243, 320, 263, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B (BMPR1B) IN COMPLEX WITH FKBP12 AND LDN- 193189
719, d5capA_, 0.8067, 2.33, 0.361, 303, 252, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 30
720, d4uwcA_, 0.8067, 2.60, 0.380, 300, 258, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P3
721, d4otqA_, 0.8067, 2.23, 0.323, 263, 251, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 1-[5-[3-(7-TERT- BUTYL-4-OXO-QUINAZOLIN-3-YL)-2-METHYL-PHENYL]-1-METHYL-2-OXO-3- PYRIDYL]-3-METHYL-UREA
722, d4dehA_, 0.8066, 2.43, 0.345, 286, 252, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH TRIAZOLOPYRIDINONE INHIBITOR 3
723, d2ckeA_, 0.8066, 2.91, 0.221, 301, 263, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
724, d4rwkA1, 0.8065, 2.77, 0.378, 307, 259, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) IN COMPLEX WITH N-{3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H- PYRAZOL-5-YL}-4-[(3R5S)-35-DIMETHYLPIPERAZIN-1-YL]BENZAMIDE (AZD4547)
725, d2srcA3, 0.8065, 2.37, 0.328, 284, 253, CRYSTAL STRUCTURE OF HUMAN TYROSINE-PROTEIN KINASE C-SRC IN COMPLEX WITH AMP-PNP
726, d5c8mA_, 0.8064, 2.37, 0.357, 302, 252, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 17
727, d3vs4A3, 0.8064, 2.34, 0.348, 270, 250, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 5-(4-PHENOXYPHENYL)-7-(TETRAHYDRO-2H-PYRAN-4-YL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
728, d3mdyA_, 0.8064, 2.77, 0.249, 320, 261, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B (BMPR1B) IN COMPLEX WITH FKBP12 AND LDN- 193189
729, d2yabB_, 0.8064, 2.91, 0.221, 299, 262, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH AMP
730, d5usqA_, 0.8062, 3.01, 0.221, 299, 267, ALK-5 KINASE INHIBITOR COMPLEX
731, d3f66A_, 0.8062, 2.46, 0.343, 288, 254, HUMAN C-MET KINASE IN COMPLEX WITH QUINOXALINE INHIBITOR
732, d3dqxA_, 0.8062, 2.52, 0.339, 267, 254, CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH ATPGS
733, d4mneB_, 0.8061, 2.68, 0.257, 270, 261, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
734, d4bciA_, 0.8061, 2.65, 0.203, 308, 261, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
735, d3lmgB_, 0.8061, 2.53, 0.355, 268, 256, CRYSTAL STRUCTURE OF THE ERBB3 KINASE DOMAIN IN COMPLEX WITH AMP-PNP
736, d2yaaB_, 0.8061, 2.90, 0.221, 299, 262, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH ATP
737, d2hz0A_, 0.8061, 2.63, 0.323, 265, 257, ABL KINASE DOMAIN IN COMPLEX WITH NVP-AEG082
738, d5e8wA1, 0.8060, 3.06, 0.228, 302, 268, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH STAUROSPORINE
739, d4k11A3, 0.8060, 2.36, 0.328, 282, 253, THE STRUCTURE OF 1NA IN COMPLEX WITH SRC T338G
740, d2c0tB3, 0.8060, 2.14, 0.340, 268, 247, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-641359
741, d5j87D_, 0.8059, 2.38, 0.310, 263, 252, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
742, d5h0eA3, 0.8059, 2.49, 0.333, 281, 252, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-4-METHYLPENTANAMIDE
743, d5h0bA3, 0.8059, 2.38, 0.335, 281, 251, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-4-METHYLPENTANOIC ACID
744, d4x2kA1, 0.8059, 3.01, 0.224, 302, 268, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
745, d4x2jA1, 0.8059, 3.01, 0.224, 302, 268, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
746, d4otwA_, 0.8059, 2.50, 0.348, 272, 256, HER3 PSEUDOKINASE DOMAIN BOUND TO BOSUTINIB
747, d3vs6B3, 0.8059, 2.26, 0.349, 269, 249, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR TERT-BUTYL {4-[4-AMINO-1-(PROPAN-2-YL)-1H-PYRAZOLO[34- D]PYRIMIDIN-3-YL]-2-METHOXYPHENYL}CARBAMATE
748, d4zsaA_, 0.8058, 2.73, 0.369, 289, 260, CRYSTAL STRUCTURE OF FGFR1 KINASE DOMAIN IN COMPLEX WITH 7N
749, d3vs6A3, 0.8058, 2.27, 0.349, 269, 249, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR TERT-BUTYL {4-[4-AMINO-1-(PROPAN-2-YL)-1H-PYRAZOLO[34- D]PYRIMIDIN-3-YL]-2-METHOXYPHENYL}CARBAMATE
750, d2c0tA3, 0.8058, 2.14, 0.340, 268, 247, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-641359
751, d5c8nA_, 0.8057, 2.33, 0.359, 300, 251, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 23
752, d4rj7A_, 0.8057, 2.20, 0.357, 295, 249, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 1
753, d3vrzA3, 0.8057, 2.23, 0.351, 268, 248, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-BENZYLUREA
754, d5mjaB_, 0.8056, 2.91, 0.285, 274, 263, KINASE DOMAIN OF HUMAN EPHB1 BOUND TO A QUINAZOLINE-BASED INHIBITOR
755, d4r5sA_, 0.8056, 2.58, 0.352, 299, 256, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH FIIN-3
756, d3vs1A3, 0.8056, 2.25, 0.351, 268, 248, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-PHENYLUREA
757, d2ckeB_, 0.8056, 2.88, 0.221, 300, 262, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
758, d4or5F_, 0.8055, 2.91, 0.197, 324, 264, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB AND AFF4
759, d5h0hA3, 0.8054, 2.37, 0.335, 281, 251, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-NN4-TRIMETHYLPENTANAMIDE
760, d4m0yA_, 0.8054, 2.52, 0.311, 263, 254, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 1 [4- (CARBAMOYLAMINO)-1-(NAPHTHALEN-1-YL)-1H-PYRAZOLE-3-CARBOXAMIDE]
761, d2ckeC_, 0.8054, 2.88, 0.225, 300, 262, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
762, d4x2gA1, 0.8053, 3.11, 0.234, 302, 269, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
763, d4rx5A1, 0.8053, 2.38, 0.306, 264, 252, BRUTON S TYROSINE KINASE (BTK) WITH PYRIDAZINONE COMPOUND 23
764, d3vryA3, 0.8053, 2.25, 0.349, 269, 249, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23-D]PYRIMIDIN-7-YL- CYCLOPENTANE
765, d2wotA1, 0.8053, 3.03, 0.220, 301, 268, ALK5 IN COMPLEX WITH 4-((56-DIMETHYL-2-(2-PYRIDYL)-3- PYRIDYL)OXY)-N-(345-TRIMETHOXYPHENYL)PYRIDIN-2-AMINE
766, d5h09A3, 0.8052, 2.37, 0.335, 281, 251, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-ETHYL2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-4-METHYLPENTANOATE
767, d3lmgA_, 0.8051, 2.50, 0.357, 268, 255, CRYSTAL STRUCTURE OF THE ERBB3 KINASE DOMAIN IN COMPLEX WITH AMP-PNP
768, d5j9zA_, 0.8050, 2.32, 0.359, 291, 251, EGFR-T790M IN COMPLEX WITH PYRAZOLOPYRIMIDINE INHIBITOR 1A
769, d4b4lA_, 0.8050, 2.80, 0.215, 299, 261, CRYSTAL STRUCTURE OF AN ARD DAP-KINASE 1 MUTANT
770, d2xuuA_, 0.8050, 2.79, 0.211, 301, 261, CRYSTAL STRUCTURE OF A DAP-KINASE 1 MUTANT
771, d2c0iA3, 0.8050, 2.15, 0.340, 268, 247, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-420983
772, d1gagA_, 0.8050, 2.98, 0.330, 300, 261, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH A BISUBSTRATE INHIBITOR
773, d1fvrA_, 0.8050, 2.54, 0.331, 299, 257, TIE2 KINASE DOMAIN
774, d4degA_, 0.8049, 2.38, 0.351, 286, 251, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH TRIAZOLOPYRIDAZINE INHIBITOR 2
775, d5h0gA3, 0.8048, 2.41, 0.335, 281, 251, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-N4-DIMETHYLPENTANAMIDE
776, d5cauA_, 0.8048, 2.32, 0.360, 297, 250, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 41B
777, d4x2fA1, 0.8048, 3.11, 0.234, 302, 269, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
778, d4rj8A_, 0.8048, 2.30, 0.360, 298, 250, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 8
779, d4rg0A_, 0.8048, 2.25, 0.323, 263, 251, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 2-[8-FLUORO-2- [2-(HYDROXYMETHYL)-3-[1-METHYL-5-[[5-(4-METHYLPIPERAZIN-1-YL)-2- PYRIDYL]AMINO]-6-OXO-3-PYRIDYL]PHENYL]-1-OXO-34-DIHYDROISOQUINOLIN- 6-YL]-2-METHYL-PROPANENITRILE
780, d2xvdA_, 0.8048, 2.52, 0.275, 270, 255, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
781, d2hckA3, 0.8048, 2.28, 0.340, 271, 250, SRC FAMILY KINASE HCK-QUERCETIN COMPLEX
782, d4yjrA_, 0.8047, 2.87, 0.358, 263, 257, SYK KINASE DOMAIN IN COMPLEX WITH INHIBITOR GTC000225
783, d4c02A_, 0.8047, 3.17, 0.251, 313, 267, CRYSTAL STRUCTURE OF HUMAN ACVR1 (ALK2) IN COMPLEX WITH FKBP12.6 AND DORSOMORPHIN
784, d3vs0A3, 0.8047, 2.25, 0.351, 268, 248, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR N-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL) PHENYL]BENZAMIDE
785, d2biyA_, 0.8047, 3.01, 0.228, 287, 263, STRUCTURE OF PDK1-S241A MUTANT KINASE DOMAIN
786, d3mftA_, 0.8046, 2.58, 0.221, 302, 258, CASK-4M CAM KINASE DOMAIN MN2+
787, d2yaaA_, 0.8046, 2.91, 0.221, 300, 262, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH ATP
788, d1kswA3, 0.8046, 2.39, 0.328, 284, 253, STRUCTURE OF HUMAN C-SRC TYROSINE KINASE (THR338GLY MUTANT) IN COMPLEX WITH N6-BENZYL ADP
789, d2a2aA_, 0.8045, 2.94, 0.224, 304, 263, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
790, d5friA1, 0.8044, 3.02, 0.221, 299, 267, ALK5 IN COMPLEX WITHA AN N-(4-ANILINO-2-PYRIDYL)ACETAMIDE INHIBITOR.
791, d4tt7A_, 0.8044, 2.69, 0.297, 291, 256, CRYSTAL STRUCTURE OF HUMAN ALK WITH A COVALENT MODIFICATION
792, d3zosB1, 0.8044, 2.82, 0.357, 301, 258, STRUCTURE OF THE DDR1 KINASE DOMAIN IN COMPLEX WITH PONATINIB
793, d4rj4A_, 0.8043, 2.37, 0.355, 299, 251, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 6
794, d3vs0B3, 0.8043, 2.23, 0.351, 268, 248, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR N-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL) PHENYL]BENZAMIDE
795, d3pxkB_, 0.8043, 2.24, 0.361, 258, 249, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH PYRROLO[23- D]THIAZOLE
796, d3ky2A1, 0.8043, 2.70, 0.360, 305, 258, CRYSTAL STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN
797, d2c0iB3, 0.8043, 2.26, 0.351, 268, 248, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-420983
798, d5c8kA_, 0.8042, 2.37, 0.359, 300, 251, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 1
799, d4x0mA1, 0.8042, 3.12, 0.234, 302, 269, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
800, d4rfmA1, 0.8042, 1.96, 0.313, 248, 246, ITK KINASE DOMAIN IN COMPLEX WITH COMPOUND 1 N-{1-[(11-DIOXO-1-THIAN- 2-YL)(PHENYL)METHYL]-1H- PYRAZOL-4-YL}-55-DIFLUORO-5A-METHYL-1H4H 4AH5H5AH6H-CYCLOPROPA[F]INDAZOLE-3-CARBOXAMIDE
801, d4ot5A_, 0.8042, 2.30, 0.315, 263, 251, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 4-TERT-BUTYL-N- (3-{8-[4-(4-METHYL-PIPERAZINE-1-CARBONYL)-PHENYLAMINO]-IMIDAZO[12- A]PYRAZIN-6-YL}-PHENYL)-BENZAMIDE
802, d4bchA_, 0.8042, 2.78, 0.202, 308, 262, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
803, d3vs4B3, 0.8042, 2.27, 0.349, 269, 249, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 5-(4-PHENOXYPHENYL)-7-(TETRAHYDRO-2H-PYRAN-4-YL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
804, d2c0oB3, 0.8042, 2.24, 0.351, 268, 248, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-770041
805, d5xp7B_, 0.8041, 2.37, 0.343, 267, 251, C-SRC IN COMPLEX WITH ATP-CHCL
806, d4rwiA_, 0.8041, 2.92, 0.373, 305, 260, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) APO
807, d2wouA_, 0.8040, 3.06, 0.225, 299, 267, ALK5 IN COMPLEX WITH 4-((4-((26-DIMETHYL-3-PYRIDYL)OXY)-2- PYRIDYL)AMINO)BENZENESULFONAMIDE
808, d1rw8A_, 0.8040, 3.19, 0.230, 301, 270, CRYSTAL STRUCTURE OF TGF-BETA RECEPTOR I KINASE WITH ATP SITE INHIBITOR
809, d4m13A_, 0.8039, 2.46, 0.311, 264, 254, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 8 [4- (CARBAMOYLAMINO)-1-(7-PROPOXYNAPHTHALEN-1-YL)-1H-PYRAZOLE-3- CARBOXAMIDE]
810, d4fobA_, 0.8039, 2.79, 0.301, 295, 259, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH ACYLIMINOBENZIMIDAZOLE INHIBITOR 1
811, d3kfaA1, 0.8039, 2.40, 0.340, 283, 253, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
812, d4nwmB_, 0.8038, 2.38, 0.311, 261, 251, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-809959 AKA 4-TERT-BUTYL-N-[2-ME THYL-3-(6-{[4- (MORPHOLINE-4-CARBONYL)PHENYL]AMINO}-9H- PURIN-2-YL)PHENYL]BENZAMIDE
813, d3kfaB1, 0.8038, 2.40, 0.340, 283, 253, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
814, d5ftoA1, 0.8037, 2.75, 0.305, 297, 259, CRYSTAL STRUCTURE OF THE ALK KINASE DOMAIN IN COMPLEX WITH ENTRECTINIB
815, d4rfzA_, 0.8037, 2.32, 0.315, 263, 251, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6- (DIMETHYLAMINO)-8-FLUORO-2-[2-(HYDROXYMETHYL)-3-[1-METHYL-5-[[5- (MORPHOLINE-4-CARBONYL)-2-PYRIDYL]AMINO]-6-OXO-3- PYRIDYL]PHENYL]ISOQUINOLIN-1-ONE
816, d1pkgB_, 0.8037, 2.37, 0.348, 277, 250, STRUCTURE OF A C-KIT KINASE PRODUCT COMPLEX
817, d1ir3A_, 0.8037, 2.97, 0.330, 300, 261, PHOSPHORYLATED INSULIN RECEPTOR TYROSINE KINASE IN COMPLEX WITH PEPTIDE SUBSTRATE AND ATP ANALOG
818, d4imyA_, 0.8036, 2.95, 0.205, 314, 264, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
819, d3lvpC_, 0.8036, 2.80, 0.318, 293, 261, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
820, d2c0oA3, 0.8036, 2.17, 0.340, 268, 247, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-770041
821, d4gu6A_, 0.8034, 2.79, 0.354, 271, 257, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH N-{3-[(5-CYANO- 2-PHENYL-1H-PYRROLO[23-B]PYRIDIN-4-YLAMINO)- METHYL]-PYRIDIN-2-YL}- N-METHYL-METHANESULFONAMIDE
822, d3vs1B3, 0.8034, 2.25, 0.351, 268, 248, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-PHENYLUREA
823, d3vryB3, 0.8034, 2.18, 0.339, 269, 248, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23-D]PYRIMIDIN-7-YL- CYCLOPENTANE
824, d3efkB_, 0.8034, 2.07, 0.341, 272, 246, STRUCTURE OF C-MET WITH PYRIMIDONE INHIBITOR 50
825, d2eb3A_, 0.8034, 2.38, 0.347, 294, 251, CRYSTAL STRUCTURE OF MUTATED EGFR KINASE DOMAIN (L858R) IN COMPLEX WITH AMPPNP
826, d1ad5A3, 0.8034, 2.41, 0.347, 271, 251, SRC FAMILY KINASE HCK-AMP-PNP COMPLEX
827, d4gg5A_, 0.8033, 2.64, 0.340, 274, 253, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
828, d2ckeD_, 0.8033, 2.96, 0.221, 300, 263, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
829, d4rj6A_, 0.8032, 2.33, 0.356, 297, 250, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 4
830, d5vgoA1, 0.8031, 2.41, 0.306, 264, 252, BRUTON S TYROSINE KINASE (BTK) WITH COMPOUND G-744
831, d4m0zA_, 0.8031, 2.48, 0.311, 264, 254, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 5 {4- (CARBAMOYLAMINO)-1-(7-METHOXYNAPHTHALEN-1-YL)-1H-PYRAZOLE-3- CARBOXAMIDE}
832, d4bcfA_, 0.8031, 2.74, 0.203, 307, 261, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
833, d5wr7A_, 0.8030, 2.67, 0.373, 301, 255, CRYSTAL STRUCTURE OF TRK-A COMPLEXED WITH A SELECTIVE INHIBITOR CH7057288
834, d5kupA1, 0.8030, 2.41, 0.306, 264, 252, BRUTON S TYROSINE KINASE (BTK) WITH PYRIDAZINONE COMPOUND 9
835, d4p2wA_, 0.8030, 2.07, 0.319, 250, 248,  
836, d3vs2A3, 0.8030, 2.19, 0.340, 268, 247, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[CIS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)-7H- PYRROLO[23-D]PYRIMIDIN-4-AMINE
837, d5e8xA_, 0.8029, 2.98, 0.229, 304, 266, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204DI211VY249FS280T Y282FS287NA350CL352F) IN COMPLEX WITH STAUROSPORINE
838, d5aabA_, 0.8028, 2.62, 0.294, 293, 255, STRUCTURE OF C1156YL1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
839, d4d55A_, 0.8028, 2.43, 0.360, 260, 253, FOCAL ADHESION KINASE CATALYTIC DOMAIN
840, d2hckB3, 0.8028, 2.31, 0.340, 271, 250, SRC FAMILY KINASE HCK-QUERCETIN COMPLEX
841, d5uhnB_, 0.8027, 2.65, 0.354, 269, 254, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A N549H/E565A DOUBLE GAIN-OF-FUNCTION MUTATION
842, d4u8zA_, 0.8027, 2.88, 0.258, 289, 260, CRYSTAL STRUCTURE OF MST3 WITH A PYRROLOPYRIMIDINE INHIBITOR (PF- 06447475)
843, d3b2wA_, 0.8027, 2.52, 0.352, 261, 253, CRYSTAL STRUCTURE OF PYRIMIDINE AMIDE 11 BOUND TO LCK
844, d2yabA_, 0.8027, 2.90, 0.218, 299, 262, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH AMP
845, d2bdfB_, 0.8027, 2.50, 0.344, 265, 253, SRC KINASE IN COMPLEX WITH INHIBITOR AP23451
846, d3wzeA_, 0.8025, 2.81, 0.344, 298, 256, KDR IN COMPLEX WITH LIGAND SORAFENIB
847, d3g6hA_, 0.8025, 2.46, 0.341, 266, 252, SRC THR338ILE INHIBITED IN THE DFG-ASP-OUT CONFORMATION
848, d3vs2B3, 0.8024, 2.16, 0.336, 268, 247, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[CIS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)-7H- PYRROLO[23-D]PYRIMIDIN-4-AMINE
849, d3js2A_, 0.8024, 2.78, 0.369, 295, 260, CRYSTAL STRUCTURE OF MINIMAL KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH 5-(2-THIENYL) NICOTINIC ACID
850, d2x9fA_, 0.8024, 2.44, 0.277, 265, 253, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
851, d4w8dA_, 0.8023, 2.99, 0.257, 289, 261, CRYSTAL STRUCTURE OF MST3 WITH A PYRROLOPYRIMIDINE INHIBITOR (PF- 06454589).
852, d4m15A_, 0.8023, 2.45, 0.312, 263, 253, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 9 [4- (CARBAMOYLAMINO)-1-[7-(PROPAN-2-YLOXY)NAPHTHALEN-1-YL]-1H-PYRAZOLE-3- CARBOXAMIDE] AND ADP
853, d4m12A_, 0.8023, 2.50, 0.311, 264, 254, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 7 [4- (CARBAMOYLAMINO)-1-(7-ETHOXYNAPHTHALEN-1-YL)-1H-PYRAZOLE-3- CARBOXAMIDE]
854, d2wouA1, 0.8023, 2.95, 0.223, 297, 265, ALK5 IN COMPLEX WITH 4-((4-((26-DIMETHYL-3-PYRIDYL)OXY)-2- PYRIDYL)AMINO)BENZENESULFONAMIDE
855, d5ig1A_, 0.8022, 2.92, 0.262, 300, 263, CRYSTAL STRUCTURE OF S. ROSETTA CAMKII KINASE DOMAIN
856, d2a2aC_, 0.8022, 2.86, 0.214, 303, 262, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
857, d1ad5B3, 0.8022, 2.43, 0.347, 271, 251, SRC FAMILY KINASE HCK-AMP-PNP COMPLEX
858, d5dg5B_, 0.8021, 2.82, 0.335, 297, 257, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH ALTIRATINIB ANALOG DP- 4157
859, d5ng0B_, 0.8020, 2.73, 0.243, 282, 259, STRUCTURE OF RIP2K(L294F) WITH BOUND AMPPCP
860, d5aaaA_, 0.8019, 2.75, 0.304, 294, 257, STRUCTURE OF L1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
861, d3vs3A3, 0.8019, 2.34, 0.349, 269, 249, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[TRANS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)- 7H-PYRROLO[23-D]PYRIMIDIN-4-AMINE
862, d3f6xD_, 0.8019, 2.49, 0.345, 267, 252, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
863, d3bbtD_, 0.8019, 2.08, 0.363, 259, 248, CRYSTAL STRUCTURE OF THE ERBB4 KINASE IN COMPLEX WITH LAPATINIB
864, d2a2aB_, 0.8019, 2.84, 0.211, 303, 261, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
865, d5mjaA_, 0.8018, 2.73, 0.287, 271, 258, KINASE DOMAIN OF HUMAN EPHB1 BOUND TO A QUINAZOLINE-BASED INHIBITOR
866, d4bkjB1, 0.8017, 2.72, 0.352, 296, 256, CRYSTAL STRUCTURE OF THE HUMAN DDR1 KINASE DOMAIN IN COMPLEX WITH IMATINIB
867, d3uo5A_, 0.8017, 2.76, 0.233, 267, 258, AURORA A IN COMPLEX WITH YL1-038-31
868, d3u4wA_, 0.8017, 2.55, 0.339, 275, 254, SRC IN COMPLEX WITH DNA-TEMPLATED MACROCYCLIC INHIBITOR MC4B
869, d5vloA_, 0.8016, 2.59, 0.216, 290, 259, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
870, d3uodA_, 0.8016, 2.79, 0.233, 266, 258, AURORA A IN COMPLEX WITH RPM1693
871, d4uwyA_, 0.8015, 2.59, 0.361, 296, 255, FGFR1 APO STRUCTURE
872, d3up2A_, 0.8015, 2.86, 0.236, 266, 259, AURORA A IN COMPLEX WITH RPM1686
873, d1ql6A_, 0.8015, 2.59, 0.222, 281, 257, THE CATALYTIC MECHANISM OF PHOSPHORYLASE KINASE PROBED BY MUTATIONAL STUDIES
874, d3vs5A3, 0.8014, 2.28, 0.351, 268, 248, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-(1-METHYLPIPERIDIN-4-YL)-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
875, d3vntA_, 0.8014, 2.82, 0.348, 301, 256, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN VEGFR2 WITH A [1 3]THIAZOLO[54-B]PYRIDINE DERIVATIVE
876, d3tn8A_, 0.8014, 2.70, 0.204, 304, 260, CDK9/CYCLIN T IN COMPLEX WITH CAN508
877, d3en4B_, 0.8014, 2.43, 0.343, 266, 251, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP121 A MULTITARGETED KINASE INHIBITOR
878, d4fodA_, 0.8013, 2.71, 0.292, 308, 257, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH ACYLIMINOBENZIMIDAZOLE INHIBITOR 36
879, d4focA_, 0.8013, 2.63, 0.294, 296, 255, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH ACYLIMINOBENZIMIDAZOLE INHIBITOR 2
880, d3vs5B3, 0.8013, 2.26, 0.351, 268, 248, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-(1-METHYLPIPERIDIN-4-YL)-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
881, d4qmoA_, 0.8012, 3.00, 0.257, 288, 261, MST3 IN COMPLEX WITH IMIDAZOLO-OXINDOLE PKR INHIBITOR C16
882, d4deaA_, 0.8012, 2.77, 0.236, 266, 258, AURORA A IN COMPLEX WITH YL1-038-18
883, d4ag8A_, 0.8012, 2.81, 0.348, 296, 256, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH AXITINIB (AG-013736) (N-METHYL-2-(3-((E)-2-PYRIDIN-2-YL-VINYL)-1H- INDAZOL-6- YLSULFANYL)-BENZAMIDE)
884, d3zosA_, 0.8011, 2.87, 0.353, 301, 258, STRUCTURE OF THE DDR1 KINASE DOMAIN IN COMPLEX WITH PONATINIB
885, d3miaA_, 0.8011, 2.94, 0.202, 324, 263, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH ATP-BOUND HUMAN P-TEFB
886, d2a2aD_, 0.8011, 2.88, 0.214, 303, 262, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
887, d4cljA_, 0.8010, 2.80, 0.306, 295, 258, STRUCTURE OF L1196M MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-210 16-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H-84-(METHENO) PYRAZOLO(43-H)(2511)BENZOXADIAZACYCLOTETRADECINE-3- CARBONITRILE).
888, d3mi9A_, 0.8010, 2.94, 0.202, 328, 263, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB
889, d3ik3A1, 0.8010, 2.46, 0.340, 279, 253, AP24534 A PAN-BCR-ABL INHIBITOR FOR CHRONIC MYELOID LEUKEMIA POTENTLY INHIBITS THE T315I MUTANT AND OVERCOMES MUTATION-BASED RESISTANCE
890, d3dkfA1, 0.8010, 2.44, 0.341, 293, 252, STRUCTURE OF MET RECEPTOR TYROSINE KINASE IN COMPLEX WITH INHIBITOR SGX-523
891, d5caoA_, 0.8009, 2.25, 0.357, 300, 249, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 29
892, d5aa9A_, 0.8009, 2.78, 0.304, 295, 257, STRUCTURE OF L1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-210 16-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H-84-(METHENO) PYRAZOLO(43-H)(2511)BENZOXADIAZACYCLOTETRADECINE-3- CARBONITRILE).
893, d4qrcA_, 0.8009, 2.97, 0.369, 297, 260, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 4 IN COMPLEX WITH PONATINIB
894, d4asxB1, 0.8009, 3.04, 0.226, 296, 265, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DIHYDRO-BAUERINE C
895, d2qu5A_, 0.8009, 2.81, 0.329, 292, 255, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZIMIDAZOLE INHIBITOR
896, d4qmpA_, 0.8008, 3.00, 0.257, 289, 261, MST3 IN COMPLEX WITH CDK1/2 INHIBITOR III 5-AMINO-3-{[4- (AMINOSULFONYL)PHENYL]AMINO}-N-(26-DIFLUOROPHENYL)-1H-124- TRIAZOLE-1-CARBOTHIOAMIDE
897, d4ogrI_, 0.8008, 3.13, 0.195, 318, 267, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
898, d4tl0A_, 0.8007, 2.89, 0.222, 300, 261, CRYSTAL STRUCTURE OF DEATH-ASSOCIATED PROTEIN KINASE 1 WITH A CRUCIAL PHOSPHOMIMICKING MUTATION
899, d1fpuB1, 0.8007, 2.40, 0.341, 266, 252, CRYSTAL STRUCTURE OF ABL KINASE DOMAIN IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
900, d5j7hA_, 0.8006, 2.39, 0.298, 291, 252, CRYSTAL STRUCTURE OF ANAPLASTIC LYMPHOMA KINASE (ALK) BOUND BY BRIGATINIB
901, d3ocsA1, 0.8006, 2.32, 0.308, 262, 250, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE IN COMPLEX WITH INHIBITOR CGI1746
902, d5fg8A_, 0.8005, 2.76, 0.216, 269, 259, DROSOPHILA CAMKII-WT IN COMPLEX WITH A FRAGMENT OF THE EAG POTASSIUM CHANNEL AND MG2+/ADP
903, d4mxcA_, 0.8005, 2.72, 0.336, 290, 256, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
904, d1k3aA_, 0.8005, 2.77, 0.309, 288, 259, STRUCTURE OF THE INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR KINASE
905, d5am7A_, 0.8004, 2.67, 0.366, 294, 257, FGFR1 MUTANT WITH AN INHIBITOR
906, d5htiA_, 0.8003, 2.81, 0.339, 290, 257, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH LXM108
907, d5am6A1, 0.8003, 2.67, 0.362, 294, 257, NATIVE FGFR1 WITH AN INHIBITOR
908, d4knbC_, 0.8003, 2.25, 0.332, 271, 247, C-MET IN COMPLEX WITH OSI LIGAND
909, d1t46A_, 0.8003, 2.67, 0.341, 297, 255, STRUCTURAL BASIS FOR THE AUTOINHIBITION AND STI-571 INHIBITION OF C-KIT TYROSINE KINASE
910, d5i9vA_, 0.8002, 2.67, 0.320, 279, 256, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH AGS
911, d5hznG_, 0.8002, 2.77, 0.307, 296, 257, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
912, d4u0iA_, 0.8002, 2.76, 0.341, 297, 255, CRYSTAL STRUCTURE OF KIT IN COMPLEX WITH PONATINIB
913, d4qmmA_, 0.8002, 3.01, 0.257, 288, 261, MST3 IN COMPLEX WITH AT-9283 4-[(2-{4-[(CYCLOPROPYLCARBAMOYL)AMINO]- 1H-PYRAZOL-3-YL}-1H-BENZIMIDAZOL-6-YL)METHYL]MORPHOLIN-4-IUM
914, d4asxA1, 0.8002, 2.72, 0.235, 295, 260, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DIHYDRO-BAUERINE C
915, d1opjA1, 0.8002, 2.48, 0.340, 282, 253, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
916, d5nkeA_, 0.8001, 3.20, 0.309, 292, 265, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3A
917, d5h9bA_, 0.8001, 2.76, 0.216, 269, 259, DROSOPHILA CAMKII-WT IN COMPLEX WITH A FRAGMENT OF THE EAG POTASSIUM CHANNEL AND MG2+/AMPPN
918, d2bdjA_, 0.8001, 2.33, 0.345, 254, 249, SRC KINASE IN COMPLEX WITH INHIBITOR AP23464
919, d5ig1B_, 0.8000, 2.98, 0.262, 304, 263, CRYSTAL STRUCTURE OF S. ROSETTA CAMKII KINASE DOMAIN
920, d4bkjA1, 0.8000, 2.68, 0.357, 294, 255, CRYSTAL STRUCTURE OF THE HUMAN DDR1 KINASE DOMAIN IN COMPLEX WITH IMATINIB
921, d2xikA_, 0.8000, 2.96, 0.259, 288, 259, STRUCTURE OF HUMAN YSK1 (YEAST SPS1-STE20-RELATED KINASE 1)
922, d2x4fB_, 0.7999, 2.60, 0.236, 288, 259, THE CRYSTAL STRUCTURE OF THE HUMAN MYOSIN LIGHT CHAIN KINASE LOC340156.
923, d4v05B_, 0.7998, 2.58, 0.371, 286, 256, FGFR1 IN COMPLEX WITH AZD4547.
924, d3vs7A3, 0.7998, 2.24, 0.352, 267, 247, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR 1-CYCLOPENTYL-3-(1H-PYRROLO[23-B]PYRIDIN-5-YL)-1H- PYRAZOLO[34-D]PYRIMIDIN-4-AMINE
925, d2ya9A_, 0.7998, 2.90, 0.222, 299, 261, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2
926, d3t9tA_, 0.7997, 2.33, 0.303, 263, 251, CRYSTAL STRUCTURE OF BTK MUTANT (F435TK596R) COMPLEXED WITH IMIDAZO[15-A]QUINOXALINE
927, d2oiqB_, 0.7997, 2.45, 0.343, 265, 251, CRYSTAL STRUCTURE OF CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH THE CANCER DRUG IMATINIB.
928, d2j0mB_, 0.7997, 2.32, 0.368, 257, 250, CRYSTAL STRUCTURE A TWO-CHAIN COMPLEX BETWEEN THE FERM AND KINASE DOMAINS OF FOCAL ADHESION KINASE.
929, d5k9iB_, 0.7996, 2.19, 0.335, 262, 248, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH A COVALENT LYSINE PROBE
930, d5jrsA1, 0.7996, 2.17, 0.312, 257, 247, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH 4-[2-FLUORO-3-(4-OXO -34-DIHYDROQUINAZOLIN-3-YL) PHENYL]-7-(2-HYDROXYPROPAN-2-Y L)-9H-CARBAZOLE-1-CARBOXAMIDE
931, d4nwmA_, 0.7996, 2.43, 0.311, 261, 251, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-809959 AKA 4-TERT-BUTYL-N-[2-ME THYL-3-(6-{[4- (MORPHOLINE-4-CARBONYL)PHENYL]AMINO}-9H- PURIN-2-YL)PHENYL]BENZAMIDE
932, d4cmoA_, 0.7996, 2.81, 0.304, 295, 257, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 2-((1R)-1-((3-AMINO-6-(2- METHOXYPYRIDIN- -YL)PYRAZIN-2-YL)OXY)ETHYL)-4-FLUORO-N-METHYLBENZAMIDE
933, d2w4kA_, 0.7996, 2.95, 0.225, 301, 262, X-RAY STRUCTURE OF A DAP-KINASE 2-302
934, d2a27A_, 0.7996, 2.90, 0.218, 304, 261, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
935, d4asdA_, 0.7995, 2.84, 0.348, 305, 256, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH SORAFENIB (BAY 43-9006)
936, d3geqB1, 0.7995, 2.32, 0.349, 270, 249, STRUCTURAL BASIS FOR THE CHEMICAL RESCUE OF SRC KINASE ACTIVITY
937, d2rfnB_, 0.7995, 2.11, 0.327, 269, 245, X-RAY STRUCTURE OF C-MET WITH INHIBITOR.
938, d2a27B_, 0.7995, 2.89, 0.218, 303, 261, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
939, d1mqbB_, 0.7995, 2.47, 0.316, 265, 253, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE
940, d4nw6A1, 0.7994, 2.97, 0.198, 296, 262, RSK2 N-TERMINAL KINASE IN COMPLEX WITH 2-AMINO-7-SUBSTITUTED BENZOXAZOLE COMPOUND 27
941, d4m14A_, 0.7994, 2.49, 0.312, 263, 253, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 9 [4- (CARBAMOYLAMINO)-1-[7-(PROPAN-2-YLOXY)NAPHTHALEN-1-YL]-1H-PYRAZOLE-3- CARBOXAMIDE]
942, d5xdlA_, 0.7993, 2.46, 0.348, 292, 250, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH CO-1686
943, d5hznC_, 0.7993, 2.88, 0.310, 296, 258, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
944, d4ccuA_, 0.7993, 2.57, 0.300, 292, 253, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 2-(5-(6-AMINO-5-((R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)PYRIDIN-3-YL)-4-METHYLTHIAZOL-2-YL)PROPAN-2-OL
945, d5osdA_, 0.7992, 2.74, 0.233, 266, 257, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
946, d4cmuA_, 0.7992, 2.80, 0.304, 294, 257, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR (10R)-7-AMINO-12-FLUORO-1310 16-TETRAMETHYL-1617-DIHYDRO-1H-84-(METHENO)PYRAZOLO(43- H)(2511)BENZOXADIAZACYCLOTETRADECIN-15(10H)-ONE
947, d3e5aA_, 0.7992, 2.74, 0.237, 264, 257, CRYSTAL STRUCTURE OF AURORA A IN COMPLEX WITH VX-680 AND TPX2
948, d2zv8A1, 0.7992, 2.65, 0.360, 256, 253, LYN TYROSINE KINASE DOMAIN-AMP-PNP COMPLEX
949, d4o0vA1, 0.7991, 3.08, 0.211, 289, 261, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
950, d4cliA_, 0.7991, 2.82, 0.304, 294, 257, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-21016-TRIMETHYL-15 -OXO-10151617-TETRAHYDRO-2H-84-(METHENO)PYRAZOLO(43-H) (2511)BENZOXADIAZACYCLOTETRADECINE-3-CARBONITRILE).
951, d3f6xA_, 0.7991, 2.13, 0.344, 264, 247, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
952, d4d4vA_, 0.7990, 2.22, 0.363, 256, 248, FOCAL ADHESION KINASE CATALYTIC DOMAIN
953, d3q4uD_, 0.7990, 3.18, 0.249, 299, 265, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
954, d3eqhA_, 0.7990, 2.81, 0.197, 314, 259, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A TERNARY COMPLEX WITH U0126 ADP AND MG2P
955, d4nw5A1, 0.7989, 2.98, 0.198, 296, 262, RSK2 N-TERMINAL KINASE IN COMPLEX WITH 2-AMINO-7-SUBSTITUTED BENZOXAZOLE COMPOUND 8
956, d3vs7B3, 0.7989, 2.13, 0.354, 266, 246, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR 1-CYCLOPENTYL-3-(1H-PYRROLO[23-B]PYRIDIN-5-YL)-1H- PYRAZOLO[34-D]PYRIMIDIN-4-AMINE
957, d3oy3B1, 0.7989, 2.50, 0.340, 283, 253, CRYSTAL STRUCTURE OF ABL T315I MUTANT KINASE DOMAIN BOUND WITH A DFG- OUT INHIBITOR AP24589
958, d3f6xB_, 0.7989, 2.35, 0.332, 267, 250, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
959, d2a27H_, 0.7989, 2.90, 0.218, 304, 261, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
960, d5hznF_, 0.7988, 2.69, 0.309, 296, 256, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
961, d5hznB_, 0.7988, 2.69, 0.309, 296, 256, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
962, d5hznA_, 0.7988, 2.70, 0.305, 296, 256, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
963, d5dg5A_, 0.7988, 2.90, 0.335, 297, 257, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH ALTIRATINIB ANALOG DP- 4157
964, d4ludB3, 0.7988, 2.19, 0.354, 264, 246, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH THE FLUORESCENT COMPOUND SKF86002
965, d3mblA_, 0.7988, 2.99, 0.196, 290, 260, CRYSTAL STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK 1) IN COMPLEX WITH LIGAND AND MGADP
966, d3lq5A_, 0.7988, 2.74, 0.200, 307, 260, STRUCTURE OF CDK9/CYCLINT IN COMPLEX WITH S-CR8
967, d2a27G_, 0.7988, 2.90, 0.218, 303, 261, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
968, d5ew8A_, 0.7987, 2.97, 0.369, 291, 260, FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH JNJ-4275693
969, d4mxzA_, 0.7987, 2.50, 0.355, 266, 251, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
970, d4mxyA_, 0.7987, 2.50, 0.355, 266, 251, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
971, d2rfnA_, 0.7987, 2.12, 0.327, 268, 245, X-RAY STRUCTURE OF C-MET WITH INHIBITOR.
972, d5os5A_, 0.7986, 2.75, 0.233, 267, 257, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
973, d4qmvA_, 0.7986, 2.96, 0.258, 288, 260, MST3 IN COMPLEX WITH PF-03814735 N-{2-[(1S4R)-6-{[4- (CYCLOBUTYLAMINO)-5-(TRIFLUOROMETHYL)PYRIMIDIN-2-YL]AMINO}-1234- TETRAHYDRO-14-EPIMINONAPHTHALEN-9-YL]-2-OXOETHYL}ACETAMIDE
974, d4aseA_, 0.7986, 2.84, 0.348, 305, 256, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH TIVOZANIB (AV-951)
975, d3ik3B1, 0.7986, 2.50, 0.340, 285, 253, AP24534 A PAN-BCR-ABL INHIBITOR FOR CHRONIC MYELOID LEUKEMIA POTENTLY INHIBITS THE T315I MUTANT AND OVERCOMES MUTATION-BASED RESISTANCE
976, d4ogrE_, 0.7985, 2.97, 0.194, 310, 263, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
977, d3gvuA1, 0.7985, 2.35, 0.339, 261, 251, THE CRYSTAL STRUCTURE OF HUMAN ABL2 IN COMPLEX WITH GLEEVEC
978, d3eqfA_, 0.7985, 2.85, 0.198, 314, 258, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A BINARY COMPLEX WITH K252A AND MG2P
979, d3eqcA_, 0.7985, 2.94, 0.196, 312, 260, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A TERNARY COMPLEX WITH COMPOUND 1 ATP-GS AND MG2P
980, d2a27C_, 0.7985, 3.03, 0.224, 303, 263, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
981, d5xy1A1, 0.7984, 2.38, 0.365, 252, 249, CRYSTAL STRUCTURE OF LYN KINASE DOMAIN IN COMPLEX WITH N-(1H-INDAZOL- 6-YL)-8-(PIPERIDIN-4-YLOXY)-6-PROPYLQUINAZOLIN-2-AMINE
982, d5t0pA_, 0.7984, 2.33, 0.345, 264, 249, C-SRC KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
983, d3oy3A1, 0.7984, 2.50, 0.340, 283, 253, CRYSTAL STRUCTURE OF ABL T315I MUTANT KINASE DOMAIN BOUND WITH A DFG- OUT INHIBITOR AP24589
984, d4o0xA1, 0.7983, 3.02, 0.204, 289, 260, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
985, d4d58B_, 0.7983, 2.74, 0.373, 261, 252, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
986, d3oomA_, 0.7983, 3.23, 0.241, 297, 266, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH THE IMIDAZO[12-B]PYRIDAZINE INHIBITOR K00507
987, d3f6xC_, 0.7983, 2.30, 0.347, 265, 248, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
988, d2ya9B_, 0.7983, 2.91, 0.222, 299, 261, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2
989, d2a27D_, 0.7983, 2.91, 0.218, 304, 261, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
990, d5d7vB1, 0.7982, 2.48, 0.315, 262, 251, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN
991, d4jajA_, 0.7982, 2.87, 0.229, 265, 258, CRYSTAL STRUCTURE OF AURORA KINASE A IN COMPLEX WITH BENZO[C][1 8]NAPHTHYRIDIN-6(5H)-ONE
992, d3vo3A_, 0.7982, 2.85, 0.348, 303, 256, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN VEGFR2 WITH IMIDAZO[1 2-B]PYRIDAZINE DERIVATIVE
993, d3k5vA1, 0.7982, 2.45, 0.341, 281, 252, STRUCTURE OF ABL KINASE IN COMPLEX WITH IMATINIB AND GNF-2
994, d2zm3B2, 0.7982, 2.86, 0.308, 295, 260, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
995, d5nk5A_, 0.7981, 3.13, 0.312, 287, 263, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1M
996, d4deeA_, 0.7981, 2.75, 0.226, 271, 257, AURORA A IN COMPLEX WITH ADP
997, d5kz0A_, 0.7980, 2.60, 0.307, 293, 254, STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 2-[(1R)- 1-{[2-AMINO-5-(13-DIMETHYL-1H-PYRAZOL-4-YL)PYRIDIN-3-YL]OXY}ETHYL]- 4-FLUORO-NN-DIMETHYLBENZAMIDE
998, d4qqjA_, 0.7980, 2.68, 0.371, 282, 256, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE DOMAIN HARBORING THE V550L GATE-KEEPER MUTATION
999, d4j8nC_, 0.7980, 2.82, 0.236, 266, 258, AURORA A KINASE APO
1000, d4a4oA_, 0.7980, 2.92, 0.277, 290, 260, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A 2- (2-AMINO-PYRIMIDIN-4-YL)-1567-TETRAHYDRO-PYRROLOPYRIDIN- 4-ONE INHIBITOR
1001, d2vn9B_, 0.7980, 2.77, 0.222, 301, 261, CRYSTAL STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II DELTA ISOFORM 1 CAMKD
1002, d2a27E_, 0.7980, 3.03, 0.224, 303, 263, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
1003, d5nkhA_, 0.7979, 3.13, 0.307, 295, 264, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3E
1004, d5e8yA_, 0.7979, 2.96, 0.217, 298, 263, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A) IN COMPLEX WITH STAUROSPORINE
1005, d4uv0A_, 0.7979, 3.00, 0.221, 300, 262, STRUCTURE OF A SEMISYNTHETIC PHOSPHORYLATED DAPK
1006, d4a4lA_, 0.7979, 2.92, 0.277, 290, 260, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A 5-(2-AMINO-PYRIMIDIN-4-YL)-1H-PYRROLE INHIBITOR
1007, d3kb7A_, 0.7979, 2.93, 0.281, 289, 260, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A PYRAZOLOQUINAZOLINE INHIBITOR
1008, d3eqgA_, 0.7979, 2.93, 0.196, 314, 260, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A TERNARY COMPLEX WITH PD ADP AND MG2P
1009, d2zm3D2, 0.7979, 2.79, 0.313, 292, 259, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
1010, d4kabB_, 0.7978, 2.51, 0.357, 258, 252, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 3-METHYL-14- DIHYDRO-PYRAZOLO[45-C]PYRAZOLE
1011, d3thbA_, 0.7978, 2.92, 0.285, 287, 260, STRUCTURE OF PLK1 KINASE DOMAIN IN COMPLEX WITH A BENZOLACTAM-DERIVED INHIBITOR
1012, d3orxC_, 0.7977, 2.81, 0.216, 283, 259, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
1013, d3orxA_, 0.7977, 2.81, 0.216, 283, 259, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
1014, d2zm3A2, 0.7977, 2.87, 0.312, 299, 260, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
1015, d2vn9A_, 0.7977, 2.78, 0.222, 301, 261, CRYSTAL STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II DELTA ISOFORM 1 CAMKD
1016, d5oxgC1, 0.7976, 3.27, 0.244, 299, 266, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
1017, d5hznE_, 0.7976, 2.88, 0.306, 296, 258, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
1018, d5a9uA_, 0.7976, 2.60, 0.296, 292, 253, STRUCTURE OF C1156Y MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-210 16-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H-84-(METHENO) PYRAZOLO(43-H)(2511)BENZOXADIAZACYCLOTETRADECINE-3- CARBONITRILE).
1019, d4debA_, 0.7976, 2.80, 0.233, 264, 258, AURORA A IN COMPLEX WITH RK2-17-01
1020, d4anqA_, 0.7976, 2.72, 0.294, 293, 255, STRUCTURE OF G1269A MUTANT ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
1021, d2a27F_, 0.7976, 3.04, 0.224, 303, 263, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
1022, d1fpuA1, 0.7976, 2.40, 0.335, 271, 251, CRYSTAL STRUCTURE OF ABL KINASE DOMAIN IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
1023, d4j8nB_, 0.7975, 2.82, 0.236, 266, 258, AURORA A KINASE APO
1024, d3zlxA_, 0.7975, 2.84, 0.194, 312, 258, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 18
1025, d3js2B_, 0.7975, 2.98, 0.369, 291, 260, CRYSTAL STRUCTURE OF MINIMAL KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH 5-(2-THIENYL) NICOTINIC ACID
1026, d3e8nA1, 0.7975, 3.09, 0.195, 290, 262, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) COMPLEXED WITH A POTENT INHIBITOR RDEA119 AND MGATP
1027, d1opjB1, 0.7975, 2.53, 0.340, 284, 253, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
1028, d4mxzB_, 0.7974, 2.45, 0.356, 264, 250, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
1029, d4mxyB_, 0.7974, 2.45, 0.356, 264, 250, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
1030, d3tzmA_, 0.7974, 2.98, 0.223, 295, 264, TGF-BETA RECEPTOR TYPE 1 IN COMPLEX WITH SB431542
1031, d3fzrA_, 0.7974, 2.42, 0.351, 261, 251, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH PF-431396
1032, d2vz6A1, 0.7974, 2.46, 0.217, 285, 254, STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE TYPE II ALPHA (CAMK2A) IN COMPLEX WITH INDIRUBIN E804
1033, d5uglB_, 0.7973, 2.74, 0.358, 271, 254, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 TYROSINE KINASE DOMAIN HARBORING THE D650V ACTIVATING MUTATION
1034, d5h2uB1, 0.7973, 2.50, 0.319, 261, 251, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN COMPLEXED WITH DASATINIB
1035, d4qqtA_, 0.7973, 2.69, 0.367, 283, 256, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 TYROSINE KINASE DOMAIN
1036, d1phkA_, 0.7973, 2.61, 0.223, 277, 256, TWO STRUCTURES OF THE CATALYTIC DOMAIN OF PHOSPHORYLASE KINASE: AN ACTIVE PROTEIN KINASE COMPLEXED WITH NUCLEOTIDE SUBSTRATE-ANALOGUE AND PRODUCT
1037, d5e92A_, 0.7972, 3.08, 0.239, 298, 264, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A) IN COMPLEX WITH AMPPNP
1038, d4j8nA_, 0.7972, 2.83, 0.236, 266, 258, AURORA A KINASE APO
1039, d4aojC_, 0.7972, 2.44, 0.381, 261, 252, HUMAN TRKA IN COMPLEX WITH THE INHIBITOR AZ-23
1040, d4otfA1, 0.7971, 2.32, 0.309, 261, 249, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH GDC0834
1041, d4imyE_, 0.7971, 2.88, 0.199, 313, 261, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
1042, d3uo4A_, 0.7971, 2.77, 0.233, 266, 258, AURORA A IN COMPLEX WITH RPM1680
1043, d3socA1, 0.7971, 3.03, 0.224, 296, 263, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH A QUINAZOLIN
1044, d5p9lA_, 0.7970, 2.37, 0.319, 252, 248, BTK1 IN COMPLEX WITH CC 292
1045, d5hznH_, 0.7970, 2.87, 0.306, 303, 258, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
1046, d4otdA_, 0.7970, 2.91, 0.266, 334, 259, CRYSTAL STRUCTURE OF PRK1 CATALYTIC DOMAIN
1047, d4mxoA_, 0.7970, 2.54, 0.347, 266, 251, HUMAN SRC KINASE BOUND TO KINASE INHIBITOR BOSUTINIB
1048, d5hznD_, 0.7969, 2.87, 0.306, 304, 258, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
1049, d4k8aB_, 0.7969, 2.59, 0.364, 258, 253, FRAGMENT-BASED DISCOVERY OF FOCAL ADHESION KINASE INHIBITORS
1050, d3zlsA_, 0.7969, 2.78, 0.194, 315, 258, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 6
1051, d3zbfA_, 0.7969, 2.58, 0.336, 281, 253, STRUCTURE OF HUMAN ROS1 KINASE DOMAIN IN COMPLEX WITH CRIZOTINIB
1052, d3tt0A_, 0.7969, 2.88, 0.359, 305, 259, CO-STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN WITH 3-(26-DICHLORO-35-DIMETHOXY-PHENYL)-1-{6-[4-(4-ETHYL-PIPERAZIN-1- YL)-PHENYLAMINO]-PYRIMIDIN-4-YL}-1-METHYL-UREA (BGJ398)
1053, d5ackA_, 0.7968, 2.94, 0.232, 286, 259, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND 7 BOUND TO THE PIF-POCKET
1054, d5aa8A_, 0.7968, 2.61, 0.296, 292, 253, STRUCTURE OF C1156YL1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12- FLUORO-21016-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H- 84-(METHENO)PYRAZOLO(43-H)(2511) BENZOXADIAZACYCLOTETRADECINE-3-CARBONITRILE).
1055, d4mxxA_, 0.7968, 2.50, 0.347, 266, 251, HUMAN SRC A403T MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
1056, d4bb4A_, 0.7968, 2.56, 0.281, 265, 253, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
1057, d4aojA_, 0.7968, 2.42, 0.375, 260, 251, HUMAN TRKA IN COMPLEX WITH THE INHIBITOR AZ-23
1058, d3zlyA_, 0.7968, 2.95, 0.193, 310, 259, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 8
1059, d3bhhB1, 0.7968, 2.48, 0.207, 288, 256, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
1060, d2bdwB_, 0.7968, 2.58, 0.244, 309, 258, CRYSTAL STRUCTURE OF THE AUTO-INHIBITED KINASE DOMAIN OF CALCIUM/CALMODULIN ACTIVATED KINASE II
1061, d1r0pA_, 0.7968, 2.67, 0.344, 301, 253, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH THE MICROBIAL ALKALOID K-252A
1062, d5d7vC1, 0.7967, 2.49, 0.319, 262, 251, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN
1063, d4xx9A_, 0.7967, 2.94, 0.232, 288, 259, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND THE PIF-POCKET LIGAND RF4
1064, d4ogrA_, 0.7967, 3.01, 0.194, 314, 263, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
1065, d3up7A_, 0.7967, 2.84, 0.233, 264, 258, AURORA A IN COMPLEX WITH YL1-038-09
1066, d3pp1A1, 0.7967, 2.88, 0.198, 290, 258, CRYSTAL STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK 1) IN COMPLEX WITH LIGAND AND MGATP
1067, d2zm3C2, 0.7967, 2.77, 0.309, 295, 259, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
1068, d2y7jB_, 0.7967, 2.74, 0.221, 281, 258, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
1069, d5edqA_, 0.7966, 2.45, 0.355, 298, 251, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 15: ~{N}-(7- CHLORANYL-1~{H}-INDAZOL-3-YL)-77-DIMETHYL-2-(1~{H}-PYRAZOL-4-YL)- 5~{H}-FURO[34-D]PYRIMIDIN-4-AMINE
1070, d4ansA_, 0.7966, 2.73, 0.298, 293, 255, STRUCTURE OF L1196MG1269A DOUBLE MUTANT ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
1071, d1vjyA_, 0.7966, 3.06, 0.226, 299, 265, CRYSTAL STRUCTURE OF A NAPHTHYRIDINE INHIBITOR OF HUMAN TGF- BETA TYPE I RECEPTOR
1072, d1t45A_, 0.7966, 2.88, 0.335, 331, 257, STRUCTURAL BASIS FOR THE AUTOINHIBITION AND STI-571 INHIBITION OF C- KIT TYROSINE KINASE
1073, d3et7A_, 0.7965, 2.43, 0.343, 261, 251, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH PF-2318841
1074, d3cs9A_, 0.7965, 2.30, 0.341, 264, 249, HUMAN ABL KINASE IN COMPLEX WITH NILOTINIB
1075, d2jkmA_, 0.7965, 2.49, 0.361, 260, 252, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
1076, d5a46B_, 0.7964, 2.89, 0.380, 297, 258, FGFR1 IN COMPLEX WITH DOVITINIB
1077, d4mneG_, 0.7964, 2.20, 0.260, 259, 250, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
1078, d4agcA_, 0.7964, 2.89, 0.348, 304, 256, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH AXITINIB (AG-013736) (N-METHYL-2-( 3-((E)-2-PYRIDIN-2-YL-VINYL)-1H-INDAZOL-6-YLSULFANYL)- BENZAMIDE)
1079, d3orxD_, 0.7964, 2.78, 0.217, 282, 258, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
1080, d1k9aF3, 0.7964, 2.17, 0.379, 264, 248, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
1081, d5ta6A_, 0.7963, 2.94, 0.277, 294, 260, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH A NOVEL 56- DIHYDROIMIDAZOLO[15-F]PTERIDINE INHIBITOR.
1082, d4uwbA_, 0.7963, 2.86, 0.376, 299, 258, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P5
1083, d4d4sB_, 0.7963, 2.72, 0.378, 260, 251, FOCAL ADHESION KINASE CATALYTIC DOMAIN
1084, d3rhxA_, 0.7963, 2.98, 0.369, 289, 260, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR1 KINASE IN COMPLEX WITH ARQ 069
1085, d5e91A_, 0.7962, 3.05, 0.236, 297, 263, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A) IN COMPLEX WITH 3-AMINO-6-[4-(2- HYDROXYETHYL)PHENYL]-N-[4- (MORPHOLIN-4-YL)PYRIDIN-3-YL] PYRAZINE-2-CARBOXAMIDE
1086, d4v05A_, 0.7962, 2.65, 0.379, 287, 256, FGFR1 IN COMPLEX WITH AZD4547.
1087, d4j52A_, 0.7962, 2.95, 0.277, 293, 260, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH A PYRIMIDODIAZEPINONE INHIBITOR
1088, d4d4yA_, 0.7962, 2.22, 0.360, 255, 247, FOCAL ADHESION KINASE CATALYTIC DOMAIN
1089, d4ccbA_, 0.7962, 2.60, 0.298, 287, 252, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 3-((R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)-5-(5-METHYL-1H-PYRAZOL-4-YL)PYRIDIN-2-AMINE
1090, d3eqiA_, 0.7962, 2.85, 0.198, 315, 258, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A BINARY COMPLEX WITH ADP AND MG2P
1091, d2hiwA1, 0.7962, 2.41, 0.335, 270, 251, CRYSTAL STRUCTURE OF INACTIVE CONFORMATION ABL KINASE CATALYTIC DOMAIN COMPLEXED WITH TYPE II INHIBITOR
1092, d4d5kA_, 0.7961, 2.22, 0.360, 255, 247, FOCAL ADHESION KINASE CATALYTIC DOMAIN
1093, d3geqA1, 0.7961, 2.31, 0.351, 269, 248, STRUCTURAL BASIS FOR THE CHEMICAL RESCUE OF SRC KINASE ACTIVITY
1094, d2zv9A1, 0.7961, 2.59, 0.357, 255, 252, LYN TYROSINE KINASE DOMAIN-PP2 COMPLEX
1095, d2bdfA_, 0.7961, 2.51, 0.347, 261, 251, SRC KINASE IN COMPLEX WITH INHIBITOR AP23451
1096, d5edpA_, 0.7960, 2.46, 0.355, 295, 251, EGFR KINASE (T790M/L858R) APO
1097, d4uwcB_, 0.7960, 2.91, 0.359, 301, 259, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P3
1098, d4ub7A_, 0.7960, 2.68, 0.195, 334, 257, HIGH-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH 4 - CARBOXY-68-BROMO-FLAVONOL (FLC26) SHOWING AN EXTREME DISTORTION OF THE ATP-BINDING LOOP COMBINED WITH A PI-HALOGEN BOND
1099, d2yacA_, 0.7960, 2.96, 0.277, 290, 260, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH NMS-P937
1100, d5t18A1, 0.7959, 2.32, 0.321, 259, 249, CRYSTAL STRUCTURE OF BRUTON AGAMMABULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-986142 AKA (2S)-6-FLUORO-5-[3-(8-FLUORO-1-METHYL-24-DIOXO- 1234-TETRAHYDROQUINAZOLIN-3-YL)-2-METHYLPHENYL]-2-(2- HYDROXYPROPAN-2-YL)-2349-TETRAHYDRO-1H-CARBAZOLE-8-CARBOXAMIDE
1101, d5j87C_, 0.7959, 2.50, 0.331, 261, 251, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
1102, d4yo4A1, 0.7959, 2.75, 0.226, 276, 257, CRYSTAL STRUCTURE OF DAPK1 CATALYTIC DOMAIN IN COMPLEX WITH THE HINGE BINDING FRAGMENT PHTHALAZINE
1103, d4qmqA_, 0.7959, 3.05, 0.257, 289, 261, MST3 IN COMPLEX WITH CP-673451
1104, d3zlwA_, 0.7959, 2.87, 0.194, 312, 258, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 3
1105, d3dv3A_, 0.7959, 2.97, 0.201, 288, 259, MEK1 WITH PF-04622664 BOUND
1106, d2etmB_, 0.7959, 2.46, 0.359, 263, 251, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN COMPLEXED WITH 7H-PYRROLO [23-D] PYRIMIDINE DERIVATIVE
1107, d5aacA_, 0.7958, 2.62, 0.296, 292, 253, STRUCTURE OF C1156Y MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
1108, d4u7zA1, 0.7958, 3.20, 0.194, 290, 263, MITOGEN-ACTIVATED PROTEIN KINASE KINASE (MEK1) BOUND TO G805
1109, d4fnyA_, 0.7958, 2.12, 0.301, 273, 246, CRYSTAL STRUCTURE OF THE R1275Q ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN IN COMPLEX WITH A BENZOXAZOLE INHIBITOR
1110, d3q4tB1, 0.7958, 2.66, 0.236, 293, 258, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DORSOMORPHIN
1111, d3gu8A1, 0.7958, 2.66, 0.219, 276, 256, CRYSTAL STRUCTURE OF DAPKL93G WITH N6-CYCLOPENTYLADENOSINE
1112, d3dgkA1, 0.7958, 2.76, 0.226, 276, 257, CRYSTAL STRUCTURE OF A GLYCINE-RICH LOOP MUTANT OF THE DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN
1113, d5vndB_, 0.7957, 2.86, 0.364, 295, 258, CRYSTAL STRUCTURE OF FGFR1-Y563C (FGFR4 SURROGATE) COVALENTLY BOUND TO H3B-6527
1114, d4uy9A_, 0.7957, 2.65, 0.312, 313, 256, STRUCTURE OF MLK1 KINASE DOMAIN WITH LEUCINE ZIPPER 1
1115, d4rqvA_, 0.7957, 2.94, 0.232, 288, 259, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND THE PIF-POCKET LIGAND RS2
1116, d1wvxA_, 0.7957, 2.79, 0.218, 275, 257, CRYSTAL STRUCTURES OF KINASE DOMAIN OF DAP KINASE IN COMPLEX WITH SMALL MOLECULAR INHIBITORS
1117, d5bx0A_, 0.7956, 2.84, 0.190, 315, 258, AN AUTOMATED MICROSCALE THERMOPHORESIS SCREENING APPROACH FOR FRAGMENT-BASED LEAD DISCOVERY
1118, d4o0sA_, 0.7956, 2.76, 0.234, 265, 256, CRYSTAL STRUCTURES OF HUMAN KINASE AURORA A
1119, d3lvpB_, 0.7956, 2.89, 0.312, 295, 260, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
1120, d5dt3A_, 0.7955, 2.77, 0.231, 263, 255, AURORA A KINASE IN COMPLEX WITH ATP IN SPACE GROUP P6122
1121, d4rqkA_, 0.7955, 2.95, 0.236, 285, 259, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND THE PIF-POCKET LIGAND RS1
1122, d4imyC_, 0.7955, 2.78, 0.197, 310, 259, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
1123, d3k5vB1, 0.7955, 2.38, 0.340, 279, 250, STRUCTURE OF ABL KINASE IN COMPLEX WITH IMATINIB AND GNF-2
1124, d5vedA_, 0.7954, 2.94, 0.205, 289, 259, PAK4 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
1125, d5ta8A_, 0.7954, 3.00, 0.285, 294, 260, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH A NOVEL 56- DIHYDROIMIDAZOLO[15-F]PTERIDINE INHIBITOR
1126, d4rj5A_, 0.7954, 2.34, 0.351, 296, 248, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 5
1127, d4d5hA_, 0.7954, 2.24, 0.360, 255, 247, FOCAL ADHESION KINASE CATALYTIC DOMAIN
1128, d3eqdA_, 0.7954, 2.87, 0.198, 315, 258, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A BINARY COMPLEX WITH ATP-GS AND MG2P
1129, d2etmA_, 0.7954, 2.67, 0.354, 262, 254, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN COMPLEXED WITH 7H-PYRROLO [23-D] PYRIMIDINE DERIVATIVE
1130, d1iepB1, 0.7954, 2.43, 0.343, 270, 251, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH STI-571.
1131, d4j53A_, 0.7953, 2.94, 0.277, 293, 260, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH TAK-960
1132, d3mtfB_, 0.7953, 3.28, 0.233, 298, 266, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH A 2- AMINOPYRIDINE INHIBITOR
1133, d2owbA_, 0.7953, 2.95, 0.281, 294, 260, STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN POLO-LIKE KINASE 1
1134, d2yakA_, 0.7952, 2.82, 0.217, 277, 258, STRUCTURE OF DEATH-ASSOCIATED PROTEIN KINASE 1 (DAPK1) IN COMPLEX WITH A RUTHENIUM OCTASPORINE LIGAND (OSV)
1135, d4txcA_, 0.7951, 2.82, 0.221, 276, 258, CRYSTAL STRUCTURE OF DAPK1 KINASE DOMAIN IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
1136, d3nrmA_, 0.7951, 2.81, 0.233, 263, 257, IMIDAZO[12-A]PYRAZINE-BASED AURORA KINASE INHIBITORS
1137, d4ypdA1, 0.7950, 2.78, 0.226, 276, 257, CRYSTAL STRUCTURE OF DAPK1 CATALYTIC DOMAIN IN COMPLEX WITH THE HINGE BINDING FRAGMENT 4-METHYLPYRIDAZINE
1138, d4njdA1, 0.7950, 2.99, 0.208, 289, 259, STRUCTURE OF P21-ACTIVATED KINASE 4 WITH A NOVEL INHIBITOR KY-04031
1139, d3my0M1, 0.7950, 3.46, 0.230, 297, 270, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
1140, d2vz6B1, 0.7950, 2.74, 0.223, 288, 256, STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE TYPE II ALPHA (CAMK2A) IN COMPLEX WITH INDIRUBIN E804
1141, d2rfsA_, 0.7950, 2.39, 0.352, 264, 247, X-RAY STRUCTURE OF SU11274 BOUND TO C-MET
1142, d5h2uC1, 0.7949, 2.53, 0.319, 261, 251, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN COMPLEXED WITH DASATINIB
1143, d4j8nD_, 0.7949, 2.82, 0.237, 265, 257, AURORA A KINASE APO
1144, d3my0L1, 0.7949, 3.41, 0.235, 295, 268, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
1145, d5av0A_, 0.7948, 2.88, 0.229, 275, 258, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH 73 4 - TRIHYDROXYISOFLAVONE.
1146, d4ks8A_, 0.7948, 3.00, 0.208, 286, 259, PAK6 KINASE DOMAIN IN COMPLEX WITH SUNITINIB
1147, d4d4yB_, 0.7948, 2.73, 0.378, 260, 251, FOCAL ADHESION KINASE CATALYTIC DOMAIN
1148, d3vvhC1, 0.7948, 2.95, 0.193, 282, 259, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH AN INHIBITOR AND MGATP
1149, d3cthA_, 0.7948, 2.88, 0.322, 295, 258, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A AMINOPYRIDINE BASED INHIBITOR
1150, d3blrA_, 0.7948, 2.75, 0.201, 300, 259, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1 IN COMPLEX WITH FLAVOPIRIDOL
1151, d2vx0A_, 0.7948, 3.01, 0.278, 273, 259, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
1152, d1s9jA1, 0.7948, 2.96, 0.201, 288, 259, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
1153, d4d5hB_, 0.7947, 2.74, 0.378, 260, 251, FOCAL ADHESION KINASE CATALYTIC DOMAIN
1154, d4d58A_, 0.7947, 2.25, 0.360, 255, 247, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
1155, d4arkA1, 0.7947, 2.94, 0.194, 290, 258, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN MAP KINASE KINASE 1 (MEK1) IN COMPLEX WITH  A SMALL MOLECULE INHIBITOR AND ADP
1156, d3my0N1, 0.7947, 3.43, 0.230, 299, 269, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
1157, d5lvlA_, 0.7946, 2.96, 0.236, 285, 259, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH COMPOUND PS653 BOUND TO THE ATP-BINDING SITE
1158, d2xb7A_, 0.7946, 2.35, 0.301, 286, 249, STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH NVP- TAE684
1159, d2e2bA1, 0.7946, 2.34, 0.337, 266, 249, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH INNO-406
1160, d5lvoA_, 0.7945, 2.95, 0.239, 285, 259, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND PSE10 BOUND TO THE PIF-POCKET
1161, d3gubA1, 0.7945, 2.78, 0.230, 276, 257, CRYSTAL STRUCTURE OF DAPKL93G COMPLEXED WITH N6-(2- PHENYLETHYL)ADENOSINE
1162, d3eqbA1, 0.7945, 2.96, 0.201, 288, 259, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
1163, d2rkuA_, 0.7945, 2.97, 0.277, 294, 260, STRUCTURE OF PLK1 IN COMPLEX WITH BI2536
1164, d5xp7A_, 0.7944, 2.51, 0.344, 265, 250, C-SRC IN COMPLEX WITH ATP-CHCL
1165, d5h2uA1, 0.7944, 2.52, 0.323, 261, 251, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN COMPLEXED WITH DASATINIB
1166, d5d7vD1, 0.7944, 2.53, 0.319, 262, 251, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN
1167, d4ymjA1, 0.7944, 2.69, 0.415, 267, 253, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
1168, d4jdiA_, 0.7944, 2.85, 0.198, 289, 258, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 IN COMPLEX WITH PAKTIDE S PEPTIDE SUBSTRATE
1169, d3vvhB1, 0.7944, 3.10, 0.196, 289, 260, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH AN INHIBITOR AND MGATP
1170, d2auhA1, 0.7944, 2.97, 0.324, 294, 259, CRYSTAL STRUCTURE OF THE GRB14 BPS REGION IN COMPLEX WITH THE INSULIN RECEPTOR TYROSINE KINASE
1171, d5ng2B_, 0.7943, 2.58, 0.248, 278, 254, STRUCTURE OF RIP2K(D146N) WITH BOUND STAUROSPORINE
1172, d5i9uA_, 0.7943, 2.72, 0.318, 281, 255, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE
1173, d5h2uD1, 0.7943, 2.54, 0.319, 261, 251, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN COMPLEXED WITH DASATINIB
1174, d5av1A_, 0.7943, 2.88, 0.229, 275, 258, CRYSTAL STRUCTURE OF DAPK1 IN THE PRESENCE OF BROMIDE IONS.
1175, d4o2pB_, 0.7943, 2.41, 0.337, 265, 249, KINASE DOMAIN OF CSRC IN COMPLEX WITH A SUBSTITUTED PYRAZOLOPYRIMIDINE
1176, d4dedA_, 0.7943, 2.87, 0.236, 265, 258, AURORA A IN COMPLEX WITH YL1-038-21
1177, d1jklA_, 0.7943, 2.89, 0.229, 280, 258, 1.6A X-RAY STRUCTURE OF BINARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE
1178, d1iepA1, 0.7943, 2.39, 0.340, 270, 250, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH STI-571.
1179, d5t0pB_, 0.7942, 2.41, 0.345, 263, 249, C-SRC KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
1180, d5oy6D_, 0.7942, 3.01, 0.249, 292, 261, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
1181, d5orpA_, 0.7942, 2.74, 0.235, 264, 255, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1182, d5dh3B_, 0.7942, 2.85, 0.230, 283, 257, CRYSTAL STRUCTURE OF MST2 IN COMPLEX WITH XMU-MP-1
1183, d4o0yA1, 0.7942, 2.90, 0.198, 289, 258, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
1184, d3gu6A1, 0.7942, 2.79, 0.230, 276, 257, CRYSTAL STRUCTURE OF DAPKQ23V-ADP
1185, d3gu5A1, 0.7942, 2.78, 0.226, 276, 257, CRYSTAL STRUCTURE OF DAPKQ23V-AMPPNP-MG2+
1186, d2zv7A1, 0.7942, 2.68, 0.360, 256, 253, LYN TYROSINE KINASE DOMAIN APO FORM
1187, d2xp2A_, 0.7942, 2.59, 0.303, 285, 251, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB (PF-02341066)
1188, d5hu3A_, 0.7941, 2.70, 0.227, 266, 256, DROSOPHILA CAMKII-D136N IN COMPLEX WITH A PHOSPHORYLATED FRAGMENT OF THE EAG POTASSIUM CHANNEL AND MG2+/ADP
1189, d5dn3A_, 0.7941, 2.93, 0.233, 264, 258, AURORA A IN COMPLEX WITH ATP AND AA35.
1190, d4mxoB_, 0.7941, 2.51, 0.348, 264, 250, HUMAN SRC KINASE BOUND TO KINASE INHIBITOR BOSUTINIB
1191, d3mj2A_, 0.7941, 2.31, 0.306, 259, 248, X-RAY CRYSTAL STRUCTURE OF ITK COMPLEXED WITH INHIBITOR BMS-509744
1192, d5av3A_, 0.7940, 2.89, 0.229, 275, 258, CRYSTAL STRUCTURE OF DAPK1-KAEMPFEROL COMPLEX IN THE PRESENCE OF IODIDE IONS.
1193, d4o0tA_, 0.7940, 3.32, 0.226, 292, 265, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
1194, d3q4uA_, 0.7940, 3.26, 0.242, 298, 265, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
1195, d3gu4A1, 0.7940, 2.70, 0.223, 276, 256, CRYSTAL STRUCTURE OF DAPKQ23V-AMPPNP
1196, d3fc2A_, 0.7940, 2.97, 0.277, 293, 260, PLK1 IN COMPLEX WITH BI6727
1197, d3cd8A_, 0.7940, 2.39, 0.352, 278, 247, X-RAY STRUCTURE OF C-MET WITH TRIAZOLOPYRIDAZINE INHIBITOR.
1198, d5osfA_, 0.7939, 2.69, 0.227, 264, 255, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1199, d5oseA_, 0.7939, 2.74, 0.235, 264, 255, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1200, d5os1A_, 0.7939, 2.73, 0.235, 264, 255, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1201, d5orzA_, 0.7939, 2.68, 0.227, 264, 255, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1202, d4zsaB_, 0.7939, 2.63, 0.376, 282, 255, CRYSTAL STRUCTURE OF FGFR1 KINASE DOMAIN IN COMPLEX WITH 7N
1203, d4u80A_, 0.7939, 2.94, 0.201, 286, 259, MEK 1 KINASE BOUND TO G799
1204, d3zfxF_, 0.7939, 2.01, 0.295, 254, 244, CRYSTAL STRUCTURE OF EPHB1
1205, d2yfxA_, 0.7939, 2.77, 0.306, 292, 255, STRUCTURE OF L1196M MUTANT ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
1206, d2w4jA_, 0.7939, 2.79, 0.226, 276, 257, X-RAY STRUCTURE OF A DAP-KINASE 2-277
1207, d2v7oA1, 0.7939, 3.00, 0.202, 297, 263, CRYSTAL STRUCTURE OF HUMAN CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE II GAMMA
1208, d5ornA_, 0.7938, 2.74, 0.235, 264, 255, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1209, d3gu7A1, 0.7938, 2.80, 0.230, 276, 257, CRYSTAL STRUCTURE OF DAPKQ23V-ADP-MG2+
1210, d5grnA_, 0.7937, 2.99, 0.336, 285, 256, CRYSTAL STRUCTURE OF PDGFRA IN COMPLEX WITH WQ-C-159
1211, d4otgA_, 0.7937, 2.95, 0.266, 322, 259, CRYSTAL STRUCTURE OF PRK1 CATALYTIC DOMAIN IN COMPLEX WITH LESTAURTINIB
1212, d4jboA_, 0.7937, 2.81, 0.233, 266, 257, NOVEL AURORA KINASE INHIBITORS REVEAL MECHANISMS OF HURP IN NUCLEATION OF CENTROSOMAL AND KINETOCHORE MICROTUBULES
1213, d4c7tA_, 0.7937, 2.70, 0.358, 259, 254, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH A DIARYLAMINO-135-TRIAZINE INHIBITOR
1214, d3zfxB_, 0.7937, 2.13, 0.290, 254, 245, CRYSTAL STRUCTURE OF EPHB1
1215, d5dr2A1, 0.7936, 2.70, 0.228, 263, 254, AURORA A KINASE IN COMPLEX WITH AA30 AND ATP IN SPACE GROUP P6122
1216, d4l67A_, 0.7936, 2.90, 0.198, 289, 258, CRYSTAL STRUCTURE OF CATALYTIC DOMAIN OF PAK4
1217, d4gu9B_, 0.7936, 2.60, 0.357, 255, 252, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH (2-FLUORO- PHENYL)-(1H-PYRAZOLO[34-D]PYRIMIDIN-4-YL)-AMINE
1218, d3p08A_, 0.7936, 2.44, 0.305, 252, 249, CRYSTAL STRUCTURE OF THE HUMAN BTK KINASE DOMAIN
1219, d3eh9A1, 0.7936, 2.72, 0.223, 274, 256, CRYSTAL STRUCTURE OF DEATH ASSOCIATED PROTEIN KINASE COMPLEXED WITH ADP
1220, d2hz4B1, 0.7936, 2.10, 0.347, 248, 245, ABL KINASE DOMAIN UNLIGATED AND IN COMPLEX WITH TETRAHYDROSTAUROSPORINE
1221, d1jksA_, 0.7936, 2.90, 0.229, 280, 258, 1.5A X-RAY STRUCTURE OF APO FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE
1222, d5orxA_, 0.7935, 2.74, 0.235, 264, 255, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1223, d5orwA_, 0.7935, 2.74, 0.235, 264, 255, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1224, d5oroA_, 0.7935, 2.69, 0.227, 264, 255, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1225, d5i0bA_, 0.7935, 3.07, 0.204, 288, 260, STRUCTURE OF PAK4
1226, d5ftqA1, 0.7935, 2.74, 0.306, 292, 255, CRYSTAL STRUCTURE OF THE ALK KINASE DOMAIN IN COMPLEX WITH CMPD 17
1227, d5d7vA1, 0.7935, 2.52, 0.319, 262, 251, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN
1228, d5auwA_, 0.7935, 2.85, 0.226, 274, 257, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH QUERCETIN.
1229, d3socB1, 0.7935, 3.04, 0.228, 294, 263, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH A QUINAZOLIN
1230, d1fgiB_, 0.7935, 2.67, 0.380, 272, 255, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU5402 INHIBITOR
1231, d5oxgA_, 0.7934, 3.12, 0.240, 293, 262, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
1232, d5oryA_, 0.7934, 2.74, 0.235, 264, 255, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1233, d5orvA_, 0.7934, 2.74, 0.235, 264, 255, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1234, d5orrA_, 0.7934, 2.73, 0.235, 264, 255, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1235, d5jfxA_, 0.7934, 2.38, 0.373, 277, 249, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-06273340
1236, d5ew3A_, 0.7934, 2.64, 0.335, 274, 251, HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (KDR) KINASE DOMAIN IN COMPLEX WITH AAL993
1237, d3q4tA1, 0.7934, 3.04, 0.225, 294, 262, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DORSOMORPHIN
1238, d3hmmA_, 0.7934, 2.97, 0.229, 293, 262, STRUCTURE OF ALK5 + GW855857
1239, d3f5gA1, 0.7934, 2.81, 0.230, 275, 257, CRYSTAL STRUCTURE OF DEATH ASSOCIATED PROTEIN KINASE IN COMPLEX WITH ADP AND MG2+
1240, d5os3A_, 0.7933, 2.70, 0.227, 264, 255, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1241, d5os0A_, 0.7933, 2.74, 0.235, 264, 255, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1242, d5auvA_, 0.7933, 2.90, 0.229, 275, 258, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH APIGENIN.
1243, d4bggA_, 0.7933, 3.24, 0.242, 296, 264, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
1244, d3q4uC_, 0.7933, 3.06, 0.244, 296, 262, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
1245, d3iw4A_, 0.7933, 2.86, 0.238, 330, 260, CRYSTAL STRUCTURE OF PKC ALPHA IN COMPLEX WITH NVP-AEB071
1246, d3dfcB1, 0.7933, 2.80, 0.230, 276, 257, CRYSTAL STRUCTURE OF A GLYCINE-RICH LOOP MUTANT OF THE DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN WITH AMPPNP
1247, d2i1mA_, 0.7933, 2.96, 0.336, 311, 256, CFMS TYROSINE KINASE (TIE2 KID) IN COMPLEX WITH AN ARYLAMIDE INHIBITOR
1248, d6babB_, 0.7932, 2.45, 0.221, 285, 253, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
1249, d5edrA_, 0.7932, 2.46, 0.356, 299, 250, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 27: ~{N}-(1~{H}- INDAZOL-3-YL)-77-DIMETHYL-2-(2-METHYLPYRAZOL-3-YL)-5~{H}-FURO[34- D]PYRIMIDIN-4-AMINE
1250, d4hvsA1, 0.7932, 2.85, 0.345, 323, 255, CRYSTAL STRUCTURE OF KIT KINASE DOMAIN WITH A SMALL MOLECULE INHIBITOR PLX647
1251, d4ctcA_, 0.7932, 2.53, 0.303, 288, 251, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 7-AMINO-3-CYCLOPROPYL-12-FLUORO- 11016-TRIMETHYL-1617-DIHYDRO-1H-84-(METHENO)PYRAZOLO(4 3-H)(2511)BENZOXADIAZACYCLOTETRADECIN-15(10H)-ONE
1252, d4b6lA_, 0.7932, 3.09, 0.245, 281, 261, DISCOVERY OF ORAL POLO-LIKE KINASE (PLK) INHIBITORS WITH ENHANCED SELECTIVITY PROFILE USING RESIDUE TARGETED DRUG DESIGN
1253, d3bhhA1, 0.7932, 2.47, 0.208, 287, 255, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
1254, d5vndA_, 0.7931, 2.89, 0.377, 302, 257, CRYSTAL STRUCTURE OF FGFR1-Y563C (FGFR4 SURROGATE) COVALENTLY BOUND TO H3B-6527
1255, d5os4A_, 0.7931, 2.71, 0.227, 264, 255, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1256, d4d4sA_, 0.7931, 2.26, 0.360, 255, 247, FOCAL ADHESION KINASE CATALYTIC DOMAIN
1257, d3uqgA_, 0.7931, 2.47, 0.345, 263, 249, C-SRC KINASE DOMAIN IN COMPLEX WITH BUMPLESS BKI ANALOG UW1243
1258, d2y0aA_, 0.7931, 2.95, 0.215, 300, 261, STRUCTURE OF DAPK1 CONSTRUCT RESIDUES 1-304
1259, d5os6A_, 0.7930, 2.70, 0.227, 264, 255, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1260, d5auyA_, 0.7930, 2.81, 0.230, 275, 257, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH MORIN.
1261, d4ckrA1, 0.7930, 2.79, 0.353, 294, 255, CRYSTAL STRUCTURE OF THE HUMAN DDR1 KINASE DOMAIN IN COMPLEX WITH DDR1-IN-1
1262, d4bkiA1, 0.7930, 2.79, 0.353, 294, 255,  
1263, d4bggB_, 0.7930, 3.23, 0.242, 293, 264, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
1264, d2x0gA_, 0.7930, 3.07, 0.218, 318, 262, X-RAY STRUCTURE OF A DAP-KINASE CALMODULIN COMPLEX
1265, d2oiqA_, 0.7930, 2.38, 0.343, 265, 248, CRYSTAL STRUCTURE OF CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH THE CANCER DRUG IMATINIB.
1266, d5dnrA_, 0.7929, 2.92, 0.233, 264, 257, AURORA A KINASE IN COMPLEX WITH ATP IN SPACE GROUP P41212
1267, d4ymjB1, 0.7929, 2.66, 0.413, 272, 252, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
1268, d4ctbA_, 0.7929, 2.72, 0.303, 292, 254, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR (5R)-8-AMINO-3-FLUORO-519-DIMETHYL-20-OXO-5181920- TETRAHYDRO-711-(AZENO)PYRIDO(2 1 :23)IMIDAZO(45-H)(2511) BENZOXADIAZACYCLOTETRADECINE-14-CARBONITRILE
1269, d3zfxG_, 0.7929, 2.05, 0.291, 253, 244, CRYSTAL STRUCTURE OF EPHB1
1270, d5k9iA_, 0.7928, 2.10, 0.343, 258, 245, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH A COVALENT LYSINE PROBE
1271, d3ehaA1, 0.7928, 2.81, 0.230, 275, 257, CRYSTAL STRUCTURE OF DEATH ASSOCIATED PROTEIN KINASE COMPLEXED WITH AMPPNP
1272, d5vefA_, 0.7927, 2.80, 0.195, 289, 257, PAK4 KINASE DOMAIN IN COMPLEX WITH FASUDIL
1273, d5tehB_, 0.7927, 2.21, 0.341, 262, 246, C-SRC V281C KINASE DOMAIN IN COMPLEX WITH RAO-IV-156
1274, d5am7B_, 0.7927, 2.68, 0.369, 287, 255, FGFR1 MUTANT WITH AN INHIBITOR
1275, d5orsA_, 0.7926, 2.70, 0.227, 264, 255, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1276, d4l7sB1, 0.7926, 2.23, 0.322, 248, 245, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH AN AMINOBENZOTHIAZOLE INHIBITOR
1277, d3oxzA1, 0.7926, 2.10, 0.343, 267, 245, CRYSTAL STRUCTURE OF ABL KINASE DOMAIN BOUND WITH A DFG-OUT INHIBITOR AP24534
1278, d1jkkA_, 0.7926, 2.81, 0.230, 277, 257, 2.4A X-RAY STRUCTURE OF TERNARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE AND MG.
1279, d5av4A_, 0.7925, 2.87, 0.230, 274, 257, CRYSTAL STRUCTURE OF DAPK1-GENISTEIN COMPLEX IN THE PRESENCE OF BROMIDE IONS.
1280, d4utdA_, 0.7925, 2.78, 0.235, 266, 255, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) BOUND TO AMPPCP IN AN ACTIVE CONFORMATION
1281, d3orxB_, 0.7925, 2.74, 0.219, 280, 256, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
1282, d2y7jD_, 0.7925, 2.79, 0.217, 281, 258, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
1283, d2y7jC_, 0.7925, 2.78, 0.221, 284, 258, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
1284, d2vx1A_, 0.7925, 3.03, 0.290, 274, 259, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
1285, d2ou7A_, 0.7925, 3.00, 0.288, 292, 260, STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN POLO-LIKE KINASE 1
1286, d2hyyA_, 0.7925, 2.38, 0.341, 263, 249, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
1287, d5jfwA_, 0.7924, 2.39, 0.369, 277, 249, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-05247452
1288, d5av2A_, 0.7924, 2.82, 0.230, 275, 257, CRYSTAL STRUCTURE OF DAPK1-KAEMPFEROL COMPLEX IN THE PRESENCE OF BROMIDE IONS.
1289, d4ybkA_, 0.7924, 2.46, 0.344, 266, 250, C-HELIX-OUT DASATINIB ANALOG CRYSTALLIZED WITH C-SRC KINASE
1290, d4riwA_, 0.7924, 2.55, 0.354, 269, 254, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
1291, d4d5kB_, 0.7924, 2.49, 0.379, 256, 248, FOCAL ADHESION KINASE CATALYTIC DOMAIN
1292, d5ew8B_, 0.7923, 2.95, 0.372, 290, 258, FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH JNJ-4275693
1293, d5auxA_, 0.7923, 2.82, 0.230, 275, 257, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH KAEMPFEROL.
1294, d3my0A1, 0.7923, 3.42, 0.231, 295, 268, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
1295, d2vwyA_, 0.7923, 2.85, 0.276, 274, 257, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
1296, d2qluA1, 0.7923, 2.82, 0.241, 295, 257, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE II KINASE DOMAIN FROM HUMAN
1297, d1ig1A_, 0.7923, 2.81, 0.230, 280, 257, 1.8A X-RAY STRUCTURE OF TERNARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE AND MN.
1298, d5jfsA_, 0.7922, 2.50, 0.384, 277, 250, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-00593174
1299, d4fijA_, 0.7922, 2.81, 0.195, 291, 257, CATALYTIC DOMAIN OF HUMAN PAK4
1300, d3rwqA_, 0.7922, 2.93, 0.221, 283, 258, DISCOVERY OF A NOVEL POTENT AND SELECTIVE INHIBITOR OF 3- PHOSPHOINOSITIDE DEPENDENT KINASE (PDK1)
1301, d2q0nA_, 0.7922, 2.84, 0.194, 293, 258, STRUCTURE OF HUMAN P21 ACTIVATING KINASE 4 (PAK4) IN COMPLEX WITH A CONSENSUS PEPTIDE
1302, d5ng2A_, 0.7921, 2.51, 0.250, 274, 252, STRUCTURE OF RIP2K(D146N) WITH BOUND STAUROSPORINE
1303, d5m4iA_, 0.7921, 2.75, 0.195, 331, 257, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO-FLAVONOL (FLC21) CRYSTALLIZED UNDER HIGH-SALT CONDITIONS
1304, d4riyA_, 0.7921, 2.63, 0.357, 269, 255, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
1305, d4fihA_, 0.7921, 2.81, 0.195, 291, 257, CATALYTIC DOMAIN OF HUMAN PAK4 WITH QKFTGLPRQW PEPTIDE
1306, d3vvhA1, 0.7921, 3.02, 0.194, 286, 258, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH AN INHIBITOR AND MGATP
1307, d5hzeA_, 0.7920, 2.83, 0.187, 305, 256, MEK1 ADOPTS DFG-OUT CONFORMATION WHEN BOUND TO AN ANALOG OF E6201.
1308, d4w8eA_, 0.7920, 3.08, 0.258, 290, 260, STRUCTURE OF MST3 WITH A PYRROLOPYRIMIDINE INHIBITOR (PF-06645342)
1309, d4u81A1, 0.7920, 3.02, 0.201, 288, 259, MEK1 KINASE BOUND TO SMALL MOLECULE INHIBITOR G659
1310, d4pf4A1, 0.7920, 2.80, 0.226, 277, 257, 1.1A X-RAY STRUCTURE OF THE APO CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE 1 AA 1-277
1311, d3wj6A_, 0.7920, 2.59, 0.360, 282, 253,  
1312, d3v04A1, 0.7920, 3.01, 0.201, 288, 259, DISCOVERY OF NOVEL ALLOSTERIC MEK INHIBITORS POSSESSING CLASSICAL AND NON-CLASSICAL BIDENTATE SER212 INTERACTIONS.
1313, d2phkA_, 0.7920, 2.65, 0.219, 277, 256, THE CRYSTAL STRUCTURE OF A PHOSPHORYLASE KINASE PEPTIDE SUBSTRATE COMPLEX: KINASE SUBSTRATE RECOGNITION
1314, d2j0iA_, 0.7920, 3.03, 0.219, 289, 260, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4
1315, d2ijmA_, 0.7920, 2.43, 0.360, 260, 250, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN WITH 2 MOLECULES IN THE ASYMMETRIC UNIT COMPLEXED WITH ADP AND ATP
1316, d5fboA_, 0.7919, 2.28, 0.321, 255, 249, BTK-INHIBITOR CO-STRUCTURE
1317, d5b7vA_, 0.7919, 2.59, 0.360, 282, 253, HUMAN FGFR1 KINASE IN COMPLEX WITH CH5183284
1318, d4lmnA1, 0.7919, 2.95, 0.198, 291, 258, CRYSTAL STRUCTURE OF MEK1 KINASE BOUND TO GDC0973
1319, d4jdhA_, 0.7919, 2.88, 0.194, 289, 258, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 IN COMPLEX WITH PAKTIDE T PEPTIDE SUBSTRATE
1320, d4bn1A_, 0.7919, 2.77, 0.235, 261, 255, CRYSTAL STRUCTURE OF V174M MUTANT OF AURORA-A KINASE
1321, d2jkkA_, 0.7919, 2.59, 0.361, 258, 252, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
1322, d4mneC_, 0.7918, 2.33, 0.259, 260, 251, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
1323, d4l7sA1, 0.7918, 2.23, 0.322, 248, 245, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH AN AMINOBENZOTHIAZOLE INHIBITOR
1324, d4a06A_, 0.7918, 2.93, 0.233, 282, 257, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC ACTIVATOR PS114 BOUND TO THE PIF-POCKET
1325, d3q4uB1, 0.7918, 3.26, 0.243, 298, 263, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
1326, d2hiwB1, 0.7918, 2.38, 0.340, 270, 250, CRYSTAL STRUCTURE OF INACTIVE CONFORMATION ABL KINASE CATALYTIC DOMAIN COMPLEXED WITH TYPE II INHIBITOR
1327, d5ng3A_, 0.7917, 2.52, 0.249, 283, 253, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
1328, d3zm4A_, 0.7917, 2.85, 0.195, 309, 256, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 1
1329, d3q9xB_, 0.7917, 2.90, 0.190, 330, 258, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH EMODIN AT PH 6.5
1330, d3hrfA_, 0.7917, 2.97, 0.233, 284, 258, CRYSTAL STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH AN ALLOSTERIC ACTIVATOR BOUND TO THE PIF-POCKET
1331, d3g6gB_, 0.7917, 2.37, 0.332, 263, 247, EQUALLY POTENT INHIBITION OF C-SRC AND ABL BY COMPOUNDS THAT RECOGNIZE INACTIVE KINASE CONFORMATIONS
1332, d3el8A_, 0.7917, 2.49, 0.345, 263, 249, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH PYRAZOLOPYRIMIDINE 5
1333, d1ol5A_, 0.7917, 2.90, 0.230, 263, 256, STRUCTURE OF AURORA-A 122-403 PHOSPHORYLATED ON THR287 THR288 AND BOUND TO TPX2 1-43
1334, d5imxA_, 0.7916, 2.06, 0.307, 266, 244, ANAPLASTIC LYMPHOMA KINASE (ALK) CATALYTIC DOMAIN COMPLEXED WITH NOVEL INHIBITOR 3-SULFONYLPYRAZOL-4-AMINO PYRIMIDINE
1335, d5auuA_, 0.7916, 2.89, 0.230, 274, 257, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH LUTEOLIN.
1336, d4fbxA_, 0.7916, 2.80, 0.191, 333, 257, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT CRYSTALLIZED IN THE PRESENCE OF A BISUBSTRATE INHIBITOR
1337, d3my0B_, 0.7916, 3.50, 0.230, 295, 269, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
1338, d3h3cA_, 0.7916, 2.43, 0.344, 263, 250, CRYSTAL STRUCTURE OF PYK2 IN COMPLEX WITH SULFOXIMINE- SUBSTITUTED TRIFLUOROMETHYLPYRIMIDINE ANALOG
1339, d2p55A2, 0.7916, 3.03, 0.201, 288, 259, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
1340, d1agwA_, 0.7916, 2.63, 0.366, 278, 254, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU4984 INHIBITOR
1341, d6babC_, 0.7915, 2.38, 0.215, 284, 251, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
1342, d4rixA_, 0.7915, 2.64, 0.361, 269, 255, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
1343, d4brxA_, 0.7915, 2.66, 0.360, 259, 253, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH A DIARYLAMINO-135-TRIAZINE INHIBITOR
1344, d3beaA_, 0.7915, 3.01, 0.328, 310, 256, CFMS TYROSINE KINASE (TIE2 KID) IN COMPLEX WITH A PYRIMIDINOPYRIDONE INHIBITOR
1345, d5oxgB_, 0.7914, 3.12, 0.240, 296, 262, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
1346, d5bmsA1, 0.7914, 3.05, 0.204, 289, 260, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 4 IN COMPLEX WITH AN INHIBITOR COMPOUND 29
1347, d3f82A_, 0.7914, 2.19, 0.343, 278, 245, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH N- (4-(2-AMINO-3-CHLOROPYRIDIN-4-YLOXY)-3-FLUOROPHENYL)-4- ETHOXY-1-(4-FLUOROPHENYL)-2-OXO-12-DIHYDROPYRIDINE-3- CARBOXAMIDE
1348, d1lufA_, 0.7914, 2.59, 0.300, 275, 250, CRYSTAL STRUCTURE OF THE MUSK TYROSINE KINASE: INSIGHTS INTO RECEPTOR AUTOREGULATION
1349, d3slsB1, 0.7913, 2.73, 0.196, 291, 255, CRYSTAL STRUCTURE OF HUMAN MEK-1 KINASE IN COMPLEX WITH UCB1353770 AND AMPPNP
1350, d3lvpD_, 0.7913, 2.42, 0.315, 282, 251, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
1351, d5jfvA_, 0.7912, 2.41, 0.369, 277, 249, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-05206283
1352, d4jdjA_, 0.7912, 2.94, 0.190, 288, 258, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 F461V MUTANT IN COMPLEX WITH PAKTIDE T PEPTIDE SUBSTRATE
1353, d4f64A_, 0.7912, 2.64, 0.366, 278, 254, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 6
1354, d3u51A_, 0.7912, 2.06, 0.342, 256, 243, SRC IN COMPLEX WITH DNA-TEMPLATED MACROCYCLIC INHIBITOR MC1
1355, d1kobA_, 0.7912, 2.89, 0.211, 352, 261, TWITCHIN KINASE FRAGMENT (APLYSIA) AUTOREGULATED PROTEIN KINASE DOMAIN
1356, d4e26A_, 0.7911, 2.83, 0.267, 270, 258, BRAF IN COMPLEX WITH AN ORGANIC INHIBITOR 7898734
1357, d1koaA2, 0.7911, 2.87, 0.177, 350, 260, TWITCHIN KINASE FRAGMENT (C.ELEGANS) AUTOREGULATED PROTEIN KINASE AND IMMUNOGLOBULIN DOMAINS
1358, d5hu9A1, 0.7910, 2.65, 0.341, 262, 252, CRYSTAL STRUCTURE OF ABL1 IN COMPLEX WITH CHMFL-074
1359, d5fd2A_, 0.7910, 2.68, 0.283, 264, 254, B-RAF WILD-TYPE KINASE DOMAIN IN COMPLEX WITH A PURINYLPYRIDINYLAMINO- BASED INHIBITOR
1360, d4appA1, 0.7910, 3.10, 0.212, 290, 260, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH (S)-N-(5-(3-BENZYL-1-METHYLPIPERAZINE-4- CARBONYL)-66-DIMETHYL-1456-TETRAHYDROPYRROLO(34-C) PYRAZOL-3-YL)-3-PHENOXYBENZAMIDE
1361, d3qa0B_, 0.7910, 2.82, 0.187, 330, 257, CRYSTAL STRUCTURE OF THE APO-FORM OF HUMAN CK2 ALPHA AT PH 6.5
1362, d3i5nA_, 0.7910, 2.50, 0.351, 280, 248, CRYSTAL STRUCTURE OF C-MET WITH TRIAZOLOPYRIDAZINE INHIBITOR 13
1363, d1ol7A_, 0.7910, 2.69, 0.229, 261, 253, STRUCTURE OF HUMAN AURORA-A 122-403 PHOSPHORYLATED ON THR287 THR288
1364, d1fgkA_, 0.7910, 2.70, 0.361, 278, 255, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1
1365, d2jkqA_, 0.7909, 2.54, 0.363, 258, 251, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
1366, d5lvnA_, 0.7908, 2.93, 0.237, 283, 257, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ADENOSINE BOUND TO THE ATP- BINDING SITE
1367, d4fzaB1, 0.7908, 2.83, 0.237, 280, 257, CRYSTAL STRUCTURE OF MST4-MO25 COMPLEX
1368, d3v01A1, 0.7908, 2.97, 0.198, 288, 258, DISCOVERY OF NOVEL ALLOSTERIC MEK INHIBITORS POSSESSING CLASSICAL AND NON-CLASSICAL BIDENTATE SER212 INTERACTIONS.
1369, p2y4iC_, 0.7908, 2.86, 0.198, 313, 257, KSR2-MEK1 HETERODIMER
1370, d5iuhA_, 0.7907, 2.31, 0.308, 285, 247, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE (ALK) IN COMPLEX WITH 5D
1371, d5auzA_, 0.7907, 2.90, 0.230, 274, 257, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH GENISTEIN.
1372, d4kioC1, 0.7907, 2.32, 0.321, 249, 246, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH A COVALENTLY-BINDING INHIBITOR
1373, d4fnwA_, 0.7907, 2.65, 0.302, 304, 252, CRYSTAL STRUCTURE OF THE APO F1174L ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
1374, d4cegA_, 0.7907, 2.74, 0.227, 264, 255, CRYSTAL STRUCTURE OF AURORA A 122-403 C290A C393A BOUND TO ADP
1375, d1s9iA_, 0.7907, 3.01, 0.201, 303, 259, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (MEK2)IN A COMPLEX WITH LIGAND AND MGATP
1376, d5iugA_, 0.7906, 2.37, 0.310, 285, 248, CRYSTAL STRUCTURE OF ANAPLASTIC LYMPHOMA KINASE (ALK) IN COMPLEX WITH 5A
1377, d4rwkB_, 0.7906, 2.76, 0.379, 282, 256, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) IN COMPLEX WITH N-{3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H- PYRAZOL-5-YL}-4-[(3R5S)-35-DIMETHYLPIPERAZIN-1-YL]BENZAMIDE (AZD4547)
1378, d4f63A_, 0.7906, 2.72, 0.361, 278, 255, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 1
1379, d4aw0A_, 0.7906, 2.93, 0.237, 283, 257, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND PS182 BOUND TO THE PIF-POCKET
1380, d2fgiA_, 0.7906, 2.57, 0.368, 274, 253, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 1 IN COMPLEX WITH INHIBITOR PD173074
1381, d4anlA_, 0.7905, 2.81, 0.294, 292, 255, STRUCTURE OF G1269A MUTANT ANAPLASTIC LYMPHOMA KINASE
1382, d1mq4A_, 0.7905, 2.81, 0.231, 261, 255, CRYSTAL STRUCTURE OF AURORA-A PROTEIN KINASE
1383, d4d4vB_, 0.7904, 2.49, 0.381, 255, 247, FOCAL ADHESION KINASE CATALYTIC DOMAIN
1384, p3u9cB_, 0.7904, 2.91, 0.194, 331, 258, STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE ATP-COMPETITIVE INHIBITOR RESORUFIN
1385, d3q6uA1, 0.7904, 2.63, 0.339, 281, 251, STRUCTURE OF THE APO MET RECEPTOR KINASE IN THE DUALLY-PHOSPHORYLATED ACTIVATED STATE
1386, d2vwzA_, 0.7904, 2.86, 0.284, 274, 257, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
1387, d2ijmB_, 0.7904, 2.40, 0.361, 261, 249, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN WITH 2 MOLECULES IN THE ASYMMETRIC UNIT COMPLEXED WITH ADP AND ATP
1388, d5a46A_, 0.7903, 2.93, 0.381, 289, 257, FGFR1 IN COMPLEX WITH DOVITINIB
1389, d3my0C1, 0.7903, 3.53, 0.230, 298, 269, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
1390, d2ogvA_, 0.7903, 2.98, 0.336, 317, 256, CRYSTAL STRUCTURE OF THE AUTOINHIBITED HUMAN C-FMS KINASE DOMAIN
1391, d5ortA_, 0.7902, 2.73, 0.227, 264, 255, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1392, d5ar5A_, 0.7902, 2.36, 0.247, 284, 251, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BENZIMIDAZOLE
1393, d5ar2B_, 0.7902, 2.34, 0.247, 285, 251, RIP2 KINASE CATALYTIC DOMAIN (1 - 310)
1394, d4rixC_, 0.7902, 2.52, 0.360, 275, 253, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
1395, d4agdA_, 0.7902, 2.97, 0.348, 303, 256, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH SUNITINIB (SU11248) (N-2- DIETHYLAMINOETHYL)-5-((Z)-(5-FLUORO-2-OXO-1H-INDOL-3- YLIDENE)METHYL)-24-DIMETHYL-1H-PYRROLE-3-CARBOXAMIDE)
1396, d3dkgA_, 0.7902, 2.33, 0.328, 281, 247, STRUCTURE OF MUTANT(Y1248L) MET RECEPTOR TYROSINE KINASE IN COMPLEX WITH INHIBITOR SGX-523
1397, d3ccnA_, 0.7902, 2.37, 0.351, 275, 245, X-RAY STRUCTURE OF C-MET WITH TRIAZOLOPYRIDAZINE INHIBITOR.
1398, d2vwxA_, 0.7902, 2.96, 0.279, 274, 258, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
1399, d4mcvB_, 0.7901, 2.34, 0.343, 265, 248, STAR 12 BOUND TO ANALOG-SENSITIVE SRC KINASE
1400, d4f0iB_, 0.7901, 2.81, 0.366, 294, 254, CRYSTAL STRUCTURE OF APO TRKA
1401, d4cmtA_, 0.7901, 2.57, 0.300, 284, 250, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 3-((1R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)-5-(3-(METHYLSULFONYL)PHENYL)PYRIDIN-2-AMINE
1402, d4at5A1, 0.7901, 2.84, 0.374, 291, 254, CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH GW2580
1403, d2xzsA_, 0.7901, 3.05, 0.222, 301, 261, DEATH ASSOCIATED PROTEIN KINASE 1 RESIDUES 1-312
1404, d2x4fA_, 0.7901, 2.61, 0.230, 289, 256, THE CRYSTAL STRUCTURE OF THE HUMAN MYOSIN LIGHT CHAIN KINASE LOC340156.
1405, d4ct1A_, 0.7899, 3.02, 0.240, 283, 258, HUMAN PDK1-PKCZETA KINASE CHIMERA IN COMPLEX WITH ALLOSTERIC COMPOUND PS315 BOUND TO THE PIF-POCKET
1406, d4jdkA_, 0.7898, 3.01, 0.201, 288, 259, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 F461V MUTANT IN COMPLEX WITH PAKTIDE S PEPTIDE SUBSTRATE
1407, d3h9rA_, 0.7898, 2.98, 0.256, 312, 258, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TYPE I ACTIVIN RECEPTOR (ACVR1) IN COMPLEX WITH FKBP12 AND DORSOMORPHIN
1408, d3d5uA_, 0.7898, 2.90, 0.247, 288, 259, CRYSTAL STRUCTURE OF A WILDTYPE POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN.
1409, d1h1wA_, 0.7898, 2.96, 0.225, 284, 258, HIGH RESOLUTION CRYSTAL STRUCTURE OF THE HUMAN PDK1 CATALYTIC DOMAIN
1410, d4pp9B1, 0.7897, 2.12, 0.313, 246, 243, ITK KINASE DOMAIN WITH COMPOUND 1 (N-[1-(3-CYANOBENZYL)-1H-PYRAZOL-4- YL]-2H-INDAZOLE-3-CARBOXAMIDE)
1411, d3ha6A1, 0.7897, 2.94, 0.230, 262, 256, CRYSTAL STRUCTURE OF AURORA A IN COMPLEX WITH TPX2 AND COMPOUND 10
1412, d3aoxA_, 0.7897, 2.70, 0.300, 298, 253, X-RAY CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CH5424802
1413, d4riyC_, 0.7896, 2.54, 0.356, 275, 253, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
1414, d4mcvA_, 0.7896, 2.30, 0.343, 267, 248, STAR 12 BOUND TO ANALOG-SENSITIVE SRC KINASE
1415, d3f5uA1, 0.7896, 2.81, 0.230, 275, 256, CRYSTAL STRUCTURE OF THE DEATH ASSOCIATED PROTEIN KINASE IN COMPLEX WITH AMPPNP AND MG2+
1416, d1kobB_, 0.7896, 2.87, 0.215, 352, 260, TWITCHIN KINASE FRAGMENT (APLYSIA) AUTOREGULATED PROTEIN KINASE DOMAIN
1417, d5ia2A_, 0.7895, 2.68, 0.324, 287, 253, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 66
1418, d5em5A_, 0.7895, 2.41, 0.355, 298, 248, EGFR KINASE DOMAIN MUTANT TMLR WITH PYRIDONE COMPOUND 2: 4-[2-(4- CHLOROPHENYL)ETHYLAMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-2- OXIDANYLIDENE-1~{H}-PYRIDINE-3-CARBOXAMIDE
1419, d4qmsA_, 0.7895, 3.17, 0.264, 283, 261, MST3 IN COMPLEX WITH DASATINIB
1420, d3rpsB_, 0.7895, 2.82, 0.195, 334, 257, STRUCTURE OF HUMAN CK2ALPHA IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 3-(4567-TETRABROMO-1H-BENZOTRIAZOL-1-YL)PROPAN-1-OL
1421, d5oy6B_, 0.7894, 2.97, 0.246, 292, 260, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
1422, d4uwbB_, 0.7894, 2.97, 0.374, 299, 257, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P5
1423, d4md7H_, 0.7894, 2.93, 0.190, 330, 258, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
1424, d3my0U1, 0.7894, 3.43, 0.232, 284, 267, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
1425, d2uztA_, 0.7894, 2.82, 0.251, 336, 255, PKA STRUCTURES OF AKT INDAZOLE-PYRIDINE INHIBITORS
1426, d1uvrA_, 0.7894, 3.07, 0.228, 284, 259, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-8
1427, d5oxgD_, 0.7893, 3.16, 0.240, 293, 262, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
1428, d4riwC_, 0.7893, 2.54, 0.360, 275, 253, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
1429, d3krjA_, 0.7893, 2.93, 0.332, 304, 253, CFMS TYROSINE KINASE IN COMPLEX WITH 4-CYANO-1H-IMIDAZOLE-2-CARBOXYLIC ACID (2-CYCLOHEX-1-ENYL-4-PIPERIDIN-4-YL-PHENYL)-AMIDE
1430, d2y7jA_, 0.7893, 2.83, 0.221, 284, 258, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
1431, d5hlwA_, 0.7892, 2.70, 0.332, 284, 250, CRYSTAL STRUCTURE OF C-MET MUTANT Y1230H IN COMPLEX WITH COMPOUND 14
1432, d5autA_, 0.7892, 2.82, 0.230, 274, 256, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH ANS.
1433, d4r7hA_, 0.7891, 2.90, 0.340, 308, 253, CRYSTAL STRUCTURE OF FMS KINASE DOMAIN WITH A SMALL MOLECULAR INHIBITOR PLX3397
1434, d3svvA_, 0.7891, 2.31, 0.329, 261, 246, CRYSTAL STRUCTURE OF T338C C-SRC COVALENTLY BOUND TO VINYLSULFONAMIDE- PYRAZOLOPYRIMIDINE 9
1435, d3g5dB_, 0.7891, 1.99, 0.342, 257, 243, KINASE DOMAIN OF CSRC IN COMPLEX WITH DASATINIB
1436, d3f3tB_, 0.7891, 2.05, 0.337, 259, 243, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL38 (TYPE III)
1437, d5d12A_, 0.7890, 2.18, 0.347, 260, 245, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL40
1438, d3q9zB_, 0.7890, 2.75, 0.187, 332, 256, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH QUINALIZARIN AT PH 6.5
1439, d2yhvA_, 0.7890, 2.81, 0.303, 291, 254, STRUCTURE OF L1196M MUTANT ANAPLASTIC LYMPHOMA KINASE
1440, d5uafA_, 0.7889, 2.35, 0.348, 291, 244, MET TYROSINE KINASE INHIBITION ENHANCES THE ANTITUMOR EFFICACY OF AN HGF ANTIBODY
1441, d5uadA_, 0.7889, 2.35, 0.348, 291, 244, MET TYROSINE KINASE INHIBITION ENHANCES THE ANTITUMOR EFFICACY OF AN HGF ANTIBODY
1442, d4md7G_, 0.7889, 2.94, 0.190, 332, 258, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
1443, p3u9cA_, 0.7889, 2.94, 0.190, 331, 258, STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE ATP-COMPETITIVE INHIBITOR RESORUFIN
1444, d3pxkA_, 0.7889, 2.26, 0.362, 256, 246, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH PYRROLO[23- D]THIAZOLE
1445, d3cquA_, 0.7889, 2.77, 0.246, 318, 256, CRYSTAL STRUCTURE OF AKT-1 COMPLEXED WITH SUBSTRATE PEPTIDE AND INHIBITOR
1446, d2hy81_, 0.7889, 3.14, 0.202, 293, 262, PAK1 COMPLEX WITH ST2001
1447, d1zwsD_, 0.7889, 3.00, 0.204, 278, 260, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
1448, d4yneA1, 0.7888, 2.29, 0.387, 276, 248, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
1449, d4rwlA_, 0.7888, 2.67, 0.366, 282, 254, CRYSTAL STRUCTURE OF FGFR1 (C488A C584C) IN COMPLEX WITH 6-(7-((1- AMINOCYCLOPROPYL) METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1- NAPHTHAMIDE (E3810)
1450, d3my0D1, 0.7888, 3.44, 0.232, 297, 267, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
1451, d3fwqA_, 0.7888, 2.80, 0.191, 334, 257, INACTIVE CONFORMATION OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT
1452, d3ckxA_, 0.7888, 2.84, 0.263, 276, 255, CRYSTAL STRUCTURE OF STERILE 20-LIKE KINASE 3 (MST3 STK24) IN COMPLEX WITH STAUROSPORINE
1453, d3u6jA1, 0.7887, 3.07, 0.344, 305, 256, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRAZOLONE INHIBITOR
1454, d3slsA1, 0.7887, 2.59, 0.198, 289, 253, CRYSTAL STRUCTURE OF HUMAN MEK-1 KINASE IN COMPLEX WITH UCB1353770 AND AMPPNP
1455, d3qlfB_, 0.7887, 2.16, 0.340, 258, 244, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH PYRAZOLOPYRIMIDINE 5
1456, d3lq8A_, 0.7887, 2.57, 0.341, 278, 249, STRUCTURE OF THE KINASE DOMAIN OF C-MET BOUND TO XL880 (GSK1363089)
1457, d3f66B_, 0.7887, 2.39, 0.350, 269, 246, HUMAN C-MET KINASE IN COMPLEX WITH QUINOXALINE INHIBITOR
1458, d3en5B_, 0.7887, 2.22, 0.347, 261, 245, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP494 A MULTITARGETED KINASE INHIBITOR
1459, d5i4nA1, 0.7886, 2.72, 0.264, 273, 254, CRYSTAL STRUCTURE OF THE E596A V617F MUTANT JAK2 PSEUDOKINASE DOMAIN BOUND TO MG-ATP
1460, d4qmyA_, 0.7886, 3.23, 0.264, 287, 261, MST3 IN COMPLEX WITH STAUROSPORINE
1461, p4md9F_, 0.7886, 2.80, 0.191, 327, 256, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
1462, d4md7F_, 0.7886, 2.94, 0.190, 332, 258, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
1463, d3juhB_, 0.7886, 2.95, 0.198, 334, 258, CRYSTAL STRUCTURE OF A MUTANT OF HUMAN PROTEIN KINASE CK2ALPHA WITH ALTERED COSUBSTRATE SPECIFICITY
1464, d3iw4C_, 0.7886, 2.91, 0.242, 332, 260, CRYSTAL STRUCTURE OF PKC ALPHA IN COMPLEX WITH NVP-AEB071
1465, d5kmnA1, 0.7885, 2.86, 0.378, 290, 254, TRKA JM-KINASE WITH 1-(2-METHYL-4-PHENYL-PYRIMIDIN-5-YL)-3-[[2- (TRIFLUOROMETHYL)PHENYL]METHYL]UREA
1466, d4xcuA1, 0.7885, 2.93, 0.358, 287, 257, CRYSTAL STRUCTURE OF FGFR4 WITH AN IRREVERSIBLE INHIBITOR
1467, d4wsqA_, 0.7885, 2.92, 0.208, 317, 255, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE (AAK1) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1468, d4uxqA_, 0.7885, 2.77, 0.362, 286, 254, FGFR4 IN COMPLEX WITH PONATINIB
1469, d3rp0D_, 0.7885, 2.78, 0.187, 329, 256,  
1470, d2hznA2, 0.7885, 2.39, 0.335, 268, 248, ABL KINASE DOMAIN IN COMPLEX WITH NVP-AFG210
1471, d2gcdB_, 0.7885, 2.99, 0.270, 308, 259, TAO2 KINASE DOMAIN-STAUROSPORINE STRUCTURE
1472, d2cdzA_, 0.7885, 2.78, 0.200, 289, 255, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH CGP74514A
1473, d3vw8A_, 0.7884, 2.61, 0.348, 303, 250, CRYSTAL STRUCTURE OF HUMAN C-MET KINASE DOMAIN WITH ITS INHIBITOR
1474, d3rcjA_, 0.7884, 3.12, 0.236, 281, 259, RAPID PREPARATION OF TRIAZOLYL SUBSTITUTED NH-HETEROCYCLIC KINASE INHIBITORS VIA ONE-POT SONOGASHIRA COUPLING TMS-DEPROTECTION CUAAC SEQUENCE
1475, d2jdrA_, 0.7884, 2.90, 0.241, 316, 257, STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH THE INHIBITOR A- 443654
1476, d1snxB_, 0.7884, 2.03, 0.314, 245, 242, CRYSTAL STRUCTURE OF APO INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
1477, d1s9iB_, 0.7884, 2.85, 0.200, 291, 255, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (MEK2)IN A COMPLEX WITH LIGAND AND MGATP
1478, d5e8vA_, 0.7883, 3.03, 0.218, 296, 261, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A)
1479, d4qmtA_, 0.7883, 3.18, 0.258, 284, 260, MST3 IN COMPLEX WITH HESPERADIN
1480, p5owlB_, 0.7882, 2.85, 0.191, 332, 257, LOW SALT STRUCTURE OF HUMAN PROTEIN KINASE CK2ALPHA IN COMPLEX WITH 3- AMINOPROPYL-4;5;6;7-TETRABROMOBENZIMIDAZOL 
1481, d4ks7A_, 0.7882, 3.09, 0.212, 286, 260, PAK6 KINASE DOMAIN IN COMPLEX WITH PF-3758309
1482, d3u51B_, 0.7882, 2.06, 0.343, 255, 242, SRC IN COMPLEX WITH DNA-TEMPLATED MACROCYCLIC INHIBITOR MC1
1483, d3ms9B1, 0.7882, 2.40, 0.339, 267, 248, ABL KINASE IN COMPLEX WITH IMATINIB AND A FRAGMENT (FRAG1) IN THE MYRISTATE POCKET
1484, d1zwsB_, 0.7882, 2.94, 0.208, 278, 259, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
1485, d1snxA_, 0.7882, 2.04, 0.314, 245, 242, CRYSTAL STRUCTURE OF APO INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
1486, d5orlA_, 0.7881, 2.68, 0.220, 264, 254, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1487, d4wunA_, 0.7881, 2.44, 0.386, 282, 249, STRUCTURE OF FGFR1 IN COMPLEX WITH AZD4547 (N-{3-[2-(35- DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE) AT 1.65 ANGSTROM
1488, d4mneE_, 0.7881, 3.16, 0.196, 286, 260, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
1489, d3g0fB_, 0.7881, 3.01, 0.341, 293, 255, KIT KINASE DOMAIN MUTANT D816H IN COMPLEX WITH SUNITINIB
1490, d3el8B_, 0.7881, 2.13, 0.350, 259, 243, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH PYRAZOLOPYRIMIDINE 5
1491, d1ymiA_, 0.7881, 2.94, 0.198, 334, 258,  
1492, d4uy9B_, 0.7880, 2.84, 0.320, 315, 256, STRUCTURE OF MLK1 KINASE DOMAIN WITH LEUCINE ZIPPER 1
1493, d4md7E_, 0.7880, 2.95, 0.190, 332, 258, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
1494, d4ct2A_, 0.7880, 2.75, 0.244, 277, 254, HUMAN PDK1-PKCZETA KINASE CHIMERA
1495, d4aw1A_, 0.7880, 2.89, 0.243, 283, 255, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND PS210 BOUND TO THE PIF-POCKET
1496, d2bujA1, 0.7880, 3.06, 0.204, 283, 260, CRYSTAL STRUCTURE OF THE HUMAN SERINE-THREONINE KINASE 16 IN COMPLEX WITH STAUROSPORINE
1497, d5j5sA_, 0.7879, 2.00, 0.329, 258, 243, SRC KINASE IN COMPLEX WITH A SULFONAMIDE INHIBITOR
1498, d4dggA_, 0.7879, 2.24, 0.339, 261, 245, C-SRC KINASE DOMAIN IN COMPLEX WITH RM-1-176
1499, d3rpsA_, 0.7879, 2.84, 0.191, 334, 257, STRUCTURE OF HUMAN CK2ALPHA IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 3-(4567-TETRABROMO-1H-BENZOTRIAZOL-1-YL)PROPAN-1-OL
1500, d3cc6A_, 0.7879, 2.91, 0.323, 269, 257, CRYSTAL STRUCTURE OF KINASE DOMAIN OF PROTEIN TYROSINE KINASE 2 BETA (PTK2B)
1501, d3bw5A_, 0.7879, 2.95, 0.202, 334, 258,  
1502, d5nkgA_, 0.7878, 2.85, 0.320, 292, 256, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3D
1503, d5ng0A_, 0.7878, 2.51, 0.247, 274, 251, STRUCTURE OF RIP2K(L294F) WITH BOUND AMPPCP
1504, d4ludA3, 0.7878, 2.14, 0.361, 261, 241, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH THE FLUORESCENT COMPOUND SKF86002
1505, d2yjrA_, 0.7878, 2.32, 0.304, 278, 247, STRUCTURE OF F1174L MUTANT ANAPLASTIC LYMPHOMA KINASE
1506, d5f9eA1, 0.7877, 2.98, 0.267, 331, 258, STRUCTURE OF PROTEIN KINASE C THETA WITH COMPOUND 10: 22-DIMETHYL-7- (2-OXIDANYLIDENE-3~{H}-IMIDAZO[45-B]PYRIDIN-1-YL)-1-(PHENYLMETHYL)- 3~{H}-QUINAZOLIN-4-ONE
1507, d4qmzA_, 0.7877, 3.17, 0.258, 286, 260, MST3 IN COMPLEX WITH SUNITINIB
1508, d4qmxA_, 0.7877, 3.24, 0.264, 287, 261, MST3 IN COMPLEX WITH SARACATINIB
1509, d4qmuA_, 0.7877, 3.24, 0.264, 286, 261, MST3 IN COMPLEX WITH JNJ-7706621 4-({5-AMINO-1-[(26-DIFLUOROPHENYL) CARBONYL]-1H-124-TRIAZOL-3-YL}AMINO)BENZENESULFONAMIDE
1510, d4nkaB_, 0.7877, 2.87, 0.366, 287, 254, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 2
1511, d4o2pA_, 0.7876, 2.48, 0.351, 265, 248, KINASE DOMAIN OF CSRC IN COMPLEX WITH A SUBSTITUTED PYRAZOLOPYRIMIDINE
1512, p4md9M_, 0.7876, 2.85, 0.191, 331, 257, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
1513, d3p08B_, 0.7876, 2.52, 0.306, 258, 248, CRYSTAL STRUCTURE OF THE HUMAN BTK KINASE DOMAIN
1514, d3lvpA_, 0.7876, 2.76, 0.310, 289, 255, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
1515, d2ptkA3, 0.7876, 2.08, 0.339, 259, 242, CHICKEN SRC TYROSINE KINASE
1516, d2eufB_, 0.7876, 2.81, 0.198, 282, 257, X-RAY STRUCTURE OF HUMAN CDK6-VCYCLIN IN COMPLEX WITH THE INHIBITOR PD0332991
1517, d3ce3A_, 0.7875, 3.07, 0.331, 293, 257, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A PYRROLOPYRIDINEPYRIDONE BASED INHIBITOR
1518, d1jktA_, 0.7875, 2.93, 0.225, 276, 258, TETRAGONAL CRYSTAL FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE
1519, d5veeA_, 0.7874, 3.17, 0.211, 289, 261, PAK4 KINASE DOMAIN IN COMPLEX WITH FRAX486
1520, d5oy6A_, 0.7874, 3.05, 0.247, 291, 259, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
1521, d5b7vB_, 0.7874, 2.76, 0.366, 277, 254, HUMAN FGFR1 KINASE IN COMPLEX WITH CH5183284
1522, d4qnaA_, 0.7874, 3.26, 0.264, 284, 261, MST3 IN COMPLEX WITH 2-(46-DIAMINO-135-TRIAZIN-2-YL)PHENOL
1523, d3wj6B_, 0.7874, 2.76, 0.366, 277, 254,  
1524, d3my0E1, 0.7874, 3.35, 0.234, 293, 265, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
1525, d3byuA_, 0.7874, 2.47, 0.356, 256, 247, CO-CRYSTAL STRUCTURE OF LCK AND AMINOPYRIMIDINE REVERSE AMIDE 23
1526, d2i0yA_, 0.7874, 3.02, 0.333, 289, 255, CFMS TYROSINE KINASE (FGF KID) IN COMPLEX WITH AN ARYLAMIDE INHIBITOR
1527, d3u87B_, 0.7873, 2.86, 0.191, 329, 257, STRUCTURE OF A CHIMERIC CONSTRUCT OF HUMAN CK2ALPHA AND HUMAN CK2ALPHA  IN COMPLEX WITH A NON-HYDROLYSABLE ATP-ANALOGUE
1528, d3my0G1, 0.7873, 3.35, 0.234, 293, 265, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
1529, d2i0vA_, 0.7873, 3.02, 0.329, 303, 255, C-FMS TYROSINE KINASE IN COMPLEX WITH A QUINOLONE INHIBITOR
1530, d1rejA_, 0.7873, 2.80, 0.244, 333, 254, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH BALANOL ANALOG 1
1531, p5omyA_, 0.7872, 2.86, 0.191, 332, 257, HIGH-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
1532, d3zh8C_, 0.7872, 3.13, 0.196, 312, 260, A NOVEL SMALL MOLECULE APKC INHIBITOR
1533, d3qtiA_, 0.7872, 2.58, 0.348, 292, 250, C-MET KINASE IN COMPLEX WITH NVP-BVU972
1534, d3mtfA_, 0.7872, 3.39, 0.238, 296, 265, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH A 2- AMINOPYRIDINE INHIBITOR
1535, d3db6A_, 0.7872, 2.97, 0.255, 287, 259, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH COMPOUND 902
1536, d2uzvA_, 0.7872, 2.96, 0.258, 336, 256, PKA STRUCTURES OF INDAZOLE-PYRIDINE SERIES OF AKT INHIBITORS
1537, d4qmlA_, 0.7871, 3.12, 0.270, 280, 259, MST3 IN COMPLEX WITH AMP-PNP
1538, d4gk4A_, 0.7871, 2.84, 0.302, 275, 255, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH LIGAND 90
1539, d4fvrA_, 0.7871, 2.72, 0.264, 274, 254, CRYSTAL STRUCTURE OF THE JAK2 PSEUDOKINASE DOMAIN MUTANT V617F (MG- ATP-BOUND FORM)
1540, d3fwqB_, 0.7871, 2.84, 0.195, 334, 257, INACTIVE CONFORMATION OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT
1541, d1zwsG_, 0.7871, 3.15, 0.211, 278, 261, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
1542, d5lvmA_, 0.7870, 3.00, 0.237, 283, 257, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ADENINE BOUND TO THE ATP- BINDING SITE
1543, d3zh8A_, 0.7870, 3.14, 0.196, 318, 260, A NOVEL SMALL MOLECULE APKC INHIBITOR
1544, d3oxtA_, 0.7870, 2.93, 0.251, 335, 255, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
1545, d3g0fA_, 0.7870, 2.98, 0.341, 291, 255, KIT KINASE DOMAIN MUTANT D816H IN COMPLEX WITH SUNITINIB
1546, d5ng3D_, 0.7869, 2.53, 0.246, 278, 252, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
1547, d4qmnA_, 0.7869, 3.28, 0.264, 283, 261, MST3 IN COMPLEX WITH BOSUTINIB
1548, p4md9K_, 0.7869, 2.93, 0.195, 328, 257, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
1549, d3uqgB_, 0.7869, 1.94, 0.344, 257, 241, C-SRC KINASE DOMAIN IN COMPLEX WITH BUMPLESS BKI ANALOG UW1243
1550, d3g0eA1, 0.7869, 2.93, 0.336, 330, 256, KIT KINASE DOMAIN IN COMPLEX WITH SUNITINIB
1551, d1wvwA_, 0.7869, 2.87, 0.222, 275, 257, CRYSTAL STRUCTURES OF KINASE DOMAIN OF DAP KINASE IN COMPLEX WITH SMALL MOLECULAR INHIBITORS
1552, d1u5rB_, 0.7869, 2.98, 0.260, 308, 258, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
1553, d5nkfA_, 0.7868, 2.91, 0.320, 291, 256, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3B
1554, d5cqwB_, 0.7868, 2.80, 0.184, 331, 256, TETRAGONAL COMPLEX STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A BENZOTRIAZOLE-BASED INHIBITOR GENERATED BY CLICK-CHEMISTRY
1555, d4nksB_, 0.7868, 2.78, 0.370, 271, 254, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 3
1556, p4md8F_, 0.7868, 2.95, 0.190, 332, 258, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
1557, d4h1jA_, 0.7868, 2.61, 0.356, 263, 253, CRYSTAL STRUCTURE OF PYK2 WITH THE PYRAZOLE 13A
1558, d2zjwA_, 0.7868, 2.71, 0.180, 332, 255, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA COMPLEXED WITH ELLAGIC ACID
1559, d1zwsC_, 0.7868, 2.95, 0.212, 278, 259, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
1560, d1uu7A_, 0.7868, 2.97, 0.222, 280, 257, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-2
1561, d4rwlB_, 0.7867, 2.91, 0.369, 285, 255, CRYSTAL STRUCTURE OF FGFR1 (C488A C584C) IN COMPLEX WITH 6-(7-((1- AMINOCYCLOPROPYL) METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1- NAPHTHAMIDE (E3810)
1562, p4md9G_, 0.7867, 2.83, 0.191, 329, 256, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
1563, d4bxaB_, 0.7867, 2.88, 0.191, 331, 257,  
1564, d3my0R1, 0.7867, 3.35, 0.234, 293, 265, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
1565, d1zwsF_, 0.7867, 3.02, 0.204, 278, 260, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
1566, p4md8H_, 0.7866, 2.95, 0.194, 331, 258, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
1567, p4md8G_, 0.7866, 2.95, 0.194, 332, 258, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
1568, p4ib5B_, 0.7866, 3.06, 0.199, 329, 261, STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH A CK2BETA-COMPETITIVE CYCLIC PEPTIDE
1569, d3rp0A_, 0.7866, 2.91, 0.187, 329, 257,  
1570, d3my0H1, 0.7866, 3.43, 0.233, 293, 266, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
1571, d3d5wA_, 0.7866, 3.04, 0.247, 284, 259, CRYSTAL STRUCTURE OF A PHOSPHORYLATED POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH ADP.
1572, d1zwsH_, 0.7866, 3.06, 0.212, 278, 260, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
1573, d1o6lA_, 0.7866, 2.94, 0.230, 316, 257, CRYSTAL STRUCTURE OF AN ACTIVATED AKT/PROTEIN KINASE B (PKB-PIF CHIMERA) TERNARY COMPLEX WITH AMP-PNP AND GSK3 PEPTIDE
1574, d5oy6C_, 0.7865, 3.22, 0.245, 291, 261, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
1575, d5h8eA_, 0.7865, 2.80, 0.187, 331, 256, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 7H
1576, d4gk3A_, 0.7865, 2.81, 0.307, 275, 254, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH LIGAND 87
1577, d3qlgB_, 0.7865, 2.19, 0.340, 260, 244, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH DASATINIB
1578, d2f7zE_, 0.7865, 2.94, 0.254, 336, 256, PROTEIN KINASE A BOUND TO (R)-1-(1H-INDOL-3-YLMETHYL)-2-(2- PYRIDIN-4-YL-[17]NAPHTYRIDIN-5-YLOXY)-EHYLAMINE
1579, d5li1A1, 0.7864, 2.90, 0.198, 329, 257, STRUCTURE OF A PAR3-INHIBITORY PEPTIDE BOUND TO PKCIOTA CORE KINASE DOMAIN
1580, d5kmlA1, 0.7864, 2.90, 0.378, 290, 254, TRKA JM-KINASE WITH 1-(5-METHYL-3-PHENYL-12-OXAZOL-4-YL)-3-[[2- (TRIFLUOROMETHYL)PHENYL]METHYL]UREA
1581, d5am6B_, 0.7864, 2.86, 0.383, 280, 253, NATIVE FGFR1 WITH AN INHIBITOR
1582, d3juhA_, 0.7863, 2.96, 0.198, 334, 258, CRYSTAL STRUCTURE OF A MUTANT OF HUMAN PROTEIN KINASE CK2ALPHA WITH ALTERED COSUBSTRATE SPECIFICITY
1583, d2ojfE_, 0.7863, 2.97, 0.258, 336, 256, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH PYRIDINE-PYRAZOLOPYRIDINE BASED INHIBITORS
1584, d1yrpA_, 0.7863, 2.79, 0.211, 275, 256, CATALYTIC DOMAIN OF HUMAN ZIP KINASE PHOSPHORYLATED AT THR265
1585, p5x02A_, 0.7862, 2.94, 0.339, 305, 254, CRYSTAL STRUCTURE OF THE FLT3 KINASE DOMAIN BOUND TO THE INHIBITOR FF- 10101
1586, d4ypsA1, 0.7862, 2.39, 0.360, 275, 247, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
1587, p4ib5A_, 0.7862, 2.92, 0.193, 331, 259, STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH A CK2BETA-COMPETITIVE CYCLIC PEPTIDE
1588, d3a7jA_, 0.7862, 3.22, 0.281, 286, 260, HUMAN MST3 KINASE IN COMPLEX WITH MNADP
1589, d3a7iA_, 0.7862, 3.18, 0.273, 286, 260, HUMAN MST3 KINASE IN COMPLEX WITH ADENINE
1590, d2x4zA1, 0.7862, 3.17, 0.188, 289, 260, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH PF-03758309
1591, d1yrpB_, 0.7862, 2.79, 0.211, 275, 256, CATALYTIC DOMAIN OF HUMAN ZIP KINASE PHOSPHORYLATED AT THR265
1592, d3my0F1, 0.7861, 3.43, 0.233, 293, 266, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
1593, d3g5dA_, 0.7861, 1.94, 0.336, 256, 241, KINASE DOMAIN OF CSRC IN COMPLEX WITH DASATINIB
1594, d2f7xE_, 0.7861, 2.95, 0.254, 336, 256, PROTEIN KINASE A BOUND TO (S)-2-(1H-INDOL-3-YL)-1-[5-((E)-2- PYRIDIN-4-YL-VINYL)-PYRIDIN-3-YLOXYMETHYL]-ETHYLAMINE
1595, d1re8A_, 0.7861, 2.81, 0.244, 337, 254, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH BALANOL ANALOG 2
1596, d5dh3A_, 0.7860, 2.73, 0.232, 287, 254, CRYSTAL STRUCTURE OF MST2 IN COMPLEX WITH XMU-MP-1
1597, d4bxaA_, 0.7860, 2.90, 0.183, 331, 257,  
1598, d3zh8B_, 0.7860, 3.16, 0.192, 317, 260, A NOVEL SMALL MOLECULE APKC INHIBITOR
1599, d5objA_, 0.7859, 2.69, 0.234, 260, 252, AURORA A KINASE IN COMPLEX WITH 2-(3-FLUOROPHENYL)QUINOLINE-4- CARBOXYLIC ACID AND ATP
1600, d5cqwA_, 0.7859, 2.90, 0.183, 331, 257, TETRAGONAL COMPLEX STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A BENZOTRIAZOLE-BASED INHIBITOR GENERATED BY CLICK-CHEMISTRY
1601, d3v5lD1, 0.7859, 2.07, 0.318, 244, 242, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 542
1602, d3fzpA_, 0.7859, 2.45, 0.361, 259, 249, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH ATPGS
1603, d3d94A_, 0.7859, 2.68, 0.317, 288, 252, CRYSTAL STRUCTURE OF THE INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE IN COMPLEX WITH PQIP
1604, d3d7tB_, 0.7859, 2.65, 0.323, 265, 251, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
1605, d1o6kA_, 0.7859, 2.94, 0.230, 317, 257, STRUCTURE OF ACTIVATED FORM OF PKB KINASE DOMAIN S474D WITH GSK3 PEPTIDE AND AMP-PNP
1606, d4v01B_, 0.7858, 2.63, 0.359, 275, 251, FGFR1 IN COMPLEX WITH PONATINIB (CO-CRYSTALLISATION).
1607, p4md9E_, 0.7858, 2.84, 0.187, 329, 256, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
1608, p4md8E_, 0.7858, 2.97, 0.194, 332, 258, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
1609, d4fnxA_, 0.7858, 2.57, 0.296, 292, 250, CRYSTAL STRUCTURE OF THE APO R1275Q ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
1610, d2helA_, 0.7858, 2.63, 0.307, 256, 251, CRYSTAL STRUCTURE OF A MUTANT EPHA4 KINASE DOMAIN (Y742A)
1611, d2f7eE_, 0.7858, 2.86, 0.247, 336, 255, PKA COMPLEXED WITH (S)-2-(1H-INDOL-3-YL)-1-(5-ISOQUINOLIN-6- YL-PYRIDIN-3-YLOXYMETHYL-ETYLAMINE
1612, d1snuA_, 0.7858, 2.25, 0.313, 245, 243, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
1613, d3my0S1, 0.7857, 3.44, 0.233, 293, 266, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
1614, d4r1yA_, 0.7856, 2.32, 0.350, 265, 243, IDENTIFICATION AND OPTIMIZATION OF PYRIDAZINONES AS POTENT AND SELECTIVE C-MET KINASE INHIBITOR
1615, d4hw7A_, 0.7856, 2.91, 0.341, 289, 252, CRYSTAL STRUCTURE OF FMS KINASE DOMAIN WITH A SMALL MOLECULAR INHIBITOR PLX647-OME
1616, d4dceB_, 0.7856, 2.29, 0.297, 284, 246, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH A PIPERIDINE-CARBOXAMIDE INHIBITOR
1617, d3my0O1, 0.7856, 3.43, 0.233, 296, 266, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
1618, d3iw4B_, 0.7856, 2.88, 0.244, 325, 258, CRYSTAL STRUCTURE OF PKC ALPHA IN COMPLEX WITH NVP-AEB071
1619, d3amaA_, 0.7856, 2.93, 0.255, 342, 255, PROTEIN KINASE A SIXFOLD MUTANT MODEL OF AURORA B WITH INHIBITOR JNJ- 7706621
1620, d2oh0E_, 0.7856, 2.96, 0.258, 336, 256, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH PYRIDINE-PYRAZOLOPYRIDINE BASED INHIBITORS
1621, d3rhxB_, 0.7855, 2.97, 0.375, 275, 256, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR1 KINASE IN COMPLEX WITH ARQ 069
1622, d3my0Q1, 0.7855, 3.41, 0.234, 293, 265, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
1623, d5xgmA_, 0.7854, 2.53, 0.351, 288, 248, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH GO6976
1624, d4gt5A_, 0.7854, 2.78, 0.375, 290, 253, CRYSTAL STRUCTURE OF THE INACTIVE TRKA KINASE DOMAIN
1625, d4f64B_, 0.7854, 2.81, 0.370, 272, 254, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 6
1626, d3v8tB1, 0.7854, 1.88, 0.321, 242, 240, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 477
1627, d3u87A_, 0.7854, 2.90, 0.183, 329, 257, STRUCTURE OF A CHIMERIC CONSTRUCT OF HUMAN CK2ALPHA AND HUMAN CK2ALPHA  IN COMPLEX WITH A NON-HYDROLYSABLE ATP-ANALOGUE
1628, d3rp0B_, 0.7854, 2.98, 0.190, 329, 258,  
1629, d2x6dA_, 0.7854, 2.87, 0.241, 255, 253, AURORA-A BOUND TO AN INHIBITOR
1630, p5owlA_, 0.7853, 3.12, 0.199, 331, 261, LOW SALT STRUCTURE OF HUMAN PROTEIN KINASE CK2ALPHA IN COMPLEX WITH 3- AMINOPROPYL-4;5;6;7-TETRABROMOBENZIMIDAZOL 
1631, d5jsmA1, 0.7853, 2.47, 0.275, 262, 251, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
1632, d5bpyB1, 0.7853, 2.21, 0.321, 246, 243, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-824171 AKA 6-[(3R)-3-(4-TERT-BU TYLBENZAMIDO) PIPERIDIN-1-YL]-2-{[4-(MORPHOLINE-4-CARBONYL) PHENYL]AMINO}PYRIDINE- 3-CARBOXAMIDE
1633, d4mxxB_, 0.7853, 2.28, 0.335, 260, 245, HUMAN SRC A403T MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
1634, d4mneF_, 0.7853, 2.32, 0.257, 258, 249, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
1635, d4a07A_, 0.7853, 2.97, 0.238, 282, 256, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC ACTIVATOR PS171 BOUND TO THE PIF-POCKET
1636, d3h30B_, 0.7853, 2.90, 0.191, 333, 257, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2 WITH 56-DICHLORO-1-BETA-D- RIBOFURANOSYLBENZIMIDAZOLE
1637, d3d4qB_, 0.7853, 2.38, 0.264, 264, 250, PYRAZOLE-BASED INHIBITORS OF B-RAF KINASE
1638, d2gnjA_, 0.7853, 2.82, 0.248, 335, 254, PKA THREE FOLD MUTANT MODEL OF RHO-KINASE WITH Y-27632
1639, d1ds5D_, 0.7853, 3.05, 0.181, 328, 260, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
1640, d4pp9A1, 0.7852, 2.14, 0.314, 245, 242, ITK KINASE DOMAIN WITH COMPOUND 1 (N-[1-(3-CYANOBENZYL)-1H-PYRAZOL-4- YL]-2H-INDAZOLE-3-CARBOXAMIDE)
1641, p4md9P_, 0.7852, 2.91, 0.187, 328, 257, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
1642, d4k8aA_, 0.7852, 2.36, 0.360, 251, 247, FRAGMENT-BASED DISCOVERY OF FOCAL ADHESION KINASE INHIBITORS
1643, d4h58A_, 0.7852, 2.37, 0.264, 263, 250, BRAF IN COMPLEX WITH COMPOUND 3
1644, d3d0eB_, 0.7852, 2.90, 0.230, 322, 256, CRYSTAL STRUCTURE OF HUMAN AKT2 IN COMPLEX WITH GSK690693
1645, d3a7fA_, 0.7852, 2.99, 0.263, 283, 255, HUMAN MST3 KINASE
1646, d4ubaB_, 0.7851, 2.90, 0.191, 333, 257, LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH 4 - CARBOXY-68-BROMO-FLAVONOL (FLC26)
1647, d4f63B_, 0.7851, 2.88, 0.365, 271, 255, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 1
1648, d2gnlA_, 0.7851, 2.93, 0.259, 338, 255, PKA THREEFOLD MUTANT MODEL OF RHO-KINASE WITH INHIBITOR H- 1152P
1649, d1xo2B_, 0.7851, 2.87, 0.206, 289, 257, CRYSTAL STRUCTURE OF A HUMAN CYCLIN-DEPENDENT KINASE 6 COMPLEX WITH A FLAVONOL INHIBITOR FISETIN
1650, d1jktB_, 0.7851, 2.96, 0.225, 276, 258, TETRAGONAL CRYSTAL FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE
1651, d3w8lB_, 0.7850, 2.94, 0.195, 326, 257, CRYSTAL STRUCTURE OF HUMAN CK2 IN COMPLEX WITH INOSITOL HEXAKISPHOSPHATE
1652, d3d0eA_, 0.7850, 2.90, 0.230, 322, 256, CRYSTAL STRUCTURE OF HUMAN AKT2 IN COMPLEX WITH GSK690693
1653, d2uw4A_, 0.7850, 2.81, 0.244, 334, 254, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 2-(4-(5-METHYL- 1H-PYRAZOL-4-YL)-PHENYL)-ETHYLAMINE
1654, d1smhA_, 0.7850, 2.90, 0.243, 348, 255, PROTEIN KINASE A VARIANT COMPLEX WITH COMPLETELY ORDERED N- TERMINAL HELIX
1655, d1sm2A_, 0.7850, 2.10, 0.310, 245, 242, CRYSTAL STRUCTURE OF THE PHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
1656, d1q62A_, 0.7850, 2.85, 0.244, 336, 254, PKA DOUBLE MUTANT MODEL OF PKB
1657, d1agwB_, 0.7850, 2.87, 0.365, 272, 255, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU4984 INHIBITOR
1658, d5j5sB_, 0.7849, 2.04, 0.335, 258, 242, SRC KINASE IN COMPLEX WITH A SULFONAMIDE INHIBITOR
1659, d3dy7A_, 0.7849, 2.79, 0.198, 260, 253, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
1660, d3d4qA_, 0.7849, 2.38, 0.264, 264, 250, PYRAZOLE-BASED INHIBITORS OF B-RAF KINASE
1661, d2qocA_, 0.7849, 2.97, 0.311, 283, 257, HUMAN EPHA3 KINASE DOMAIN PHOSPHORYLATED AMP-PNP BOUND STRUCTURE
1662, d1u5qB_, 0.7849, 2.97, 0.260, 308, 258, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
1663, d5os2A_, 0.7848, 2.70, 0.226, 261, 252, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1664, d4r7iA_, 0.7848, 2.92, 0.341, 290, 252, CRYSTAL STRUCTURE OF FMS KINASE DOMAIN WITH A SMALL MOLECULAR INHIBITOR GLEEVEC
1665, d4nusA_, 0.7848, 3.41, 0.189, 301, 264, RSK2 N-TERMINAL KINASE IN COMPLEX WITH LJH685
1666, d3kxmA_, 0.7848, 3.04, 0.188, 326, 260, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR K74
1667, d5kmoA1, 0.7847, 2.64, 0.384, 290, 250, TRKA JM-KINASE WITH 1-(2-METHYL-4-PHENYL-PYRIMIDIN-5-YL)-3-(2- PYRIDYL)UREA
1668, d5kmjA_, 0.7847, 2.77, 0.378, 300, 251, TRKA JM-KINASE WITH {N}-(2-PYRIDYLMETHYL)-2-[2-(2-THIENYL)INDOL-1- YL]ACETAMIDE
1669, d4yhtB_, 0.7847, 2.38, 0.272, 258, 250, BRAF COMPLEXED WITH AN INHIBITOR
1670, d3uqfA_, 0.7847, 2.43, 0.350, 260, 246, C-SRC KINASE DOMAIN IN COMPLEX WITH BKI RM-1-89
1671, d3qa0A_, 0.7847, 2.92, 0.183, 330, 257, CRYSTAL STRUCTURE OF THE APO-FORM OF HUMAN CK2 ALPHA AT PH 6.5
1672, d3pooA_, 0.7847, 2.93, 0.255, 331, 255, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
1673, d3oogA_, 0.7847, 2.84, 0.248, 333, 254, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH A SMALL FRAGMENT
1674, d2oxdA_, 0.7847, 3.13, 0.184, 325, 261, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE K17 K22 AND K32 INHIBITORS
1675, d1zwsA_, 0.7847, 3.10, 0.215, 278, 260, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
1676, d5h8bA_, 0.7846, 2.92, 0.183, 331, 257, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 2
1677, d4tyjA1, 0.7846, 2.69, 0.368, 275, 250, STRUCTURAL ANALYSIS OF THE HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE
1678, d2rkpA_, 0.7846, 3.01, 0.190, 334, 258,  
1679, d5kwhA_, 0.7845, 2.83, 0.184, 331, 256, CRYSTAL STRUCTURE OF CK2
1680, d4dgmA_, 0.7845, 3.14, 0.188, 326, 261, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH THE INHIBITOR APIGENIN
1681, d3kxgA_, 0.7845, 3.12, 0.180, 326, 261, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR 34567-PENTABROMO-1H-INDAZOLE (K64)
1682, d3f5pT1, 0.7845, 2.95, 0.309, 294, 259, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
1683, d2x39A_, 0.7845, 2.96, 0.241, 316, 257, STRUCTURE OF 4-AMINO-N-(4-CHLOROBENZYL)-1-(7H-PYRROLO(23-D) PYRIMIDIN-4-YL)PIPERIDINE-4-CARBOXAMIDE BOUND TO PKB
1684, d2uzuE_, 0.7845, 2.98, 0.258, 336, 256, PKA STRUCTURES OF INDAZOLE-PYRIDINE SERIES OF AKT INHIBITORS
1685, d1bkxA_, 0.7845, 2.86, 0.239, 337, 255, A BINARY COMPLEX OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE AND ADENOSINE FURTHER DEFINES CONFORMATIONAL FLEXIBILITY
1686, d4pmmA1, 0.7844, 2.75, 0.380, 281, 250, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR N-(3-CYCLOPROPYL- 1-PHENYL-1H-PYRAZOL-5-YL)-2-{4-[3-METHOXY-4-(4-METHYL-1H-IMIDAZOL-1- YL)PHENYL]-1H-123-TRIAZOL-1-YL}ACETAMIDE
1687, d4o0rA_, 0.7844, 3.15, 0.222, 293, 261, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
1688, p4md9L_, 0.7844, 3.04, 0.194, 328, 258, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
1689, d2e2bB1, 0.7844, 2.31, 0.343, 258, 245, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH INNO-406
1690, d1q61A_, 0.7844, 2.90, 0.251, 335, 255, PKA TRIPLE MUTANT MODEL OF PKB
1691, d5mrdA_, 0.7843, 3.05, 0.233, 283, 257, HUMAN PDK1-PKCIOTA KINASE CHIMERA IN COMPLEX WITH ALLOSTERIC COMPOUND PS267 BOUND TO THE PIF-POCKET
1692, d4zs0A_, 0.7843, 2.73, 0.243, 257, 251, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO SB-6-OH
1693, d4yznA_, 0.7843, 2.76, 0.272, 269, 254, HUMANIZED ROCO4 BOUND TO COMPOUND 19
1694, d4bggD_, 0.7843, 3.10, 0.251, 286, 259, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
1695, d2uw3A_, 0.7843, 2.87, 0.244, 334, 254, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 5-METHYL-4- PHENYL-1H-PYRAZOLE
1696, d2p2iA2, 0.7843, 2.67, 0.337, 283, 249, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NICOTINAMIDE INHIBITOR
1697, d2dwbA_, 0.7843, 2.64, 0.219, 259, 251, AURORA-A KINASE COMPLEXED WITH AMPPNP
1698, d5t1hA_, 0.7842, 3.04, 0.190, 331, 258, CRYSTAL STRUCTURE OF CK2
1699, d3e88B_, 0.7842, 2.99, 0.230, 319, 257, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1700, d3e88A_, 0.7842, 2.99, 0.230, 319, 257, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1701, d2yjsA_, 0.7842, 2.50, 0.298, 286, 248, STRUCTURE OF C1156Y MUTANT ANAPLASTIC LYMPHOMA KINASE
1702, d2uw7A_, 0.7842, 2.85, 0.248, 335, 254, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  4-(4-CHLORO- PHENYL)-4-(4-(1H-PYRAZOL-4-YL)-PHENYL)-PIPERIDINE
1703, d2uvxA_, 0.7842, 2.91, 0.251, 335, 255, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 7-AZAINDOLE
1704, p2pvnA_, 0.7842, 3.11, 0.184, 327, 261, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
1705, d4w9wA_, 0.7841, 2.73, 0.206, 306, 252, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH SMALL MOLECULE AZD-7762
1706, d4mneA_, 0.7841, 3.18, 0.197, 286, 259, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
1707, d4dgnA_, 0.7841, 3.13, 0.180, 325, 261, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH THE INHIBITOR LUTEOLIN
1708, d3b8rA1, 0.7841, 2.59, 0.335, 282, 248, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
1709, d3a8xA1, 0.7841, 2.93, 0.205, 331, 259, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
1710, d2uw9A_, 0.7841, 2.96, 0.241, 316, 257, STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH 4-(4-CHLORO- PHENYL)-4-(4-(1H-PYRAZOL-4-YL)-PHENYL)-PIPERIDINE
1711, d1jbpE_, 0.7841, 2.81, 0.244, 339, 254, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE COMPLEXED WITH A SUBSTRATE PEPTIDE ADP AND DETERGENT
1712, d5uyjA1, 0.7840, 3.02, 0.226, 279, 257, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B
1713, d4rwiB_, 0.7840, 2.81, 0.370, 280, 254, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) APO
1714, p4lfiB_, 0.7840, 3.13, 0.203, 371, 261, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH GMPPNP
1715, d4dceA_, 0.7840, 2.46, 0.298, 288, 248, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH A PIPERIDINE-CARBOXAMIDE INHIBITOR
1716, d3ppkB_, 0.7840, 2.48, 0.259, 264, 251, HUMAN B-RAF KINASE IN COMPLEX WITH A NON-OXIME FUROPYRIDINE INHIBITOR
1717, d3fhiA_, 0.7840, 2.91, 0.251, 336, 255, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN THE CATALYTIC AND REGULATORY (RI{ALPHA}) SUBUNITS OF PKA
1718, d2uvyA_, 0.7840, 2.93, 0.255, 333, 255, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH METHYL-(4-(9H- PURIN-6-YL)-BENZYL)-AMINE
1719, d1tkiB_, 0.7840, 2.74, 0.184, 321, 256, AUTOINHIBITED SERINE KINASE DOMAIN OF THE GIANT MUSCLE PROTEIN TITIN
1720, d1tkiA_, 0.7840, 2.74, 0.184, 321, 256, AUTOINHIBITED SERINE KINASE DOMAIN OF THE GIANT MUSCLE PROTEIN TITIN
1721, d1jluE_, 0.7840, 2.84, 0.244, 337, 254, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A PHOSPHORYLATED SUBSTRATE PEPTIDE AND DETERGENT
1722, d5a4cB1, 0.7839, 2.88, 0.365, 284, 255, FGFR1 LIGAND COMPLEX
1723, d4ra5A1, 0.7839, 3.06, 0.267, 331, 258, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH LIGAND COMPOUND 11A (6- [(13-DIMETHYL-AZETIDIN-3-YL)-METHYL-AMINO]-4(R)-METHYL-7-PHENYL-2 10-DIHYDRO-9-OXA-124A-TRIAZA-PHENANTHREN-3-ONE)
1724, p4lfiA_, 0.7839, 3.13, 0.203, 370, 261, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH GMPPNP
1725, d4dggB_, 0.7839, 2.22, 0.354, 259, 243, C-SRC KINASE DOMAIN IN COMPLEX WITH RM-1-176
1726, d3l9lA_, 0.7839, 2.97, 0.262, 338, 256, CRYSTAL STRUCTURE OF PKA WITH COMPOUND 36
1727, d3b8qA1, 0.7839, 2.80, 0.332, 285, 250, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
1728, d3ambA_, 0.7839, 2.95, 0.255, 340, 255, PROTEIN KINASE A SIXFOLD MUTANT MODEL OF AURORA B WITH INHIBITOR VX- 680
1729, p2pvlA_, 0.7839, 3.15, 0.188, 327, 261, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
1730, d2gfcA_, 0.7839, 2.83, 0.244, 335, 254, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
1731, d1xh9A_, 0.7839, 2.86, 0.252, 336, 254, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1732, d1xh8A_, 0.7839, 2.81, 0.252, 337, 254, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1733, d1xh5A_, 0.7839, 3.05, 0.258, 335, 256, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1734, d4yxrA_, 0.7838, 2.86, 0.252, 334, 254, CRYSTAL STRUCTURE OF PKA IN COMPLEX WITH INHIBITOR.
1735, d4lueA3, 0.7838, 2.14, 0.349, 261, 241, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH 7-[TRANS-4-(4- METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE (RESULTING FROM DISPLACEMENT OF SKF86002)
1736, d4fvqA_, 0.7838, 2.80, 0.264, 274, 254, CRYSTAL STRUCTURE OF THE JAK2 PSEUDOKINASE DOMAIN (MG-ATP-BOUND FORM)
1737, d2uw6A_, 0.7838, 2.97, 0.251, 334, 255, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  (S)-2-(4- CHLORO-PHENYL)-2-(4-1H-PYRAZOL-4-YL)-PHENYL)-ETHYLAMINE
1738, p2pvmA_, 0.7838, 3.16, 0.188, 327, 261, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
1739, d2erzE_, 0.7838, 2.85, 0.244, 334, 254, CRYSTAL STRUCTURE OF C-AMP DEPENDENT KINASE (PKA) BOUND TO HYDROXYFASUDIL
1740, d1u7eA_, 0.7838, 2.91, 0.251, 338, 255,  
1741, d1rdqE_, 0.7838, 2.92, 0.243, 340, 255, HYDROLYSIS OF ATP IN THE CRYSTAL OF Y204A MUTANT OF CAMP-DEPENDENT PROTEIN KINASE
1742, p6ehuA_, 0.7837, 2.85, 0.188, 327, 255, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 32
1743, d5m56B_, 0.7837, 3.09, 0.207, 328, 261, MONOCLINIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO- FLAVONOL (FLC21)
1744, d4q9zA1, 0.7837, 2.98, 0.268, 330, 257, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH COMPOUND35 ((1R)-9- (AZETIDIN-3-YLAMINO)-18-DIMETHYL-35-DIHYDRO[124]TRIAZINO[34- C][14]BENZOXAZIN-2(1H)-ONE)
1745, d3ngaB_, 0.7837, 2.92, 0.183, 331, 257, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH CX-4945
1746, d3gxlA_, 0.7837, 3.03, 0.223, 285, 260, ALK-5 KINASE COMPLEX WITH GW857175
1747, d3aglB_, 0.7837, 2.96, 0.259, 335, 255, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1039
1748, d1q24A_, 0.7837, 2.93, 0.247, 335, 255, PKA DOUBLE MUTANT MODEL OF PKB IN COMPLEX WITH MGATP
1749, d4figB_, 0.7836, 3.03, 0.205, 292, 259, CATALYTIC DOMAIN OF HUMAN PAK4
1750, d3l9mA_, 0.7836, 2.97, 0.254, 338, 256, CRYSTAL STRUCTURE OF PKAB3 (PKA TRIPLE MUTANT V123A L173M Q181K) WITH COMPOUND 18
1751, d2qc6A_, 0.7836, 2.94, 0.179, 326, 257, PROTEIN KINASE CK2 IN COMPLEX WITH DBC
1752, d2gnhA_, 0.7836, 2.91, 0.255, 338, 255, PKA FIVE FOLD MUTANT MODEL OF RHO-KINASE WITH H1152P
1753, d1okyA_, 0.7836, 2.94, 0.227, 281, 256, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
1754, d4nk9B_, 0.7835, 2.76, 0.356, 282, 253, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 1
1755, d4eklA_, 0.7835, 2.95, 0.254, 329, 256, AKT1 WITH GDC0068
1756, d2gcdA_, 0.7835, 3.09, 0.270, 308, 259, TAO2 KINASE DOMAIN-STAUROSPORINE STRUCTURE
1757, d1vebA_, 0.7835, 2.84, 0.248, 338, 254, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 5
1758, d1ds5C_, 0.7835, 3.09, 0.181, 328, 260, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
1759, d4nk9A_, 0.7834, 2.67, 0.361, 281, 252, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 1
1760, d3rp0C_, 0.7834, 3.01, 0.190, 329, 258,  
1761, d3qkmA_, 0.7834, 2.97, 0.254, 329, 256, SPIROCYCLIC SULFONAMIDES AS AKT INHIBITORS
1762, d3mv5A_, 0.7834, 3.02, 0.249, 315, 257, CRYSTAL STRUCTURE OF AKT-1-INHIBITOR COMPLEXES
1763, d3l9mB_, 0.7834, 2.87, 0.255, 336, 255, CRYSTAL STRUCTURE OF PKAB3 (PKA TRIPLE MUTANT V123A L173M Q181K) WITH COMPOUND 18
1764, d3dtwA1, 0.7834, 2.59, 0.327, 281, 248, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZISOXAZOLE INHIBITOR
1765, d2uzwE_, 0.7834, 3.00, 0.254, 336, 256, PKA STRUCTURES OF INDAZOLE-PYRIDINE SERIES OF AKT INHIBITORS
1766, d1zogA_, 0.7834, 3.13, 0.184, 325, 261, CRYSTAL STRUCTURE OF PROTEIN KINASE CK2 IN COMPLEX WITH TBB- DERIVATIVES
1767, d1zoeA_, 0.7834, 2.95, 0.179, 325, 257, CRYSTAL STRUCTURE OF PROTEIN KINASE CK2 IN COMPLEX WITH TBB- DERIVATIVES INHIBITORS
1768, d1rekA_, 0.7834, 2.95, 0.243, 336, 255, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH BALANOL ANALOG 8
1769, d5da3A1, 0.7833, 2.49, 0.331, 261, 248, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN WITH INHIBITOR
1770, d4eevA_, 0.7833, 2.85, 0.336, 283, 253, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH LY2801653
1771, d3v8wB1, 0.7833, 1.78, 0.319, 240, 238, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 469
1772, d3tudA1, 0.7833, 2.56, 0.341, 255, 249, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH N-(4-METHYL-3-(8-METHYL-7- OXO-2-(PHENYLAMINO)-78-DIHYDROPYRIDO[23-D]PYRIMIDIN-6-YL)PHENYL)-3- (TRIFLUOROMETHYL)BENZAMIDE
1773, d3e8dB_, 0.7833, 2.95, 0.254, 317, 256, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1774, d3bz3A_, 0.7833, 2.60, 0.364, 259, 250, CRYSTAL STRUCTURE ANALYSIS OF FOCAL ADHESION KINASE WITH A METHANESULFONAMIDE DIAMINOPYRIMIDINE INHIBITOR
1775, d1zohA_, 0.7833, 3.18, 0.188, 326, 261, CRYSTAL STRUCTURE OF PROTEIN KINASE CK2 IN COMPLEX WITH TBB- DERIVATIVES INHIBITORS
1776, d1fgkB_, 0.7833, 3.04, 0.375, 272, 256, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1
1777, d1f0qA_, 0.7833, 3.08, 0.181, 329, 260, CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT OF PROTEIN KINASE CK2 IN COMPLEX WITH THE NUCLEOTIDE COMPETITIVE INHIBITOR EMODIN
1778, d5nk6A_, 0.7832, 2.81, 0.328, 284, 253, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2D
1779, d3qklA_, 0.7832, 2.93, 0.246, 317, 256, SPIROCHROMANE AKT INHIBITORS
1780, d3qamE_, 0.7832, 2.92, 0.239, 348, 255, CRYSTAL STRUCTURE OF GLU208ALA MUTANT OF CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE
1781, d3fjqE_, 0.7832, 2.92, 0.243, 334, 255, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA IN COMPLEX WITH PEPTIDE INHIBITOR PKI ALPHA (6-25)
1782, d3eknA_, 0.7832, 3.03, 0.310, 297, 258, INSULIN RECEPTOR KINASE COMPLEXED WITH AN INHIBITOR
1783, d3e8dA_, 0.7832, 2.92, 0.246, 315, 256, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1784, d3dneA_, 0.7832, 2.97, 0.255, 336, 255, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
1785, d2uw5A_, 0.7832, 2.90, 0.244, 333, 254, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  (R)-2-(4- CHLORO-PHENYL)-2-(4-1H-PYRAZOL-4-YL)-PHENYL)-ETHYLAMINE
1786, d1wvyA_, 0.7832, 3.03, 0.229, 273, 258, CRYSTAL STRUCTURES OF KINASE DOMAIN OF DAP KINASE IN COMPLEX WITH SMALL MOLECULAR INHIBITORS
1787, d1sveA_, 0.7832, 2.85, 0.252, 341, 254, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 1
1788, d4qmwA_, 0.7831, 3.24, 0.269, 286, 260, MST3 IN COMPLEX WITH PP-121 1-CYCLOPENTYL-3-(1H-PYRROLO[23- B]PYRIDIN-5-YL)-1H-PYRAZOLO[34-D]PYRIMIDIN-4-AMINE
1789, d4figA_, 0.7831, 3.05, 0.205, 292, 259, CATALYTIC DOMAIN OF HUMAN PAK4
1790, d3l9lB_, 0.7831, 2.88, 0.259, 337, 255, CRYSTAL STRUCTURE OF PKA WITH COMPOUND 36
1791, d2jedA_, 0.7831, 3.03, 0.264, 324, 258, THE CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF THE PROTEIN KINASE C THETA IN COMPLEX WITH NVP-XAA228 AT 2.32A RESOLUTION.
1792, d2jdtA_, 0.7831, 2.98, 0.255, 334, 255, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH ISOQUINOLINE-5- SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL) AMIDE
1793, d2gniA_, 0.7831, 2.83, 0.252, 338, 254, PKA FIVEFOLD MUTANT MODEL OF RHO-KINASE WITH INHIBITOR FASUDIL (HA1077)
1794, d1ydrE_, 0.7831, 2.85, 0.248, 334, 254, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H7 PROTEIN KINASE INHIBITOR 1-(5- ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE
1795, d1ds5A_, 0.7831, 3.06, 0.185, 328, 260, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
1796, d1bx6A_, 0.7831, 2.83, 0.235, 337, 255, CRYSTAL STRUCTURE OF THE POTENT NATURAL PRODUCT INHIBITOR BALANOL IN COMPLEX WITH THE CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE
1797, d1apmE_, 0.7831, 2.85, 0.240, 338, 254, 2.0 ANGSTROM REFINED CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A PEPTIDE INHIBITOR AND DETERGENT
1798, d5hq0A1, 0.7830, 2.83, 0.205, 289, 254, TERNARY COMPLEX OF HUMAN PROTEINS CDK1 CYCLIN B AND CKS2 BOUND TO AN INHIBITOR
1799, d4y72A1, 0.7830, 2.83, 0.205, 289, 254, HUMAN CDK1/CYCLINB1/CKS2 WITH INHIBITOR
1800, d3kxnA_, 0.7830, 3.17, 0.184, 327, 261, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR TETRAIODOBENZIMIDAZOLE (K88)
1801, p2pvjA_, 0.7830, 3.08, 0.188, 326, 260, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
1802, d2oxxA_, 0.7830, 3.15, 0.184, 325, 261, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE DERIVATIVES K17 K22 AND K32
1803, d2gnfA_, 0.7830, 2.92, 0.255, 339, 255, PROTEIN KINASE A FIVEFOLD MUTANT MODEL OF RHO-KINASE WITH Y- 27632
1804, d1svgA_, 0.7830, 2.86, 0.252, 338, 254, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 4
1805, d5nqcA_, 0.7829, 3.03, 0.190, 331, 258, CK2ALPHA IN COMPLEX WITH NMR154
1806, d5ng3B_, 0.7829, 2.43, 0.253, 275, 249, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
1807, d5ia5A_, 0.7829, 2.93, 0.325, 273, 255, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH GOLVATINIB (E7050)
1808, d4rlkA_, 0.7829, 3.14, 0.180, 327, 261, CRYSTAL STRUCTURE OF Z. MAYS CK2ALPHA IN COMPLEX WITH THE ATP- COMPETITIVE INHIBITOR 4-[(E)-(FLUOREN-9-YLIDENEHYDRAZINYLIDENE)- METHYL] BENZOATE
1809, d4itjB_, 0.7829, 2.48, 0.288, 276, 250, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-4
1810, d4g2fA_, 0.7829, 2.81, 0.304, 275, 253, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH COMPOUND 7
1811, d4dymA_, 0.7829, 3.33, 0.240, 293, 262, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH THE IMIDAZO[12-B]PYRIDAZINE INHIBITOR K00135
1812, d3cjgA_, 0.7829, 2.65, 0.336, 280, 250, CRYSTAL STRUCTURE OF VEGFR2 IN COMPLEX WITH A 345-TRIMETHOXY ANILINE CONTAINING PYRIMIDINE
1813, d2jdvA_, 0.7829, 2.92, 0.255, 334, 255, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH A-443654
1814, d1svhA_, 0.7829, 2.86, 0.252, 335, 254, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 8
1815, d4x6qC_, 0.7828, 2.91, 0.255, 334, 255, AN ISOFORM-SPECIFIC MYRISTYLATION SWITCH TARGETS RIIB PKA HOLOENZYMES TO MEMBRANES
1816, d4v04B_, 0.7828, 2.90, 0.368, 287, 253, FGFR1 IN COMPLEX WITH PONATINIB.
1817, d4kabA_, 0.7828, 2.37, 0.358, 255, 246, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 3-METHYL-14- DIHYDRO-PYRAZOLO[45-C]PYRAZOLE
1818, d4dgoA_, 0.7828, 3.13, 0.184, 325, 261, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH TYRPHOSTIN AG99
1819, d3tnqB_, 0.7828, 2.88, 0.248, 331, 254, STRUCTURE AND ALLOSTERY OF THE PKA RIIB TETRAMERIC HOLOENZYME
1820, d3q53A_, 0.7828, 3.25, 0.210, 291, 262, STRUCTURE OF PHOSPHORYLATED PAK1 KINASE DOMAIN IN COMPLEX WITH ATP
1821, d3nx8A_, 0.7828, 2.84, 0.256, 333, 254, HUMAN CAMP DEPENDENT PROTEIN KINASE IN COMPLEX WITH PHENOL
1822, d3my0I1, 0.7828, 3.43, 0.234, 292, 265, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
1823, d3e8eA_, 0.7828, 3.08, 0.258, 341, 256, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1824, p2pvkA_, 0.7828, 3.08, 0.185, 327, 260, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
1825, d1fvvA_, 0.7828, 2.81, 0.212, 298, 255, THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLE INHIBITOR
1826, d5i9yA_, 0.7827, 3.01, 0.324, 287, 256, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH DASATINIB
1827, d4wbbB_, 0.7827, 2.96, 0.251, 334, 255, SINGLE TURNOVER AUTOPHOSPHORYLATION CYCLE OF THE PKA RIIB HOLOENZYME
1828, p4mwhA_, 0.7827, 3.12, 0.199, 371, 261, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH ATP
1829, p4md9H_, 0.7827, 3.00, 0.201, 328, 259, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
1830, d4gu9A_, 0.7827, 2.44, 0.360, 252, 247, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH (2-FLUORO- PHENYL)-(1H-PYRAZOLO[34-D]PYRIMIDIN-4-YL)-AMINE
1831, d4bggC_, 0.7827, 3.14, 0.252, 279, 258, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
1832, d3qhrC1, 0.7827, 2.63, 0.202, 295, 253, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
1833, d3h30A_, 0.7827, 3.02, 0.190, 333, 258, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2 WITH 56-DICHLORO-1-BETA-D- RIBOFURANOSYLBENZIMIDAZOLE
1834, d2uvzA_, 0.7827, 2.95, 0.255, 334, 255, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH C-PHENYL-C-(4-( 9H-PURIN-6-YL)-PHENYL)-METHYLAMINE
1835, d1ydsE_, 0.7827, 2.86, 0.248, 334, 254, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H8 PROTEIN KINASE INHIBITOR [N-(2-METHYLAMINO)ETHYL]-5- ISOQUINOLINESULFONAMIDE
1836, d5a4cA_, 0.7826, 2.71, 0.377, 294, 252, FGFR1 LIGAND COMPLEX
1837, d4q9zB_, 0.7826, 3.03, 0.267, 308, 258, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH COMPOUND35 ((1R)-9- (AZETIDIN-3-YLAMINO)-18-DIMETHYL-35-DIHYDRO[124]TRIAZINO[34- C][14]BENZOXAZIN-2(1H)-ONE)
1838, p4fi1A_, 0.7826, 3.12, 0.199, 371, 261, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH ATP
1839, d3l9nA_, 0.7826, 2.86, 0.255, 332, 255, CRYSTAL STRUCTURE OF PKAB3 (PKA TRIPLE MUTANT V123A L173M Q181K) WITH COMPOUND 27
1840, d3idbA_, 0.7826, 2.97, 0.247, 341, 255, CRYSTAL STRUCTURE OF (108-268)RIIB:C HOLOENZYME OF CAMP- DEPENDENT PROTEIN KINASE
1841, d3gqlA_, 0.7826, 2.92, 0.369, 287, 255, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
1842, d2gu8A_, 0.7826, 2.88, 0.244, 335, 254, DISCOVERY OF 2-PYRIMIDYL-5-AMIDOTHIOPHENES AS NOVEL AND POTENT INHIBITORS FOR AKT: SYNTHESIS AND SAR STUDIES
1843, d4zk5A_, 0.7825, 2.72, 0.236, 286, 254, MAP4K4 IN COMPLEX WITH INHIBITOR GNE-495
1844, d4nkaA_, 0.7825, 2.58, 0.360, 279, 250, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 2
1845, d3tnpF_, 0.7825, 2.92, 0.255, 334, 255, STRUCTURE AND ALLOSTERY OF THE PKA RIIB TETRAMERIC HOLOENZYME
1846, d3tnpC_, 0.7825, 2.92, 0.255, 334, 255, STRUCTURE AND ALLOSTERY OF THE PKA RIIB TETRAMERIC HOLOENZYME
1847, d3qhwC1, 0.7825, 2.63, 0.202, 295, 253, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
1848, d3qhrA1, 0.7825, 2.63, 0.202, 295, 253, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
1849, d3blqA_, 0.7825, 2.81, 0.192, 295, 255, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1 IN COMPLEX WITH ATP
1850, d2qcsA_, 0.7825, 2.96, 0.255, 335, 255, A COMPLEX STRUCTURE BETWEEN THE CATALYTIC AND REGULATORY SUBUNIT OF PROTEIN KINASE A THAT REPRESENTS THE INHIBITED STATE
1851, d1xhaA_, 0.7825, 2.83, 0.244, 348, 254, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1852, d1q8tA_, 0.7825, 2.86, 0.252, 338, 254, THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH RHO-KINASE INHIBITOR Y-27632
1853, d5nk2A_, 0.7824, 2.82, 0.328, 290, 253, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2B
1854, d5n1vA_, 0.7824, 2.95, 0.183, 331, 257, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH PYRAZOLO-PYRIMIDINE MACROCYCLIC LIGAND
1855, d4v01A_, 0.7824, 2.48, 0.367, 273, 248, FGFR1 IN COMPLEX WITH PONATINIB (CO-CRYSTALLISATION).
1856, d4ubaA_, 0.7824, 3.15, 0.199, 333, 261, LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH 4 - CARBOXY-68-BROMO-FLAVONOL (FLC26)
1857, d4rwjB_, 0.7824, 2.82, 0.374, 282, 254, CRYSTAL STRUCTURE OF FGFR1 (C488A C584S) IN COMPLEX WITH AZD4547 (N- {3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE)
1858, d4ebvA1, 0.7824, 2.76, 0.364, 261, 250, STRUCTURE OF FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH NOVEL ALLOSTERIC INHIBITOR
1859, d3qalE_, 0.7824, 2.93, 0.243, 339, 255, CRYSTAL STRUCTURE OF ARG280ALA MUTANT OF CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE
1860, d3pwdA_, 0.7824, 3.15, 0.184, 327, 261, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH NBC (Z1)
1861, d3f5pK1, 0.7824, 3.00, 0.309, 292, 259, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
1862, d3e8cA_, 0.7824, 2.99, 0.263, 341, 255, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1863, d3e87A_, 0.7824, 3.02, 0.230, 321, 257, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1864, d2vnwA_, 0.7824, 2.89, 0.244, 334, 254, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH (1-(9H-PURIN-6- YL)PIPERIDIN-4-YL)METHANAMINE
1865, d2uw0A_, 0.7824, 2.90, 0.248, 334, 254, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  6-(4-(4-(4- CHLORO-PHENYL)-PIPERIDIN-4-YL)-PHENYL)-9H-PURINE
1866, d1m2rA_, 0.7824, 3.17, 0.184, 327, 261, CRYSTAL STRUCTURE OF 58-DI-AMINO-14-DI-HYDROXY- ANTHRAQUINONE/CK2 KINASE COMPLEX
1867, d5j95A_, 0.7823, 2.55, 0.224, 284, 250, MAP4K4 IN COMPLEX WITH INHIBITOR
1868, d4mf1B1, 0.7823, 2.04, 0.314, 244, 242, ITK KINASE DOMAIN IN COMPLEX WITH BENZOTHIAZOLE INHIBITOR 12B (1S2S)- 2-{4-[(DIMETHYLAMINO)METHYL]PHENYL}-N-[6-(1H-PYRAZOL-4-YL)-13- BENZOTHIAZOL-2-YL]CYCLOPROPANECARBOXAMIDE
1869, d3eflA1, 0.7823, 2.54, 0.336, 279, 247, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH MOTESANIB
1870, d3e8eB_, 0.7823, 2.99, 0.255, 337, 255, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1871, d3e8cC_, 0.7823, 2.99, 0.263, 341, 255, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1872, d3e87B_, 0.7823, 3.02, 0.230, 321, 257, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1873, d2vo0A_, 0.7823, 2.97, 0.255, 340, 255, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  C-(4-(4- CHLOROPHENYL)-1-(7H-PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN- 4-YL)METHYLAMINE
1874, p2pvhA_, 0.7823, 3.06, 0.188, 327, 260, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
1875, d2c1aA_, 0.7823, 2.98, 0.259, 335, 255, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL)AMIDE
1876, d1xh7A_, 0.7823, 2.90, 0.252, 337, 254, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1877, d5di1A_, 0.7822, 2.65, 0.219, 285, 251, MAP4K4 IN COMPLEX WITH AN INHIBITOR
1878, d4x6rA_, 0.7822, 2.96, 0.255, 347, 255, AN ISOFORM-SPECIFIC MYRISTYLATION SWITCH TARGETS RIIB PKA HOLOENZYMES TO MEMBRANES
1879, d4gv1A1, 0.7822, 3.01, 0.254, 328, 256, PKB ALPHA IN COMPLEX WITH AZD5363
1880, d3q9xA_, 0.7822, 3.14, 0.199, 330, 261, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH EMODIN AT PH 6.5
1881, d3b8qB_, 0.7822, 2.70, 0.333, 271, 249, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
1882, d2vo6A_, 0.7822, 2.91, 0.244, 335, 254, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  4-(4- CHLOROBENZYL)-1-(7H-PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN- 4-YLAMINE
1883, d2vo3A_, 0.7822, 2.90, 0.248, 334, 254, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  C-(4-(4- CHLOROPHENYL)-1-(7H-PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN- 4-YL)METHYLAMINE
1884, d2vnyA_, 0.7822, 2.89, 0.244, 334, 254, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH (1-(9H-PURIN-6- YL)PIPERIDIN-4-YL)AMINE
1885, d2uw8A_, 0.7822, 2.98, 0.251, 334, 255, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 2-(4-CHLORO- PHENYL)-2-PHENYL-ETHYLAMINE
1886, d2qu6B_, 0.7822, 2.45, 0.327, 260, 245, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZOXAZOLE INHIBITOR
1887, d2jedB1, 0.7822, 3.03, 0.267, 315, 258, THE CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF THE PROTEIN KINASE C THETA IN COMPLEX WITH NVP-XAA228 AT 2.32A RESOLUTION.
1888, d1jamA_, 0.7822, 3.08, 0.188, 327, 260, CRYSTAL STRUCTURE OF APO-FORM OF Z. MAYS CK2 PROTEIN KINASE ALPHA SUBUNIT
1889, d1fmoE_, 0.7822, 2.86, 0.240, 336, 254, CRYSTAL STRUCTURE OF A POLYHISTIDINE-TAGGED RECOMBINANT CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH THE PEPTIDE INHIBITOR PKI(5-24) AND ADENOSINE
1890, d5ia4A_, 0.7821, 2.91, 0.327, 269, 254, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH FORETINIB (XL880)
1891, d4gu6B_, 0.7821, 2.62, 0.364, 258, 250, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH N-{3-[(5-CYANO- 2-PHENYL-1H-PYRROLO[23-B]PYRIDIN-4-YLAMINO)- METHYL]-PYRIDIN-2-YL}- N-METHYL-METHANESULFONAMIDE
1892, d4anmA1, 0.7821, 3.08, 0.188, 327, 260, COMPLEX OF CK2 WITH A CDC7 INHIBITOR
1893, d3v5qB1, 0.7821, 2.43, 0.409, 262, 247, DISCOVERY OF A SELECTIVE TRK INHIBITOR WITH EFFICACY IN RODENT CANCER TUMOR MODELS
1894, d3qhwA1, 0.7821, 2.74, 0.209, 295, 254, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
1895, d3ow3A_, 0.7821, 2.98, 0.247, 334, 255, DISCOVERY OF DIHYDROTHIENO- AND DIHYDROFUROPYRIMIDINES AS POTENT PAN AKT INHIBITORS
1896, d3e8cF_, 0.7821, 2.99, 0.263, 341, 255, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1897, d3e8cE_, 0.7821, 2.99, 0.263, 336, 255, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1898, d3b8rB_, 0.7821, 2.58, 0.340, 267, 247, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
1899, d3agmA_, 0.7821, 2.99, 0.263, 337, 255, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-670
1900, d2vo7A_, 0.7821, 2.88, 0.252, 335, 254, STRUCTURE OF PKA COMPLEXED WITH 4-(4-CHLOROBENZYL)-1-(7H- PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN-4-YLAMINE
1901, d2fgiB_, 0.7821, 3.05, 0.375, 272, 256, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 1 IN COMPLEX WITH INHIBITOR PD173074
1902, d1xh6A_, 0.7821, 2.90, 0.252, 331, 254, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1903, d1atpE_, 0.7821, 2.93, 0.247, 334, 255, 2.2 ANGSTROM REFINED CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH MNATP AND A PEPTIDE INHIBITOR
1904, d5nk9A_, 0.7820, 2.83, 0.328, 285, 253, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2E
1905, d5hesA_, 0.7820, 2.40, 0.324, 287, 247, HUMAN LEUCINE ZIPPER- AND STERILE ALPHA MOTIF-CONTAINING KINASE (ZAK MLT HCCS-4 MRK AZK MLTK) IN COMPLEX WITH VEMURAFENIB
1906, d4ra4A_, 0.7820, 2.91, 0.245, 317, 257, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE C ALPHA IN COMPLEX WITH COMPOUND 28 ((R)-6-((3S4S)-13-DIMETHYL-PIPERIDIN-4-YL)-7-(2-FLUORO- PHENYL)-4-METHYL-210-DIHYDRO-9-OXA-124A-TRIAZA-PHENANTHREN-3-ONE)
1907, d3oezB_, 0.7820, 2.30, 0.340, 261, 244, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE CHICKEN C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH IMATINIB
1908, d3f5pI1, 0.7820, 2.99, 0.309, 293, 259, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
1909, d3d14A1, 0.7820, 2.64, 0.227, 257, 251, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240->ARG MET302- >LEU) IN COMPLEX WITH 1-{5-[2-(THIENO[32-D]PYRIMIDIN-4-YLAMINO)- ETHYL]- THIAZOL-2-YL}-3-(3-TRIFLUOROMETHYL-PHENYL)-UREA
1910, d2xzsB_, 0.7820, 3.18, 0.226, 293, 261, DEATH ASSOCIATED PROTEIN KINASE 1 RESIDUES 1-312
1911, d1lr4A_, 0.7820, 3.14, 0.184, 327, 261, ROOM TEMPERATURE CRYSTAL STRUCTURE OF THE APO-FORM OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 FROM ZEA MAYS
1912, d5i9xA_, 0.7819, 2.82, 0.328, 284, 253, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH BOSUTINIB (SKI-606)
1913, d5ct0B_, 0.7819, 2.85, 0.184, 326, 255, CRYSTAL STRUCTURE OF CK2ALPHA WITH 3-(3-CHLORO-4-(PHENYL)BENZYLAMINO) PROPAN-1-OL BOUND
1914, d4wsqB_, 0.7819, 2.70, 0.199, 310, 251, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE (AAK1) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1915, d4kaoB_, 0.7819, 2.49, 0.359, 254, 248, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 1-(5-TERT- BUTYL-2-P-TOLYL-2H-PYRAZOL-3-YL)-3-(4-PYRIDIN-3- YL-PHENYL)-UREA
1916, d4aojB_, 0.7819, 2.38, 0.381, 258, 247, HUMAN TRKA IN COMPLEX WITH THE INHIBITOR AZ-23
1917, d3v8wA1, 0.7819, 1.93, 0.318, 241, 239, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 469
1918, d3f5pA1, 0.7819, 2.99, 0.309, 298, 259, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
1919, d3e8cD_, 0.7819, 3.00, 0.263, 344, 255, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1920, d3c1xA_, 0.7819, 2.69, 0.323, 290, 251, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A PYRROLOTRIAZINE BASED INHIBITOR
1921, d1cdkB_, 0.7819, 2.93, 0.255, 342, 255, CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT (E.C.2.7.1.37) (PROTEIN KINASE A) COMPLEXED WITH PROTEIN KINASE INHIBITOR PEPTIDE FRAGMENT 5-24 (PKI(5-24) ISOELECTRIC VARIANT CA) AND MN2+ ADENYLYL IMIDODIPHOSPHATE (MNAMP-PNP) AT PH 5.6 AND 7C AND 4C
1922, d5nk7A_, 0.7818, 2.85, 0.328, 284, 253, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2A
1923, d3mvjE_, 0.7818, 2.89, 0.247, 334, 255, HUMAN CYCLIC AMP-DEPENDENT PROTEIN KINASE PKA INHIBITOR COMPLEX
1924, d3f5pD1, 0.7818, 3.00, 0.309, 296, 259, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
1925, d3e8cB_, 0.7818, 3.00, 0.263, 344, 255, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1926, d3bysA_, 0.7818, 2.47, 0.355, 255, 245, CO-CRYSTAL STRUCTURE OF LCK AND AMINOPYRIMIDINE AMIDE 10B
1927, d4u40A_, 0.7817, 2.84, 0.236, 295, 254, MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4) BOUND TO AMPPNP
1928, d4ra5B_, 0.7817, 3.04, 0.268, 310, 257, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH LIGAND COMPOUND 11A (6- [(13-DIMETHYL-AZETIDIN-3-YL)-METHYL-AMINO]-4(R)-METHYL-7-PHENYL-2 10-DIHYDRO-9-OXA-124A-TRIAZA-PHENANTHREN-3-ONE)
1929, d4knbB_, 0.7817, 2.32, 0.335, 256, 242, C-MET IN COMPLEX WITH OSI LIGAND
1930, d3hrcA_, 0.7817, 2.99, 0.235, 279, 255, CRYSTAL STRUCTURE OF A MUTANT OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ATP
1931, d2gngA_, 0.7817, 2.93, 0.259, 338, 255, PROTEIN KINASE A FIVEFOLD MUTANT MODEL OF RHO-KINASE
1932, d1p4fA_, 0.7817, 2.69, 0.219, 269, 251, DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN WITH BOUND INHIBITOR FRAGMENT
1933, d5nk1A_, 0.7816, 2.84, 0.328, 284, 253, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1K
1934, d5m4uA_, 0.7816, 3.01, 0.201, 332, 259, ORTHORHOMBIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO- FLAVONOL (FLC21)
1935, d5i9zA_, 0.7816, 2.69, 0.315, 273, 251, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH DANUSERTIB (PHA739358)
1936, d4obpA_, 0.7816, 2.67, 0.237, 285, 253, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 29) 6-(2-FLUOROPYRIDIN-4- YL)PYRIDO[32-D]PYRIMIDIN-4-AMINE
1937, d3ngaA_, 0.7816, 2.96, 0.183, 331, 257, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH CX-4945
1938, d3my0V1, 0.7816, 3.24, 0.242, 281, 260, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
1939, d3gxjA_, 0.7816, 2.99, 0.220, 288, 259,  
1940, d3g6gA_, 0.7816, 2.48, 0.340, 264, 247, EQUALLY POTENT INHIBITION OF C-SRC AND ABL BY COMPOUNDS THAT RECOGNIZE INACTIVE KINASE CONFORMATIONS
1941, d3f5pS1, 0.7816, 2.99, 0.309, 294, 259, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
1942, d3f5pB1, 0.7816, 3.00, 0.309, 297, 259, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
1943, p3be9A_, 0.7816, 3.20, 0.188, 327, 261, STRUCTURE-BASED DESIGN AND SYNTHESIS OF NOVEL MACROCYCLIC PYRAZOLO[15-A] [135]TRIAZINE COMPOUNDS AS POTENT INHIBITORS OF PROTEIN KINASE CK2 AND THEIR ANTICANCER ACTIVITIES
1944, d2c1bA_, 0.7816, 2.98, 0.251, 335, 255, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH ( 4R2S)-5 -(4-(4-CHLOROBENZYLOXY)PYRROLIDIN-2- YLMETHANESULFONYL)ISOQUINOLINE
1945, d1m2qA_, 0.7816, 3.09, 0.181, 327, 260, CRYSTAL STRUCTURE OF 18-DI-HYDROXY-4-NITRO-XANTEN-9- ONE/CK2 KINASE COMPLEX
1946, p6c3eA_, 0.7815, 2.37, 0.276, 258, 246, CRYSTAL STRUCTURE OF RIP1 KINASE BOUND TO INHIBITOR
1947, d5m56A_, 0.7815, 3.15, 0.207, 331, 261, MONOCLINIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO- FLAVONOL (FLC21)
1948, d4fnzA_, 0.7815, 2.45, 0.298, 287, 248, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PIPERIDINE-CARBOXAMIDE INHIBITOR 2
1949, d4f0iA_, 0.7815, 2.74, 0.384, 284, 250, CRYSTAL STRUCTURE OF APO TRKA
1950, d3ow4A_, 0.7815, 3.00, 0.254, 317, 256, DISCOVERY OF DIHYDROTHIENO- AND DIHYDROFUROPYRIMIDINES AS POTENT PAN AKT INHIBITORS
1951, d3f5pL1, 0.7815, 3.01, 0.309, 292, 259, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
1952, d3f5pG1, 0.7815, 3.01, 0.309, 298, 259, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
1953, d1lpuA_, 0.7815, 3.17, 0.184, 327, 261, LOW TEMPERATURE CRYSTAL STRUCTURE OF THE APO-FORM OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 FROM ZEA MAYS
1954, d5i3oB_, 0.7814, 3.00, 0.209, 302, 254, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
1955, d5dt4A_, 0.7814, 2.69, 0.228, 259, 250, AURORA A KINASE IN COMPLEX WITH AA35 AND ATP IN SPACE GROUP P6122
1956, d4o21A_, 0.7814, 2.98, 0.247, 333, 255, PRODUCT COMPLEX OF METAL-FREE PKAC ATP-GAMMA-S AND SP20.
1957, d3my0T1, 0.7814, 3.42, 0.235, 291, 264, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
1958, d3mssB1, 0.7814, 2.36, 0.343, 260, 245, ABL KINASE IN COMPLEX WITH IMATINIB AND FRAGMENT (FRAG2) IN THE MYRISTATE SITE
1959, d3kxhA_, 0.7814, 3.18, 0.184, 326, 261, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR (2-DYMETHYLAMMINO-4567-TETRABROMOBENZOIMIDAZOL-1YL- ACETIC ACID (K66)
1960, d3f5pH1, 0.7814, 3.00, 0.309, 298, 259, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
1961, d3f5pC1, 0.7814, 3.00, 0.305, 300, 259, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
1962, d3bhhD1, 0.7814, 2.61, 0.217, 285, 253, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
1963, d1zwsE_, 0.7814, 3.14, 0.215, 278, 260, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
1964, d1u5rA_, 0.7814, 3.03, 0.260, 308, 258, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
1965, d1q8uA_, 0.7814, 2.97, 0.259, 341, 255, THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH RHO-KINASE INHIBITOR H-1152P
1966, d1m2pA_, 0.7814, 3.09, 0.188, 325, 260, CRYSTAL STRUCTURE OF 18-DI-HYDROXY-4-NITRO- ANTHRAQUINONE/CK2 KINASE COMPLEX
1967, d5uy6A1, 0.7813, 3.05, 0.211, 280, 256, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B
1968, d5jrqA1, 0.7813, 2.50, 0.264, 257, 250, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-6-VEM
1969, d4dglD_, 0.7813, 3.00, 0.197, 328, 259, CRYSTAL STRUCTURE OF THE CK2 TETRAMERIC HOLOENZYME
1970, d3qgyB1, 0.7813, 2.13, 0.311, 244, 241, CRYSTAL STRUCTURE OF ITK INHIBITOR COMPLEX
1971, d3q9zA_, 0.7813, 3.09, 0.196, 332, 260, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH QUINALIZARIN AT PH 6.5
1972, d3fl5A_, 0.7813, 2.99, 0.185, 324, 259, PROTEIN KINASE CK2 IN COMPLEX WITH THE INHIBITOR QUINALIZARIN
1973, d3dj7A_, 0.7813, 2.59, 0.224, 257, 250, CRYSTAL STRUCTURE OF THE MOUSE AURORA-A CATALYTIC DOMAIN (ASN186->GLY LYS240->ARG MET302->LEU) IN COMPLEX WITH COMPOUND 130.
1974, d3cp9B_, 0.7813, 2.63, 0.340, 269, 247, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDONE INHIBITOR
1975, d4pmpA1, 0.7812, 2.67, 0.383, 276, 248, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR 1-CYCLOPROPYL-1- [3-(13-THIAZOL-2-YL)BENZYL]-3-[4-(TRIFLUOROMETHOXY)PHENYL]UREA
1976, d3tucA_, 0.7812, 2.61, 0.340, 257, 250, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH 1-BENZYL-N-(5-(67- DIMETHOXYQUINOLIN-4-YLOXY)PYRIDIN-2-YL)-2-OXO-12-DIHYDROPYRIDINE-3- CARBOXAMIDE
1977, d3pzhA_, 0.7812, 3.08, 0.188, 327, 260, CRYSTAL STRUCTURE OF MAIZE CK2 ALPHA IN COMPLEX WITH EMODIN AT 1.92 A RESOLUTION
1978, d3pvgA_, 0.7812, 3.08, 0.188, 326, 260, CRYSTAL STRUCTURE OF Z. MAYS CK2 ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMO-1-CARBOXYMETHYLBENZIMIDAZOLE (K68)
1979, d3blhA1, 0.7812, 2.78, 0.189, 291, 254, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1
1980, d2cpkE_, 0.7812, 2.90, 0.240, 333, 254, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CYCLIC ADENOSINE MONOPHOSPHATE-DEPENDENT PROTEIN KINASE
1981, d1stcE_, 0.7812, 2.99, 0.262, 334, 256, CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH STAUROSPORINE
1982, d1om1A_, 0.7812, 3.08, 0.185, 325, 260, CRYSTAL STRUCTURE OF MAIZE CK2 ALPHA IN COMPLEX WITH IQA
1983, d4fx3C_, 0.7811, 2.71, 0.205, 298, 254, CRYSTAL STRUCTURE OF THE CDK2/CYCLIN A COMPLEX WITH OXINDOLE INHIBITOR
1984, d3qriA1, 0.7811, 2.61, 0.344, 270, 250, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN IN COMPLEX WITH DCC- 2036
1985, d3ocbB_, 0.7811, 3.05, 0.245, 319, 257, AKT1 KINASE DOMAIN WITH PYRROLOPYRIMIDINE INHIBITOR
1986, d3mssA1, 0.7811, 2.34, 0.343, 260, 245, ABL KINASE IN COMPLEX WITH IMATINIB AND FRAGMENT (FRAG2) IN THE MYRISTATE SITE
1987, d3kxjA_, 0.7811, 3.09, 0.188, 326, 260,  
1988, d3f5pM1, 0.7811, 3.02, 0.305, 294, 259, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
1989, d2jdoA_, 0.7811, 3.00, 0.241, 314, 257, STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH ISOQUINOLINE-5- SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL) AMIDE
1990, d1xh4A_, 0.7811, 2.90, 0.248, 334, 254, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1991, d1ds5B_, 0.7811, 3.20, 0.184, 328, 261, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
1992, d5h8bB_, 0.7810, 2.96, 0.183, 331, 257, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 2
1993, d5cu0A_, 0.7810, 2.94, 0.184, 327, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND N-(3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)ACETAMIDE BOUND
1994, d3en4A_, 0.7810, 2.26, 0.346, 257, 243, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP121 A MULTITARGETED KINASE INHIBITOR
1995, d1unlB_, 0.7810, 2.94, 0.203, 292, 256, STRUCTURAL MECHANISM FOR THE INHIBITION OF CD5-P25 FROM THE ROSCOVITINE ALOISINE AND INDIRUBIN.
1996, d1l3rE_, 0.7810, 2.98, 0.247, 338, 255, CRYSTAL STRUCTURE OF A TRANSITION STATE MIMIC OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE
1997, d1cdkA_, 0.7810, 2.93, 0.251, 342, 255, CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT (E.C.2.7.1.37) (PROTEIN KINASE A) COMPLEXED WITH PROTEIN KINASE INHIBITOR PEPTIDE FRAGMENT 5-24 (PKI(5-24) ISOELECTRIC VARIANT CA) AND MN2+ ADENYLYL IMIDODIPHOSPHATE (MNAMP-PNP) AT PH 5.6 AND 7C AND 4C
1998, d5ek7B_, 0.7809, 2.86, 0.328, 286, 253, STRUCTURE OF THE AUTOINHIBITED EPHA2 JMS-KD
1999, d5bvkA_, 0.7809, 2.84, 0.353, 278, 252, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
2000, d4w9xA_, 0.7809, 3.01, 0.205, 300, 254, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH BARICITINIB
2001, d3warA_, 0.7809, 3.19, 0.188, 334, 261, CRYSTAL STRUCTURE OF HUMAN CK2A
2002, d3qgwA_, 0.7809, 2.16, 0.320, 244, 241, CRYSTAL STRUCTURE OF ITK KINASE BOUND TO AN INHIBITOR
2003, d3oezA_, 0.7809, 2.28, 0.332, 261, 244, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE CHICKEN C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH IMATINIB
2004, d3mvhA_, 0.7809, 3.02, 0.246, 311, 256, CRYSTAL STRUCTURE OF AKT-1-INHIBITOR COMPLEXES
2005, d3ms9A1, 0.7809, 2.34, 0.343, 261, 245, ABL KINASE IN COMPLEX WITH IMATINIB AND A FRAGMENT (FRAG1) IN THE MYRISTATE POCKET
2006, d3e8eP_, 0.7809, 3.00, 0.263, 341, 255, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2007, d5moeA_, 0.7808, 2.93, 0.191, 325, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
2008, d5ew3B_, 0.7808, 2.57, 0.333, 266, 246, HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (KDR) KINASE DOMAIN IN COMPLEX WITH AAL993
2009, d4mf1A1, 0.7808, 1.88, 0.314, 241, 239, ITK KINASE DOMAIN IN COMPLEX WITH BENZOTHIAZOLE INHIBITOR 12B (1S2S)- 2-{4-[(DIMETHYLAMINO)METHYL]PHENYL}-N-[6-(1H-PYRAZOL-4-YL)-13- BENZOTHIAZOL-2-YL]CYCLOPROPANECARBOXAMIDE
2010, d4ithB_, 0.7808, 2.29, 0.268, 270, 246, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-1 ANALOG
2011, d3p0mA_, 0.7808, 3.09, 0.254, 335, 256, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
2012, d3my0P_, 0.7808, 3.50, 0.234, 290, 265, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
2013, d3at2A_, 0.7808, 2.98, 0.183, 334, 257, CRYSTAL STRUCTURE OF CK2ALPHA
2014, d1ydtE_, 0.7808, 2.99, 0.255, 334, 255, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H89 PROTEIN KINASE INHIBITOR N-[2- (4-BROMOCINNAMYLAMINO)ETHYL]-5-ISOQUINOLINE
2015, p6ehuB_, 0.7807, 3.04, 0.194, 327, 258, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 32
2016, d5ut4A_, 0.7807, 2.82, 0.264, 273, 254, JAK2 JH2 IN COMPLEX WITH NVP-BSK805
2017, d5nk3A_, 0.7807, 3.14, 0.323, 281, 257, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1L
2018, d5kwhB_, 0.7807, 3.10, 0.192, 331, 260, CRYSTAL STRUCTURE OF CK2
2019, d5dosA_, 0.7807, 2.70, 0.228, 259, 250, AURORA A KINASE IN COMPLEX WITH AA35 AND ATP IN SPACE GROUP P6122
2020, d3mvjA_, 0.7807, 2.97, 0.255, 334, 255, HUMAN CYCLIC AMP-DEPENDENT PROTEIN KINASE PKA INHIBITOR COMPLEX
2021, d3mssD1, 0.7807, 2.37, 0.343, 260, 245, ABL KINASE IN COMPLEX WITH IMATINIB AND FRAGMENT (FRAG2) IN THE MYRISTATE SITE
2022, d3dndA_, 0.7807, 2.98, 0.259, 334, 255, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
2023, d3a7gA_, 0.7807, 3.36, 0.284, 289, 261, HUMAN MST3 KINASE
2024, d1u5qA_, 0.7807, 3.09, 0.263, 308, 259, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
2025, d5nkcA_, 0.7806, 2.85, 0.320, 286, 253, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2H
2026, d5clpB_, 0.7806, 2.85, 0.184, 327, 255, CRYSTAL STRUCTURE OF CK2ALPHA WITH 34-DICHLOROPHENETHYLAMINE BOUND
2027, d3qlgA_, 0.7806, 2.45, 0.339, 259, 245, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH DASATINIB
2028, d2wxvA1, 0.7806, 2.84, 0.212, 298, 255, STRUCTURE OF CDK2-CYCLIN A WITH A PYRAZOLO(43-H) QUINAZOLINE-3-CARBOXAMIDE INHIBITOR
2029, d2c5vA_, 0.7806, 2.79, 0.208, 296, 255, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
2030, d1dawA_, 0.7806, 3.18, 0.184, 327, 261, CRYSTAL STRUCTURE OF A BINARY COMPLEX OF PROTEIN KINASE CK2 (ALPHA-SUBUNIT) AND MG-AMPPNP
2031, d5nk4A_, 0.7805, 2.80, 0.329, 290, 252, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2C
2032, d4o22A1, 0.7805, 3.00, 0.247, 333, 255, BINARY COMPLEX OF METAL-FREE PKAC WITH SP20.
2033, d3mssC1, 0.7805, 2.35, 0.343, 260, 245, ABL KINASE IN COMPLEX WITH IMATINIB AND FRAGMENT (FRAG2) IN THE MYRISTATE SITE
2034, d2f2cB_, 0.7805, 2.74, 0.206, 280, 253, X-RAY STRUCTURE OF HUMAN CDK6-VCYCLINWITH THE INHIBITOR AMINOPURVALANOL
2035, d5n1vB_, 0.7804, 2.99, 0.183, 331, 257, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH PYRAZOLO-PYRIMIDINE MACROCYCLIC LIGAND
2036, d5moeB_, 0.7804, 3.01, 0.198, 323, 258, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
2037, d5ku8A_, 0.7804, 3.01, 0.195, 328, 256, CRYSTAL STRUCTURE OF CK2
2038, d5i3rB_, 0.7804, 3.03, 0.205, 302, 254, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
2039, d5h8eB_, 0.7804, 3.19, 0.199, 331, 261, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 7H
2040, d5cenA_, 0.7804, 2.37, 0.300, 281, 247, CRYSTAL STRUCTURE OF DLK (KINASE DOMAIN)
2041, d4crsA1, 0.7804, 2.88, 0.264, 329, 254, HUMAN PROTEIN KINASE N2 (PKN2 PRKCL2) IN COMPLEX WITH ATPGAMMAS
2042, d3ow4B_, 0.7804, 3.01, 0.254, 317, 256, DISCOVERY OF DIHYDROTHIENO- AND DIHYDROFUROPYRIMIDINES AS POTENT PAN AKT INHIBITORS
2043, d3ocbA_, 0.7804, 3.07, 0.245, 315, 257, AKT1 KINASE DOMAIN WITH PYRROLOPYRIMIDINE INHIBITOR
2044, d3bwjA_, 0.7804, 3.01, 0.255, 338, 255, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR LEAD COMPOUND ARC-1034
2045, d2f57B1, 0.7804, 3.17, 0.216, 293, 259, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 5
2046, d1dayA_, 0.7804, 3.19, 0.188, 327, 261, CRYSTAL STRUCTURE OF A BINARY COMPLEX OF PROTEIN KINASE CK2 (ALPHA-SUBUNIT) AND MG-GMPPNP
2047, d3qkkA_, 0.7803, 3.02, 0.254, 326, 256, SPIROCHROMANE AKT INHIBITORS
2048, d3idcA_, 0.7803, 2.98, 0.235, 341, 255, CRYSTAL STRUCTURE OF (102-265)RIIB:C HOLOENZYME OF CAMP- DEPENDENT PROTEIN KINASE
2049, d2clqA_, 0.7803, 2.59, 0.228, 263, 250, STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 2 5
2050, d1okuA_, 0.7803, 2.80, 0.208, 296, 255,  
2051, d5nkbA_, 0.7802, 2.85, 0.328, 285, 253, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 4A
2052, d5kmkA1, 0.7802, 2.81, 0.378, 302, 251, TRKA JM-KINASE WITH 2-FLUORO-{N}-[2-(4-FLUOROPHENYL)-6-METHYL-3- PYRIDYL]-4-(TRIFLUOROMETHYL)BENZAMIDE
2053, d4yhtA_, 0.7802, 2.36, 0.274, 256, 248, BRAF COMPLEXED WITH AN INHIBITOR
2054, d4p2kA_, 0.7802, 2.66, 0.328, 259, 250, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
2055, d4itiA_, 0.7802, 2.42, 0.262, 272, 248, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-3 ANALOG
2056, d3sc1A_, 0.7802, 2.81, 0.213, 278, 253, NOVEL ISOQUINOLONE PDK1 INHIBITORS DISCOVERED THROUGH FRAGMENT-BASED LEAD DISCOVERY
2057, d3iecD_, 0.7802, 2.77, 0.292, 311, 253, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
2058, d2c5nA_, 0.7802, 2.90, 0.215, 296, 256, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
2059, d1lp4A_, 0.7802, 3.21, 0.184, 327, 261, CRYSTAL STRUCTURE OF A BINARY COMPLEX OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 WITH MG-AMPPNP
2060, d5ho7A_, 0.7801, 2.81, 0.213, 280, 253, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
2061, d5hngA_, 0.7801, 2.82, 0.213, 280, 253, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
2062, d5drdA_, 0.7801, 2.73, 0.227, 259, 251, AURORA A KINASE IN COMPLEX WITH ATP IN SPACE GROUP P6122
2063, d5cu2A_, 0.7801, 2.94, 0.187, 328, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND (METHYL 4-((3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)AMINO)-4- OXOBUTANOAT BOUND
2064, p4nh1B_, 0.7801, 3.06, 0.190, 332, 258, CRYSTAL STRUCTURE OF A HETEROTETRAMERIC CK2 HOLOENZYME COMPLEX CARRYING THE ANDANTE-MUTATION IN CK2BETA AND CONSISTENT WITH PROPOSED MODELS OF AUTOINHIBITION AND TRANS-AUTOPHOSPHORYLATION
2065, d4ii5C_, 0.7801, 2.83, 0.209, 295, 254, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 1 MAGNESIUM ION
2066, d4ii5A_, 0.7801, 2.83, 0.209, 295, 254, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 1 MAGNESIUM ION
2067, p4ib5C_, 0.7801, 3.17, 0.195, 332, 261, STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH A CK2BETA-COMPETITIVE CYCLIC PEPTIDE
2068, d4f65A_, 0.7801, 2.77, 0.355, 279, 251, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 8
2069, d3f5pJ1, 0.7801, 3.04, 0.305, 292, 259, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2070, d2uzdA_, 0.7801, 2.75, 0.205, 295, 254, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2071, d1zrzA_, 0.7801, 3.06, 0.202, 310, 258, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF ATYPICAL PROTEIN KINASE C-IOTA
2072, d5ia0B_, 0.7800, 2.79, 0.312, 266, 253, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ALISERTIB (MLN8237)
2073, d5cu2B_, 0.7800, 3.01, 0.194, 325, 258, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND (METHYL 4-((3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)AMINO)-4- OXOBUTANOAT BOUND
2074, d5cu0B_, 0.7800, 3.08, 0.193, 325, 259, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND N-(3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)ACETAMIDE BOUND
2075, d3cs9D_, 0.7800, 2.54, 0.347, 263, 248, HUMAN ABL KINASE IN COMPLEX WITH NILOTINIB
2076, d3cp9A1, 0.7800, 2.54, 0.329, 281, 246, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDONE INHIBITOR
2077, d3dtwB_, 0.7799, 2.71, 0.339, 269, 248, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZISOXAZOLE INHIBITOR
2078, d2qo9A_, 0.7799, 2.98, 0.314, 277, 255, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION PHOSPHORYLATED AMP-PNP BOUND
2079, d5ku8B_, 0.7798, 3.24, 0.199, 331, 261, CRYSTAL STRUCTURE OF CK2
2080, d5cu4A_, 0.7798, 3.01, 0.191, 327, 257, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 10 BOUND
2081, d4h58B_, 0.7798, 2.44, 0.265, 262, 249, BRAF IN COMPLEX WITH COMPOUND 3
2082, d3tz8B_, 0.7798, 2.56, 0.340, 263, 247, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL104
2083, d3ky2B_, 0.7798, 2.90, 0.366, 280, 254, CRYSTAL STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN
2084, d3cqwA_, 0.7798, 3.06, 0.245, 318, 257, CRYSTAL STRUCTURE OF AKT-1 COMPLEXED WITH SUBSTRATE PEPTIDE AND INHIBITOR
2085, p5ooiA_, 0.7797, 3.10, 0.200, 329, 260, STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
2086, d3v5lB1, 0.7797, 1.79, 0.321, 239, 237, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 542
2087, d5mpjA_, 0.7796, 3.02, 0.191, 326, 257, 1-(2-CHLORO-[11 -BIPHENYL]-4-YL)-N-METHYLETHANAMINE
2088, p4nh1A_, 0.7796, 3.07, 0.186, 330, 258, CRYSTAL STRUCTURE OF A HETEROTETRAMERIC CK2 HOLOENZYME COMPLEX CARRYING THE ANDANTE-MUTATION IN CK2BETA AND CONSISTENT WITH PROPOSED MODELS OF AUTOINHIBITION AND TRANS-AUTOPHOSPHORYLATION
2089, d3f5pR1, 0.7796, 3.03, 0.305, 293, 259, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2090, d3f5pF1, 0.7796, 3.02, 0.309, 298, 259, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2091, d1urcC_, 0.7796, 2.75, 0.205, 296, 254, CYCLIN A BINDING GROOVE INHIBITOR ACE-ARG-LYS-LEU-PHE-GLY
2092, d5nkdA_, 0.7795, 2.80, 0.325, 287, 252, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2I
2093, d5mmrB_, 0.7795, 3.01, 0.194, 325, 258, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-((2-CHLORO-[11 -BIPHENYL]-4-YL) METHYL)BUTANE-14-DIAMINE BOUND
2094, d3e8eL_, 0.7795, 3.03, 0.263, 336, 255, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2095, d2reiA1, 0.7795, 2.71, 0.309, 274, 249, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 7 (EPHA7)
2096, d5mo5A_, 0.7794, 2.79, 0.189, 326, 254, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
2097, d5mmrA_, 0.7794, 3.12, 0.197, 326, 259, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-((2-CHLORO-[11 -BIPHENYL]-4-YL) METHYL)BUTANE-14-DIAMINE BOUND
2098, d5d7aB_, 0.7794, 2.61, 0.212, 286, 250, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TRAF2 AND NCK-INTERACTING PROTEIN KINASE WITH NCB-0846
2099, d4i3zC_, 0.7794, 2.77, 0.209, 295, 253, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 2 MAGNESIUM IONS
2100, d3ppkA_, 0.7794, 2.45, 0.265, 262, 249, HUMAN B-RAF KINASE IN COMPLEX WITH A NON-OXIME FUROPYRIDINE INHIBITOR
2101, d2jdsA_, 0.7794, 3.04, 0.255, 334, 255, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A- 443654
2102, d2cchC2, 0.7794, 2.84, 0.209, 295, 254, THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA- LINKED ATP ANALOGUE
2103, d6bqpA1, 0.7793, 2.95, 0.231, 262, 255, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH CRENOLANIB
2104, d4krcA_, 0.7793, 2.99, 0.206, 297, 257, CRYSTAL STRUCTURE OF PHO85-PCL10-ATP-GAMMA-S COMPLEX
2105, d4i3zA_, 0.7793, 2.77, 0.209, 295, 253, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 2 MAGNESIUM IONS
2106, d4fx3A_, 0.7793, 2.87, 0.212, 298, 255, CRYSTAL STRUCTURE OF THE CDK2/CYCLIN A COMPLEX WITH OXINDOLE INHIBITOR
2107, d3wzdA_, 0.7793, 2.71, 0.341, 278, 249, KDR IN COMPLEX WITH LIGAND LENVATINIB
2108, d1sm2B_, 0.7793, 1.98, 0.319, 241, 238, CRYSTAL STRUCTURE OF THE PHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
2109, d1okuC_, 0.7793, 2.82, 0.208, 296, 255,  
2110, d1jwhB_, 0.7793, 3.10, 0.192, 335, 260, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 HOLOENZYME
2111, d4qo9B_, 0.7792, 3.42, 0.280, 285, 261, MST3 IN COMPLEX WITH DANUSERTIB
2112, d3qgyA1, 0.7792, 2.20, 0.324, 244, 241, CRYSTAL STRUCTURE OF ITK INHIBITOR COMPLEX
2113, d3o7lB_, 0.7792, 2.79, 0.234, 326, 252, CRYSTAL STRUCTURE OF PHOSPHOLAMBAN (1-19):PKA C-SUBUNIT:AMP-PNP:MG2+ COMPLEX
2114, d3e8eE_, 0.7792, 3.05, 0.259, 341, 255, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2115, d2c5vC_, 0.7792, 2.82, 0.208, 296, 255, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
2116, d2c5pA_, 0.7792, 2.83, 0.208, 296, 255,  
2117, d5t1hB_, 0.7791, 3.24, 0.192, 331, 261, CRYSTAL STRUCTURE OF CK2
2118, d5f9eB_, 0.7791, 3.03, 0.268, 293, 257, STRUCTURE OF PROTEIN KINASE C THETA WITH COMPOUND 10: 22-DIMETHYL-7- (2-OXIDANYLIDENE-3~{H}-IMIDAZO[45-B]PYRIDIN-1-YL)-1-(PHENYLMETHYL)- 3~{H}-QUINAZOLIN-4-ONE
2119, d5cquA_, 0.7791, 2.92, 0.180, 328, 256, MONOCLINIC COMPLEX STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A BENZOTRIAZOLE-BASED INHIBITOR GENERATED BY CLICK-CHEMISTRY
2120, d3at4A_, 0.7791, 3.10, 0.193, 331, 259, CRYSTAL STRUCTURE OF CK2ALPHA WITH PYRADINE DERIVERTIVE
2121, d1uu8A_, 0.7791, 2.95, 0.224, 277, 254, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-1
2122, d5hx6A_, 0.7790, 2.29, 0.287, 259, 244, CRYSTAL STRUCTURE OF RIP1 KINASE WITH A BENZO[B][14]OXAZEPIN-4-ONE
2123, d4dhfB_, 0.7790, 2.76, 0.227, 258, 251, STRUCTURE OF AURORA A MUTANT BOUND TO BIOGENIDEC CPD 15
2124, d4dawA_, 0.7790, 3.30, 0.210, 293, 262, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH THE RUTHENIUM PHTHALIMIDE COMPLEX
2125, d4bxbA_, 0.7790, 2.92, 0.180, 328, 256,  
2126, d3zfxC_, 0.7790, 1.98, 0.301, 248, 239, CRYSTAL STRUCTURE OF EPHB1
2127, d3v5lC1, 0.7790, 2.11, 0.317, 242, 240, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 542
2128, d3kmwA_, 0.7790, 2.83, 0.268, 268, 254, CRYSTAL STRUCTURE OF THE ILK/ALPHA-PARVIN CORE COMPLEX (MGATP)
2129, d2xh5A_, 0.7790, 3.04, 0.250, 316, 256, STRUCTURE OF 4-(4-TERT-BUTYLBENZYL)-1-(7H-PYRROLO(23-D) PYRIMIDIN-4-YL)PIPERIDIN-4-AMINE BOUND TO PKB
2130, d2wqbA_, 0.7790, 2.65, 0.323, 289, 251, STRUCTURE OF THE TIE2 KINASE DOMAIN IN COMPLEX WITH A THIAZOLOPYRIMIDINE INHIBITOR
2131, d6bleA1, 0.7789, 2.86, 0.232, 263, 254, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH CP673451
2132, d5ia0C_, 0.7789, 2.65, 0.321, 269, 249, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ALISERTIB (MLN8237)
2133, d4aw5A_, 0.7789, 2.64, 0.281, 261, 249, COMPLEX OF THE EPHB4 KINASE DOMAIN WITH AN OXINDOLE INHIBITOR
2134, d3iecC_, 0.7789, 2.77, 0.292, 311, 253, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
2135, d2wevA_, 0.7789, 2.83, 0.208, 296, 255, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
2136, d5xvuC_, 0.7788, 2.88, 0.177, 321, 254, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC DOMAIN FROM PLASMODIUM FALCIPARUM BOUND TO ATP
2137, d5ng3C_, 0.7788, 2.44, 0.255, 272, 247, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
2138, d5cshA_, 0.7788, 2.94, 0.191, 324, 257, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 4 BOUND
2139, d1h1pC1, 0.7788, 2.82, 0.212, 295, 255, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU2058
2140, d5ek7A_, 0.7787, 2.88, 0.328, 286, 253, STRUCTURE OF THE AUTOINHIBITED EPHA2 JMS-KD
2141, d4dhfA_, 0.7787, 2.80, 0.235, 258, 251, STRUCTURE OF AURORA A MUTANT BOUND TO BIOGENIDEC CPD 15
2142, d3of0A_, 0.7787, 2.48, 0.339, 260, 245, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE CHICKEN C-SRC TYROSINE KINASE DOMAIN
2143, d3f3uA_, 0.7787, 2.41, 0.339, 261, 245, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL37 (TYPE III)
2144, d3e8eI_, 0.7787, 3.03, 0.259, 345, 255, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2145, d2xchA_, 0.7787, 2.95, 0.224, 278, 254, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH A PYRAZOLOQUINAZOLINE INHIBITOR
2146, d2wpaA1, 0.7787, 2.85, 0.212, 298, 255, OPTIMISATION OF 66-DIMETHYL PYRROLO 34-C PYRAZOLES: IDENTIFICATION OF PHA-793887 A POTENT CDK INHIBITOR SUITABLE FOR INTRAVENOUS DOSING
2147, d3f5pE1, 0.7786, 3.04, 0.309, 298, 259, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2148, d3c13A_, 0.7786, 2.95, 0.187, 328, 256, LOW PH-VALUE CRYSTAL STRUCTURE OF EMODIN IN COMPLEX WITH THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
2149, d1snuB_, 0.7786, 1.98, 0.315, 241, 238, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
2150, d5mo7A_, 0.7785, 2.99, 0.184, 327, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
2151, d5j79A_, 0.7785, 2.54, 0.273, 283, 249, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE COMPOUND 3 COMPLEX
2152, d5ia3A_, 0.7785, 2.73, 0.328, 275, 250, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH PD173955
2153, p4fmqA_, 0.7785, 3.15, 0.217, 350, 258, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
2154, d3repA_, 0.7785, 2.84, 0.268, 268, 254, CRYSTAL STRUCTURE OF THE ILK/ALPHA-PARVIN CORE COMPLEX (MNATP)
2155, d3eflB_, 0.7785, 2.60, 0.337, 263, 246, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH MOTESANIB
2156, d4zp5A_, 0.7784, 2.61, 0.224, 284, 250, MAP4K4 IN COMPLEX WITH INHIBITOR
2157, d4v04A_, 0.7784, 2.66, 0.360, 290, 250, FGFR1 IN COMPLEX WITH PONATINIB.
2158, d4tygA1, 0.7784, 3.15, 0.374, 290, 257, STRUCTURAL ANALYSIS OF THE HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE
2159, d3w8lA_, 0.7784, 3.01, 0.187, 326, 257, CRYSTAL STRUCTURE OF HUMAN CK2 IN COMPLEX WITH INOSITOL HEXAKISPHOSPHATE
2160, d3bqcA_, 0.7784, 2.97, 0.187, 328, 256, HIGH PH-VALUE CRYSTAL STRUCTURE OF EMODIN IN COMPLEX WITH THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
2161, d2qurA_, 0.7784, 3.03, 0.247, 338, 255, CRYSTAL STRUCTURE OF F327A/K285P MUTANT OF CAMP-DEPENDENT PROTEIN KINASE
2162, d2fb8A_, 0.7784, 2.38, 0.266, 259, 248, STRUCTURE OF THE B-RAF KINASE DOMAIN BOUND TO SB-590885
2163, d1r1wA_, 0.7784, 2.54, 0.350, 287, 246, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET
2164, d5mmfB_, 0.7783, 3.06, 0.194, 325, 258, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 7 BOUND
2165, d5kmiA_, 0.7783, 2.85, 0.382, 300, 251, TRKA JM-KINASE WITH 1-(9{H}-FLUOREN-9-YL)-3-(2-METHYL-4-PHENYL- PYRIMIDIN-5-YL)UREA
2166, d5ct0A_, 0.7783, 3.03, 0.198, 326, 258, CRYSTAL STRUCTURE OF CK2ALPHA WITH 3-(3-CHLORO-4-(PHENYL)BENZYLAMINO) PROPAN-1-OL BOUND
2167, d4fvpA_, 0.7783, 2.87, 0.264, 274, 254, CRYSTAL STRUCTURE OF THE JAK2 PSEUDOKINASE DOMAIN (APO FORM)
2168, d4e26B_, 0.7783, 2.63, 0.262, 264, 252, BRAF IN COMPLEX WITH AN ORGANIC INHIBITOR 7898734
2169, d3pixA_, 0.7783, 2.79, 0.333, 268, 252, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 2-ISOPROPYL-7- (4-METHYL-PIPERAZIN-1-YL)-4-(5-METHYL-2H-PYRAZOL-3-YLAMINO)-2H- PHTHALAZIN-1-ONE
2170, d6bkuA1, 0.7782, 2.85, 0.233, 264, 253, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B BOUND TO GSK650394
2171, d5xvuA_, 0.7782, 2.79, 0.178, 321, 253, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC DOMAIN FROM PLASMODIUM FALCIPARUM BOUND TO ATP
2172, d5uq0A_, 0.7782, 2.55, 0.381, 266, 247, FGFR1 KINASE DOMAIN COMPLEX WITH FRAGMENT 22-DIMETHYL-23- DIHYDROBENZOFURAN-7-CARBOXAMIDE
2173, p4jqeA_, 0.7782, 3.16, 0.196, 369, 260, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH AMPPN
2174, d2cciC2, 0.7782, 2.84, 0.205, 295, 254, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A PEPTIDE CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6
2175, d2c5oA_, 0.7782, 2.84, 0.208, 296, 255, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
2176, d2c4gC2, 0.7782, 2.93, 0.215, 298, 256, STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514
2177, d5mpjB_, 0.7781, 3.01, 0.194, 324, 258, 1-(2-CHLORO-[11 -BIPHENYL]-4-YL)-N-METHYLETHANAMINE
2178, d5ikwA_, 0.7781, 3.01, 0.209, 297, 254, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
2179, d5ar2A_, 0.7781, 2.17, 0.246, 277, 244, RIP2 KINASE CATALYTIC DOMAIN (1 - 310)
2180, d3axwA_, 0.7781, 3.08, 0.190, 329, 258, CRYSTAL STRUCTURE OF HUMAN CK2ALPHA COMPLEXED WITH A POTENT INHIBITOR
2181, d2c5oC_, 0.7781, 2.84, 0.208, 296, 255, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
2182, d5kmmA1, 0.7780, 2.84, 0.382, 300, 251, TRKA JM-KINASE WITH 1-(2-METHYL-4-PHENYL-PYRIMIDIN-5-YL)-3-(1- NAPHTHYL)UREA
2183, d3d15A_, 0.7780, 2.70, 0.236, 256, 250, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240->ARG MET302- >LEU) IN COMPLEX WITH 1-(3-CHLORO-PHENYL)-3-{5-[2-(THIENO[32- D]PYRIMIDIN-4-YLAMINO)- ETHYL]-THIAZOL-2-YL}-UREA [SNS-314]
2184, d3cpbA1, 0.7780, 2.53, 0.322, 278, 245, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BISAMIDE INHIBITOR
2185, d3a7hA_, 0.7780, 3.40, 0.272, 289, 261, HUMAN MST3 KINASE IN COMPLEX WITH ATP
2186, d2qi8A_, 0.7780, 2.06, 0.354, 255, 240, CRYSTAL STRUCTURE OF DRUG RESISTANT SRC KINASE DOMAIN
2187, d3tl8D_, 0.7779, 2.82, 0.266, 306, 252, THE AVRPTOB-BAK1 COMPLEX REVEALS TWO STRUCTURALLY SIMILAR KINASEINTERACTING DOMAINS IN A SINGLE TYPE III EFFECTOR
2188, d3prfA_, 0.7779, 2.47, 0.257, 262, 249, CRYSTAL STRUCTURE OF HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH A NON- OXIME FUROPYRIDINE INHIBITOR
2189, d3f3uB_, 0.7779, 2.41, 0.340, 259, 244, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL37 (TYPE III)
2190, d3aglA_, 0.7779, 2.96, 0.243, 338, 255, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1039
2191, d2uzlA_, 0.7779, 2.76, 0.205, 295, 254, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2192, d2bkzC2, 0.7779, 2.94, 0.215, 297, 256, STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611
2193, d1qmzA1, 0.7779, 2.81, 0.205, 295, 254, PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX
2194, d5nkaA_, 0.7778, 2.68, 0.321, 271, 249, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2G
2195, d5m4fA_, 0.7778, 3.07, 0.190, 330, 258, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO-FLAVONOL (FLC21) CRYSTALLIZED UNDER LOW-SALT CONDITIONS
2196, d4wunB_, 0.7778, 2.69, 0.384, 268, 250, STRUCTURE OF FGFR1 IN COMPLEX WITH AZD4547 (N-{3-[2-(35- DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE) AT 1.65 ANGSTROM
2197, d4cnhA_, 0.7778, 2.66, 0.298, 285, 248, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 3-((1R)-1-(5-FLUORO-2- METHOXYPHENYL)ETHOXY)-5-(1-METHYL-1H-123-TRIAZOL-5-YL) PYRIDIN-2-AMINE
2198, d3q9wA_, 0.7778, 2.95, 0.187, 328, 256, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH EMODIN AT PH 8.5
2199, d3bhyA1, 0.7778, 2.77, 0.223, 267, 251, CRYSTAL STRUCTURE OF HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3) IN COMPLEX WITH A BETA-CARBOLINE LIGAND
2200, d5xvuB_, 0.7777, 2.79, 0.178, 321, 253, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC DOMAIN FROM PLASMODIUM FALCIPARUM BOUND TO ATP
2201, d5jsmB1, 0.7777, 2.57, 0.267, 259, 251, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
2202, d5d7aC_, 0.7777, 2.68, 0.212, 286, 250, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TRAF2 AND NCK-INTERACTING PROTEIN KINASE WITH NCB-0846
2203, d3qcqA_, 0.7777, 2.83, 0.214, 276, 252, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-(3- AMINO-1H-INDAZOL-6-YL)-N4-ETHYL-24-PYRIMIDINEDIAMINE
2204, d3nunA_, 0.7777, 2.94, 0.225, 278, 253, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH LEAD COMPOUND
2205, d3at3A_, 0.7777, 3.10, 0.185, 332, 259, CRYSTAL STRUCTURE OF CK2ALPHA WITH PYRADINE DERIVATIVE
2206, d2bkzA2, 0.7777, 2.87, 0.212, 298, 255, STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611
2207, d1ol1C_, 0.7777, 2.87, 0.208, 296, 255, CYCLIN A BINDING GROOVE INHIBITOR H-CIT-CIT-LEU-ILE-(P-F-PHE)-NH2
2208, d1gy3A_, 0.7777, 2.79, 0.205, 295, 254, PCDK2/CYCLIN A IN COMPLEX WITH MGADP NITRATE AND PEPTIDE SUBSTRATE
2209, d4kioD1, 0.7776, 1.98, 0.328, 240, 238, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH A COVALENTLY-BINDING INHIBITOR
2210, d3rwpA_, 0.7776, 2.93, 0.225, 277, 253, DISCOVERY OF A NOVEL POTENT AND SELECTIVE INHIBITOR OF 3- PHOSPHOINOSITIDE DEPENDENT KINASE (PDK1)
2211, d3qcsA_, 0.7776, 2.83, 0.214, 276, 252, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-[2- AMINO-6-(4-MORPHOLINYL)-4-PYRIMIDINYL]-1H-INDAZOL-3-AMINE
2212, d3a7gB_, 0.7776, 3.21, 0.281, 290, 260, HUMAN MST3 KINASE
2213, d2wihA1, 0.7776, 2.87, 0.212, 298, 255, STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125
2214, d2uzeA_, 0.7776, 2.77, 0.205, 295, 254, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2215, d5swhB_, 0.7775, 2.47, 0.340, 261, 244, C-SRC V281C KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
2216, d5if1A_, 0.7775, 2.77, 0.201, 298, 254, CRYSTAL STRUCTURE APO CDK2/CYCLIN A
2217, d5i3oA_, 0.7775, 2.83, 0.194, 302, 252, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
2218, d4kioA1, 0.7775, 1.78, 0.322, 238, 236, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH A COVALENTLY-BINDING INHIBITOR
2219, d4eqcA1, 0.7775, 3.45, 0.216, 292, 264, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN IN COMPLEX WITH FRAX597 INHIBITOR
2220, d4aszA1, 0.7775, 2.83, 0.378, 286, 251, CRYSTAL STRUCTURE OF APO TRKB KINASE DOMAIN
2221, d2c4gA2, 0.7775, 2.90, 0.212, 297, 255, STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514
2222, d1vywA1, 0.7775, 2.90, 0.212, 298, 255, STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137
2223, d1qmzC1, 0.7775, 2.81, 0.205, 295, 254, PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX
2224, d5l8lA_, 0.7774, 3.01, 0.234, 263, 256, AURORA-A KINASE DOMAIN IN COMPLEX WITH VNAR-D01 (CRYSTAL FORM 1)
2225, d4at4A1, 0.7774, 3.08, 0.370, 289, 254, CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH EX429
2226, d3prfB_, 0.7774, 2.46, 0.257, 262, 249, CRYSTAL STRUCTURE OF HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH A NON- OXIME FUROPYRIDINE INHIBITOR
2227, d3cpcA1, 0.7774, 2.65, 0.312, 277, 247, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDONE INHIBITOR
2228, d3ag9B_, 0.7774, 3.05, 0.263, 317, 255, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1012
2229, d1fq1B_, 0.7774, 2.71, 0.213, 295, 253, CRYSTAL STRUCTURE OF KINASE ASSOCIATED PHOSPHATASE (KAP) IN COMPLEX WITH PHOSPHO-CDK2
2230, d5ho8A_, 0.7773, 2.81, 0.214, 278, 252, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
2231, d5dt0A_, 0.7773, 2.85, 0.235, 259, 251, AURORA A KINASE IN COMPLEX WITH JNJ-7706621 IN SPACE GROUP P6122
2232, d5cyiC1, 0.7773, 2.79, 0.205, 295, 254, CDK2/CYCLIN A COVALENT COMPLEX WITH 6-(CYCLOHEXYLMETHOXY)-N-(4- (VINYLSULFONYL)PHENYL)-9H-PURIN-2-AMINE (NU6300)
2233, d4uwyB_, 0.7773, 2.75, 0.371, 273, 251, FGFR1 APO STRUCTURE
2234, d3v5qA1, 0.7773, 2.42, 0.404, 260, 245, DISCOVERY OF A SELECTIVE TRK INHIBITOR WITH EFFICACY IN RODENT CANCER TUMOR MODELS
2235, d2wpaC1, 0.7773, 2.95, 0.215, 298, 256, OPTIMISATION OF 66-DIMETHYL PYRROLO 34-C PYRAZOLES: IDENTIFICATION OF PHA-793887 A POTENT CDK INHIBITOR SUITABLE FOR INTRAVENOUS DOSING
2236, d4kwpA_, 0.7772, 3.07, 0.185, 329, 259, CRYSTAL STRUCTURE OF HUMAN CK2-ALPHA IN COMPLEX WITH A BENZIMIDAZOLE INHIBITOR (K164) AT 1.25 A RESOLUTION
2237, d4i6fA_, 0.7772, 3.11, 0.213, 285, 258, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
2238, d3svvB_, 0.7772, 2.13, 0.336, 257, 241, CRYSTAL STRUCTURE OF T338C C-SRC COVALENTLY BOUND TO VINYLSULFONAMIDE- PYRAZOLOPYRIMIDINE 9
2239, d3qcxA_, 0.7772, 2.83, 0.214, 276, 252, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-{2- AMINO-6-[(3R)-3-METHYL-4-MORPHOLINYL]-4-PYRIMIDINYL}-1H-INDAZOL-3- AMINE
2240, d3ewhA1, 0.7772, 3.21, 0.341, 295, 255, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDYL-PYRIMIDINE BENZIMIDAZOLE INHIBITOR
2241, d2uzlC_, 0.7772, 2.78, 0.201, 295, 254, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2242, d5uabA_, 0.7771, 2.37, 0.357, 288, 241, MET TYROSINE KINASE INHIBITION ENHANCES THE ANTITUMOR EFFICACY OF AN HGF ANTIBODY
2243, d5mo8B_, 0.7771, 2.81, 0.189, 324, 254, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
2244, d5cx9A_, 0.7771, 2.94, 0.192, 328, 255, CRYSTAL STRUCTURE OF CK2ALPHA WITH (METHYL 4-((3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)AMINO)-4-OXOBUTANOATE BOUND
2245, d3nusA_, 0.7771, 2.82, 0.214, 276, 252, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT8
2246, d3cs9B_, 0.7771, 2.22, 0.342, 247, 243, HUMAN ABL KINASE IN COMPLEX WITH NILOTINIB
2247, d5tehA_, 0.7770, 2.40, 0.335, 261, 245, C-SRC V281C KINASE DOMAIN IN COMPLEX WITH RAO-IV-156
2248, d3v5jB1, 0.7770, 1.80, 0.314, 239, 236, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 090
2249, d3ggfA_, 0.7770, 2.73, 0.259, 275, 251, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE MST4 IN COMPLEX WITH AN QUINAZOLIN
2250, d2c5xA_, 0.7770, 2.86, 0.208, 296, 255, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
2251, d1xjdA_, 0.7770, 2.79, 0.265, 280, 253, CRYSTAL STRUCTURE OF PKC-THETA COMPLEXED WITH STAUROSPORINE AT 2A RESOLUTION
2252, d5sysA_, 0.7769, 2.45, 0.340, 258, 244, C-SRC V281C BOUND TO N-[3-({6-[(1E)-2-CYANO-3-(METHYLAMINO)-3-OXOPROP- 1-EN-1-YL]-7-(2-METHOXYETHYL)-7H-PYRROLO[23-D]PYRIMIDIN-5- YL}ETHYNYL)-4-METHYLPHENYL]-3-(TRIFLUOROMETHYL)BENZAMIDE INHIBITOR
2253, d5modB_, 0.7769, 2.82, 0.185, 324, 254, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
2254, d5mo7B_, 0.7769, 3.06, 0.194, 325, 258, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
2255, d4mneD_, 0.7769, 3.15, 0.199, 285, 256, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
2256, d4krdA_, 0.7769, 3.06, 0.210, 294, 257, CRYSTAL STRUCTURE OF PHO85-PCL10 COMPLEX
2257, d4eokC1, 0.7769, 2.80, 0.209, 296, 254, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
2258, d3orzD_, 0.7769, 3.07, 0.244, 278, 254, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
2259, d3f69B_, 0.7769, 2.99, 0.210, 282, 257, CRYSTAL STRUCTURE OF THE MYCOBACTERIUM TUBERCULOSIS PKNB MUTANT KINASE DOMAIN IN COMPLEX WITH KT5720
2260, d2pl0A_, 0.7769, 2.71, 0.364, 268, 247, LCK BOUND TO IMATINIB
2261, d2c5xC_, 0.7769, 2.87, 0.208, 296, 255, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
2262, d5cx9B_, 0.7768, 3.05, 0.194, 325, 258, CRYSTAL STRUCTURE OF CK2ALPHA WITH (METHYL 4-((3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)AMINO)-4-OXOBUTANOATE BOUND
2263, d4ybjA_, 0.7768, 2.23, 0.339, 255, 242, TYPE II DASATINIB ANALOG CRYSTALLIZED WITH C-SRC KINASE
2264, d4o0wA_, 0.7768, 2.75, 0.236, 259, 250, CRYSTAL STRUCTURES OF HUMAN KINASE AURORA A
2265, d4cxaA_, 0.7768, 3.16, 0.249, 329, 261, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLIN K COMPLEX BOUND TO AMPPNP
2266, d3g6hB_, 0.7768, 2.50, 0.347, 259, 245, SRC THR338ILE INHIBITED IN THE DFG-ASP-OUT CONFORMATION
2267, d1okwC_, 0.7768, 2.86, 0.204, 296, 255, CYCLIN A BINDING GROOVE INHIBITOR AC-ARG-ARG-LEU-ASN-(M-CL-PHE)-NH2
2268, d1gy3C_, 0.7768, 2.82, 0.205, 295, 254, PCDK2/CYCLIN A IN COMPLEX WITH MGADP NITRATE AND PEPTIDE SUBSTRATE
2269, d5te0A_, 0.7767, 3.13, 0.205, 316, 254, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE (AAK1) IN COMPLEX WITH BIBF 1120
2270, p5otzA_, 0.7767, 3.07, 0.191, 327, 257, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 1
2271, p5os8A_, 0.7767, 3.06, 0.191, 327, 257, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 11
2272, d5cwzB_, 0.7767, 2.67, 0.212, 284, 250, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE
2273, d3wilA_, 0.7767, 3.10, 0.189, 331, 259, CRYSTAL STRUCTURE OF THE CK2ALPHA/COMPOUND3 COMPLEX
2274, d3orzB_, 0.7767, 3.07, 0.244, 278, 254, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
2275, d2oxyB_, 0.7767, 3.07, 0.179, 327, 257, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE DERIVATIVES K17 K22 AND K32
2276, d4i6hA_, 0.7766, 3.18, 0.224, 285, 259, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE ALPHA-SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
2277, d3q9yA_, 0.7766, 2.96, 0.187, 327, 256, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH QUINALIZARIN AT PH 8.5
2278, d3iecB_, 0.7766, 2.87, 0.290, 313, 255, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
2279, d1urcA_, 0.7766, 2.86, 0.208, 296, 255, CYCLIN A BINDING GROOVE INHIBITOR ACE-ARG-LYS-LEU-PHE-GLY
2280, d1ol1A_, 0.7766, 2.86, 0.208, 296, 255, CYCLIN A BINDING GROOVE INHIBITOR H-CIT-CIT-LEU-ILE-(P-F-PHE)-NH2
2281, d5mo6B_, 0.7765, 2.98, 0.191, 324, 257, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
2282, d5i3rA_, 0.7765, 2.86, 0.194, 302, 252, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
2283, d4l00B_, 0.7765, 2.83, 0.224, 278, 255, CRYSTAL STRUCTURE OF THE APO JAK1 PSEUDOKINASE DOMAIN
2284, d4l00A_, 0.7765, 2.77, 0.233, 277, 253, CRYSTAL STRUCTURE OF THE APO JAK1 PSEUDOKINASE DOMAIN
2285, d3lw0A_, 0.7765, 2.71, 0.312, 292, 250, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
2286, d2whaC_, 0.7765, 2.88, 0.208, 296, 255,  
2287, d2uzbA_, 0.7765, 2.83, 0.205, 295, 254, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2288, d2qu6A1, 0.7765, 2.39, 0.337, 276, 243, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZOXAZOLE INHIBITOR
2289, d2c6tA_, 0.7765, 2.81, 0.205, 295, 254, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
2290, d1szmA_, 0.7765, 2.93, 0.259, 317, 255, DUAL BINDING MODE OF BISINDOLYLMALEIMIDE 2 TO PROTEIN KINASE A (PKA)
2291, d5tx5A_, 0.7764, 2.33, 0.287, 259, 244, RIP1 KINASE ( FLAG 1-294 C34A C127A C233A C240A) WITH GSK772
2292, d5mo6A_, 0.7764, 2.83, 0.189, 325, 254, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
2293, d5jsmC1, 0.7764, 2.32, 0.264, 259, 246, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
2294, d4qo9A_, 0.7764, 3.13, 0.277, 280, 256, MST3 IN COMPLEX WITH DANUSERTIB
2295, d4i6bA_, 0.7764, 3.24, 0.215, 285, 260, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
2296, d3nuyA_, 0.7764, 2.95, 0.225, 276, 253, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT17
2297, d3lw0D_, 0.7764, 2.71, 0.312, 292, 250, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
2298, d3lw0C_, 0.7764, 2.71, 0.312, 292, 250, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
2299, d2v22C_, 0.7764, 2.87, 0.204, 296, 255, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
2300, d2uzeC_, 0.7764, 2.81, 0.205, 295, 254, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2301, d1okzA_, 0.7764, 2.82, 0.214, 276, 252, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH UCN-01
2302, d5mo5B_, 0.7763, 3.07, 0.194, 325, 258, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
2303, d4twoA_, 0.7763, 2.84, 0.306, 278, 252, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH COMPOUND 164
2304, d3q04A_, 0.7763, 3.09, 0.189, 328, 259, CRYSTAL STRUCTURE OF THE APO-FORM OF HUMAN CK2 ALPHA AT PH 8.5
2305, d3lw0B_, 0.7763, 2.72, 0.312, 292, 250, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
2306, d2wxvC1, 0.7763, 2.96, 0.215, 298, 256, STRUCTURE OF CDK2-CYCLIN A WITH A PYRAZOLO(43-H) QUINAZOLINE-3-CARBOXAMIDE INHIBITOR
2307, d2wfyC_, 0.7763, 2.86, 0.204, 296, 255, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
2308, d1rjbA_, 0.7763, 2.94, 0.341, 298, 249, CRYSTAL STRUCTURE OF FLT3
2309, d5dpvA_, 0.7762, 2.80, 0.240, 257, 250, AURORA A KINASE IN COMPLEX WITH AA35 AND JNJ-7706621 IN SPACE GROUP P6122
2310, d5bvwA_, 0.7762, 2.82, 0.355, 274, 251, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
2311, d4oa2A_, 0.7762, 2.94, 0.250, 280, 252,  
2312, d4mnfB_, 0.7762, 2.39, 0.259, 257, 247, CRYSTAL STRUCTURE OF BRAF-V600E BOUND TO GDC0879
2313, d3qupA_, 0.7762, 1.84, 0.335, 241, 236, INHIBITOR BOUND STRUCTURE OF THE KINASE DOMAIN OF THE MURINE RECEPTOR TYROSINE KINASE TYRO3 (SKY)
2314, d3qtiB_, 0.7762, 2.49, 0.344, 280, 244, C-MET KINASE IN COMPLEX WITH NVP-BVU972
2315, d1jwhA_, 0.7762, 3.14, 0.190, 336, 258, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 HOLOENZYME
2316, d1fvvC_, 0.7762, 2.95, 0.215, 298, 256, THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLE INHIBITOR
2317, d1finA_, 0.7762, 3.01, 0.215, 298, 256, CYCLIN A-CYCLIN-DEPENDENT KINASE 2 COMPLEX
2318, d5m4cA_, 0.7761, 3.04, 0.183, 329, 257, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A THIENO[23-D]PYRIMIDIN INHIBITOR CRYSTALLIZED UNDER LOW-SALT CONDITIONS
2319, d5cvhB_, 0.7761, 2.96, 0.183, 324, 257, CRYSTAL STRUCTURE OF CK2ALPHA
2320, d5ctpA_, 0.7761, 2.84, 0.185, 324, 254, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)ACETAMIDE BOUND
2321, d4itjA_, 0.7761, 2.38, 0.290, 261, 245, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-4
2322, d3nuuA_, 0.7761, 2.82, 0.214, 276, 252, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT11
2323, d5njzA_, 0.7760, 2.72, 0.324, 273, 250, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1G
2324, d5ar5B_, 0.7760, 2.36, 0.252, 279, 246, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BENZIMIDAZOLE
2325, d4pmsA1, 0.7760, 2.62, 0.371, 279, 248, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR 4-NAPHTHALEN-1-YL- 1-[(5-PHENYL-124-OXADIAZOL-3-YL)METHYL]-1H-PYRROLO[32-C]PYRIDINE- 2-CARBOXYLIC ACID
2326, d3ofmA_, 0.7760, 3.23, 0.203, 325, 261, STRUCTURE OF A HUMAN CK2ALPHA PRIME THE PARALOG ISOFORM OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 FROM HOMO SAPIENS
2327, d3f3vB_, 0.7760, 2.57, 0.337, 262, 246, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL45 (TYPE II)
2328, d3dzqA_, 0.7760, 2.73, 0.308, 268, 250, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH INHIBITOR AWL-II- 38.3
2329, d2p2iB_, 0.7760, 2.50, 0.328, 263, 244, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NICOTINAMIDE INHIBITOR
2330, d5ur1A_, 0.7759, 2.64, 0.375, 278, 248, FGFR1 KINASE DOMAIN COMPLEX WITH SN37333 IN REVERSIBLE BINDING MODE
2331, d5mmfA_, 0.7759, 3.17, 0.197, 326, 259, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 7 BOUND
2332, d4mneH_, 0.7759, 3.09, 0.200, 275, 255, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
2333, d4eonA1, 0.7759, 2.74, 0.206, 297, 253, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
2334, d1h1sC1, 0.7759, 2.79, 0.205, 295, 254, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6102
2335, d5mp8A_, 0.7758, 3.06, 0.194, 325, 258, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
2336, d5mohA_, 0.7758, 3.19, 0.188, 326, 260, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0583 BOUND.
2337, d5kbqA_, 0.7758, 3.19, 0.218, 289, 261, PAK1 IN COMPLEX WITH BIS-ANILINO PYRIMIDINE INHIBITOR
2338, d5cwzA_, 0.7758, 2.58, 0.213, 284, 249, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE
2339, d5cspA_, 0.7758, 2.97, 0.180, 327, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 5 BOUND
2340, d4eopC1, 0.7758, 2.82, 0.205, 295, 254, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
2341, d4eolA1, 0.7758, 2.68, 0.206, 293, 252, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
2342, d3v5jA1, 0.7758, 1.90, 0.321, 239, 237, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 090
2343, d2whbC_, 0.7758, 2.86, 0.204, 296, 255, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
2344, d4mnfA_, 0.7757, 2.32, 0.268, 257, 246, CRYSTAL STRUCTURE OF BRAF-V600E BOUND TO GDC0879
2345, d4eolC1, 0.7757, 2.80, 0.209, 296, 254, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
2346, d3f3wA_, 0.7757, 2.44, 0.331, 261, 245, DRUG RESISTANT CSRC KINASE DOMAIN IN COMPLEX WITH INHIBITOR RL45 (TYPE II)
2347, d3a7hB_, 0.7757, 3.22, 0.269, 290, 260, HUMAN MST3 KINASE IN COMPLEX WITH ATP
2348, d2x1nC_, 0.7757, 2.90, 0.208, 296, 255, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
2349, d1h1pA1, 0.7757, 2.96, 0.210, 295, 257, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU2058
2350, d5d11B_, 0.7756, 2.15, 0.350, 255, 240, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL235
2351, d4i4fA_, 0.7756, 2.66, 0.364, 255, 247, STRUCTURE OF FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH AN ALLOSTERIC BINDING PYRAZOLOBENZOTHIAZINE COMPOUND.
2352, d4eonC1, 0.7756, 2.81, 0.205, 296, 254, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
2353, d3d2iA_, 0.7756, 2.68, 0.241, 255, 249, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240- >ARG MET302->LEU) IN COMPLEX WITH 1-{5-[2-(1-METHYL-1H- PYRAZOLO[43-D]PYRIMIDIN-7-YLAMINO)-ETHYL]-THIAZOL-2-YL}-3- (3-TRIFLUOROMETHYL-PHENYL)-UREA
2354, d2jkoA_, 0.7756, 2.59, 0.367, 256, 248, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
2355, d1yhwA_, 0.7756, 3.34, 0.213, 293, 263, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH ONE POINT MUTATIONS (K299R)
2356, d1k9aD3, 0.7756, 2.75, 0.376, 268, 250, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
2357, p5otyA_, 0.7755, 3.00, 0.184, 327, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH CAM4712
2358, p5n9lA_, 0.7755, 3.09, 0.185, 329, 259, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE DIBENZOFURAN INHIBITOR TF (4B)
2359, d4f65B_, 0.7755, 2.77, 0.355, 279, 251, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 8
2360, d3mpmA_, 0.7755, 2.61, 0.354, 257, 246, LCK COMPLEXED WITH A PYRAZOLOPYRIMIDINE
2361, d3h9oA_, 0.7755, 2.82, 0.215, 275, 251, PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK-1) IN COMPLEX WITH COMPOUND 9
2362, d2cchA2, 0.7755, 2.92, 0.209, 295, 254, THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA- LINKED ATP ANALOGUE
2363, d5ut5A_, 0.7754, 2.85, 0.265, 272, 253, JAK2 JH2 IN COMPLEX WITH GLPG0634
2364, d5ut0A_, 0.7754, 2.81, 0.262, 272, 252, JAK2 JH2 IN COMPLEX WITH AT9283
2365, d5swhA_, 0.7754, 2.49, 0.340, 258, 244, C-SRC V281C KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
2366, d4kioB1, 0.7754, 1.75, 0.323, 237, 235, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH A COVALENTLY-BINDING INHIBITOR
2367, d3r0tA_, 0.7754, 3.10, 0.189, 327, 259, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR CX-5279
2368, d2whbA_, 0.7754, 2.89, 0.208, 296, 255, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
2369, d2fb8B_, 0.7754, 2.50, 0.265, 259, 249, STRUCTURE OF THE B-RAF KINASE DOMAIN BOUND TO SB-590885
2370, d1q8wA_, 0.7754, 3.01, 0.263, 334, 255, THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH RHO-KINASE INHIBITOR FASUDIL (HA-1077)
2371, d5jznA_, 0.7753, 2.81, 0.225, 268, 253, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH NVP-TAE684
2372, d5if1C_, 0.7753, 2.86, 0.208, 296, 255, CRYSTAL STRUCTURE APO CDK2/CYCLIN A
2373, d5cvhA_, 0.7753, 3.23, 0.192, 327, 260, CRYSTAL STRUCTURE OF CK2ALPHA
2374, d3qd3A_, 0.7753, 2.98, 0.225, 278, 253, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 11- DIMETHYLETHYL {(3R6S)-1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4- PYRIMIDINYL]-6-METHYL-3-PIPERIDINYL}CARBAMATE
2375, d2xbaA_, 0.7753, 2.60, 0.300, 283, 247, STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PHA-E429
2376, d3wowA_, 0.7752, 3.20, 0.188, 334, 260, CRYSTAL STRUCTURE OF HUMAN CK2A WITH AMPPNP
2377, d3v5lA1, 0.7752, 1.83, 0.322, 238, 236, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 542
2378, d3my0W1, 0.7752, 3.30, 0.243, 280, 259, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
2379, d3dlsD_, 0.7752, 2.92, 0.237, 284, 253, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
2380, d2wevC_, 0.7752, 2.91, 0.208, 296, 255, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
2381, d1pjkA_, 0.7752, 3.01, 0.191, 331, 256, CRYSTAL STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT
2382, d1oiyC1, 0.7752, 2.83, 0.205, 295, 254, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
2383, d4f1oA1, 0.7751, 3.07, 0.259, 274, 255, CRYSTAL STRUCTURE OF THE L1180T MUTANT ROCO4 KINASE DOMAIN FROM D. DISCOIDEUM BOUND TO APPCP
2384, d3otuA_, 0.7751, 2.89, 0.235, 276, 251, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR JS30
2385, d3lm0A1, 0.7751, 2.93, 0.202, 271, 252, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE 17B (STK17B)
2386, d2whaA_, 0.7751, 2.90, 0.208, 296, 255,  
2387, d2g9xC2, 0.7751, 2.84, 0.209, 273, 254, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR NU6271
2388, d1yhvA_, 0.7751, 3.35, 0.213, 293, 263, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH TWO POINT MUTATIONS (K299R T423E)
2389, d5ut1A_, 0.7750, 2.86, 0.265, 272, 253, JAK2 JH2 IN COMPLEX WITH BI-D1870
2390, d5mo4A3, 0.7750, 2.31, 0.344, 271, 244, ABL1 KINASE (T334I_D382N) IN COMPLEX WITH ASCIMINIB AND NILOTINIB
2391, d5d7aA_, 0.7750, 2.55, 0.217, 289, 249, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TRAF2 AND NCK-INTERACTING PROTEIN KINASE WITH NCB-0846
2392, d4bcnC1, 0.7750, 2.85, 0.205, 293, 254, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
2393, d3wikA_, 0.7750, 3.28, 0.195, 334, 261, CRYSTAL STRUCTURE OF THE CK2ALPHA/COMPOUND10 COMPLEX
2394, d2uzbC_, 0.7750, 2.69, 0.199, 292, 251, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2395, d2c5tC_, 0.7750, 2.90, 0.208, 296, 255,  
2396, d1yomB_, 0.7750, 2.43, 0.340, 261, 244, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH PURVALANOL A
2397, d5cu3B_, 0.7749, 3.08, 0.194, 324, 258, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 10 BOUND
2398, d4pmtA1, 0.7749, 2.46, 0.381, 269, 244, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR N~4~-(4-MORPHOLIN- 4-YLPHENYL)-N~6~-(PYRIDIN-3-YLMETHYL)PYRIDO[32-D]PYRIMIDINE-46- DIAMINE
2399, d4i5pA_, 0.7749, 3.18, 0.216, 284, 259, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
2400, d4grbA_, 0.7749, 2.94, 0.180, 327, 255, CASEIN KINASE 2 (CK2) BOUND TO INHIBITOR
2401, d3nszA_, 0.7749, 2.93, 0.184, 327, 255, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH AMPPN
2402, d3gqlB_, 0.7749, 2.72, 0.372, 276, 250, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
2403, d2yn8B_, 0.7749, 2.64, 0.286, 260, 248, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
2404, d2welA_, 0.7749, 2.93, 0.218, 304, 257, CRYSTAL STRUCTURE OF SU6656-BOUND CALCIUM/CALMODULIN- DEPENDENT PROTEIN KINASE II DELTA IN COMPLEX WITH CALMODULIN
2405, d2v22A_, 0.7749, 2.88, 0.208, 296, 255, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
2406, d2c5pC_, 0.7749, 2.90, 0.208, 296, 255,  
2407, d3pe2A_, 0.7748, 3.02, 0.182, 327, 258, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 IN COMPLEX WITH THE INHIBITOR CX-5011
2408, d3ddpC1, 0.7748, 2.77, 0.202, 297, 253, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR CR8
2409, d3bhuC1, 0.7748, 2.87, 0.213, 269, 254, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 5
2410, d3bhtC1, 0.7748, 2.87, 0.209, 269, 254, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 3
2411, d2x1nA_, 0.7748, 2.91, 0.208, 296, 255, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
2412, d6bqqA1, 0.7747, 3.13, 0.234, 269, 256, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH BI2526
2413, d5uszA_, 0.7747, 2.85, 0.265, 272, 253, JAK2 JH2 IN COMPLEX WITH JNJ-7706621
2414, d4u45A_, 0.7747, 2.77, 0.234, 289, 252, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 25)
2415, d1uu9A_, 0.7747, 2.96, 0.225, 276, 253, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-3
2416, d5ut6A_, 0.7746, 2.88, 0.265, 272, 253, JAK2 JH2 IN COMPLEX WITH A DIAMINOPYRIMIDINE
2417, d4p5qA_, 0.7746, 2.89, 0.306, 275, 252, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH QUINOXALINE DERIVATIVES
2418, d4eooC1, 0.7746, 2.89, 0.205, 295, 254, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
2419, d4eojC1, 0.7746, 2.86, 0.217, 278, 254, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH ATP
2420, d3bhtA2, 0.7746, 2.92, 0.224, 295, 254, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 3
2421, d5ia1A_, 0.7745, 2.50, 0.320, 261, 247, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH MLN8054
2422, d4bcmC1, 0.7745, 3.00, 0.212, 293, 255, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
2423, d3tt0B_, 0.7745, 2.82, 0.372, 272, 250, CO-STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN WITH 3-(26-DICHLORO-35-DIMETHOXY-PHENYL)-1-{6-[4-(4-ETHYL-PIPERAZIN-1- YL)-PHENYLAMINO]-PYRIMIDIN-4-YL}-1-METHYL-UREA (BGJ398)
2424, d3q52A_, 0.7745, 3.32, 0.221, 292, 262, STRUCTURE OF PHOSPHORYLATED PAK1 KINASE DOMAIN
2425, d3f3vA_, 0.7745, 2.59, 0.337, 261, 246, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL45 (TYPE II)
2426, d3bhuA1, 0.7745, 2.85, 0.213, 295, 253, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 5
2427, d1ol2C_, 0.7745, 2.89, 0.208, 296, 255, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ASN-(P-F-PHE)-NH2
2428, d5lpvA_, 0.7744, 2.89, 0.242, 282, 252, CRYSTAL STRUCTURE OF THE BRI1 KINASE DOMAIN (865-1160) IN COMPLEX WITH AMPPNP AND MN FROM ARABIDOPSIS THALIANA
2429, p4gubA_, 0.7744, 3.07, 0.178, 329, 258, CASEIN KINASE II BOUND TO INHIBITOR
2430, d4bcoC1, 0.7744, 2.87, 0.205, 268, 254, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
2431, d3pe1A_, 0.7744, 3.11, 0.181, 327, 259, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR CX-4945
2432, d3orzC_, 0.7744, 3.10, 0.236, 276, 254, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
2433, d3lm5A1, 0.7744, 2.96, 0.190, 267, 252, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE 17B (STK17B) IN COMPLEX WITH QUERCETIN
2434, d3bhhC1, 0.7744, 2.64, 0.206, 284, 252, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
2435, d2wfyA_, 0.7744, 2.89, 0.204, 295, 255, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
2436, d2iw8A1, 0.7744, 2.84, 0.209, 296, 254, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A F82H-L83V- H84D MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR
2437, d1h1qC1, 0.7744, 2.82, 0.205, 295, 254, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6094
2438, d5ut3A_, 0.7743, 2.87, 0.265, 272, 253, JAK2 JH2 IN COMPLEX WITH IKK-2 INHIBITOR VI
2439, d5l2wA1, 0.7743, 2.77, 0.202, 296, 253, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK2/CYCLINE AND DINACICLIB.
2440, d4eosC1, 0.7743, 2.83, 0.205, 295, 254, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
2441, d3krlA_, 0.7743, 2.96, 0.336, 281, 250, CFMS TYROSINE KINASE IN COMPLEX WITH 5-CYANO-FURAN-2-CARBOXYLIC ACID [4-(4-METHYL-PIPERAZIN-1-YL)-2-PIPERIDIN-1-YL-PHENYL]-AMIDE
2442, d2uueC_, 0.7743, 2.92, 0.208, 296, 255, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
2443, d1eh4A_, 0.7743, 3.25, 0.159, 293, 264, BINARY COMPLEX OF CASEIN KINASE-1 FROM S. POMBE WITH AN ATP COMPETITIVE INHIBITOR IC261
2444, p5n9nA_, 0.7742, 3.12, 0.189, 329, 259, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE TIGHT-BINDING DIBENZOFURAN INHIBITOR TF85 (4A)
2445, d5modA_, 0.7742, 2.81, 0.190, 327, 253, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
2446, d5m44A_, 0.7742, 2.95, 0.196, 329, 255, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A THIENO[23-D]PYRIMIDIN INHIBITOR CRYSTALLIZED UNDER HIGH-SALT CONDITIONS
2447, d5ax9C_, 0.7742, 2.65, 0.213, 282, 249, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE IN COMPLEX WITH COMPUND 9
2448, d4cfnC1, 0.7742, 2.82, 0.201, 293, 254, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
2449, d3tl8G_, 0.7742, 2.85, 0.270, 301, 252, THE AVRPTOB-BAK1 COMPLEX REVEALS TWO STRUCTURALLY SIMILAR KINASEINTERACTING DOMAINS IN A SINGLE TYPE III EFFECTOR
2450, d3fzoA_, 0.7742, 3.01, 0.328, 262, 253, CRYSTAL STRUCTURE OF PYK2-APO PROLINE-RICH TYROSINE KINASE
2451, d1yomA_, 0.7742, 2.37, 0.337, 260, 243, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH PURVALANOL A
2452, d5mowB_, 0.7741, 3.10, 0.198, 324, 258, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
2453, d4i4eA_, 0.7741, 2.55, 0.360, 254, 247, STRUCTURE OF FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH HINGE BINDING PYRAZOLOBENZOTHIAZINE COMPOUND.
2454, d4cfwC1, 0.7741, 2.98, 0.212, 295, 255, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
2455, d3orzA_, 0.7741, 3.02, 0.237, 276, 253, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
2456, d2r7iA_, 0.7741, 2.92, 0.193, 322, 254, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
2457, d1vywC1, 0.7741, 3.00, 0.215, 298, 256, STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137
2458, d1okvC_, 0.7741, 2.88, 0.204, 296, 255, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ILE-PHE-NH2
2459, d5deyA_, 0.7740, 3.41, 0.217, 295, 263, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND G-5555
2460, d4rllA_, 0.7740, 3.12, 0.189, 329, 259, CRYSTAL STRUCTURE OF HUMAN CK2ALPHA IN COMPLEX WITH THE ATP- COMPETITIVE INHIBITOR 4-[(E)-(FLUOREN-9-YLIDENEHYDRAZINYLIDENE)- METHYL] BENZOATE
2461, d3zrkB_, 0.7740, 3.03, 0.230, 348, 256, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
2462, d3mb6A_, 0.7740, 3.13, 0.189, 329, 259, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A DIFURANE DERIVATIVE INHIBITOR (CPA)
2463, d2oxyA_, 0.7740, 3.19, 0.177, 327, 260, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE DERIVATIVES K17 K22 AND K32
2464, d2cciA2, 0.7740, 2.89, 0.205, 295, 254, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A PEPTIDE CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6
2465, p5oulA_, 0.7739, 3.13, 0.191, 327, 257, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 9
2466, d5dfpA_, 0.7739, 3.25, 0.215, 292, 261, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND FRAX1036
2467, p4jr7A_, 0.7739, 3.04, 0.199, 367, 256, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH GMPPNP
2468, d4eomC1, 0.7739, 2.89, 0.213, 271, 254, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
2469, d4eoiC1, 0.7739, 2.85, 0.205, 295, 254, THR 160 PHOSPHORYLATED CDK2 K89D Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
2470, d3iopA_, 0.7739, 2.96, 0.226, 275, 252, PDK-1 IN COMPLEX WITH THE INHIBITOR COMPOUND-8I
2471, d2xckA_, 0.7739, 2.97, 0.222, 275, 252, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH A PYRAZOLOQUINAZOLINE INHIBITOR
2472, d2i40C_, 0.7739, 2.94, 0.216, 296, 255, CDK2/CYCLIN A COMPLEXED WITH A THIOPHENE CARBOXAMIDE INHIBITOR
2473, d1yolB_, 0.7739, 2.12, 0.333, 253, 240, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH CGP77675
2474, d1bygA_, 0.7739, 2.12, 0.373, 246, 241, KINASE DOMAIN OF HUMAN C-TERMINAL SRC KINASE (CSK) IN COMPLEX WITH INHIBITOR STAUROSPORINE
2475, d5ut2A_, 0.7738, 2.87, 0.265, 273, 253, JAK2 JH2 IN COMPLEX WITH PRT062607
2476, d5mo8A_, 0.7738, 3.01, 0.191, 325, 257, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
2477, d5d11A_, 0.7738, 2.19, 0.350, 254, 240, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL235
2478, d5csvA_, 0.7738, 3.14, 0.189, 327, 259, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 6 BOUND
2479, d4f1mA1, 0.7738, 3.06, 0.267, 274, 255, CRYSTAL STRUCTURE OF THE G1179S ROCO4 KINASE DOMAIN BOUND TO APPCP FROM D. DISCOIDEUM.
2480, d4c3fA_, 0.7738, 2.63, 0.354, 257, 246, STRUCTURE OF LCK IN COMPLEX WITH A COMPOUND DISCOVERED BY VIRTUAL FRAGMENT LINKING
2481, d3cpcB_, 0.7738, 2.48, 0.337, 262, 243, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDONE INHIBITOR
2482, d2wmbC1, 0.7738, 2.72, 0.210, 265, 252, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
2483, d2pe0A_, 0.7738, 2.83, 0.219, 275, 251, CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) 5-HYDROXY-3-[1-(1H-PYRROL-2-YL)-ETH-(Z)-YLIDENE]-13-DIHYDRO- INDOL-2-ONE COMPLEX
2484, d2jgzA_, 0.7738, 2.79, 0.202, 288, 253, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 IN COMPLEX WITH CYCLIN B
2485, d1z5mA_, 0.7738, 2.82, 0.219, 275, 251, CRYSTAL STRUCTURE OF N1-[3-[[5-BROMO-2-[[3-[(1-PYRROLIDINYLCARBONYL) AMINO]PHENYL]AMINO]-4-PYRIMIDINYL]AMINO]PROPYL]-22- DIMETHYLPROPANEDIAMIDE COMPLEXED WITH HUMAN PDK1
2486, d1jstC_, 0.7738, 2.97, 0.212, 297, 255, PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A
2487, d5u94A_, 0.7737, 2.73, 0.233, 263, 249, CRYSTAL STRUCTURE OF THE MYCOBACTERIUM TUBERCULOSIS PASTA KINASE PKNB IN COMPLEX WITH THE POTENTIAL THERAPUTIC KINASE INHIBITOR GSK690693.
2488, d5dr9A_, 0.7737, 2.77, 0.241, 257, 249, AURORA A KINASE IN COMPLEX WITH AA29 AND JNJ-7706621 IN SPACE GROUP P6122
2489, d3uqfB_, 0.7737, 1.94, 0.346, 253, 237, C-SRC KINASE DOMAIN IN COMPLEX WITH BKI RM-1-89
2490, d2uueA_, 0.7737, 2.91, 0.204, 296, 255, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
2491, d2bpmA2, 0.7737, 2.95, 0.212, 298, 255, STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529
2492, d5vamB_, 0.7736, 2.73, 0.264, 260, 250, BRAF IN COMPLEX WITH RAF709
2493, d3iecA_, 0.7736, 2.82, 0.292, 311, 253, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
2494, d2o5kA1, 0.7736, 3.04, 0.230, 350, 257, CRYSTAL STRUCTURE OF GSK3BETA IN COMPLEX WITH A BENZOIMIDAZOL INHIBITOR
2495, d2c5nC_, 0.7736, 2.92, 0.208, 296, 255, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
2496, d1uv5A_, 0.7736, 2.97, 0.223, 348, 256, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH 6-BROMOINDIRUBIN-3 -OXIME
2497, d1h1rA1, 0.7736, 2.85, 0.205, 295, 254, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6086
2498, d5nk0A_, 0.7735, 2.79, 0.329, 273, 249, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1J
2499, d5dr6A_, 0.7735, 2.77, 0.237, 257, 249, AURORA A KINASE IN COMPLEX WITH AA30 AND JNJ-7706621 IN SPACE GROUP P6122
2500, d4bcoA1, 0.7735, 2.79, 0.198, 297, 253, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
2501, d2np8A_, 0.7735, 2.70, 0.229, 256, 249, STRUCTURAL BASIS FOR THE INHIBITION OF AURORA A KINASE BY A NOVEL CLASS OF HIGH AFFINITY DISUBSTITUTED PYRIMIDINE INHIBITORS
2502, d1j91A_, 0.7735, 3.18, 0.174, 327, 258, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 4567- TETRABROMOBENZOTRIAZOLE
2503, p5n9kA_, 0.7734, 3.14, 0.189, 329, 259, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE TIGHT-BINDING DIBENZOFURAN INHIBITOR TF107 (5)
2504, d5motA_, 0.7734, 3.16, 0.189, 328, 259, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0627 BOUND
2505, d5i9wA_, 0.7734, 2.53, 0.313, 267, 246, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ANP
2506, d5cyiA1, 0.7734, 2.78, 0.202, 297, 253, CDK2/CYCLIN A COVALENT COMPLEX WITH 6-(CYCLOHEXYLMETHOXY)-N-(4- (VINYLSULFONYL)PHENYL)-9H-PURIN-2-AMINE (NU6300)
2507, d5ctpB_, 0.7734, 3.14, 0.194, 327, 258, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)ACETAMIDE BOUND
2508, d4u44A_, 0.7734, 2.70, 0.235, 286, 251, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 16)
2509, d3f3tA_, 0.7734, 2.48, 0.339, 261, 245, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL38 (TYPE III)
2510, d4f1tA1, 0.7733, 3.06, 0.270, 267, 256, CRYSTAL STRUCTURE OF THE ROCO4 KINASE DOMAIN FROM D. DISCOIDEUM BOUND TO THE ROCK INHIBITOR H1152
2511, d3zrlB_, 0.7733, 3.05, 0.230, 347, 256, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
2512, d3tz8A_, 0.7733, 2.52, 0.339, 261, 245, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL104
2513, d3sayA_, 0.7733, 3.05, 0.230, 347, 256, CRYSTAL STRUCTURE OF HUMAN GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH INHIBITOR 142
2514, d3miyA1, 0.7733, 1.77, 0.319, 237, 235, X-RAY CRYSTAL STRUCTURE OF ITK COMPLEXED WITH SUNITINIB
2515, d2c5tA_, 0.7733, 2.91, 0.204, 296, 255,  
2516, d5jzjA_, 0.7732, 2.75, 0.227, 271, 251, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH AMPPN
2517, d3ionA_, 0.7732, 2.82, 0.216, 274, 250, PDK1 IN COMPLEX WITH COMPOUND 8H
2518, p3e3bX_, 0.7732, 3.14, 0.201, 334, 259, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2ALPHA PRIME WITH A POTENT INDAZOLE-DERIVATIVE INHIBITOR
2519, d2c6tC_, 0.7732, 2.86, 0.205, 295, 254, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
2520, d1ol2A_, 0.7732, 2.91, 0.208, 296, 255, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ASN-(P-F-PHE)-NH2
2521, p5v61A_, 0.7731, 3.23, 0.212, 348, 259, PHOSPHO-ERK2 BOUND TO BIVALENT INHIBITOR SBP2
2522, d4b8mB_, 0.7731, 3.08, 0.210, 279, 257, AURORA B KINASE IN COMPLEX WITH VX-680
2523, d3zrmB_, 0.7731, 3.05, 0.230, 347, 256, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK- 3BETA INHIBITORS
2524, d3fztA_, 0.7731, 2.65, 0.361, 259, 249, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH PF-4618433
2525, d3f5xC_, 0.7731, 3.04, 0.215, 298, 256, CDK-2-CYCLIN COMPLEX WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
2526, d2wipA1, 0.7731, 2.62, 0.204, 293, 250, STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO-1- METHYL-45-DIHYDRO-1H-PYRAZOLO[43-H] QUINAZOLINE-3- CARBOXYLIC ACID
2527, d1na7A_, 0.7731, 3.14, 0.189, 326, 259, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2
2528, d4oa9A_, 0.7730, 2.96, 0.246, 280, 252,  
2529, d4l01A_, 0.7730, 2.78, 0.233, 274, 253, CRYSTAL STRUCTURE OF THE V658F APO JAK1 PSEUDOKINASE DOMAIN
2530, d2wihC1, 0.7730, 3.00, 0.215, 298, 256, STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125
2531, d2uzdC_, 0.7730, 2.88, 0.205, 295, 254, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2532, d5mowA1, 0.7729, 3.11, 0.190, 326, 258, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
2533, d5cu3A_, 0.7729, 3.02, 0.191, 325, 257, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 10 BOUND
2534, d4eoqC1, 0.7729, 2.90, 0.213, 271, 254, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH ATP
2535, d3tz9A_, 0.7729, 2.63, 0.337, 261, 246, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL130
2536, d3tnwC_, 0.7729, 2.79, 0.206, 291, 253, STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH CAN508
2537, d3c4cA1, 0.7729, 2.46, 0.255, 257, 247, B-RAF KINASE IN COMPLEX WITH PLX4720
2538, d2pe1A_, 0.7729, 2.84, 0.223, 275, 251, CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) {2-OXO-3-[1-(1H-PYRROL-2-YL)-ETH-(Z)-YLIDENE]-23-DIHYDRO-1H- INDOL-5-YL}-UREA {BX-517} COMPLEX
2539, d5v60A_, 0.7728, 3.19, 0.213, 347, 258, PHOSPHO-ERK2 BOUND TO AMP-PCP
2540, d5hhwA_, 0.7728, 2.82, 0.321, 306, 252, CRYSTAL STRUCTURE OF INSULIN RECEPTOR KINASE DOMAIN IN COMPLEX WITH CIS-(R)-7-(3-(AZETIDIN-1-YLMETHYL)CYCLOBUTYL)-5-(3-((TETRAHYDRO-2H- PYRAN-2-YL)METHOXY)PHENYL)-7H-PYRROLO[23-D]PYRIMIDIN-4-AMINE.
2541, d4bcpA1, 0.7728, 2.81, 0.202, 297, 253, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
2542, d3qcyA_, 0.7728, 2.85, 0.215, 275, 251, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 4-[2- AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4-PYRIMIDINYL]-N-PHENYL-2- MORPHOLINECARBOXAMIDE
2543, d3f3zA_, 0.7728, 3.02, 0.210, 271, 257, CRYSTAL STRUCTURE OF CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840 IN PRESENCE OF INDIRUBIN E804
2544, d3ddpA1, 0.7728, 2.87, 0.205, 296, 254, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR CR8
2545, d2wmbA1, 0.7728, 2.88, 0.205, 295, 254, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
2546, d2gphA_, 0.7728, 3.16, 0.209, 345, 258, DOCKING MOTIF INTERACTIONS IN THE MAP KINASE ERK2
2547, d1oi9C1, 0.7728, 2.94, 0.212, 295, 255, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
2548, d1h1rC1, 0.7728, 2.84, 0.205, 295, 254, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6086
2549, d4ebwA_, 0.7727, 2.74, 0.359, 259, 248, STRUCTURE OF FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH NOVEL ALLOSTERIC INHIBITOR
2550, d3qriB_, 0.7727, 2.48, 0.343, 262, 245, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN IN COMPLEX WITH DCC- 2036
2551, d1xr1A_, 0.7727, 2.70, 0.225, 277, 249, CRYSTAL STRUCTURE OF HPIM-1 KINASE IN COMPLEX WITH AMP-PNP AT 2.1 A RESOLUTION
2552, d1j91B_, 0.7727, 2.97, 0.183, 327, 257, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 4567- TETRABROMOBENZOTRIAZOLE
2553, d1h1sA1, 0.7727, 2.85, 0.205, 295, 254, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6102
2554, d1fmkA3, 0.7727, 2.54, 0.336, 270, 247, CRYSTAL STRUCTURE OF HUMAN TYROSINE-PROTEIN KINASE C-SRC
2555, d5mp8B_, 0.7726, 3.02, 0.199, 323, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
2556, d5jrsB1, 0.7726, 2.14, 0.324, 239, 238, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH 4-[2-FLUORO-3-(4-OXO -34-DIHYDROQUINAZOLIN-3-YL) PHENYL]-7-(2-HYDROXYPROPAN-2-Y L)-9H-CARBAZOLE-1-CARBOXAMIDE
2557, d4pdoB_, 0.7726, 2.41, 0.321, 261, 243, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
2558, d3qrkA1, 0.7726, 2.64, 0.347, 268, 248, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN IN COMPLEX WITH DP- 987
2559, d5b0xA_, 0.7725, 3.21, 0.188, 329, 260, CRYSTAL STRUCTURE OF THE CK2A/BENZOIC ACID DERIVATIVE COMPLEX
2560, d3dlsE_, 0.7725, 3.00, 0.241, 282, 253, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
2561, d2r7iB_, 0.7725, 2.96, 0.193, 322, 254, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
2562, d6brcA1, 0.7724, 3.00, 0.228, 263, 254, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH AP26113-ANALOG (ALK-IN-1)
2563, d4pdoA_, 0.7724, 2.42, 0.321, 261, 243, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
2564, d4oacA_, 0.7724, 2.99, 0.246, 280, 252,  
2565, d4cfuC1, 0.7724, 2.92, 0.213, 269, 254, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
2566, d2qokA_, 0.7724, 3.11, 0.319, 281, 254, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F:Y602F:S768A TRIPLE MUTANT
2567, d1h1qA1, 0.7724, 2.85, 0.205, 295, 254, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6094
2568, d3jy0A_, 0.7723, 2.65, 0.226, 275, 248, DISCOVERY OF 3H-BENZO[45]THIENO[32-D]PYRIMIDIN-4-ONES AS POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PIM KINASES INHIBITORS
2569, d1h28C1, 0.7723, 2.89, 0.205, 295, 254, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P107
2570, d5movA_, 0.7722, 3.14, 0.189, 325, 259, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0633 BOUND
2571, d4f0fA1, 0.7722, 3.05, 0.255, 274, 255, CRYSTAL STRUCTURE OF THE ROCO4 KINASE DOMAIN BOUND TO APPCP FROM D. DISCOIDEUM
2572, d4bicA_, 0.7722, 2.59, 0.239, 260, 247, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
2573, d3bhvC1, 0.7722, 3.03, 0.220, 269, 255, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR VARIOLIN B
2574, d4u43A_, 0.7721, 2.77, 0.215, 287, 251, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 6)
2575, d4cfvA1, 0.7721, 3.01, 0.212, 297, 255, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
2576, d4cfmA1, 0.7721, 2.89, 0.201, 295, 254, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
2577, d3owjA_, 0.7721, 2.93, 0.180, 328, 255, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A PYRIDOCARBAZOLE DERIVATIVE INHIBITOR
2578, d3dlsF_, 0.7721, 2.98, 0.241, 281, 253, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
2579, d3dlsA_, 0.7721, 2.96, 0.232, 285, 254, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
2580, d2r7iD_, 0.7721, 2.96, 0.197, 322, 254, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
2581, d2pe2A_, 0.7721, 2.86, 0.223, 275, 251, CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) 3-{5-[2-OXO-5-UREIDO-12-DIHYDRO-INDOL-(3Z)-YLIDENEMETHYL]-1H- PYRROL-3-YL}-N-(2-PIPERIDIN-1-YL-ETHYL)-BENZAMIDE COMPLEX
2582, d1okwA_, 0.7721, 2.93, 0.208, 296, 255, CYCLIN A BINDING GROOVE INHIBITOR AC-ARG-ARG-LEU-ASN-(M-CL-PHE)-NH2
2583, d5sysB_, 0.7720, 2.41, 0.333, 258, 243, C-SRC V281C BOUND TO N-[3-({6-[(1E)-2-CYANO-3-(METHYLAMINO)-3-OXOPROP- 1-EN-1-YL]-7-(2-METHOXYETHYL)-7H-PYRROLO[23-D]PYRIMIDIN-5- YL}ETHYNYL)-4-METHYLPHENYL]-3-(TRIFLUOROMETHYL)BENZAMIDE INHIBITOR
2584, d5cs6A_, 0.7720, 2.95, 0.189, 327, 254, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 3 BOUND
2585, d4ybjB_, 0.7720, 2.20, 0.342, 253, 240, TYPE II DASATINIB ANALOG CRYSTALLIZED WITH C-SRC KINASE
2586, d3ggfB_, 0.7720, 2.76, 0.263, 270, 251, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE MST4 IN COMPLEX WITH AN QUINAZOLIN
2587, d1oguC1, 0.7720, 2.88, 0.209, 269, 254, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR
2588, d5l8kA_, 0.7719, 3.04, 0.215, 266, 256, AURORA-A KINASE DOMAIN IN COMPLEX WITH VNAR-D01 (CRYSTAL FORM 2)
2589, d4nstA_, 0.7719, 3.11, 0.263, 322, 259, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
2590, d4ibmA_, 0.7719, 2.92, 0.317, 301, 252, CRYSTAL STRUCTURE OF INSULIN RECEPTOR KINASE DOMAIN IN COMPLEX WITH AN INHIBITOR IRFIN-1
2591, p4h3qA_, 0.7719, 3.13, 0.202, 352, 257, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
2592, d4byiA_, 0.7719, 2.84, 0.241, 254, 249, AURORA A KINASE BOUND TO A HIGHLY SELECTIVE IMIDAZOPYRIDINE INHIBITOR
2593, d3owlA_, 0.7719, 3.07, 0.182, 330, 258, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A BENZOPYRIDOINDOLE DERIVATIVE INHIBITOR
2594, d1mruB_, 0.7719, 2.75, 0.229, 271, 249, INTRACELLULAR SER/THR PROTEIN KINASE DOMAIN OF MYCOBACTERIUM TUBERCULOSIS PKNB.
2595, d1e9hC1, 0.7719, 2.98, 0.216, 295, 255, THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR INDIRUBIN-5-SULPHONATE BOUND
2596, d5efqA_, 0.7718, 3.09, 0.256, 321, 258, CRYSTAL STRUCTURE OF HUMAN CDK13/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
2597, d3d5xA_, 0.7718, 2.97, 0.253, 279, 253, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH WORTMANNIN.
2598, d2zv2A_, 0.7718, 2.81, 0.232, 256, 250, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE KINASE 2 BETA CAMKK2 KINASE DOMAIN IN COMPLEX WITH STO-609
2599, d2pvrA_, 0.7718, 3.17, 0.189, 328, 259, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 (C- TERMINAL DELETION MUTANT 1-335) IN COMPLEX WITH TWO SULFATE IONS
2600, p5v62A_, 0.7717, 3.43, 0.214, 349, 262, PHOSPHO-ERK2 BOUND TO BIVALENT INHIBITOR SBP3
2601, d5ia0A_, 0.7717, 2.63, 0.316, 263, 247, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ALISERTIB (MLN8237)
2602, d5cu6A_, 0.7717, 3.20, 0.189, 327, 259, CRYSTAL STRUCTURE OF CK2ALPHA
2603, d4c2vB_, 0.7717, 3.00, 0.211, 280, 256, AURORA B KINASE IN COMPLEX WITH THE SPECIFIC INHIBITOR BARASERTIB
2604, d2wipC1, 0.7717, 2.71, 0.207, 291, 251, STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO-1- METHYL-45-DIHYDRO-1H-PYRAZOLO[43-H] QUINAZOLINE-3- CARBOXYLIC ACID
2605, d2qq7A_, 0.7717, 1.94, 0.352, 251, 236, CRYSTAL STRUCTURE OF DRUG RESISTANT SRC KINASE DOMAIN WITH IRREVERSIBLE INHIBITOR
2606, d2fysA_, 0.7717, 3.22, 0.189, 348, 259, CRYSTAL STRUCTURE OF ERK2 COMPLEX WITH KIM PEPTIDE DERIVED FROM MKP3
2607, d1h26A1, 0.7717, 2.91, 0.205, 295, 254, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P53
2608, d5aafA_, 0.7716, 2.77, 0.242, 254, 248, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (14A)
2609, d4nksA_, 0.7716, 2.66, 0.367, 265, 248, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 3
2610, d4iz5D_, 0.7716, 3.12, 0.206, 347, 257, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
2611, d4iz5C_, 0.7716, 3.12, 0.206, 347, 257, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
2612, d4eomA1, 0.7716, 2.87, 0.213, 294, 253, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
2613, d3piyA_, 0.7716, 2.52, 0.335, 262, 245, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH R406
2614, d3fxzA_, 0.7716, 3.39, 0.214, 292, 262, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH RUTHENIUM COMPLEX LAMBDA-FL172
2615, d2qobA_, 0.7716, 2.98, 0.304, 279, 253, HUMAN EPHA3 KINASE DOMAIN BASE STRUCTURE
2616, d2iw6C2, 0.7716, 2.87, 0.201, 294, 254, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
2617, d5nevA1, 0.7715, 2.87, 0.205, 294, 254, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
2618, d4iz5B_, 0.7715, 3.12, 0.206, 347, 257, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
2619, d4iz5A_, 0.7715, 3.13, 0.206, 347, 257, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
2620, d3zewB_, 0.7715, 2.42, 0.288, 252, 243, CRYSTAL STRUCTURE OF EPHB4 IN COMPLEX WITH STAUROSPORINE
2621, d2g9xA2, 0.7715, 2.90, 0.205, 297, 254, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR NU6271
2622, d3el7A_, 0.7714, 2.10, 0.339, 254, 239, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH PYRAZOLOPYRIMIDINE 3
2623, d3bhvA1, 0.7714, 2.87, 0.217, 295, 253, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR VARIOLIN B
2624, d1csnA_, 0.7714, 3.44, 0.174, 293, 265, BINARY COMPLEX OF CASEIN KINASE-1 WITH MGATP
2625, d5jsmD1, 0.7713, 2.46, 0.267, 255, 247, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
2626, d4nm0A1, 0.7713, 3.13, 0.230, 355, 257, CRYSTAL STRUCTURE OF PEPTIDE INHIBITOR-FREE GSK-3/AXIN COMPLEX
2627, d4nifE_, 0.7713, 3.17, 0.214, 348, 257, HETERODIMERIC STRUCTURE OF ERK2 AND RSK1
2628, d4bcnA1, 0.7713, 2.80, 0.206, 295, 252, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
2629, d3owkA_, 0.7713, 3.17, 0.189, 330, 259, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A BENZOPYRIDOINDOLE DERIVATIVE INHIBITOR
2630, d4zy4A_, 0.7712, 3.09, 0.222, 288, 257, CRYSTAL STRUCTURE OF P21 ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 4
2631, d4qteA_, 0.7712, 3.21, 0.202, 348, 258, STRUCTURE OF ERK2 IN COMPLEX WITH VTX-11E 4-{2-[(2-CHLORO-4- FLUOROPHENYL)AMINO]-5-METHYLPYRIMIDIN-4-YL}-N-[(1S)-1-(3- CHLOROPHENYL)-2-HYDROXYETHYL]-1H-PYRROLE-2-CARBOXAMIDE
2632, d4nifB_, 0.7712, 3.18, 0.214, 349, 257, HETERODIMERIC STRUCTURE OF ERK2 AND RSK1
2633, d4gk2A_, 0.7712, 2.81, 0.309, 265, 249, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH LIGAND 66
2634, d4bcpC1, 0.7712, 2.78, 0.210, 266, 252, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
2635, d3qd4A_, 0.7712, 2.83, 0.216, 276, 250, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 11- DIMETHYLETHYL{(3R5R)-1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4- PYRIMIDINYL]-5-METHYL-3-PIPERIDINYL}CARBAMATE
2636, d2vgpB_, 0.7712, 3.18, 0.198, 277, 258, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH A AMINOTHIAZOLE INHIBITOR
2637, d1oi9A1, 0.7712, 2.82, 0.202, 294, 253, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
2638, d5v24B_, 0.7711, 2.72, 0.233, 263, 249, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
2639, d5i8aA1, 0.7711, 2.20, 0.379, 265, 240, TRKA WITH (6~{R})-3-METHYLSULFANYL-6-PHENYL-1-(1~{H}-PYRAZOL-3-YL)-6 7-DIHYDRO-5~{H}-THIENO[34-C]PYRIDIN-4-ONE
2640, d4u42A_, 0.7711, 2.56, 0.226, 282, 248, MAP4K4 T181E MUTANT BOUND TO INHIBITOR COMPOUND 1
2641, p3o17B_, 0.7711, 3.18, 0.201, 357, 259, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM
2642, d3cjfA_, 0.7711, 2.98, 0.336, 276, 250, CRYSTAL STRUCTURE OF VEGFR2 IN COMPLEX WITH A 345-TRIMETHOXY ANILINE CONTAINING PYRIMIDINE
2643, d2rl5A1, 0.7711, 2.91, 0.340, 290, 250, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A 23-DIHYDRO-14-BENZOXAZINE INHIBITOR
2644, p6gihA_, 0.7710, 3.10, 0.191, 324, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH CAM187 BOUND 
2645, d5lpzA_, 0.7710, 2.84, 0.252, 283, 250, CRYSTAL STRUCTURE OF THE BRI1 KINASE DOMAIN (865-1196) IN COMPLEX WITH ADP FROM ARABIDOPSIS THALIANA
2646, d4cfuA1, 0.7710, 2.88, 0.217, 295, 253, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
2647, d3my5C1, 0.7710, 2.83, 0.206, 265, 252, CDK2/CYCLINA IN COMPLEX WITH DRB
2648, d5hesB_, 0.7709, 2.20, 0.329, 278, 240, HUMAN LEUCINE ZIPPER- AND STERILE ALPHA MOTIF-CONTAINING KINASE (ZAK MLT HCCS-4 MRK AZK MLTK) IN COMPLEX WITH VEMURAFENIB
2649, d4oa6A_, 0.7709, 2.95, 0.251, 279, 251,  
2650, d3a8xB1, 0.7709, 2.85, 0.205, 325, 254, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
2651, d2vwvA_, 0.7709, 2.62, 0.276, 255, 246, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
2652, d1h28A1, 0.7709, 2.91, 0.205, 295, 254, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P107
2653, d5w5oM_, 0.7708, 2.28, 0.251, 276, 243, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2654, d4lueB3, 0.7708, 2.05, 0.356, 256, 236, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH 7-[TRANS-4-(4- METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE (RESULTING FROM DISPLACEMENT OF SKF86002)
2655, d4gt4B_, 0.7708, 2.69, 0.274, 273, 248, STRUCTURE OF UNLIGANDED INACTIVE ROR2 KINASE DOMAIN
2656, d3sayB_, 0.7708, 3.09, 0.230, 347, 256, CRYSTAL STRUCTURE OF HUMAN GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH INHIBITOR 142
2657, d3qgwB_, 0.7708, 2.10, 0.321, 240, 237, CRYSTAL STRUCTURE OF ITK KINASE BOUND TO AN INHIBITOR
2658, d3dogA1, 0.7708, 2.85, 0.202, 296, 253, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR N-&-N1
2659, d3ctjA_, 0.7708, 2.95, 0.323, 289, 251, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A AMINOPYRIDINE BASED INHIBITOR
2660, d2r7iC_, 0.7708, 2.93, 0.198, 321, 253, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
2661, d1h27C1, 0.7708, 2.89, 0.205, 290, 254, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P27
2662, d5vamA_, 0.7707, 3.01, 0.255, 269, 255, BRAF IN COMPLEX WITH RAF709
2663, d3nayB_, 0.7707, 2.74, 0.216, 278, 250, PDK1 IN COMPLEX WITH INHIBITOR MP6
2664, d3gqlC_, 0.7707, 2.91, 0.382, 275, 251, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
2665, d1uu3A_, 0.7707, 2.97, 0.226, 276, 252, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH LY333531
2666, d5nevC1, 0.7706, 2.88, 0.205, 295, 254, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
2667, d3tz9B_, 0.7706, 2.42, 0.321, 259, 243, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL130
2668, d3tl8A_, 0.7706, 2.89, 0.266, 300, 252, THE AVRPTOB-BAK1 COMPLEX REVEALS TWO STRUCTURALLY SIMILAR KINASEINTERACTING DOMAINS IN A SINGLE TYPE III EFFECTOR
2669, d5li9A1, 0.7705, 3.15, 0.199, 328, 256, STRUCTURE OF A NUCLEOTIDE-BOUND FORM OF PKCIOTA CORE KINASE DOMAIN
2670, d5itaB_, 0.7705, 2.30, 0.258, 252, 244, CRYSTAL STRUCTURE OF BRAF KINASE DOMAIN BOUND TO AZ-VEM
2671, d3mb7A_, 0.7705, 3.18, 0.185, 330, 259, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A DIFURANE DERIVATIVE INHIBITOR (AMR)
2672, d1pyxA_, 0.7705, 3.11, 0.233, 343, 257, GSK-3 BETA COMPLEXED WITH AMP-PNP
2673, d5uoxA_, 0.7704, 2.84, 0.232, 263, 250, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
2674, d5lqfA1, 0.7704, 2.70, 0.205, 284, 249, CDK1/CYCLINB1/CKS2 IN COMPLEX WITH NU6102
2675, d3ztxA_, 0.7704, 3.03, 0.216, 269, 255, AURORA KINASE SELECTIVE INHIBITORS IDENTIFIED USING A TAXOL- INDUCED CHECKPOINT SENSITIVITY SCREEN.
2676, d3krxA2, 0.7704, 3.22, 0.198, 349, 258, HUMAN GRK2 IN COMPLEX WITH GBETGAMMA SUBUNITS AND BALANOL (CO-CRYSTAL)
2677, d5hlnB_, 0.7703, 3.13, 0.236, 346, 259, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH CHIR99021
2678, d4eopA1, 0.7703, 2.77, 0.206, 294, 252, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
2679, d4c2wB_, 0.7703, 3.02, 0.211, 277, 256, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH AMP-PNP
2680, d3f3wB_, 0.7703, 2.53, 0.331, 260, 245, DRUG RESISTANT CSRC KINASE DOMAIN IN COMPLEX WITH INHIBITOR RL45 (TYPE II)
2681, d3c4dA1, 0.7703, 2.51, 0.255, 257, 247,  
2682, d1p5eA1, 0.7703, 2.96, 0.205, 295, 254, THE STRUCTURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMOBENZOTRIAZOLE (TBS)
2683, d1okvA_, 0.7703, 2.93, 0.204, 295, 255, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ILE-PHE-NH2
2684, d5hkmA_, 0.7702, 2.80, 0.217, 272, 249, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
2685, d4eokA1, 0.7702, 2.70, 0.208, 292, 250, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
2686, d4apcB1, 0.7702, 2.77, 0.203, 291, 251, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1)
2687, d3zrkA_, 0.7702, 3.10, 0.230, 345, 256, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
2688, d3qd0A_, 0.7702, 2.96, 0.227, 274, 251, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH (2R5S)- 1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4-PYRIMIDINYL]-6-METHYL-N- PHENYL-3-PIPERIDINECARBOXAMIDE
2689, d3f5xA_, 0.7702, 3.04, 0.216, 297, 255, CDK-2-CYCLIN COMPLEX WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
2690, d2og8A_, 0.7702, 2.34, 0.357, 246, 241, CRYSTAL STRUCTURE OF AMINOQUINAZOLINE 36 BOUND TO LCK
2691, d3krwA2, 0.7701, 3.22, 0.198, 349, 258, HUMAN GRK2 IN COMPLEX WITH GBETGAMMA SUBUNITS AND BALANOL (SOAK)
2692, d1q5kA_, 0.7701, 3.12, 0.230, 345, 257, CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 IN COMPLEXED WITH INHIBITOR
2693, d1p5eC1, 0.7701, 3.06, 0.212, 295, 255, THE STRUCTURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMOBENZOTRIAZOLE (TBS)
2694, d1mruA_, 0.7701, 2.72, 0.234, 269, 248, INTRACELLULAR SER/THR PROTEIN KINASE DOMAIN OF MYCOBACTERIUM TUBERCULOSIS PKNB.
2695, d5itaA_, 0.7700, 2.32, 0.263, 250, 243, CRYSTAL STRUCTURE OF BRAF KINASE DOMAIN BOUND TO AZ-VEM
2696, d4prjA_, 0.7700, 2.58, 0.229, 251, 245, AURORA A KINASE DOMAIN WITH COMPOUND 2 (N-[1-(3-CYANOBENZYL)-1H- PYRAZOL-4-YL]-6-(1H-PYRAZOL-4-YL)-1H-INDAZOLE-3-CARBOXAMIDE)
2697, d2i0eA_, 0.7700, 3.04, 0.239, 326, 255, STRUCTURE OF CATALYTIC DOMAIN OF HUMAN PROTEIN KINASE C BETA II COMPLEXED WITH A BISINDOLYLMALEIMIDE INHIBITOR
2698, d2csnA_, 0.7700, 3.50, 0.173, 293, 266, BINARY COMPLEX OF CASEIN KINASE-1 WITH CKI7
2699, d2bpmC2, 0.7700, 3.06, 0.215, 298, 256, STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529
2700, d1j1bA_, 0.7700, 3.13, 0.230, 354, 257, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH AMPPNP
2701, d3dpkA_, 0.7699, 2.93, 0.339, 279, 248, CFMS TYROSINE KINASE IN COMPLEX WITH A PYRIDOPYRIMIDINONE INHIBITOR
2702, d2iw9C2, 0.7699, 2.83, 0.210, 267, 252, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
2703, d1pkdC1, 0.7699, 2.94, 0.205, 295, 254, THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO- CDK2/CYCLIN A
2704, d5jznB_, 0.7698, 2.78, 0.227, 266, 251, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH NVP-TAE684
2705, d4qnyA_, 0.7698, 3.04, 0.207, 333, 256, CRYSTAL STRUCTURE OF MAPK FROM LEISHMANIA DONOVANI LDBPK_331470
2706, d4c8bB_, 0.7698, 2.33, 0.235, 281, 243, STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH PONATINIB
2707, d3u4uA_, 0.7698, 3.14, 0.186, 327, 258, CASEIN KINASE 2 IN COMPLEX WITH AZ-INHIBITOR
2708, d3tl8H_, 0.7698, 2.93, 0.266, 303, 252, THE AVRPTOB-BAK1 COMPLEX REVEALS TWO STRUCTURALLY SIMILAR KINASEINTERACTING DOMAINS IN A SINGLE TYPE III EFFECTOR
2709, d3fy0A_, 0.7698, 3.40, 0.207, 292, 261, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH RUTHENIUM COMPLEX DW1
2710, d5uq2A_, 0.7697, 3.05, 0.211, 296, 256, CRYSTAL STRUCTURE OF HUMAN CDK2-SPY1 COMPLEX
2711, d3miyB1, 0.7697, 1.88, 0.318, 238, 236, X-RAY CRYSTAL STRUCTURE OF ITK COMPLEXED WITH SUNITINIB
2712, d2iw6A1, 0.7697, 2.83, 0.214, 291, 252, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
2713, d5cvfA_, 0.7696, 3.16, 0.209, 325, 258, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 5 BOUND
2714, d3cpbB_, 0.7696, 2.58, 0.337, 263, 243, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BISAMIDE INHIBITOR
2715, d1pkdA1, 0.7696, 2.96, 0.205, 295, 254, THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO- CDK2/CYCLIN A
2716, d1h25A1, 0.7696, 2.94, 0.205, 292, 254, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM RETINOBLASTOMA-ASSOCIATED PROTEIN
2717, d5w5oL_, 0.7695, 2.43, 0.262, 275, 244, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2718, d4qnyB_, 0.7695, 3.09, 0.206, 339, 257, CRYSTAL STRUCTURE OF MAPK FROM LEISHMANIA DONOVANI LDBPK_331470
2719, d4nstC_, 0.7695, 3.15, 0.251, 317, 259, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
2720, d4kd1A_, 0.7695, 3.02, 0.225, 298, 253, CDK2 IN COMPLEX WITH DINACICLIB
2721, d3my5A1, 0.7695, 2.86, 0.218, 294, 252, CDK2/CYCLINA IN COMPLEX WITH DRB
2722, d5j79B_, 0.7694, 2.45, 0.261, 277, 245, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE COMPOUND 3 COMPLEX
2723, d4bicB_, 0.7694, 2.52, 0.236, 259, 246, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
2724, d3a99A_, 0.7694, 2.69, 0.234, 273, 248, STRUCTURE OF PIM-1 KINASE CRYSTALLIZED IN THE PRESENCE OF P27KIP1 CARBOXY-TERMINAL PEPTIDE
2725, d2zoqB_, 0.7694, 3.37, 0.203, 351, 261, STRUCTURAL DISSECTION OF HUMAN MITOGEN-ACTIVATED KINASE ERK1
2726, d2gsfA_, 0.7694, 2.92, 0.307, 281, 251, THE HUMAN EPHA3 RECEPTOR TYROSINE KINASE AND JUXTAMEMBRANE REGION
2727, d1pyxB_, 0.7694, 3.12, 0.233, 338, 257, GSK-3 BETA COMPLEXED WITH AMP-PNP
2728, d1h27A1, 0.7694, 2.95, 0.205, 295, 254, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P27
2729, d5w5oO_, 0.7693, 2.31, 0.251, 276, 243, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2730, d4c2vA_, 0.7693, 2.91, 0.205, 270, 254, AURORA B KINASE IN COMPLEX WITH THE SPECIFIC INHIBITOR BARASERTIB
2731, d3nayA_, 0.7693, 2.77, 0.216, 278, 250, PDK1 IN COMPLEX WITH INHIBITOR MP6
2732, d3l1sB_, 0.7693, 3.13, 0.233, 330, 257, 3-ARYL-4-(ARYLHYDRAZONO)-1H-PYRAZOL-5-ONES: HIGHLY LIGAND EFFICIENT AND POTENT INHIBITORS OF GSK3
2733, d3eidA_, 0.7693, 2.75, 0.208, 292, 250, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
2734, d3ddqA1, 0.7693, 2.82, 0.206, 295, 252, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR ROSCOVITINE
2735, d2o3pA_, 0.7693, 2.71, 0.234, 274, 248, CRYSTAL STRUCTURE OF PIM1 WITH QUERCETIN
2736, d2henB1, 0.7693, 2.62, 0.297, 258, 246, CRYSTAL STRUCTURE OF THE EPHB2 RECEPTOR KINASE DOMAIN IN COMPLEX WITH ADP
2737, d2cjmC_, 0.7693, 2.94, 0.205, 294, 254, MECHANISM OF CDK INHIBITION BY ACTIVE SITE PHOSPHORYLATION: CDK2 Y15P T160P IN COMPLEX WITH CYCLIN A STRUCTURE
2738, d5bvoA_, 0.7692, 2.85, 0.359, 276, 251, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
2739, d5aagA_, 0.7692, 2.74, 0.243, 253, 247, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (14B)
2740, d4oabA_, 0.7692, 3.00, 0.247, 279, 251,  
2741, d2r7bA_, 0.7692, 2.84, 0.220, 274, 250, CRYSTAL STRUCTURE OF THE PHOSPHOINOSITIDE-DEPENDENT KINASE- 1 (PDK-1)CATALYTIC DOMAIN BOUND TO A DIBENZONAPHTHYRIDINE INHIBITOR
2742, d5telA_, 0.7691, 2.70, 0.230, 273, 248, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
2743, d5l6oA_, 0.7691, 2.54, 0.287, 267, 244, EPHB3 KINASE DOMAIN COVALENTLY BOUND TO AN IRREVERSIBLE INHIBITOR (COMPOUND 3)
2744, d3jyaA_, 0.7691, 2.71, 0.238, 274, 248, DISCOVERY OF 3H-BENZO[45]THIENO[32-D]PYRIMIDIN-4-ONES AS POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PIM KINASES INHIBITORS
2745, d2clqB_, 0.7691, 2.53, 0.232, 259, 246, STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 2 5
2746, d2aypA_, 0.7691, 3.45, 0.256, 268, 258, CRYSTAL STRUCTURE OF CHK1 WITH AN INDOL INHIBITOR
2747, d1h26C1, 0.7691, 2.84, 0.210, 266, 252, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P53
2748, d1e9hA_, 0.7691, 2.95, 0.205, 295, 254, THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR INDIRUBIN-5-SULPHONATE BOUND
2749, d5efqC_, 0.7690, 3.13, 0.256, 325, 258, CRYSTAL STRUCTURE OF HUMAN CDK13/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
2750, d4eorC1, 0.7690, 2.89, 0.209, 269, 253, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
2751, d2iw8C2, 0.7690, 2.79, 0.215, 264, 251, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A F82H-L83V- H84D MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR
2752, d5ar8B_, 0.7689, 2.24, 0.256, 274, 242, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIPHENYLSULFONAMIDE
2753, d2o64A_, 0.7689, 2.82, 0.225, 274, 249, CRYSTAL STRUCTURE OF PIM1 WITH QUERCETAGETIN
2754, d2henD1, 0.7689, 2.63, 0.297, 258, 246, CRYSTAL STRUCTURE OF THE EPHB2 RECEPTOR KINASE DOMAIN IN COMPLEX WITH ADP
2755, d3o2mB_, 0.7688, 3.28, 0.197, 358, 259, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM COMPLEX WITH A BIARYL TETRAZOL (A-82118)
2756, p3nieA_, 0.7688, 3.57, 0.203, 369, 261, CRYSTAL STRUCTURE OF PF11_0147
2757, d2fumA_, 0.7688, 2.73, 0.225, 263, 249, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
2758, d6bqlA1, 0.7687, 3.29, 0.230, 276, 256, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH TAE-226
2759, d5u6iA_, 0.7687, 3.33, 0.203, 339, 261, DISCOVERY OF MLI-2 AN ORALLY AVAILABLE AND SELECTIVE LRRK2 INHIBITOR THAT REDUCES BRAIN KINASE ACTIVITY
2760, d5o26A_, 0.7687, 3.02, 0.245, 271, 257, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A DIPHOSPHORYLATED STATE AND IN COMPLEX WITH AMP-PNP/MG2+
2761, d5ci7A_, 0.7687, 3.20, 0.268, 276, 257, STRUCTURE OF ULK1 BOUND TO A SELECTIVE INHIBITOR
2762, d3t9iA_, 0.7687, 2.60, 0.227, 273, 247, PIM1 COMPLEXED WITH A NOVEL 36-DISUBSTITUTED INDOLE AT 2.6 ANG RESOLUTION
2763, d3m1sB_, 0.7687, 3.13, 0.230, 349, 257, STRUCTURE OF RUTHENIUM HALF-SANDWICH COMPLEX BOUND TO GLYCOGEN SYNTHASE KINASE 3
2764, d3m1sA_, 0.7687, 3.11, 0.230, 348, 257, STRUCTURE OF RUTHENIUM HALF-SANDWICH COMPLEX BOUND TO GLYCOGEN SYNTHASE KINASE 3
2765, d2fumB_, 0.7687, 2.66, 0.230, 262, 248, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
2766, d1j1bB_, 0.7687, 3.14, 0.230, 364, 257, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH AMPPNP
2767, d4u40B_, 0.7686, 3.00, 0.223, 299, 256, MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4) BOUND TO AMPPNP
2768, d2oh4A1, 0.7686, 3.24, 0.336, 296, 253, CRYSTAL STRUCTURE OF VEGFR2 WITH A BENZIMIDAZOLE-UREA INHIBITOR
2769, d2i0eB_, 0.7686, 3.01, 0.239, 300, 255, STRUCTURE OF CATALYTIC DOMAIN OF HUMAN PROTEIN KINASE C BETA II COMPLEXED WITH A BISINDOLYLMALEIMIDE INHIBITOR
2770, d1yxvA_, 0.7686, 2.71, 0.226, 274, 248, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH 34-DIHYDROXY-1- METHYLQUINOLIN-2(1H)-ONE
2771, d1j1cA_, 0.7686, 3.15, 0.230, 354, 257, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH ADP
2772, d4rvtA_, 0.7685, 2.69, 0.238, 281, 248, MAP4K4 IN COMPLEX WITH A PYRIDIN-2(1H)-ONE DERIVATIVE
2773, d3r01A_, 0.7685, 2.71, 0.230, 274, 248, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
2774, d2xyuA_, 0.7685, 2.93, 0.312, 260, 250, CRYSTAL STRUCTURE OF EPHA4 KINASE DOMAIN IN COMPLEX WITH VUF 12058
2775, d2wmaA1, 0.7685, 3.02, 0.220, 295, 254, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
2776, d2vgoB_, 0.7685, 3.12, 0.191, 277, 257, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH REVERSINE INHIBITOR
2777, d1yolA_, 0.7685, 2.29, 0.329, 256, 240, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH CGP77675
2778, d5w5oI_, 0.7684, 2.24, 0.252, 275, 242, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2779, d4o0uA_, 0.7684, 2.82, 0.236, 259, 250, CRYSTAL STRUCTURES OF HUMAN KINASE AURORA A
2780, d4b9dB1, 0.7684, 2.78, 0.203, 291, 251, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1) WITH INHIBITOR.
2781, d3ii5A_, 0.7684, 2.84, 0.268, 262, 250, THE COMPLEX OF WILD-TYPE B-RAF WITH PYRAZOLO PYRIMIDINE INHIBITOR
2782, d2p2hA1, 0.7684, 2.91, 0.332, 289, 250, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDINYL-TRIAZINE INHIBITOR
2783, d5diaA_, 0.7683, 2.72, 0.226, 273, 248, PIM1 IN COMPLEX WITH CPD36 ((1S3S)-N1-(6-(5-(PYRIDIN-3-YL)-1H- PYRAZOLO[34-C]PYRIDIN-3-YL)PYRIDIN-2-YL)CYCLOHEXANE-13-DIAMINE)
2784, d5clpA_, 0.7683, 3.16, 0.200, 322, 255, CRYSTAL STRUCTURE OF CK2ALPHA WITH 34-DICHLOROPHENETHYLAMINE BOUND
2785, d3d7tA_, 0.7683, 2.41, 0.374, 249, 243, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
2786, d1h25C1, 0.7683, 2.86, 0.206, 277, 252, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM RETINOBLASTOMA-ASSOCIATED PROTEIN
2787, d5lmkA1, 0.7682, 2.82, 0.206, 295, 252, STRUCTURE OF PHOPSHO-CDK2-CYCLIN A IN COMPLEX WITH AN ATP-COMPETITIVE INHIBITOR
2788, d5bvnA_, 0.7682, 2.91, 0.349, 278, 252, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
2789, d3pj2A_, 0.7682, 2.26, 0.318, 248, 242, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 2-[4-(2- DIETHYLAMINO-ETHOXY)-PHENYLAMINO]-6-(4-FLUORO-PHENOXY)-8-METHYL-8H- PYRIDO[23-D]PYRIMIDIN-7-ONE
2790, d3fdnA_, 0.7682, 2.82, 0.233, 261, 249, STRUCTURE-BASED DRUG DESIGN OF NOVEL AURORA KINASE A INHIBITORS: STRUCTURE BASIS FOR POTENCY AND SPECIFICITY
2791, d3dogC1, 0.7682, 2.82, 0.211, 266, 251, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR N-&-N1
2792, d3dlsC_, 0.7682, 2.84, 0.235, 281, 251, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
2793, d2e9uA_, 0.7682, 3.48, 0.256, 269, 258, STRUCTURE OF H-CHK1 COMPLEXED WITH A780125
2794, d2e9oA_, 0.7682, 3.57, 0.259, 269, 259, STRUCTURE OF H-CHK1 COMPLEXED WITH AA582939
2795, d2bfxA_, 0.7682, 3.12, 0.215, 269, 256, MECHANISM OF AURORA-B ACTIVATION BY INCENP AND INHIBITION BY HESPERADIN.
2796, d1yxxA_, 0.7682, 2.72, 0.226, 274, 248, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH (3E)-3-[(4- HYDROXYPHENYL)IMINO]-1H-INDOL-2(3H)-ONE
2797, d1oiuA1, 0.7682, 2.85, 0.218, 293, 252, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
2798, d1mqbA_, 0.7682, 2.75, 0.321, 263, 249, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE
2799, d1j1cB_, 0.7682, 3.16, 0.230, 364, 257, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH ADP
2800, d5texA_, 0.7681, 2.82, 0.237, 274, 249, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
2801, d5kggA_, 0.7681, 2.72, 0.226, 273, 248, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 2-(5-CHLORANYL-1~{H}-INDOL- 3-YL)ETHANAMINE
2802, d5he1A2, 0.7681, 3.23, 0.194, 342, 258, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224062
2803, d3f88A_, 0.7681, 3.04, 0.235, 340, 255, GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR COMPLEX
2804, d1oiuC1, 0.7681, 2.82, 0.215, 264, 251, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
2805, d4bcmA1, 0.7680, 2.87, 0.214, 292, 252, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
2806, d4aluA_, 0.7680, 2.72, 0.222, 274, 248, BENZOFUROPYRIMIDINONE INHIBITORS OF PIM-1
2807, d2qonA_, 0.7680, 3.03, 0.311, 281, 251, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F:Y602F:Y742A TRIPLE MUTANT
2808, d1h24C1, 0.7680, 2.98, 0.205, 292, 254, CDK2/CYCLIN A IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM E2F
2809, d1finC_, 0.7680, 3.10, 0.215, 298, 256, CYCLIN A-CYCLIN-DEPENDENT KINASE 2 COMPLEX
2810, d5kgeA_, 0.7679, 2.72, 0.226, 273, 248, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 5-(34-DICHLOROPHENYL)- 1~{H}-PYRAZOL-3-AMINE
2811, d4ztlD_, 0.7679, 3.07, 0.267, 285, 251, IRAK4-INHIBITOR CO-STRUCTURE
2812, d4pnkA2, 0.7679, 3.22, 0.193, 350, 259, G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH GSK180736A
2813, d3zrmA_, 0.7679, 3.14, 0.230, 344, 256, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK- 3BETA INHIBITORS
2814, d3zrlA_, 0.7679, 3.15, 0.230, 345, 256, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
2815, d3qyiA_, 0.7679, 3.17, 0.198, 346, 258,  
2816, d3be2A1, 0.7679, 2.96, 0.341, 285, 249, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZAMIDE INHIBITOR
2817, d5dewA_, 0.7678, 3.32, 0.223, 295, 260, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND 5
2818, d4q9sA_, 0.7678, 2.54, 0.358, 252, 246, CRYSTAL STRUCTURE OF HUMAN FOCAL ADHESION KINASE (FAK) BOUND TO COMPOUND1 (35-DIHYDRO[124]TRIAZINO[34-C][14]BENZOXAZIN-2(1H)- ONE)
2819, d2oibD_, 0.7678, 2.95, 0.267, 288, 251, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN APO FORM
2820, d1oiyA1, 0.7678, 2.84, 0.218, 292, 252, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
2821, d6brcB_, 0.7677, 3.14, 0.232, 260, 254, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH AP26113-ANALOG (ALK-IN-1)
2822, d5jkgA_, 0.7677, 2.79, 0.367, 266, 248, THE CRYSTAL STRUCTURE OF FGFR4 KINASE DOMAIN IN COMPLEX WITH LY2874455
2823, d4mbiA_, 0.7677, 2.72, 0.226, 274, 248, DISCOVERY OF PYRAZOLO[15A]PYRIMIDINE-BASED PIM1 INHIBITORS
2824, d4eoqA1, 0.7677, 2.89, 0.222, 293, 252, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH ATP
2825, d3r00A_, 0.7677, 2.72, 0.230, 274, 248, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
2826, d3ddqC1, 0.7677, 2.83, 0.211, 265, 251, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR ROSCOVITINE
2827, d2erkA_, 0.7677, 3.21, 0.202, 351, 258, PHOSPHORYLATED MAP KINASE ERK2
2828, d5k3yB_, 0.7676, 3.18, 0.195, 277, 257, CRYSTAL STRUCTURE OF AURORAB/INCENP IN COMPLEX WITH BI 811283
2829, d3r22A_, 0.7676, 2.78, 0.230, 255, 248, DESIGN SYNTHESIS AND BIOLOGICAL EVALUATION OF PYRAZOLOPYRIDINE- SULFONAMIDES AS POTENT MULTIPLE-MITOTIC KINASE (MMK) INHIBITORS (PART I)
2830, d3og7B_, 0.7676, 2.60, 0.262, 254, 248, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX4032
2831, d3of0B_, 0.7676, 2.03, 0.343, 251, 236, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE CHICKEN C-SRC TYROSINE KINASE DOMAIN
2832, d3c4eB_, 0.7676, 2.81, 0.225, 273, 249, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
2833, d1yxtA_, 0.7676, 2.74, 0.222, 274, 248, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMPPNP
2834, d1uwhA_, 0.7676, 2.95, 0.263, 264, 251, THE COMPLEX OF WILD TYPE B-RAF AND BAY439006
2835, d1k9aC3, 0.7676, 2.79, 0.379, 266, 248, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
2836, d5v19B_, 0.7675, 2.60, 0.228, 260, 246, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
2837, d4mtaA_, 0.7675, 2.74, 0.226, 273, 248, CRYSTAL STRUCTURE OF PIM-1 KINASE DOMAIN IN COMPLEX WITH 2-METHYL-5- PHENYLFURAN-3-CARBOXYLIC ACID
2838, d4ficA_, 0.7675, 1.80, 0.342, 251, 234, KINASE DOMAIN OF CSRC IN COMPLEX WITH A HINGE REGION-BINDING FRAGMENT
2839, d3c4eD_, 0.7675, 2.75, 0.226, 273, 248, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
2840, d2fgaA_, 0.7675, 3.47, 0.260, 269, 258,  
2841, d1o9uA_, 0.7675, 3.14, 0.234, 349, 256, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH AXIN PEPTIDE
2842, d5kgdA_, 0.7674, 2.73, 0.226, 273, 248, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 2-PYRIDIN-3-YL-1~{H}- BENZIMIDAZOLE
2843, d4wt6A_, 0.7674, 2.74, 0.222, 273, 248, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A THIADIAZOLAMINE-INDOLE INHIBITOR.
2844, p2h96B_, 0.7674, 3.24, 0.189, 357, 259, DISCOVERY OF POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PYRIDINE CARBOXAMIDE C-JUN NH2-TERMINAL KINASE INHIBITORS
2845, d5uorB_, 0.7673, 2.73, 0.234, 262, 248, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
2846, d5eolA_, 0.7673, 2.74, 0.226, 273, 248, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A MACROCYCLIC QUINOXALINE-PYRROLODIHYDROPIPERIDINONE INHIBITOR
2847, d4xh6A_, 0.7673, 2.73, 0.226, 273, 248, CRYSTAL STRUCTURE OF PROTO-ONCOGENE KINASE PIM1 BOUND TO HISPIDULIN
2848, d4jbqA_, 0.7673, 2.78, 0.234, 257, 248, NOVEL AURORA KINASE INHIBITORS REVEAL MECHANISMS OF HURP IN NUCLEATION OF CENTROSOMAL AND KINETOCHORE MICROTUBULES
2849, d3vc4A_, 0.7673, 2.74, 0.222, 274, 248, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
2850, d3octA_, 0.7673, 2.24, 0.314, 244, 242, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE MUTANT V555R IN COMPLEX WITH DASATINIB
2851, d2xj0A_, 0.7673, 2.72, 0.238, 274, 248, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-4 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
2852, d3tubA_, 0.7672, 2.78, 0.349, 253, 249, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH 1-(5-(67- DIMETHOXYQUINOLIN-4-YLOXY)PYRIDIN-2-YL)-3-((1R2S)-2- PHENYLCYCLOPROPYL)UREA
2853, d3qwkA_, 0.7672, 2.94, 0.224, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-150
2854, d2o63A_, 0.7672, 2.73, 0.234, 274, 248, CRYSTAL STRUCTURE OF PIM1 WITH MYRICETIN
2855, d2nruA_, 0.7672, 3.16, 0.263, 293, 255, CRYSTAL STRUCTURE OF IRAK-4
2856, d1yxuB_, 0.7672, 2.74, 0.234, 273, 248, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
2857, d1oguA1, 0.7672, 2.86, 0.218, 293, 252, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR
2858, d5w5oJ_, 0.7671, 2.41, 0.247, 275, 243, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2859, d5obrA_, 0.7671, 2.85, 0.238, 255, 248, AURORA A KINASE IN COMPLEX WITH 2-(3-CHLORO-5-FLUOROPHENYL)QUINOLINE- 4-CARBOXYLIC ACID AND JNJ-7706621
2860, d5kgiA_, 0.7671, 2.73, 0.234, 273, 248, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR 2-[34-BIS(CHLORANYL) PHENOXY]ETHANAMINE
2861, d5cvgA_, 0.7671, 2.88, 0.183, 326, 252, CRYSTAL STRUCTURE OF CK2ALPHA WITH A NOVEL CLOSED CONFORMATION OF THE AD LOOP
2862, d4wnoA_, 0.7671, 3.29, 0.267, 272, 258, STRUCTURE OF ULK1 BOUND TO AN INHIBITOR
2863, d4jx3A_, 0.7671, 2.71, 0.230, 274, 248, CRYSTAL STRUCTURE OF PIM1 KINASE
2864, p4f9bA_, 0.7671, 3.45, 0.195, 318, 261, HUMAN CDC7 KINASE IN COMPLEX WITH DBF4 AND PHA767491
2865, d3jxwA_, 0.7671, 2.76, 0.230, 274, 248, DISCOVERY OF 3H-BENZO[45]THIENO[32-D]PYRIMIDIN-4-ONES AS POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PIM KINASES INHIBITORS
2866, d2xruA_, 0.7671, 2.81, 0.239, 253, 247, AURORA-A T288E COMPLEXED WITH PHA-828300
2867, d5nk8A_, 0.7670, 2.61, 0.322, 266, 245, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2F
2868, d5lpwA_, 0.7670, 2.86, 0.253, 280, 249, CRYSTAL STRUCTURE OF THE APO-BRI1 KINASE DOMAIN (865-1160)
2869, d5lmkC1, 0.7670, 2.75, 0.212, 264, 250, STRUCTURE OF PHOPSHO-CDK2-CYCLIN A IN COMPLEX WITH AN ATP-COMPETITIVE INHIBITOR
2870, d5acbC_, 0.7670, 3.17, 0.239, 324, 259, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
2871, d4jx7A_, 0.7670, 2.74, 0.226, 274, 248, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH INHIBITOR 2-[(TRANS- 4-AMINOCYCLOHEXYL)AMINO]-4-{[3-(TRIFLUOROMETHYL) PHENYL]AMINO}PYRIDO[43-D]PYRIMIDIN-5(6H)-ONE
2872, d4itiB_, 0.7670, 2.55, 0.272, 270, 246, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-3 ANALOG
2873, d3i4bB_, 0.7670, 3.07, 0.223, 347, 256, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH A PYRIMIDYLPYRROLE INHIBITOR
2874, d2nruB_, 0.7670, 3.17, 0.259, 294, 255, CRYSTAL STRUCTURE OF IRAK-4
2875, d2jd5A_, 0.7670, 2.98, 0.209, 353, 253, SKY1P BOUND TO NPL3P-DERIVED SUBSTRATE PEPTIDE
2876, d2bfyB_, 0.7670, 3.08, 0.187, 278, 256, COMPLEX OF AURORA-B WITH INCENP AND HESPERADIN.
2877, d5ipjA_, 0.7669, 2.74, 0.226, 273, 248, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A QUINAZOLINONE-PYRROLOPYRROLONE INHIBITOR.
2878, d5dhjA_, 0.7669, 2.73, 0.234, 273, 248, PIM1 IN COMPLEX WITH CPD4 (3-METHYL-5-(PYRIDIN-3-YL)-1H-PYRAZOLO[34- C]PYRIDINE)
2879, d5dgzA_, 0.7669, 2.74, 0.222, 273, 248, DISCOVERY OF 35-SUBSTITUTED 6-AZAINDAZOLES AS POTENT PAN-PIM INHIBITORS
2880, d4wsyA_, 0.7669, 2.74, 0.226, 273, 248, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A THIAZOLAMINE-INDAZOLE INHIBITOR.
2881, d4wrsA_, 0.7669, 2.74, 0.226, 273, 248, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH AN AZASPIRO PYRAZINYL-INDAZOLE INHIBITOR.
2882, d4cfwA1, 0.7669, 3.08, 0.212, 297, 255, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
2883, d2f57A1, 0.7669, 3.39, 0.200, 290, 260, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 5
2884, d1q41B_, 0.7669, 3.12, 0.230, 343, 256, GSK-3 BETA COMPLEXED WITH INDIRUBIN-3 -MONOXIME
2885, d1eh4B_, 0.7669, 3.39, 0.162, 293, 265, BINARY COMPLEX OF CASEIN KINASE-1 FROM S. POMBE WITH AN ATP COMPETITIVE INHIBITOR IC261
2886, d5nhjA_, 0.7668, 3.37, 0.203, 345, 261, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
2887, d5hlnA_, 0.7668, 3.20, 0.236, 346, 259, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH CHIR99021
2888, d5f94B_, 0.7668, 3.18, 0.230, 349, 257, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 15: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-METHOXYPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
2889, d4qtbB_, 0.7668, 3.39, 0.212, 348, 259, STRUCTURE OF HUMAN ERK1 IN COMPLEX WITH SCH772984 REVEALING A NOVEL INHIBITOR-INDUCED BINDING POCKET
2890, d4nm7A1, 0.7668, 3.22, 0.233, 354, 257, CRYSTAL STRUCTURE OF GSK-3/AXIN COMPLEX BOUND TO PHOSPHORYLATED WNT RECEPTOR LRP6 E-MOTIF
2891, d4mblA_, 0.7668, 2.76, 0.226, 274, 248, DISCOVERY OF PYRAZOLO[15A]PYRIMIDINE-BASED PIM1 INHIBITORS
2892, d4k18A_, 0.7668, 2.78, 0.233, 277, 249, STRUCTURE OF PIM-1 KINASE BOUND TO 5-(4-CYANOBENZYL)-N-(4- FLUOROPHENYL)-7-HYDROXYPYRAZOLO[15-A]PYRIMIDINE-3-CARBOXAMIDE
2893, d4eosA1, 0.7668, 2.86, 0.222, 293, 252, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
2894, d4b8mA_, 0.7668, 3.08, 0.212, 270, 255, AURORA B KINASE IN COMPLEX WITH VX-680
2895, p3zuvA_, 0.7668, 3.27, 0.209, 357, 258, CRYSTAL STRUCTURE OF A DESIGNED SELECTED ANKYRIN REPEAT PROTEIN IN COMPLEX WITH THE PHOSPHORYLATED MAP KINASE ERK2
2896, d3k5uA_, 0.7668, 2.81, 0.238, 260, 248, IDENTIFICATION SAR STUDIES AND X-RAY COCRYSTAL ANALYSIS OF A NOVEL FURANO-PYRIMIDINE AURORA KINASE A INHIBITOR
2897, d2ywpA_, 0.7668, 3.51, 0.259, 269, 259, CRYSTAL STRUCTURE OF CHK1 WITH A UREA INHIBITOR
2898, d5d12B_, 0.7667, 2.24, 0.351, 253, 239, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL40
2899, d4l01B_, 0.7667, 2.79, 0.227, 274, 251, CRYSTAL STRUCTURE OF THE V658F APO JAK1 PSEUDOKINASE DOMAIN
2900, p3n9xB_, 0.7667, 3.37, 0.189, 362, 259, CRYSTAL STRUCTURE OF MAP KINASE FROM PLASMODIUM BERGHEI PB000659.00.0
2901, d3m11A_, 0.7667, 2.74, 0.239, 256, 247, CRYSTAL STRUCTURE OF AURORA A KINASE COMPLEXED WITH INHIBITOR
2902, d2y6oA_, 0.7667, 2.95, 0.312, 263, 250, CRYSTAL STRUCTURE OF EPHA4 KINASE DOMAIN IN COMPLEX WITH DASATINIB.
2903, d2xngA_, 0.7667, 2.68, 0.233, 253, 245, STRUCTURE OF AURORA-A BOUND TO A SELECTIVE IMIDAZOPYRAZINE INHIBITOR
2904, d2w1gA1, 0.7667, 2.82, 0.243, 254, 247, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
2905, d1q4lB_, 0.7667, 3.09, 0.223, 337, 256, GSK-3 BETA COMPLEXED WITH INHIBITOR I-5
2906, d5ax9A_, 0.7666, 2.79, 0.233, 282, 249, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE IN COMPLEX WITH COMPUND 9
2907, d4yc3A1, 0.7666, 3.07, 0.212, 294, 255, CDK1/CYCLINB1/CKS2 APO
2908, d4wnpD_, 0.7666, 3.24, 0.265, 272, 257, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
2909, d4k0yA_, 0.7666, 2.74, 0.226, 274, 248, STRUCTURE OF PIM-1 KINASE BOUND TO N-(4-FLUOROPHENYL)-7-HYDROXY-5- (PIPERIDIN-4-YL)PYRAZOLO[15-A]PYRIMIDINE-3-CARBOXAMIDE
2910, d4eojA1, 0.7666, 2.86, 0.227, 293, 251, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH ATP
2911, d3i4bA_, 0.7666, 3.08, 0.223, 359, 256, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH A PYRIMIDYLPYRROLE INHIBITOR
2912, d3f88B_, 0.7666, 3.05, 0.235, 340, 255, GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR COMPLEX
2913, d2qi8B_, 0.7666, 1.92, 0.349, 249, 235, CRYSTAL STRUCTURE OF DRUG RESISTANT SRC KINASE DOMAIN
2914, d5w5oF_, 0.7665, 2.30, 0.248, 275, 242, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2915, d5w5oC_, 0.7665, 2.45, 0.242, 275, 244, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2916, d5nhoA_, 0.7665, 3.28, 0.205, 343, 258, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
2917, d5nhhA_, 0.7665, 3.38, 0.203, 348, 261, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
2918, d5f94A_, 0.7665, 3.18, 0.230, 346, 257, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 15: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-METHOXYPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
2919, d4eooA1, 0.7665, 2.85, 0.219, 292, 251, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
2920, d4bidB_, 0.7665, 2.52, 0.233, 258, 245, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
2921, p3zuvC_, 0.7665, 3.24, 0.202, 357, 258, CRYSTAL STRUCTURE OF A DESIGNED SELECTED ANKYRIN REPEAT PROTEIN IN COMPLEX WITH THE PHOSPHORYLATED MAP KINASE ERK2
2922, d3rniA_, 0.7665, 2.94, 0.224, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR RC-3-86
2923, d3qruA_, 0.7665, 2.96, 0.227, 295, 251, CDK2 IN COMPLEX WITH INHIBITOR NSK-MC1-12
2924, d2iw9A2, 0.7665, 2.82, 0.219, 292, 251, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
2925, d5toeA_, 0.7664, 2.71, 0.231, 272, 247, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
2926, d5lqfD1, 0.7664, 2.76, 0.214, 282, 248, CDK1/CYCLINB1/CKS2 IN COMPLEX WITH NU6102
2927, d5lpbA_, 0.7664, 2.93, 0.244, 280, 250, CRYSTAL STRUCTURE OF THE BRI1 KINASE DOMAIN (865-1160) IN COMPLEX WITH ADP FROM ARABIDOPSIS THALIANA
2928, d4cfvC1, 0.7664, 2.79, 0.208, 263, 250, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
2929, d3r8pA_, 0.7664, 2.94, 0.228, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR NSK-MC1-6
2930, d5w5oK_, 0.7663, 2.32, 0.248, 275, 242, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2931, d5w5oD_, 0.7663, 2.31, 0.248, 275, 242, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2932, d3p86A_, 0.7663, 2.47, 0.300, 250, 243, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN MUTANT D676N IN COMPLEX WITH STAUROSPORINE
2933, d2yn8A_, 0.7663, 2.47, 0.292, 253, 243, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
2934, d2yexA_, 0.7663, 3.37, 0.248, 269, 258, SYNTHESIS AND EVALUATION OF TRIAZOLONES AS CHECKPOINT KINASE 1 INHIBITORS
2935, d1yxuA_, 0.7663, 2.75, 0.226, 273, 248, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
2936, d1o6yA_, 0.7663, 2.70, 0.236, 260, 246, CATALYTIC DOMAIN OF PKNB KINASE FROM MYCOBACTERIUM TUBERCULOSIS
2937, d1i09B_, 0.7663, 3.19, 0.230, 341, 257, STRUCTURE OF GLYCOGEN SYNTHASE KINASE-3 (GSK3B)
2938, d5h8gA_, 0.7662, 3.15, 0.183, 324, 257, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 7B
2939, d4alvA_, 0.7662, 2.75, 0.218, 274, 248, BENZOFUROPYRIMIDINONE INHIBITORS OF PIM-1
2940, d3qziA_, 0.7662, 2.92, 0.220, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-126
2941, d3lokA_, 0.7662, 1.79, 0.348, 248, 233, DRUG RESISTANT CSRC KINASE DOMAIN IN COMPLEX WITH COVALENT INHIBITOR PD168393
2942, d2vrxA_, 0.7662, 3.10, 0.216, 268, 255, STRUCTURE OF AURORA B KINASE IN COMPLEX WITH ZM447439
2943, d2bfxB_, 0.7662, 3.18, 0.208, 275, 255, MECHANISM OF AURORA-B ACTIVATION BY INCENP AND INHIBITION BY HESPERADIN.
2944, d1q5kB_, 0.7662, 3.17, 0.230, 344, 257, CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 IN COMPLEXED WITH INHIBITOR
2945, d1p4oB_, 0.7662, 2.86, 0.312, 314, 250, STRUCTURE OF APO UNACTIVATED IGF-1R KINASE DOMAIN AT 1.5A RESOLUTION.
2946, d5kgkA_, 0.7661, 2.73, 0.234, 273, 248, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 3-(4-METHOXYPHENYL)-1~{H}- PYRAZOL-5-AMINE
2947, d3qx4A_, 0.7661, 2.92, 0.220, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-78
2948, d2vgoA_, 0.7661, 3.09, 0.212, 268, 255, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH REVERSINE INHIBITOR
2949, d1q4lA_, 0.7661, 3.09, 0.219, 342, 256, GSK-3 BETA COMPLEXED WITH INHIBITOR I-5
2950, d1q3wB_, 0.7661, 3.19, 0.230, 341, 257, GSK-3 BETA COMPLEXED WITH ALSTERPAULLONE
2951, d1p4oA_, 0.7661, 2.85, 0.312, 308, 250, STRUCTURE OF APO UNACTIVATED IGF-1R KINASE DOMAIN AT 1.5A RESOLUTION.
2952, d1mp8A_, 0.7661, 2.64, 0.358, 252, 246, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE (FAK)
2953, d1h24A1, 0.7661, 3.00, 0.205, 292, 254, CDK2/CYCLIN A IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM E2F
2954, d1cmkE_, 0.7661, 3.15, 0.259, 348, 255, CRYSTAL STRUCTURES OF THE MYRISTYLATED CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE REVEAL OPEN AND CLOSED CONFORMATIONS
2955, d5w5oH_, 0.7660, 2.46, 0.242, 275, 244, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2956, d5kcxA_, 0.7660, 2.72, 0.231, 272, 247, PIM-1 KINASE IN COMPLEX WITH A SELECTIVE N-SUBSTITUTED 7-AZAINDOLE INHIBITOR
2957, d5ar4B_, 0.7660, 2.36, 0.238, 279, 244, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH SB-203580
2958, d4dtkA_, 0.7660, 2.75, 0.234, 273, 248, NOVEL AND SELECTIVE PAN-PIM KINASE INHIBITOR
2959, d3r21A_, 0.7660, 2.79, 0.243, 254, 247, DESIGN SYNTHESIS AND BIOLOGICAL EVALUATION OF PYRAZOLOPYRIDINE- SULFONAMIDES AS POTENT MULTIPLE-MITOTIC KINASE (MMK) INHIBITORS (PART I)
2960, d3c4eA_, 0.7660, 2.75, 0.226, 273, 248, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
2961, d2bfyA_, 0.7660, 3.11, 0.195, 270, 256, COMPLEX OF AURORA-B WITH INCENP AND HESPERADIN.
2962, d1yxuC_, 0.7660, 2.70, 0.223, 272, 247, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
2963, d1yxsA_, 0.7660, 2.75, 0.226, 274, 248, CRYSTAL STRUCTURE OF KINASE PIM1 WITH P123M MUTATION
2964, d1ctpE_, 0.7660, 3.15, 0.259, 332, 255, STRUCTURE OF THE MAMMALIAN CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE AND AN INHIBITOR PEPTIDE DISPLAYS AN OPEN CONFORMATION
2965, d5w5oG_, 0.7659, 2.31, 0.244, 275, 242, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2966, d5w5oA_, 0.7659, 2.40, 0.255, 275, 243, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2967, d4n70A_, 0.7659, 2.77, 0.218, 274, 248, PIM1 COMPLEXED WITH A PYRIDYLCARBOXAMIDE
2968, d4izaA_, 0.7659, 3.25, 0.206, 346, 257, STRUCTURE OF DUALLY PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
2969, p3nieB_, 0.7659, 3.56, 0.204, 367, 260, CRYSTAL STRUCTURE OF PF11_0147
2970, d2x7fB_, 0.7659, 2.79, 0.236, 288, 250, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
2971, d2e9nA_, 0.7659, 3.50, 0.256, 269, 258, STRUCTURE OF H-CHK1 COMPLEXED WITH A767085
2972, d1xqzA_, 0.7659, 2.80, 0.225, 277, 249, CRYSTAL STRUCTURE OF HPIM-1 KINASE AT 2.1 A RESOLUTION
2973, d5w5oE_, 0.7658, 2.28, 0.252, 275, 242, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2974, d4nm5A1, 0.7658, 3.23, 0.233, 360, 257, CRYSTAL STRUCTURE OF GSK-3/AXIN COMPLEX BOUND TO PHOSPHORYLATED WNT RECEPTOR LRP6 C-MOTIF
2975, d4jbpA_, 0.7658, 2.77, 0.243, 255, 247, NOVEL AURORA KINASE INHIBITORS REVEAL MECHANISMS OF HURP IN NUCLEATION OF CENTROSOMAL AND KINETOCHORE MICROTUBULES
2976, d2yerA_, 0.7658, 3.34, 0.253, 268, 257, SYNTHESIS AND EVALUATION OF TRIAZOLONES AS CHECKPOINT KINASE 1 INHIBITORS
2977, d2og8B2, 0.7658, 2.44, 0.361, 247, 241, CRYSTAL STRUCTURE OF AMINOQUINAZOLINE 36 BOUND TO LCK
2978, d2bzhB_, 0.7658, 2.80, 0.229, 275, 249, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU1
2979, d5turA_, 0.7657, 2.71, 0.231, 270, 247, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
2980, d5e1sA_, 0.7657, 2.74, 0.319, 284, 248, THE CRYSTAL STRUCTURE OF INSR TYROSINE KINASE IN COMPLEX WITH THE INHIBITOR BI 885578
2981, d5csxA_, 0.7657, 2.74, 0.261, 261, 249, CRYSTAL STRUCTURE OF B-RAF IN COMPLEX WITH BI 882370
2982, d5aaeA_, 0.7657, 2.74, 0.240, 252, 246, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (14D)
2983, d5v82A_, 0.7656, 2.70, 0.235, 273, 247, PIM1 KINASE IN COMPLEX WITH CPD17 (1-(6-(44-DIFLUOROPIPERIDIN-3-YL) PYRIDIN-2-YL)-6-(6-METHYLPYRAZIN-2-YL)-1H-PYRAZOLO[43-C]PYRIDINE)
2984, d5he0A2, 0.7656, 3.27, 0.198, 346, 258, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG215022
2985, d4k1bA_, 0.7656, 2.78, 0.234, 273, 248, STRUCTURE OF PIM-1 KINASE BOUND TO N-(5-(2-FLUOROPHENYL)-1H-PYRROLO[2 3-B]PYRIDIN-3-YL)-5-((((3R4R)-3-FLUOROPIPERIDIN-4-YL)METHYL)AMINO) PYRAZOLO[15-A]PYRIMIDINE-3-CARBOXAMIDE
2986, d3qwjA_, 0.7656, 2.92, 0.220, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-142
2987, d3f7zA1, 0.7656, 3.12, 0.234, 338, 256, X-RAY CO-CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3BETA IN COMPLEX WITH AN INHIBITOR
2988, d3c4eC_, 0.7656, 2.71, 0.227, 272, 247, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
2989, d1yxuD_, 0.7656, 2.78, 0.226, 273, 248, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
2990, d5w5oP_, 0.7655, 2.36, 0.243, 275, 243, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2991, d5kziA_, 0.7655, 2.76, 0.222, 273, 248, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH AN IMIDAZOPYRIDAZINE INHIBITOR.
2992, d4cfnA1, 0.7655, 2.87, 0.210, 293, 252, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
2993, d3r1qA_, 0.7655, 2.90, 0.224, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-102
2994, d3o0gA_, 0.7655, 3.08, 0.200, 289, 255, CRYSTAL STRUCTURE OF CDK5:P25 IN COMPLEX WITH AN ATP ANALOGUE
2995, d2xizA_, 0.7655, 2.81, 0.234, 273, 248, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-3 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
2996, d2j4zA_, 0.7655, 2.84, 0.242, 263, 248, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-680626
2997, d1unlA_, 0.7655, 3.10, 0.204, 292, 255, STRUCTURAL MECHANISM FOR THE INHIBITION OF CD5-P25 FROM THE ROSCOVITINE ALOISINE AND INDIRUBIN.
2998, d5j7bA_, 0.7654, 2.42, 0.238, 277, 244, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE GSK583 COMPLEX
2999, d4j71A_, 0.7654, 3.25, 0.241, 347, 257, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 1R
3000, d4ic7A_, 0.7654, 3.41, 0.207, 355, 261, CRYSTAL STRUCTURE OF THE ERK5 KINASE DOMAIN IN COMPLEX WITH AN MKK5 BINDING FRAGMENT
3001, d3gb2A_, 0.7654, 3.26, 0.245, 340, 257, GSK3BETA INHIBITOR COMPLEX
3002, d3dcvA_, 0.7654, 2.90, 0.225, 273, 249, CRYSTAL STRUCTURE OF HUMAN PIM1 KINASE COMPLEXED WITH 4-(4- HYDROXY-3-METHYL-PHENYL)-6-PHENYLPYRIMIDIN-2(1H)-ONE
3003, d2jldB_, 0.7654, 3.16, 0.230, 349, 257, EXTREMELY TIGHT BINDING OF RUTHENIUM COMPLEX TO GLYCOGEN SYNTHASE KINASE 3
3004, d5jt2B1, 0.7653, 2.26, 0.289, 250, 242, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-BISAMIDE
3005, d3an0A_, 0.7653, 3.19, 0.248, 291, 258,  
3006, d3a8wB1, 0.7653, 2.97, 0.202, 324, 253, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
3007, d2i40A_, 0.7653, 2.97, 0.235, 291, 251, CDK2/CYCLIN A COMPLEXED WITH A THIOPHENE CARBOXAMIDE INHIBITOR
3008, d2exmA_, 0.7653, 2.98, 0.219, 298, 251, HUMAN CDK2 IN COMPLEX WITH ISOPENTENYLADENINE
3009, d1q41A_, 0.7653, 3.13, 0.230, 339, 256, GSK-3 BETA COMPLEXED WITH INDIRUBIN-3 -MONOXIME
3010, d5oq5A_, 0.7652, 3.33, 0.271, 265, 255, STRUCTURE OF CHK1 8-PT. MUTANT COMPLEX WITH AMINOPYRIMIDO- BENZODIAZEPINONE LRRK2 INHIBITOR
3011, d4pteB_, 0.7652, 3.20, 0.233, 347, 257, STRUCTURE OF A CARVOXAMIDE COMPOUND (15) (N-[4-(ISOQUINOLIN-7-YL) PYRIDIN-2-YL]CYCLOPROPANECARBOXAMIDE) TO GSK3B
3012, d4eoiA1, 0.7652, 2.85, 0.223, 293, 251, THR 160 PHOSPHORYLATED CDK2 K89D Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
3013, d4cxaC_, 0.7652, 3.30, 0.245, 330, 261, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLIN K COMPLEX BOUND TO AMPPNP
3014, d3qqlA_, 0.7652, 2.95, 0.228, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR L3
3015, d3qlfA_, 0.7652, 2.02, 0.349, 249, 235, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH PYRAZOLOPYRIMIDINE 5
3016, d3a8wA1, 0.7652, 2.97, 0.202, 323, 253, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
3017, d2b53A_, 0.7652, 2.94, 0.217, 294, 249, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DIN- 234325
3018, d5w5oB_, 0.7651, 2.46, 0.242, 275, 244, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3019, d5ceoA_, 0.7651, 2.29, 0.307, 269, 241, DLK IN COMPLEX WITH INHIBITOR 2-((6-(33-DIFLUOROPYRROLIDIN-1-YL)-4- (1-(OXETAN-3-YL)PIPERIDIN-4-YL)PYRIDIN-2-YL)AMINO)ISONICOTINONITRILE
3020, d3vn9A_, 0.7651, 3.19, 0.248, 291, 258, RIFINED CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED MAP2K6 IN A PUTATIVE AUTO-INHIBITION STATE
3021, d3rm7A_, 0.7651, 2.93, 0.220, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-91
3022, d3o23A_, 0.7651, 3.03, 0.307, 293, 251, HUMAN UNPHOSPHORYLATED IGF1-R KINASE DOMAIN IN COMPLEX WITH AN HYDANTOIN INHIBITOR
3023, d3du8A_, 0.7651, 3.13, 0.230, 336, 256, CRYSTAL STRUCTURE OF GSK-3 BETA IN COMPLEX WITH NMS-869553A
3024, d2o65A_, 0.7651, 2.77, 0.234, 274, 248, CRYSTAL STRUCTURE OF PIM1 WITH PENTAHYDROXYFLAVONE
3025, d4pqnA_, 0.7650, 2.17, 0.316, 240, 237, ITK KINASE DOMAIN WITH COMPOUND GNE-9822
3026, d3qx2A_, 0.7650, 2.96, 0.220, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-190
3027, d3bwfA_, 0.7650, 2.76, 0.230, 273, 248, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH AN OSMIUM COMPOUND
3028, d2oi4X_, 0.7650, 2.81, 0.221, 275, 249, CRYSTAL STRUCTURE OF HUMAN PIM1 IN COMPLEX WITH FLUORINATED RUTHENIUM PYRIDOCARBAZOLE
3029, d2bujB1, 0.7650, 3.21, 0.190, 277, 258, CRYSTAL STRUCTURE OF THE HUMAN SERINE-THREONINE KINASE 16 IN COMPLEX WITH STAUROSPORINE
3030, d1ywvA_, 0.7650, 2.76, 0.238, 274, 248, CRYSTAL STRUCTURES OF PROTO-ONCOGENE KINASE PIM1: A TARGET OF ABERRANT SOMATIC HYPERMUTATIONS IN DIFFUSE LARGE CELL LYMPHOMA
3031, d4cfmC1, 0.7649, 2.82, 0.204, 265, 250, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
3032, d3qqfA_, 0.7649, 2.93, 0.220, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR L1
3033, d3q3bA_, 0.7649, 3.21, 0.233, 344, 257, 6-AMINO-4-(PYRIMIDIN-4-YL)PYRIDONES: NOVEL GLYCOGEN SYNTHASE KINASE-3 INHIBITORS
3034, d2xmyA_, 0.7649, 2.99, 0.231, 295, 251, DISCOVERY AND CHARACTERISATION OF 2-ANILINO-4-(THIAZOL-5-YL) PYRIMIDINE TRANSCRIPTIONAL CDK INHIBITORS AS ANTICANCER AGENTS
3035, d2hwoA_, 0.7649, 1.89, 0.350, 251, 234, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH COVALENT INHIBITOR
3036, d5ke0A_, 0.7648, 3.40, 0.203, 340, 261, DISCOVERY OF 1-1H-PYRAZOLO 43-C PYRIDINE-6-YL UREA INHIBITORS OF EXTRACELLULAR SIGNAL REGULATED KINASE ERK FOR THE TREATMENT OF CANCERS
3037, d5iisA_, 0.7648, 2.80, 0.222, 273, 248, DESIGN SYNTHESIS AND STRUCTURE ACTIVITY RELATIONSHIP OF POTENT PAN- PIM KINASE INHIBITORS DERIVED FROM THE PYRIDYL-AMIDE SCAFFOLD
3038, d5ct7A_, 0.7648, 2.89, 0.265, 257, 249, BRAF IN COMPLEX WITH RAF265
3039, d4wnpC_, 0.7648, 3.17, 0.266, 271, 256, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
3040, d4un0C_, 0.7648, 3.26, 0.254, 308, 260, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
3041, d4j1rC_, 0.7648, 3.27, 0.241, 344, 257, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
3042, d4j1rB_, 0.7648, 3.26, 0.241, 346, 257, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
3043, d4bznA_, 0.7648, 2.75, 0.223, 272, 247, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH A PYRROLO(12-A) PYRAZINONE INHIBITOR
3044, d3vbtA_, 0.7648, 2.69, 0.228, 267, 246, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
3045, d3jpvA_, 0.7648, 2.85, 0.221, 273, 249, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND A PYRROLO[23- A]CARBAZOLE LIGAND
3046, d2xiyA_, 0.7648, 2.73, 0.235, 273, 247, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-2 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
3047, d4ptcA_, 0.7647, 3.19, 0.230, 342, 257, STRUCTURE OF A CARBOXAMIDE COMPOUND (3) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-OXO-4H-1LAMBDA~4~3-THIAZOLE-5-CARBOXAMIDE) TO GSK3B
3048, d4eorA1, 0.7647, 2.80, 0.204, 292, 250, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
3049, d3r02A_, 0.7647, 2.78, 0.231, 271, 247, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
3050, d5x17A_, 0.7646, 3.31, 0.214, 290, 262, CRYSTAL STRUCTURE OF MURINE CK1D IN COMPLEX WITH ADP
3051, d5j7bB_, 0.7646, 2.41, 0.242, 281, 244, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE GSK583 COMPLEX
3052, d4ty1A_, 0.7646, 2.71, 0.215, 273, 247, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH AN AMINOOXADIAZOLE-INDOLE INHIBITOR.
3053, d3uzpA_, 0.7646, 3.41, 0.220, 292, 264, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P21 CRYSTAL FORM
3054, d2bzjA_, 0.7646, 2.76, 0.230, 273, 248, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU3
3055, d5cshB_, 0.7645, 3.13, 0.196, 323, 255, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 4 BOUND
3056, d4rpvA_, 0.7645, 2.75, 0.226, 273, 248, CO-CRYSTAL STRUCTURE OF PIM1 WITH COMPOUND 3
3057, d4h1mA_, 0.7645, 2.67, 0.329, 256, 246, CRYSTAL STRUCTURE OF PYK2 WITH THE INDOLE 10C
3058, d3vbvA_, 0.7645, 2.70, 0.228, 268, 246, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
3059, d3q3bB_, 0.7645, 3.22, 0.230, 341, 257, 6-AMINO-4-(PYRIMIDIN-4-YL)PYRIDONES: NOVEL GLYCOGEN SYNTHASE KINASE-3 INHIBITORS
3060, d3orxE_, 0.7645, 3.09, 0.242, 274, 252, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
3061, d2nruC_, 0.7645, 3.21, 0.263, 293, 255, CRYSTAL STRUCTURE OF IRAK-4
3062, d1h8fB_, 0.7645, 3.21, 0.230, 350, 257, GLYCOGEN SYNTHASE KINASE 3 BETA.
3063, d4bibB_, 0.7644, 2.55, 0.241, 258, 245, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3064, d4agwA_, 0.7644, 2.56, 0.337, 258, 243, DISCOVERY OF A SMALL MOLECULE TYPE II INHIBITOR OF WILD- TYPE AND GATEKEEPER MUTANTS OF BCR-ABL PDGFRALPHA KIT AND SRC KINASES
3065, d3rm6A_, 0.7644, 2.90, 0.225, 293, 249, CDK2 IN COMPLEX WITH INHIBITOR KVR-2-80
3066, d3ql8A_, 0.7644, 2.92, 0.228, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR JWS-6-260
3067, p2h96A_, 0.7644, 3.34, 0.196, 358, 260, DISCOVERY OF POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PYRIDINE CARBOXAMIDE C-JUN NH2-TERMINAL KINASE INHIBITORS
3068, d1jowB_, 0.7644, 2.70, 0.206, 277, 247, CRYSTAL STRUCTURE OF A COMPLEX OF HUMAN CDK6 AND A VIRAL CYCLIN
3069, d1ckjA_, 0.7644, 3.37, 0.220, 296, 264, CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317 COMPLEX WITH BOUND TUNGSTATE
3070, d4ptgB_, 0.7643, 3.20, 0.230, 332, 257, STRUCTURE OF A CARBOXAMINE COMPOUND (26) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-METHOXYPYRIMIDINE-5-CARBOXAMIDE) TO GSK3B
3071, d3tnwA1, 0.7643, 2.93, 0.214, 294, 252, STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH CAN508
3072, d3qrtA_, 0.7643, 2.95, 0.224, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR NSK-MC2-55
3073, d3bgqA_, 0.7643, 2.85, 0.214, 272, 248, HUMAN PIM-1 KINASE IN COMPLEX WITH AN TRIAZOLO PYRIDAZINE INHIBITOR VX2
3074, d2jldA_, 0.7643, 3.17, 0.230, 349, 257, EXTREMELY TIGHT BINDING OF RUTHENIUM COMPLEX TO GLYCOGEN SYNTHASE KINASE 3
3075, d2j2iB_, 0.7643, 2.75, 0.226, 273, 248, CRYSTAL STRUCTURE OF THE HUMAB PIM1 IN COMPLEX WITH LY333531
3076, d1q8zB_, 0.7643, 3.24, 0.185, 364, 259, THE APOENZYME STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P
3077, d1h8fA_, 0.7643, 3.22, 0.233, 352, 257, GLYCOGEN SYNTHASE KINASE 3 BETA.
3078, d5lpyA_, 0.7642, 2.89, 0.245, 282, 249, CRYSTAL STRUCTURE OF THE BRI1 KINASE DOMAIN (865-1160) IN COMPLEX WITH ATP FROM ARABIDOPSIS THALIANA
3079, d5h3qA_, 0.7642, 2.87, 0.379, 302, 248, CRYSTAL STRUCTURE OF TRKA KINASE WITH LIGAND
3080, d4tyeA_, 0.7642, 3.21, 0.362, 292, 254, STRUCTURAL ANALYSIS OF THE HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE
3081, d4rc2A_, 0.7642, 2.73, 0.231, 272, 247, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
3082, d4acgA_, 0.7642, 3.21, 0.230, 350, 257, GSK3B IN COMPLEX WITH INHIBITOR
3083, d4a7cA_, 0.7642, 2.83, 0.234, 273, 248, CRYSTAL STRUCTURE OF PIM1 KINASE WITH ETP46546
3084, d3we8A_, 0.7642, 2.77, 0.230, 273, 248, PIM-1 KINASE IN COMPLEX WITH RUTHENIUM-BASED INHIBITOR
3085, d3r83A_, 0.7642, 2.98, 0.220, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR KVR-2-92
3086, d3orxG_, 0.7642, 3.10, 0.238, 274, 252, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
3087, d3o2mA_, 0.7642, 3.27, 0.189, 358, 259, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM COMPLEX WITH A BIARYL TETRAZOL (A-82118)
3088, d3cqeA_, 0.7642, 2.81, 0.210, 258, 248, WEE1 KINASE COMPLEX WITH INHIBITOR PD074291
3089, d1q99B_, 0.7642, 3.32, 0.200, 364, 260, CRYSTAL STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINSAE SKY1P COMPLEXED WITH THE NON-HYDROLYZABLE ATP ANALOGUE AMP-PNP
3090, d5c1qB_, 0.7641, 2.77, 0.230, 273, 248, SERINE/THREONINE-PROTEIN KINASE PIM-1
3091, d4j1rD_, 0.7641, 3.28, 0.241, 345, 257, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
3092, d4j1rA_, 0.7641, 3.27, 0.245, 343, 257, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
3093, d4cjyC_, 0.7641, 3.30, 0.250, 303, 260,  
3094, d3qzfA_, 0.7641, 2.93, 0.224, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR JWS-6-52
3095, d2e9vA_, 0.7641, 3.41, 0.262, 268, 256, STRUCTURE OF H-CHK1 COMPLEXED WITH A859017
3096, d4ztmA_, 0.7640, 2.78, 0.274, 287, 248, IRAK4-INHIBITOR CO-STRUCTURE
3097, d4twcA_, 0.7640, 3.43, 0.216, 293, 264, 2-BENZAMIDO-N-(1H-BENZO[D]IMIDAZOL-2-YL)THIAZOLE-4- CARBOXAMIDE DERIVATIVES AS POTENT INHIBITORS OF CK1D/E
3098, d4gcjA1, 0.7640, 2.86, 0.206, 298, 248, CDK2 IN COMPLEX WITH INHIBITOR RC-3-89
3099, d4bieA_, 0.7640, 2.57, 0.238, 257, 244, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3100, d4bhnB_, 0.7640, 2.53, 0.234, 257, 244, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3101, d4alwA_, 0.7640, 2.78, 0.227, 273, 247, BENZOFUROPYRIMIDINONE INHIBITORS OF PIM-1
3102, d3r7vA_, 0.7640, 2.94, 0.220, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-9
3103, d3r7eA_, 0.7640, 2.95, 0.224, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-67
3104, d5eykB_, 0.7639, 3.10, 0.187, 275, 256, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH BI 847325
3105, d4acgB_, 0.7639, 3.19, 0.230, 350, 257, GSK3B IN COMPLEX WITH INHIBITOR
3106, d3r04A_, 0.7639, 2.80, 0.227, 271, 247, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
3107, d3pvuA2, 0.7639, 3.18, 0.186, 340, 258, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND A SELECTIVE KINASE INHIBITOR (CMPD101)
3108, d2a0cX_, 0.7639, 2.97, 0.224, 294, 250, HUMAN CDK2 IN COMPLEX WITH OLOMOUCINE II A NOVEL 269- TRISUBSTITUTED PURINE CYCLIN-DEPENDENT KINASE INHIBITOR
3109, d5up3A_, 0.7638, 2.61, 0.237, 258, 245, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
3110, d5he2A2, 0.7638, 3.23, 0.182, 353, 258, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224406
3111, d5ar7B_, 0.7638, 2.56, 0.241, 278, 245, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIARYL UREA
3112, d4wnpA_, 0.7638, 3.21, 0.265, 273, 257, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
3113, d4rc3A_, 0.7638, 2.67, 0.228, 271, 246, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
3114, d4j7bA_, 0.7638, 2.95, 0.264, 284, 250, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1
3115, d4ixpA_, 0.7638, 3.25, 0.265, 334, 257, CRYSTAL STRUCTURE OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE (MELK)
3116, d4c8bA_, 0.7638, 2.38, 0.236, 279, 242, STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH PONATINIB
3117, d4bzoA_, 0.7638, 2.74, 0.223, 272, 247, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH A PYRROLO- PYRAZINONE INHIBITOR
3118, d4achB_, 0.7638, 3.21, 0.230, 350, 257, GSK3B IN COMPLEX WITH INHIBITOR
3119, d3vbxA_, 0.7638, 2.71, 0.228, 268, 246, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
3120, d3uimA_, 0.7638, 2.98, 0.258, 291, 248, STRUCTURAL BASIS FOR THE IMPACT OF PHOSPHORYLATION ON PLANT RECEPTOR- LIKE KINASE BAK1 ACTIVATION
3121, d3orxH_, 0.7638, 3.11, 0.238, 274, 252, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
3122, d2nryB_, 0.7638, 3.11, 0.259, 286, 251, CRYSTAL STRUCTURE OF IRAK-4
3123, d2e9vB_, 0.7638, 3.41, 0.258, 268, 256, STRUCTURE OF H-CHK1 COMPLEXED WITH A859017
3124, d5nhlA_, 0.7637, 3.31, 0.202, 345, 258, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
3125, d5hd7A_, 0.7637, 3.37, 0.213, 347, 258, DISSECTING THERAPEUTIC RESISTANCE TO ERK INHIBITION RAT MUTANT SCH772984 IN COMPLEX WITH (3R)-1-(2-OXO-2-{4-[4-(PYRIMIDIN-2-YL) PHENYL]PIPERAZIN-1-YL}ETHYL)-N-[3-(PYRIDIN-4-YL)-2H-INDAZOL-5- YL]PYRROLIDINE-3-CARBOXAMIDE
3126, d5dwrA_, 0.7637, 2.75, 0.223, 273, 247, IDENTIFICATION OF N-(4-((1R3S5S)-3-AMINO-5-METHYLCYCLOHEXYL)PYRIDIN- 3-YL)-6-(26-DIFLUOROPHENYL)-5-FLUOROPICOLINAMIDE (PIM447) A POTENT AND SELECTIVE PROVIRAL INSERTION SITE OF MOLONEY MURINE LEUKEMIA (PIM) 12 AND 3 KINASE INHIBITOR IN CLINICAL TRIALS FOR HEMATOLOGICAL MALIGNANCIES
3127, d4medA_, 0.7637, 2.83, 0.230, 272, 248, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH THIORIDAZINE DERIVATIVES
3128, d3qzhA_, 0.7637, 2.94, 0.224, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-124
3129, d3qu0A_, 0.7637, 2.93, 0.224, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR RC-2-38
3130, d3qtwA_, 0.7637, 2.90, 0.220, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR RC-2-13
3131, d2xj2A_, 0.7637, 2.84, 0.230, 273, 248, PROTEIN KINASE PIM-1 IN COMPLEX WITH SMALL MOLECULE INHIBITOR
3132, d2wmaC1, 0.7637, 2.81, 0.216, 264, 250, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
3133, d2e9pA_, 0.7637, 3.44, 0.258, 269, 256, STRUCTURE OF H-CHK1 COMPLEXED WITH A771129
3134, d1w98A2, 0.7637, 2.99, 0.214, 296, 252, THE STRUCTURAL BASIS OF CDK2 ACTIVATION BY CYCLIN E
3135, d5tobA_, 0.7636, 2.23, 0.370, 245, 238, SELECTIVITY SWITCH BETWEEN FAK AND PYK2: MACROCYCLIZATION OF FAK INHIBITORS IMPROVES PYK2 POTENCY
3136, d5eymB_, 0.7636, 2.84, 0.195, 292, 246, MEK1 IN COMPLEX WITH BI 847325
3137, d5aadA_, 0.7636, 2.78, 0.236, 252, 246, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (7A)
3138, d4ll5A_, 0.7636, 2.81, 0.226, 268, 248, CRYSTAL STRUCTURE OF PIM-1 IN COMPLEX WITH THE FLUORESCENT COMPOUND SKF86002
3139, d4bckC1, 0.7636, 3.00, 0.209, 291, 253, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
3140, d3pupB_, 0.7636, 3.21, 0.230, 347, 257, STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH A RUTHENIUM OCTASPORINE LIGAND (OS1)
3141, d3orxF_, 0.7636, 3.12, 0.238, 274, 252, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
3142, d2ydiA_, 0.7636, 3.58, 0.256, 279, 258, DISCOVERY OF CHECKPOINT KINASE INHIBITOR AZD7762 BY STRUCTURE BASED DESIGN AND OPTIMIZATION OF THIOPHENE CARBOXAMIDE UREAS
3143, d2ghgA1, 0.7636, 3.52, 0.256, 269, 258, H-CHK1 COMPLEXED WITH A431994
3144, d4qtbA_, 0.7635, 3.43, 0.212, 351, 259, STRUCTURE OF HUMAN ERK1 IN COMPLEX WITH SCH772984 REVEALING A NOVEL INHIBITOR-INDUCED BINDING POCKET
3145, d4bcqC1, 0.7635, 2.95, 0.213, 291, 253, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
3146, d3rk5A_, 0.7635, 2.93, 0.224, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR RC-2-72
3147, d3pxrA_, 0.7635, 2.95, 0.220, 294, 250, APO CDK2 CRYSTALLIZED FROM JEFFAMINE
3148, d3bgpA_, 0.7635, 2.74, 0.227, 272, 247, HUMAN PIM-1 COMPLEXED WITH A BENZOISOXAZOLE INHIBITOR VX1
3149, d2nruD_, 0.7635, 3.23, 0.275, 293, 255, CRYSTAL STRUCTURE OF IRAK-4
3150, p2g01B_, 0.7635, 3.31, 0.193, 356, 259, PYRAZOLOQUINOLONES AS NOVEL SELECTIVE JNK1 INHIBITORS
3151, d5f95A_, 0.7634, 3.22, 0.230, 345, 257, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 18: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-PHENYLPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
3152, d4qq5A1, 0.7634, 2.96, 0.364, 272, 250, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE HARBORING THE V550L GATE-KEEPER MUTATION IN COMPLEX WITH FIIN-2 AN IRREVERSIBLE TYROSINE KINASE INHIBITOR CAPABLE OF OVERCOMING FGFR KINASE GATE-KEEPER MUTATIONS
3153, d4n6zA_, 0.7634, 2.86, 0.218, 272, 248, PIM1 COMPLEXED WITH A PYRIDYLCARBOXAMIDE
3154, d4gt4A_, 0.7634, 2.69, 0.276, 274, 246, STRUCTURE OF UNLIGANDED INACTIVE ROR2 KINASE DOMAIN
3155, d4bckA1, 0.7634, 2.95, 0.202, 296, 253, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
3156, d3v8tA1, 0.7634, 1.94, 0.326, 236, 233, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 477
3157, d3r1yA_, 0.7634, 2.97, 0.224, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-134
3158, d3pupA_, 0.7634, 3.22, 0.230, 346, 257, STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH A RUTHENIUM OCTASPORINE LIGAND (OS1)
3159, d3l1sA_, 0.7634, 3.12, 0.231, 336, 255, 3-ARYL-4-(ARYLHYDRAZONO)-1H-PYRAZOL-5-ONES: HIGHLY LIGAND EFFICIENT AND POTENT INHIBITORS OF GSK3
3160, d4j71B_, 0.7633, 3.29, 0.241, 347, 257, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 1R
3161, d3vbyA_, 0.7633, 2.72, 0.228, 267, 246, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
3162, d3mygA_, 0.7633, 2.76, 0.232, 252, 246, AURORA A KINASE COMPLEXED WITH SCH 1473759
3163, d3bi6A_, 0.7633, 2.88, 0.205, 258, 249, WEE1 KINASE COMPLEX WITH INHIBITOR PD352396
3164, d2vgpA_, 0.7633, 2.85, 0.203, 265, 251, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH A AMINOTHIAZOLE INHIBITOR
3165, d1x8bA_, 0.7633, 2.81, 0.219, 259, 247, STRUCTURE OF HUMAN WEE1A KINASE: KINASE DOMAIN COMPLEXED WITH INHIBITOR PD0407824
3166, d3sd0B_, 0.7632, 3.22, 0.230, 349, 257, IDENTIFICATION OF A GLYCOGEN SYNTHASE KINASE-3B INHIBITOR THAT ATTENUATES HYPERACTIVITY IN CLOCK MUTANT MICE
3167, d3r28A_, 0.7632, 2.93, 0.224, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-140
3168, d3du8B_, 0.7632, 3.15, 0.230, 339, 256, CRYSTAL STRUCTURE OF GSK-3 BETA IN COMPLEX WITH NMS-869553A
3169, p2no3B_, 0.7632, 3.31, 0.197, 357, 259, NOVEL 4-ANILINOPYRIMIDINES AS POTENT JNK1 INHIBITORS
3170, d1ykrA_, 0.7632, 3.12, 0.225, 298, 253, CRYSTAL STRUCTURE OF CDK2 WITH AN AMINOIMIDAZO PYRIDINE INHIBITOR
3171, d5t1tC_, 0.7631, 2.96, 0.268, 286, 250, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
3172, d5op7A_, 0.7631, 3.12, 0.259, 261, 251, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIMIDINE LRRK2 INHIBITOR
3173, d3qtuA_, 0.7631, 2.94, 0.228, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR RC-2-132
3174, d2xj1A_, 0.7631, 2.76, 0.227, 273, 247, PROTEIN KINASE PIM-1 IN COMPLEX WITH SMALL MOLECULE INIBITOR
3175, d2b54A_, 0.7631, 2.97, 0.211, 298, 251, HUMAN CYCLIN DEPENDENT KINASE 2 (CKD2)COMPLEXED WITH DIN- 232305
3176, d4rc4A_, 0.7630, 2.75, 0.231, 272, 247, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
3177, d3ulzA_, 0.7630, 2.99, 0.254, 291, 248, CRYSTAL STRUCTURE OF APO BAK1
3178, p3o17A_, 0.7630, 3.36, 0.204, 357, 260, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM
3179, d3fzsA_, 0.7630, 2.54, 0.340, 254, 244, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH BIRB796
3180, d3f2aA_, 0.7630, 2.81, 0.222, 276, 248, CRYSTAL STRUCTURE OF HUMAN PIM-1 IN COMPLEX WITH DAPPA
3181, d1q97B_, 0.7630, 3.31, 0.193, 361, 259, THE STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINASE SKY1P WITH BOUND ATP
3182, d4ptgA_, 0.7629, 3.17, 0.234, 333, 256, STRUCTURE OF A CARBOXAMINE COMPOUND (26) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-METHOXYPYRIMIDINE-5-CARBOXAMIDE) TO GSK3B
3183, d4ez3A_, 0.7629, 2.85, 0.222, 294, 248, CDK2 IN COMPLEX WITH NSC 134199
3184, d4acdA_, 0.7629, 3.23, 0.233, 350, 257, GSK3B IN COMPLEX WITH INHIBITOR
3185, d3rk7A_, 0.7629, 2.96, 0.224, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR RC-2-71
3186, d3dlsB_, 0.7629, 2.83, 0.241, 280, 249, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
3187, d2z2wA_, 0.7629, 2.87, 0.205, 260, 249, HUMAND WEE1 KINASE COMPLEXED WITH INHIBITOR PF0335770
3188, d2w1fA1, 0.7629, 2.81, 0.244, 253, 246, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
3189, d2cguA_, 0.7629, 3.38, 0.263, 263, 255, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
3190, d5cs6B_, 0.7628, 2.67, 0.187, 316, 246, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 3 BOUND
3191, d4xhkB_, 0.7628, 2.81, 0.226, 269, 248, PIM1 KINASE IN COMPLEX WITH COMPOUND 1S
3192, d5nkiA_, 0.7627, 2.57, 0.320, 268, 244, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 4B
3193, d4i41A_, 0.7627, 2.76, 0.231, 272, 247, CRYSTAL STRUCTURE OF HUMAN SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE
3194, d4hyhA_, 0.7627, 3.26, 0.265, 263, 253, X-RAY CRYSTAL STRUCTURE OF COMPOUND 39 BOUND TO HUMAN CHK1 KINASE DOMAIN
3195, d4hgsA1, 0.7627, 3.50, 0.170, 301, 264, CRYSTAL STRUCTURE OF CK1GS WITH COMPOUND 13
3196, d1zysA_, 0.7627, 3.59, 0.264, 271, 258, CO-CRYSTAL STRUCTURE OF CHECKPOINT KINASE CHK1 WITH A PYRROLO-PYRIDINE INHIBITOR
3197, d1q99A_, 0.7627, 3.00, 0.190, 354, 253, CRYSTAL STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINSAE SKY1P COMPLEXED WITH THE NON-HYDROLYZABLE ATP ANALOGUE AMP-PNP
3198, d4y73C_, 0.7626, 3.11, 0.270, 290, 252, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN WITH INHIBITOR
3199, d4agwB_, 0.7626, 2.52, 0.339, 257, 242, DISCOVERY OF A SMALL MOLECULE TYPE II INHIBITOR OF WILD- TYPE AND GATEKEEPER MUTANTS OF BCR-ABL PDGFRALPHA KIT AND SRC KINASES
3200, d3vbqA_, 0.7626, 2.71, 0.215, 271, 246, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
3201, d3r8lA_, 0.7626, 2.96, 0.224, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR L3-4
3202, d3qxoA_, 0.7625, 2.95, 0.220, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-84
3203, d3f7zB1, 0.7625, 3.18, 0.235, 338, 255, X-RAY CO-CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3BETA IN COMPLEX WITH AN INHIBITOR
3204, d6b16A_, 0.7624, 3.24, 0.226, 285, 257, P21-ACTIVATED KINASE 1 IN COMPLEX WITH A 4-AZAINDOLE INHIBITOR
3205, d4ptcB_, 0.7624, 3.23, 0.230, 347, 257, STRUCTURE OF A CARBOXAMIDE COMPOUND (3) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-OXO-4H-1LAMBDA~4~3-THIAZOLE-5-CARBOXAMIDE) TO GSK3B
3206, d4accA_, 0.7624, 3.23, 0.230, 350, 257, GSK3B IN COMPLEX WITH INHIBITOR
3207, d3sd0A_, 0.7624, 3.23, 0.230, 350, 257, IDENTIFICATION OF A GLYCOGEN SYNTHASE KINASE-3B INHIBITOR THAT ATTENUATES HYPERACTIVITY IN CLOCK MUTANT MICE
3208, d3r7yA_, 0.7624, 3.01, 0.224, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR KVR-2-88
3209, d3pvwA2, 0.7624, 3.25, 0.202, 343, 258, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND A SELECTIVE KINASE INHIBITOR (CMPD103A)
3210, d3amyA_, 0.7624, 2.87, 0.189, 318, 249, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA COMPLEXED WITH APIGENIN
3211, d5hd4A_, 0.7623, 3.36, 0.217, 347, 258, DISSECTING THERAPEUTIC RESISTANCE TO ERK INHIBITION RAT WILD TYPE SCH772984 IN COMPLEX WITH (3R)-1-(2-OXO-2-{4-[4-(PYRIMIDIN-2-YL) PHENYL]PIPERAZIN-1-YL}ETHYL)-N-[3-(PYRIDIN-4-YL)-2H-INDAZOL-5- YL]PYRROLIDINE-3-CARBOXAMIDE
3212, d4g16A1, 0.7623, 3.46, 0.170, 301, 264, CRYSTAL STRUCTURE OF CK1G3 WITH 2-[(4-{[3-(TRIFLUOROMETHYL)PYRIDIN2- YL]OXY}PHENYL)AMINO]-1H-BENZIMIDAZOLE-6-CARBONITRILE
3213, d4bhnA_, 0.7623, 2.52, 0.239, 256, 243, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3214, d4as0A_, 0.7623, 2.79, 0.226, 273, 248, CYCLOMETALATED PHTHALIMIDES AS PROTEIN KINASE INHIBITORS
3215, d3uokB_, 0.7623, 3.12, 0.237, 265, 249, AURORA A IN COMPLEX WITH YL5-81-1
3216, d3royA_, 0.7623, 2.97, 0.220, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-154
3217, d3r6xA_, 0.7623, 2.98, 0.224, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-158
3218, p3n9xA_, 0.7623, 3.29, 0.191, 374, 257, CRYSTAL STRUCTURE OF MAP KINASE FROM PLASMODIUM BERGHEI PB000659.00.0
3219, d1vr2A_, 0.7623, 3.15, 0.336, 275, 250, HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (KDR) KINASE DOMAIN
3220, d5eymA_, 0.7622, 2.84, 0.199, 292, 246, MEK1 IN COMPLEX WITH BI 847325
3221, d4n6yA_, 0.7622, 2.80, 0.222, 273, 248, PIM1 COMPLEXED WITH A PHENYLCARBOXAMIDE
3222, d3uohB_, 0.7622, 2.99, 0.243, 264, 247, AURORA A IN COMPLEX WITH RPM1722
3223, d3uohA_, 0.7622, 2.99, 0.243, 264, 247, AURORA A IN COMPLEX WITH RPM1722
3224, d2vrxB_, 0.7622, 3.01, 0.210, 274, 252, STRUCTURE OF AURORA B KINASE IN COMPLEX WITH ZM447439
3225, d1q97A_, 0.7622, 2.94, 0.215, 351, 251, THE STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINASE SKY1P WITH BOUND ATP
3226, d5k3yA_, 0.7621, 3.02, 0.193, 267, 254, CRYSTAL STRUCTURE OF AURORAB/INCENP IN COMPLEX WITH BI 811283
3227, d5jzjB_, 0.7621, 2.83, 0.229, 261, 249, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH AMPPN
3228, d4ztmD_, 0.7621, 2.79, 0.276, 282, 246, IRAK4-INHIBITOR CO-STRUCTURE
3229, d4bieB_, 0.7621, 2.54, 0.234, 257, 244, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3230, d4afjB_, 0.7621, 3.04, 0.234, 346, 252, 5-ARYL-4-CARBOXAMIDE-13-OXAZOLES: POTENT AND SELECTIVE GSK-3 INHIBITORS
3231, d4achA_, 0.7621, 3.25, 0.233, 350, 257, GSK3B IN COMPLEX WITH INHIBITOR
3232, d3r1sA_, 0.7621, 2.98, 0.224, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-127
3233, d3dkoA1, 0.7621, 3.06, 0.309, 272, 249, COMPLEX BETWEEN THE KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 7 (EPHA7) AND INHIBITOR ALW-II-49-7
3234, d4tw9A_, 0.7620, 3.33, 0.211, 290, 261, DIFLUORO-DIOXOLO-BENZOIMIDAZOL-BENZAMIDES AS POTENT INHIBITORS OF CK1DELTA AND EPSILON WITH NANOMOLAR INHIBITORY ACTIVITY ON CANCER CELL PROLIFERATION
3235, d3rk9A_, 0.7620, 2.97, 0.224, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR RC-2-74
3236, d2gdoA_, 0.7620, 3.37, 0.268, 269, 254, 4-(AMINOALKYLAMINO)-3-BENZIMIDAZOLE-QUINOLINONES AS POTENT CHK1 INHIBITORS
3237, d1q8yA_, 0.7620, 2.94, 0.215, 351, 251, THE STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P WITH BOUND ADP
3238, d4qqcA1, 0.7619, 2.94, 0.369, 271, 249, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE DOMAIN IN COMPLEX WITH FIIN-2 AN IRREVERSIBLE TYROSINE KINASE INHIBITOR CAPABLE OF OVERCOMING FGFR KINASE GATE-KEEPER MUTATIONS
3239, d3uokA_, 0.7619, 3.14, 0.237, 265, 249, AURORA A IN COMPLEX WITH YL5-81-1
3240, d3ti1A_, 0.7619, 2.99, 0.228, 294, 250, CDK2 IN COMPLEX WITH SUNITINIB
3241, d3rjcA_, 0.7619, 2.96, 0.224, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR L4-12
3242, d2brnA_, 0.7619, 3.43, 0.259, 268, 255, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
3243, d1uwjA_, 0.7619, 2.92, 0.264, 264, 250, THE COMPLEX OF MUTANT V599E B-RAF AND BAY439006
3244, d4p5zA_, 0.7618, 2.85, 0.300, 267, 247, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH QUINOXALINE DERIVATIVES
3245, d4g17A1, 0.7618, 3.47, 0.170, 301, 264, CRYSTAL STRUCTURE OF CK1G3 WITH 2-[(4-TERT-BUTYLPHENYL)AMINO]-1H- BENZIMIDAZOLE-6-CARBONITRILE
3246, d4fc0A_, 0.7618, 2.70, 0.268, 254, 246, CRYSTAL STRUCTURE OF HUMAN KINASE DOMAIN OF B-RAF WITH A DFG-OUT INHIBITOR
3247, d2vwwA_, 0.7618, 2.49, 0.281, 253, 242, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
3248, d2izsA_, 0.7618, 3.53, 0.163, 298, 264, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
3249, d2bziB_, 0.7618, 2.76, 0.231, 272, 247, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU2
3250, d1ym7D3, 0.7618, 3.33, 0.189, 340, 259, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
3251, d1xwsA_, 0.7618, 2.78, 0.222, 273, 248, CRYSTAL STRUCTURE OF THE HUMAN PIM1 KINASE DOMAIN
3252, d5we8A_, 0.7617, 2.97, 0.231, 270, 247, CRYSTAL STRUCTURE OF WNK1 IN COMPLEX WITH N-{(3R)-1-[(4-CHLOROPHENYL) METHYL]PYRROLIDIN-3-YL}-2-(3-METHOXYPHENYL)-N-METHYLQUINOLINE-4- CARBOXAMIDE (COMPOUND 8)
3253, d5w4wC_, 0.7617, 3.39, 0.217, 284, 263, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
3254, d4c2wA_, 0.7617, 3.12, 0.213, 268, 254, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH AMP-PNP
3255, d3tiyA_, 0.7617, 2.93, 0.229, 293, 249, CDK2 IN COMPLEX WITH NSC 35676
3256, d3bgzA_, 0.7617, 2.77, 0.219, 267, 247, HUMAN PIM-1 KINASE IN COMPLEX WITH DIPHENYL INDOLE INHIBITOR VX3
3257, p2no3A_, 0.7617, 3.30, 0.193, 357, 259, NOVEL 4-ANILINOPYRIMIDINES AS POTENT JNK1 INHIBITORS
3258, d1q3wA_, 0.7617, 3.24, 0.233, 344, 257, GSK-3 BETA COMPLEXED WITH ALSTERPAULLONE
3259, d5nhpA_, 0.7616, 3.55, 0.210, 338, 262, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
3260, d3unkA_, 0.7616, 2.98, 0.227, 295, 251, CDK2 IN COMPLEX WITH INHIBITOR YL5-083
3261, d2y6mA_, 0.7616, 2.98, 0.313, 262, 249, CRYSTAL STRUCTURE OF EPHA4 KINASE DOMAIN
3262, d1ym7A3, 0.7616, 3.33, 0.189, 347, 259, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
3263, d1m7nB_, 0.7616, 3.08, 0.306, 299, 252, CRYSTAL STRUCTURE OF UNACTIVATED APO INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE DOMAIN
3264, d1hckA_, 0.7616, 2.92, 0.221, 294, 249, HUMAN CYCLIN-DEPENDENT KINASE 2
3265, p6g97A_, 0.7615, 3.41, 0.204, 344, 260, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
3266, d5vc4A_, 0.7615, 3.05, 0.204, 261, 250, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH BOSUTINIB-ISOMER
3267, d5o13A_, 0.7615, 2.68, 0.237, 270, 245, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL-MOLECULE INHIBITOR
3268, d5he3A2, 0.7615, 3.31, 0.198, 346, 258, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224411
3269, d5ceqA_, 0.7615, 2.36, 0.307, 269, 241, DLK IN COMPLEX WITH INHIBITOR 2-((1-CYCLOPENTYL-5-(1-(OXETAN-3-YL) PIPERIDIN-4-YL)-1H-PYRAZOL-3-YL)AMINO)ISONICOTINONITRILE
3270, d4yp8C_, 0.7615, 2.88, 0.273, 287, 249, IRAK4-INHIBITOR CO-STRUCTURE
3271, d2cgxA_, 0.7615, 3.40, 0.263, 265, 255, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
3272, d4wa9A1, 0.7614, 1.65, 0.345, 236, 229, THE CRYSTAL STRUCTURE OF HUMAN ABL1 WILD TYPE KINASE DOMAIN IN COMPLEX WITH AXITINIB
3273, d4c3rA_, 0.7614, 2.79, 0.244, 252, 246, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) BOUND TO AMPPCP
3274, d2zoqA_, 0.7614, 3.44, 0.203, 351, 261, STRUCTURAL DISSECTION OF HUMAN MITOGEN-ACTIVATED KINASE ERK1
3275, d2x7fC_, 0.7614, 2.74, 0.238, 285, 248, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
3276, d2x7fA_, 0.7614, 2.67, 0.240, 276, 246, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
3277, d2objA_, 0.7614, 2.80, 0.219, 272, 247, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH INHIBITOR
3278, d1pxpA_, 0.7614, 2.98, 0.224, 294, 250, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR N-[4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]- N N -DIMETHYL-BENZENE-14-DIAMINE
3279, d1pxiA_, 0.7614, 3.01, 0.220, 294, 250, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-(25-DICHLORO-THIOPHEN-3-YL)-PYRIMIDIN-2- YLAMINE
3280, d5f95B_, 0.7613, 3.26, 0.230, 338, 257, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 18: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-PHENYLPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
3281, d4u44B_, 0.7613, 3.05, 0.217, 296, 254, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 16)
3282, d4qyyA_, 0.7613, 3.46, 0.216, 337, 259, DISCOVERY OF NOVEL DUAL MECHANISM ERK INHIBITORS BY AFFINITY SELECTION SCREENING OF AN INACTIVE KINASE STATE
3283, p5w5qB_, 0.7612, 3.03, 0.217, 297, 254, MAP4K4 IN COMPLEX WITH INHIBITOR COMPOUND 12 (N3-METHYL-10-(3-METHYL- 3-(5-METHYLOXAZOL-2-YL)BUT-1-YN-1-YL)-6;7-DIHYDRO-5H-5;7- METHANOBENZO[C]IMIDAZO[1;2-A]AZEPINE-2;3-DICARBOXAMIDE) 
3284, d5aneA_, 0.7612, 2.92, 0.225, 294, 249, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 6-METHOXY-7H- PURINE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
3285, d4yo6A_, 0.7612, 2.92, 0.273, 286, 249, IRAK4-INHIBITOR CO-STRUCTURE
3286, d4oboA_, 0.7612, 2.77, 0.239, 275, 247, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 22) 6-(3-CHLOROPHENYL) QUINAZOLIN-4-AMINE
3287, d3rpoA_, 0.7612, 3.00, 0.220, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-156
3288, d3r73A_, 0.7612, 3.00, 0.224, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-164
3289, d2hxqA_, 0.7612, 3.44, 0.259, 272, 255, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 2
3290, d1ym7C3, 0.7612, 3.26, 0.186, 346, 258, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
3291, d5w5oN_, 0.7611, 2.30, 0.258, 272, 240, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3292, d5nhvA_, 0.7611, 3.27, 0.210, 345, 257, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
3293, d4zy5A_, 0.7611, 3.03, 0.221, 283, 253, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 17
3294, d4rblA_, 0.7611, 2.70, 0.236, 271, 246, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
3295, d4k9yA_, 0.7611, 3.17, 0.362, 271, 254, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 1-[4-(6-AMINO- PURIN-9-YL)-PHENYL]-3-(5-TERT-BUTYL-2-P-TOLYL-2H-PYRAZOL-3-YL)-UREA
3296, d4acdB_, 0.7611, 3.25, 0.230, 350, 257, GSK3B IN COMPLEX WITH INHIBITOR
3297, d3unjA_, 0.7611, 2.92, 0.228, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR YL1-038-31
3298, p2gmxB_, 0.7611, 3.30, 0.197, 357, 259, SELECTIVE AMINOPYRIDINE-BASED C-JUN N-TERMINAL KINASE INHIBITORS WITH CELLULAR ACTIVITY
3299, d1m7nA_, 0.7611, 2.93, 0.312, 299, 250, CRYSTAL STRUCTURE OF UNACTIVATED APO INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE DOMAIN
3300, d4hglA1, 0.7610, 3.48, 0.170, 301, 264, CRYSTAL STRUCTURE OF CK1G3 WITH COMPOUND 1
3301, d4dglC_, 0.7610, 3.31, 0.195, 334, 256, CRYSTAL STRUCTURE OF THE CK2 TETRAMERIC HOLOENZYME
3302, d3ztxB_, 0.7610, 2.95, 0.203, 272, 251, AURORA KINASE SELECTIVE INHIBITORS IDENTIFIED USING A TAXOL- INDUCED CHECKPOINT SENSITIVITY SCREEN.
3303, d3kk8A_, 0.7610, 3.39, 0.254, 283, 260, CAMKII SUBSTRATE COMPLEX A
3304, d3cikA2, 0.7610, 3.37, 0.189, 347, 259, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS
3305, d2xneA_, 0.7610, 2.71, 0.246, 246, 244, STRUCTURE OF AURORA-A BOUND TO AN IMIDAZOPYRAZINE INHIBITOR
3306, d2xixA_, 0.7610, 2.73, 0.232, 272, 246, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-1 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
3307, d2clxA_, 0.7610, 2.98, 0.225, 293, 249, 4-ARYLAZO-35-DIAMINO-1H-PYRAZOLE CDK INHIBITORS: SAR STUDY CRYSTAL STRUCTURE IN COMPLEX WITH CDK2 SELECTIVITY AND CELLULAR EFFECTS
3308, d5to8A_, 0.7609, 2.41, 0.357, 250, 241, SELECTIVITY SWITCH BETWEEN FAK AND PYK2: MACROCYCLIZATION OF FAK INHIBITORS IMPROVES PYK2 POTENCY
3309, d5hlpA_, 0.7609, 3.25, 0.246, 337, 256, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH BRD3937
3310, d4accB_, 0.7609, 3.24, 0.230, 350, 257, GSK3B IN COMPLEX WITH INHIBITOR
3311, d3sv0A_, 0.7609, 3.55, 0.201, 294, 264, CRYSTAL STRUCTURE OF CASEIN KINASE-1 LIKE PROTEIN IN PLANT
3312, d3qzgA_, 0.7609, 2.96, 0.228, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR JWS-6-76
3313, d3cr0A_, 0.7609, 2.70, 0.199, 257, 246, WEE1 KINASE COMPLEX WITH INHIBITOR PD259_809
3314, d2cgvA_, 0.7609, 3.43, 0.266, 264, 256, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
3315, d4u41A_, 0.7608, 2.77, 0.239, 275, 247, MAP4K4 BOUND TO INHIBITOR COMPOUND 1
3316, d4iaaA_, 0.7608, 2.77, 0.235, 272, 247, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH THIORIDAZINE
3317, d4hnfB_, 0.7608, 3.37, 0.221, 290, 263, CRYSTAL STRUCTURE OF CK1D IN COMPLEX WITH PF4800567
3318, d2qoqA_, 0.7608, 3.01, 0.313, 284, 249, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION BASE AMP-PNP BOUND STRUCTURE
3319, d1ym7B3, 0.7608, 3.26, 0.186, 347, 258, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
3320, d1q8zA_, 0.7608, 3.03, 0.190, 354, 253, THE APOENZYME STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P
3321, d4ztnC_, 0.7607, 2.92, 0.262, 284, 248, IRAK4-INHIBITOR CO-STRUCTURE
3322, d4apcA1, 0.7607, 2.85, 0.204, 289, 250, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1)
3323, d3r8zA_, 0.7607, 2.95, 0.225, 290, 249, CDK2 IN COMPLEX WITH INHIBITOR RC-1-136
3324, d5ur1B_, 0.7606, 2.97, 0.357, 265, 249, FGFR1 KINASE DOMAIN COMPLEX WITH SN37333 IN REVERSIBLE BINDING MODE
3325, d5imeA1, 0.7606, 2.85, 0.210, 279, 248, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 (PAK1) IN COMPLEX WITH COMPOUND 9
3326, d4iq6B_, 0.7606, 3.20, 0.230, 332, 256, GSK-3BETA WITH INHIBITOR 6-CHLORO-N-CYCLOHEXYL-4-(1H-PYRROLO[23- B]PYRIDIN-3-YL)PYRIDIN-2-AMINE
3327, d4bibA_, 0.7606, 2.46, 0.241, 254, 241, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3328, d3v5wA2, 0.7606, 3.34, 0.166, 355, 259, HUMAN G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH SOLUBLE GBETAGAMMA SUBUNITS AND PAROXETINE
3329, d2x8dA_, 0.7606, 3.64, 0.256, 279, 258, DISCOVERY OF A NOVEL CLASS OF TRIAZOLONES AS CHECKPOINT KINASE INHIBITORS - HIT TO LEAD EXPLORATION
3330, d2vwuA_, 0.7606, 2.54, 0.281, 253, 242, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
3331, d2bcjA3, 0.7606, 3.28, 0.186, 348, 258, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH GALPHA-Q AND GBETAGAMMA SUBUNITS
3332, d1j3hB_, 0.7606, 3.15, 0.252, 327, 254, CRYSTAL STRUCTURE OF APOENZYME CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT
3333, d1howA_, 0.7606, 3.15, 0.205, 346, 254, THE X-RAY CRYSTAL STRUCTURE OF SKY1P AN SR PROTEIN KINASE IN YEAST
3334, d4kspA_, 0.7605, 2.75, 0.268, 257, 246, CRYSTAL STRUCTURE OF HUMAN B-RAF BOUND TO A DFG-OUT INHIBITOR TAK-632
3335, d4afjA_, 0.7605, 3.10, 0.233, 342, 253, 5-ARYL-4-CARBOXAMIDE-13-OXAZOLES: POTENT AND SELECTIVE GSK-3 INHIBITORS
3336, d2jd5B_, 0.7605, 3.29, 0.185, 360, 259, SKY1P BOUND TO NPL3P-DERIVED SUBSTRATE PEPTIDE
3337, p2g01A_, 0.7605, 3.32, 0.189, 355, 259, PYRAZOLOQUINOLONES AS NOVEL SELECTIVE JNK1 INHIBITORS
3338, d5vo2A_, 0.7604, 2.38, 0.307, 269, 241, DLK IN COMPLEX WITH INHIBITOR 5-(1-ISOPROPYL-5-(1-(OXETAN-3-YL) PIPERIDIN-4-YL)-1H-PYRAZOL-3-YL)-3-(TRIFLUOROMETHYL)PYRIDIN-2-AMINE (COMPOUND 7)
3339, d1yi4A_, 0.7604, 2.74, 0.232, 267, 246, STRUCTURE OF PIM-1 BOUND TO ADENOSINE
3340, d1i44A_, 0.7604, 2.81, 0.319, 282, 248, CRYSTALLOGRAPHIC STUDIES OF AN ACTIVATION LOOP MUTANT OF THE INSULIN RECEPTOR TYROSINE KINASE
3341, d5t1sA_, 0.7603, 2.92, 0.274, 280, 248, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
3342, d4ztnD_, 0.7603, 3.02, 0.272, 285, 250, IRAK4-INHIBITOR CO-STRUCTURE
3343, d4yo6C_, 0.7603, 2.82, 0.270, 286, 248, IRAK4-INHIBITOR CO-STRUCTURE
3344, d4r6vA1, 0.7603, 2.97, 0.369, 271, 249, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE HARBORING THE V550L GATE-KEEPER MUTATION IN COMPLEX WITH FIIN-3 AN IRREVERSIBLE TYROSINE KINASE INHIBITOR CAPABLE OF OVERCOMING FGFR KINASE GATE-KEEPER MUTATIONS
3345, d4j7bD_, 0.7603, 3.06, 0.260, 281, 250, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1
3346, d2cgwA_, 0.7603, 3.38, 0.260, 262, 254, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
3347, d1h4lA_, 0.7603, 2.78, 0.219, 278, 247, STRUCTURE AND REGULATION OF THE CDK5-P25(NCK5A) COMPLEX
3348, d5o21A_, 0.7602, 3.19, 0.228, 272, 254, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED STATE WITH CHLORIDE BOUND IN THE ACTIVE SITE
3349, d5fqdC_, 0.7602, 3.47, 0.183, 294, 262, STRUCTURAL BASIS OF LENALIDOMIDE INDUCED CK1A DEGRADATION BY THE CRL4CRBN UBIQUITIN LIGASE
3350, d5c03B_, 0.7602, 2.80, 0.235, 260, 247, CRYSTAL STRUCTURE OF KINASE
3351, d4usdA_, 0.7602, 2.66, 0.246, 268, 244, HUMAN STK10 (LOK) WITH SB-633825
3352, d4qp3B_, 0.7602, 3.25, 0.199, 331, 256, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH (S)-2-((9H-PURIN-6-YL) AMINO)-3-PHENYLPROPAN-1-OL
3353, d2ow3B_, 0.7602, 3.20, 0.230, 351, 256, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH BIS- (INDOLE)MALEIMIDE PYRIDINOPHANE INHIBITOR
3354, d5kx8C_, 0.7601, 3.18, 0.266, 287, 252, IRAK4-INHIBITOR CO-STRUCTURE
3355, d5hlpB_, 0.7601, 3.20, 0.235, 335, 255, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH BRD3937
3356, d5cepA_, 0.7601, 2.40, 0.307, 269, 241, DLK IN COMPLEX WITH INHIBITOR N-(1-ISOPROPYL-5-(PIPERIDIN-4-YL)-1H- PYRAZOL-3-YL)-4-(TRIFLUOROMETHYL)PYRIDIN-2-AMINE
3357, d4usdB_, 0.7601, 2.67, 0.246, 267, 244, HUMAN STK10 (LOK) WITH SB-633825
3358, d4lmuA_, 0.7601, 2.71, 0.229, 265, 245, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH THE INHIBITOR QUERCETIN (RESULTING FROM DISPLACEMENT OF SKF86002)
3359, d3raiA_, 0.7601, 3.01, 0.224, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-160
3360, d2hyyC1, 0.7601, 2.40, 0.357, 249, 238, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
3361, d5vd2A_, 0.7600, 2.95, 0.205, 258, 249, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH PF- 03814735
3362, d5vc3A_, 0.7600, 2.98, 0.204, 260, 250, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH BOSUTINIB
3363, d5uq0B_, 0.7600, 2.57, 0.379, 256, 243, FGFR1 KINASE DOMAIN COMPLEX WITH FRAGMENT 22-DIMETHYL-23- DIHYDROBENZOFURAN-7-CARBOXAMIDE
3364, d4qp8B_, 0.7600, 3.12, 0.209, 337, 253, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-7- (PYRIDIN-3-YL)-5H-PYRROLO[23-B]PYRAZINE
3365, d4kbcA_, 0.7600, 3.31, 0.212, 288, 260, CK1D IN COMPLEX WITH {4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDIN-2- YL}METHANOL INHIBITOR
3366, d4ditA_, 0.7600, 3.07, 0.238, 328, 252, CRYSTAL STRUCTURE OF GSK3BETA IN COMPLEX WITH A IMIDAZOPYRIDINE INHIBITOR
3367, d4b9dA1, 0.7600, 2.95, 0.203, 286, 251, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1) WITH INHIBITOR.
3368, d3uolB_, 0.7600, 2.86, 0.241, 263, 245, AURORA A IN COMPLEX WITH SO2-162
3369, d3uolA_, 0.7600, 2.86, 0.241, 263, 245, AURORA A IN COMPLEX WITH SO2-162
3370, d3py0A_, 0.7600, 2.94, 0.224, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR SU9516
3371, d1yhsA_, 0.7600, 2.76, 0.228, 267, 246, CRYSTAL STRUCTURE OF PIM-1 BOUND TO STAUROSPORINE
3372, d1uwhB_, 0.7600, 2.94, 0.264, 264, 250, THE COMPLEX OF WILD TYPE B-RAF AND BAY439006
3373, d1pw2A_, 0.7600, 3.04, 0.220, 294, 250, APO STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2
3374, d1hclA_, 0.7600, 3.04, 0.220, 294, 250, HUMAN CYCLIN-DEPENDENT KINASE 2
3375, d5fqdF_, 0.7599, 3.51, 0.190, 294, 263, STRUCTURAL BASIS OF LENALIDOMIDE INDUCED CK1A DEGRADATION BY THE CRL4CRBN UBIQUITIN LIGASE
3376, d5cswB_, 0.7599, 2.50, 0.254, 252, 244, B-RAF IN COMPLEX WITH DABRAFENIB
3377, d4ztnA_, 0.7599, 2.96, 0.273, 286, 249, IRAK4-INHIBITOR CO-STRUCTURE
3378, d4twnA1, 0.7599, 3.24, 0.313, 275, 252, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH BIRB796
3379, d2hyyB1, 0.7599, 2.37, 0.357, 252, 238, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
3380, p2gmxA_, 0.7599, 3.33, 0.193, 357, 259, SELECTIVE AMINOPYRIDINE-BASED C-JUN N-TERMINAL KINASE INHIBITORS WITH CELLULAR ACTIVITY
3381, d1pxjA_, 0.7599, 3.03, 0.220, 294, 250, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YLAMINE
3382, d1jpaA_, 0.7599, 2.79, 0.280, 273, 246, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED EPHB2 RECEPTOR TYROSINE KINASE AND JUXTAMEMBRANE REGION
3383, d5w4wB_, 0.7598, 3.49, 0.216, 291, 264, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
3384, d5fdxA_, 0.7598, 3.11, 0.364, 280, 250, STRUCTURE OF DDR1 RECEPTOR TYROSINE KINASE IN COMPLEX WITH D2164 INHIBITOR AT 2.65 ANGSTROMS RESOLUTION.
3385, d3r9hA_, 0.7598, 3.01, 0.224, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR RC-2-142
3386, d3r71A_, 0.7598, 3.04, 0.220, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-162
3387, d2hxlA_, 0.7598, 3.48, 0.263, 272, 255, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 1
3388, d3qtxA_, 0.7597, 2.99, 0.224, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR RC-2-35
3389, d3pizA_, 0.7597, 2.23, 0.326, 245, 239, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH (5-AMINO-1-O- TOLYL-1H-PYRAZOL-4-YL)-[3-(1-METHANESULFONYL-PIPERIDIN-4-YL)-PHENYL]- METHANONE
3390, d3og7A_, 0.7597, 2.50, 0.263, 247, 243, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX4032
3391, d5t1sC_, 0.7596, 2.97, 0.263, 284, 247, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
3392, d5jrqB1, 0.7596, 2.25, 0.272, 245, 239, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-6-VEM
3393, d5hx6B_, 0.7596, 2.47, 0.282, 264, 241, CRYSTAL STRUCTURE OF RIP1 KINASE WITH A BENZO[B][14]OXAZEPIN-4-ONE
3394, d5ax9B_, 0.7596, 2.70, 0.220, 274, 245, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE IN COMPLEX WITH COMPUND 9
3395, d4tn6A_, 0.7596, 3.58, 0.230, 292, 265, CK1D IN COMPLEX WITH INHIBITOR
3396, d2broA_, 0.7596, 3.53, 0.258, 272, 256, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
3397, d1zltA_, 0.7596, 3.47, 0.255, 272, 255, CRYSTAL STRUCTURE OF CHK1 COMPLEXED WITH A HYMENALDISINE ANALOG
3398, d4u3yB_, 0.7595, 3.19, 0.220, 300, 255, APO MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4)
3399, d4qp1B_, 0.7595, 3.37, 0.202, 343, 258, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
3400, d4pteA_, 0.7595, 3.20, 0.235, 341, 255, STRUCTURE OF A CARVOXAMIDE COMPOUND (15) (N-[4-(ISOQUINOLIN-7-YL) PYRIDIN-2-YL]CYCLOPROPANECARBOXAMIDE) TO GSK3B
3401, d4bidA_, 0.7595, 2.46, 0.241, 254, 241, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3402, d2b9iA_, 0.7595, 3.12, 0.194, 338, 253, CRYSTAL STRUCTURE OF FUS3 WITH A DOCKING MOTIF FROM MSG5
3403, d5x17B_, 0.7594, 3.46, 0.223, 289, 264, CRYSTAL STRUCTURE OF MURINE CK1D IN COMPLEX WITH ADP
3404, d4xs2D_, 0.7594, 2.86, 0.276, 277, 246, IRAK4-INHIBITOR CO-STRUCTURE
3405, d4fv7A_, 0.7594, 3.40, 0.200, 342, 260, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E94
3406, d3qqgA_, 0.7594, 2.96, 0.228, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR L2-5
3407, d5oopA_, 0.7593, 3.33, 0.265, 261, 253, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMP-PNP
3408, d5o26B_, 0.7593, 3.01, 0.249, 265, 253, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A DIPHOSPHORYLATED STATE AND IN COMPLEX WITH AMP-PNP/MG2+
3409, d5o23B1, 0.7593, 3.26, 0.224, 276, 254, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED APO STATE
3410, d3uzpB_, 0.7593, 3.16, 0.223, 284, 256, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P21 CRYSTAL FORM
3411, d3tizA_, 0.7593, 2.93, 0.229, 293, 249, CDK2 IN COMPLEX WITH NSC 111848
3412, d3pscA2, 0.7593, 3.28, 0.182, 344, 258, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS
3413, d2cjmA_, 0.7593, 2.94, 0.224, 285, 250, MECHANISM OF CDK INHIBITION BY ACTIVE SITE PHOSPHORYLATION: CDK2 Y15P T160P IN COMPLEX WITH CYCLIN A STRUCTURE
3414, d1pxnA_, 0.7593, 2.97, 0.224, 294, 250, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-[4-(4-METHYL-2-METHYLAMINO-THIAZOL-5-YL)- PYRIMIDIN-2-YLAMINO]-PHENOL
3415, d4twcB_, 0.7592, 3.39, 0.214, 292, 262, 2-BENZAMIDO-N-(1H-BENZO[D]IMIDAZOL-2-YL)THIAZOLE-4- CARBOXAMIDE DERIVATIVES AS POTENT INHIBITORS OF CK1D/E
3416, d4qp7A_, 0.7592, 3.05, 0.198, 337, 252, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-5H- PYRROLO[23-B]PYRAZINE
3417, d3qqkA_, 0.7592, 3.00, 0.224, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR L4
3418, d3cs9C_, 0.7592, 2.27, 0.349, 243, 238, HUMAN ABL KINASE IN COMPLEX WITH NILOTINIB
3419, d2w1eA1, 0.7592, 2.82, 0.245, 252, 245, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
3420, d1jstA_, 0.7592, 3.21, 0.212, 297, 255, PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A
3421, d5w4wA_, 0.7591, 3.49, 0.216, 291, 264, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
3422, d5vo1A_, 0.7591, 2.41, 0.307, 269, 241, DLK IN COMPLEX WITH COMPOUND 10 (5-(1-ISOPROPYL-5-(3-(OXETAN-3-YL)-3- AZABICYCLO[3.1.0]HEXAN-6-YL)-1H-PYRAZOL-3-YL)-3-(TRIFLUOROMETHYL) PYRIDIN-2-AMINE)
3423, d5ootA_, 0.7591, 3.24, 0.267, 260, 251, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMINOPYRIMIDO- BENZODIAZEPINONE LRRK2 INHIBITOR
3424, d4kbkB_, 0.7591, 3.38, 0.209, 289, 263, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
3425, d4hyiA_, 0.7591, 3.42, 0.259, 269, 255, X-RAY CRYSTAL STRUCTURE OF COMPOUND 40 BOUND TO HUMAN CHK1 KINASE DOMAIN
3426, d3qtzA_, 0.7591, 3.00, 0.224, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR RC-2-36
3427, d3qtqA_, 0.7591, 2.94, 0.225, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR RC-1-137
3428, d3o7lD_, 0.7591, 3.11, 0.252, 333, 254, CRYSTAL STRUCTURE OF PHOSPHOLAMBAN (1-19):PKA C-SUBUNIT:AMP-PNP:MG2+ COMPLEX
3429, d3eidC_, 0.7591, 2.95, 0.216, 290, 250, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
3430, d4mygA_, 0.7590, 3.13, 0.198, 335, 252, MAPK13 ACTIVE FORM
3431, d3s00A_, 0.7590, 3.01, 0.220, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR L4-14
3432, d5ukkA2, 0.7589, 3.34, 0.195, 348, 257, HUMAN GRK2 IN COMPLEX WITH HUMAN G-BETA-GAMMA SUBUNITS AND CCG211998 (14AK)
3433, d5k5nA_, 0.7589, 3.03, 0.239, 331, 251, CRYSTAL STRUCTURE OF GSK-3BETA COMPLEXED WITH PF-04802367 A HIGHLY SELECTIVE BRAIN-PENETRANT KINASE INHIBITOR
3434, d5jt2A1, 0.7589, 2.59, 0.265, 253, 245, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-BISAMIDE
3435, d5d9lA_, 0.7589, 3.13, 0.238, 299, 252, RSK2 N-TERMINAL KINASE IN COMPLEX WITH BIS-PHENOL PYRAZOLE
3436, d3q4zA1, 0.7589, 2.93, 0.216, 281, 250, STRUCTURE OF UNPHOSPHORYLATED PAK1 KINASE DOMAIN
3437, d2c3kA_, 0.7589, 3.43, 0.259, 262, 255, IDENTIFICATION OF A BURIED POCKET FOR POTENT AND SELECTIVE INHIBITION OF CHK1: PREDICTION AND VERIFICATION
3438, d1yi3A_, 0.7589, 2.80, 0.228, 267, 246, CRYSTAL STRUCTURE OF PIM-1 BOUND TO LY294002
3439, d1gngB_, 0.7589, 3.29, 0.233, 355, 258, GLYCOGEN SYNTHASE KINASE-3 BETA (GSK3) COMPLEX WITH FRATTIDE PEPTIDE
3440, d5vc6A_, 0.7588, 3.06, 0.201, 259, 249, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH PHA- 848125
3441, d2bikB_, 0.7588, 2.78, 0.231, 272, 247, HUMAN PIM1 PHOSPHORYLATED ON SER261
3442, d5v5yA_, 0.7587, 3.05, 0.210, 259, 248, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH MK1775
3443, d5drbA_, 0.7587, 3.15, 0.260, 273, 254, CRYSTAL STRUCTURE OF WNK1 IN COMPLEX WITH WNK463
3444, d5cswA_, 0.7587, 2.57, 0.253, 254, 245, B-RAF IN COMPLEX WITH DABRAFENIB
3445, d4qp2B_, 0.7587, 3.28, 0.207, 329, 256, CRYSTAL STRUCTURE OF ERKS IN COMPLEX WITH 5-CHLOROBENZO[D]OXAZOL-2- AMINE
3446, d4ic7D_, 0.7587, 3.40, 0.204, 353, 260, CRYSTAL STRUCTURE OF THE ERK5 KINASE DOMAIN IN COMPLEX WITH AN MKK5 BINDING FRAGMENT
3447, d4cqeA_, 0.7587, 2.55, 0.254, 250, 244, B-RAF KINASE V600E MUTANT IN COMPLEX WITH  A DIARYLTHIAZOLE B-RAF INHIBITOR
3448, d3qxpA_, 0.7587, 2.96, 0.210, 294, 248, CDK2 IN COMPLEX WITH INHIBITOR RC-3-89
3449, d3qc4A_, 0.7587, 3.11, 0.222, 276, 252, PDK1 IN COMPLEX WITH DFG-OUT INHIBITOR XXX
3450, d1r0eB_, 0.7587, 3.24, 0.233, 344, 257, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH 3-INDOLYL-4- ARYLMALEIMIDE INHIBITOR
3451, p6g93A_, 0.7586, 3.27, 0.199, 343, 256, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
3452, d3uo6B_, 0.7586, 2.94, 0.240, 264, 246, AURORA A IN COMPLEX WITH YL5-083
3453, d3uo6A_, 0.7586, 2.94, 0.240, 264, 246, AURORA A IN COMPLEX WITH YL5-083
3454, d3rpvA_, 0.7586, 2.99, 0.224, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR RC-2-88
3455, d3r8uA_, 0.7586, 3.03, 0.224, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR RC-1-132
3456, d5uklA2, 0.7585, 3.37, 0.166, 353, 259, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG222886 (14BD)
3457, d3uysC_, 0.7585, 3.49, 0.216, 286, 264, CRYSTAL STRUCTURE OF APO HUMAN CK1D
3458, d3etaB_, 0.7585, 3.01, 0.327, 292, 248, KINASE DOMAIN OF INSULIN RECEPTOR COMPLEXED WITH A PYRROLO PYRIDINE INHIBITOR
3459, d1pf8A_, 0.7585, 2.87, 0.226, 298, 248, CRYSTAL STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH A NUCLEOSIDE INHIBITOR
3460, d1ia8A_, 0.7585, 3.47, 0.267, 272, 255, THE 1.7 A CRYSTAL STRUCTURE OF HUMAN CELL CYCLE CHECKPOINT KINASE CHK1
3461, d1h4lB_, 0.7585, 2.79, 0.219, 278, 247, STRUCTURE AND REGULATION OF THE CDK5-P25(NCK5A) COMPLEX
3462, d2ow3A_, 0.7584, 3.24, 0.230, 346, 256, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH BIS- (INDOLE)MALEIMIDE PYRIDINOPHANE INHIBITOR
3463, d1r0eA_, 0.7584, 3.25, 0.233, 344, 257, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH 3-INDOLYL-4- ARYLMALEIMIDE INHIBITOR
3464, d5ukmA2, 0.7583, 3.36, 0.166, 353, 259, BOVINE GRK2 IN COMPLEX WITH HUMAN GBETAGAMMA SUBUNITS AND CCG258208 (14AS)
3465, d5anjA_, 0.7583, 3.00, 0.224, 291, 250, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH N-(9H-PURIN-6-YL) THIOPHENE-2-CARBOXAMIDE  PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
3466, d5ajqA_, 0.7583, 3.04, 0.226, 280, 248, HUMAN LOK (STK10) IN COMPLEX WITH BOSUTINIB
3467, d4lm5A_, 0.7583, 2.74, 0.233, 264, 245, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH 2-{4-[(3-AMINOPROPYL) AMINO]QUINAZOLIN-2-YL}PHENOL (RESULTING FROM DISPLACEMENT OF SKF86002)
3468, d4lghB_, 0.7583, 2.12, 0.346, 247, 234, CRYSTAL STRUCTURE OF 1NM-PP1 BOUND TO ANALOG-SENSITIVE SRC KINASE
3469, d4erwA_, 0.7583, 3.06, 0.225, 292, 249, CDK2 IN COMPLEX WITH STAUROSPORINE
3470, d3s0oA_, 0.7583, 2.98, 0.213, 293, 249, CDK2 IN COMPLEX WITH INHIBITOR RC-1-138
3471, d3en7A_, 0.7583, 1.80, 0.346, 247, 231, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH S1 A MULTITARGETED KINASE INHIBITOR
3472, d4dbnA_, 0.7582, 2.88, 0.271, 257, 247, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN B-RAF WITH A [1 3]THIAZOLO[54-B]PYRIDINE DERIVATIVE
3473, d1jpaB_, 0.7582, 2.69, 0.284, 269, 243, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED EPHB2 RECEPTOR TYROSINE KINASE AND JUXTAMEMBRANE REGION
3474, d6bu6A_, 0.7581, 3.52, 0.162, 322, 265, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
3475, d5vt1A1, 0.7581, 3.28, 0.231, 264, 255, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B BOUND TO A BENZAMIDE INHIBITOR
3476, d4qpaA_, 0.7581, 3.22, 0.204, 331, 255, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 7-(1-BENZYL-1H-PYRAZOL-4- YL)-2-(PYRIDIN-4-YL)-5H-PYRROLO[23-B]PYRAZINE
3477, d4qp6B_, 0.7581, 3.21, 0.200, 334, 255, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 5H-PYRROLO[23-B]PYRAZINE
3478, d1ckjB_, 0.7581, 3.41, 0.221, 293, 263, CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317 COMPLEX WITH BOUND TUNGSTATE
3479, d2ojgA_, 0.7580, 3.42, 0.217, 337, 258, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH NN-DIMETHYL-4-(4- PHENYL-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
3480, d2chlA_, 0.7580, 3.58, 0.174, 298, 264, STRUCTURE OF CASEIN KINASE 1 GAMMA 3
3481, d4qp4A_, 0.7579, 3.06, 0.198, 337, 252, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
3482, d4ntsB_, 0.7579, 3.17, 0.227, 341, 255, APO STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE
3483, d2oibC_, 0.7579, 2.83, 0.278, 278, 245, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN APO FORM
3484, p4h3pA_, 0.7578, 3.28, 0.220, 342, 254, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
3485, d3qqhA_, 0.7578, 2.98, 0.228, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR L2-2
3486, d2x8eA_, 0.7578, 3.21, 0.259, 259, 251, DISCOVERY OF A NOVEL CLASS OF TRIAZOLONES AS CHECKPOINT KINASE INHIBITORS - HIT TO LEAD EXPLORATION
3487, d2c3jA_, 0.7578, 3.16, 0.252, 257, 250, IDENTIFICATION OF A BURIED POCKET FOR POTENT AND SELECTIVE INHIBITION OF CHK1: PREDICTION AND VERIFICATION
3488, d1irkA_, 0.7578, 3.19, 0.317, 303, 252, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HUMAN INSULIN RECEPTOR
3489, d5c03A_, 0.7577, 2.78, 0.236, 260, 246, CRYSTAL STRUCTURE OF KINASE
3490, d4xs2A_, 0.7577, 2.91, 0.275, 283, 247, IRAK4-INHIBITOR CO-STRUCTURE
3491, d3qqjA_, 0.7577, 3.00, 0.228, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR L2
3492, d5uitB_, 0.7576, 2.91, 0.271, 283, 247, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 14
3493, d4ztsA_, 0.7576, 2.70, 0.230, 249, 243, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO FK1142
3494, p4ux9D_, 0.7576, 3.16, 0.186, 344, 253, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
3495, d4l44A_, 0.7576, 3.28, 0.221, 321, 253, CRYSTAL STRUCTURES OF HUMAN P70S6K1-T389A (FORM II)
3496, d3r9dA_, 0.7576, 3.03, 0.224, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR RC-2-135
3497, d3nizA1, 0.7576, 3.05, 0.235, 284, 251, CRYPTOSPORIDIUM PARVUM CYCLIN-DEPENDENT KINASE CGD5_2510 WITH ADP BOUND.
3498, d3naxA_, 0.7576, 3.13, 0.221, 278, 253, PDK1 IN COMPLEX WITH INHIBITOR MP7
3499, d2izrA_, 0.7576, 3.54, 0.160, 298, 263, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
3500, d2brbA_, 0.7576, 3.52, 0.263, 272, 255, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
3501, p6gdqA_, 0.7575, 3.29, 0.203, 339, 256, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
3502, d5t1tD_, 0.7575, 2.99, 0.266, 283, 248, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
3503, d5m57A1, 0.7575, 2.37, 0.225, 253, 240, NEK2 BOUND TO ARYLAMINOPURINE 6
3504, d4zk5B_, 0.7575, 2.97, 0.219, 294, 251, MAP4K4 IN COMPLEX WITH INHIBITOR GNE-495
3505, d4u43B_, 0.7575, 3.06, 0.230, 302, 252, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 6)
3506, d4btjB_, 0.7575, 3.33, 0.212, 293, 259, TTBK1 IN COMPLEX WITH ATP
3507, d3r8vA_, 0.7575, 3.04, 0.224, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR RC-1-135
3508, d2xnbA_, 0.7575, 3.08, 0.227, 296, 251, DISCOVERY AND CHARACTERISATION OF 2-ANILINO-4-(THIAZOL-5-YL) PYRIMIDINE TRANSCRIPTIONAL CDK INHIBITORS AS ANTICANCER AGENTS
3509, d5m51A1, 0.7574, 2.37, 0.225, 253, 240, NEK2 BOUND TO ARYLAMINOPURINE COMPOUND 8
3510, d4zy6A_, 0.7574, 3.18, 0.227, 284, 255, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 29
3511, d4yp8A_, 0.7574, 3.03, 0.265, 284, 249, IRAK4-INHIBITOR CO-STRUCTURE
3512, d3uojB_, 0.7574, 2.88, 0.241, 263, 245, AURORA A IN COMPLEX WITH RPM1715
3513, d3uojA_, 0.7574, 2.88, 0.241, 263, 245, AURORA A IN COMPLEX WITH RPM1715
3514, d2wtkC1, 0.7574, 3.00, 0.260, 261, 250, STRUCTURE OF THE HETEROTRIMERIC LKB1-STRADALPHA-MO25ALPHA COMPLEX
3515, d2br1A_, 0.7574, 3.52, 0.259, 272, 255, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
3516, d1unhA_, 0.7574, 2.73, 0.216, 276, 245, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
3517, d5kx7B_, 0.7573, 3.12, 0.268, 286, 250, IRAK4-INHIBITOR CO-STRUCTURE
3518, d5buiA_, 0.7573, 3.22, 0.217, 338, 254, ERK2 COMPLEXED WITH 2-PYRIDIYL TETRAHYDROAZAINDAZOLE
3519, d4mwiA_, 0.7573, 2.78, 0.212, 266, 250, CRYSTAL STRUCTURE OF THE HUMAN MLKL PSEUDOKINASE DOMAIN
3520, d4ae6A_, 0.7573, 3.22, 0.263, 319, 255, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT CALPHA 2
3521, d3vw6A_, 0.7573, 2.57, 0.240, 255, 242, CRYSTAL STRUCTURE OF HUMAN APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) WITH IMIDAZOPYRIDINE INHIBITOR
3522, d3od6X_, 0.7573, 3.39, 0.194, 344, 258, CRYSTAL STRUCTURE OF P38ALPHA Y323T ACTIVE MUTANT
3523, d1p14A_, 0.7573, 2.77, 0.321, 287, 246, CRYSTAL STRUCTURE OF A CATALYTIC-LOOP MUTANT OF THE INSULIN RECEPTOR TYROSINE KINASE
3524, d5opuA_, 0.7572, 3.19, 0.267, 261, 251, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIDINE LRRK2 INHIBITOR
3525, d4d4rB_, 0.7572, 3.44, 0.368, 270, 258, FOCAL ADHESION KINASE CATALYTIC DOMAIN
3526, d5vc5A_, 0.7571, 3.12, 0.195, 261, 251, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH PD- 166285
3527, d3ekkA_, 0.7571, 2.76, 0.317, 285, 246, INSULIN RECEPTOR KINASE COMPLEXED WITH AN INHIBITOR
3528, d2ydkA_, 0.7571, 3.32, 0.257, 263, 253, DISCOVERY OF CHECKPOINT KINASE INHIBITOR AZD7762 BY STRUCTURE BASED DESIGN AND OPTIMIZATION OF THIOPHENE CARBOXAMIDE UREAS
3529, d1ungA_, 0.7571, 3.10, 0.198, 288, 252, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
3530, d1q3dB_, 0.7571, 3.31, 0.233, 339, 257, GSK-3 BETA COMPLEXED WITH STAUROSPORINE
3531, d1pxoA_, 0.7571, 3.02, 0.224, 294, 250, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR [4-(2-AMINO-4-METHYL-THIAZOL-5-YL)-PYRIMIDIN-2- YL]-(3-NITRO-PHENYL)-AMINE
3532, d3pj1A_, 0.7570, 2.18, 0.329, 241, 237, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 3-(26-DICHLORO- PHENYL)-7-[4-(2-DIETHYLAMINO-ETHOXY)-PHENYLAMINO]-1-METHYL-34- DIHYDRO-1H-PYRIMIDO[45-D]PYRIMIDIN-2-ONE
3533, d2oicD_, 0.7570, 2.73, 0.279, 284, 244, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN COMPLEXED WITH STAUROSPORINE
3534, d2in6A_, 0.7570, 2.85, 0.220, 256, 245, WEE1 KINASE COMPLEX WITH INHIBITOR PD311839
3535, d1q8yB_, 0.7570, 3.26, 0.195, 357, 257, THE STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P WITH BOUND ADP
3536, d5o21B_, 0.7569, 3.24, 0.228, 273, 254, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED STATE WITH CHLORIDE BOUND IN THE ACTIVE SITE
3537, d3c4dB1, 0.7569, 2.72, 0.264, 256, 246,  
3538, d2i6lA_, 0.7569, 2.94, 0.235, 292, 247, CRYSTAL STRUCTURE OF HUMAN MITOGEN ACTIVATED PROTEIN KINASE 6 (MAPK6)
3539, d6bu6D_, 0.7568, 3.47, 0.163, 318, 263, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
3540, d4zp5B_, 0.7568, 3.07, 0.218, 300, 252, MAP4K4 IN COMPLEX WITH INHIBITOR
3541, d4qp9A_, 0.7568, 3.12, 0.210, 335, 252, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 7-(1-PROPYL-1H-PYRAZOL-4- YL)-2-(PYRIDIN-4-YL)-5H-PYRROLO[23-B]PYRAZINE
3542, d3uixA_, 0.7568, 2.71, 0.234, 266, 244, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
3543, d3h0yA_, 0.7568, 2.77, 0.238, 250, 244, AURORA A IN COMPLEX WITH A BISANILINOPYRIMIDINE
3544, d2oibA_, 0.7568, 2.87, 0.273, 280, 245, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN APO FORM
3545, p6g9aA_, 0.7567, 3.35, 0.211, 341, 256, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
3546, d5uiqC_, 0.7567, 2.96, 0.267, 280, 247, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 9
3547, d5oprA_, 0.7567, 3.14, 0.269, 258, 249, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMINOPYRIDINE LRRK2 INHIBITOR
3548, d4usfB1, 0.7567, 3.19, 0.252, 283, 250, HUMAN SLK WITH SB-440719
3549, d3c4cB1, 0.7567, 2.66, 0.252, 256, 246, B-RAF KINASE IN COMPLEX WITH PLX4720
3550, d5op5A_, 0.7566, 3.15, 0.264, 259, 250, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIMIDINE LRRK2 INHIBITOR
3551, d5j95B_, 0.7566, 3.11, 0.218, 300, 252, MAP4K4 IN COMPLEX WITH INHIBITOR
3552, d4xj0B_, 0.7566, 3.55, 0.216, 338, 259, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR 14K
3553, d4wnpB_, 0.7566, 3.34, 0.267, 272, 258, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
3554, d2w1dA1, 0.7566, 2.82, 0.246, 251, 244, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
3555, d2oibB_, 0.7566, 2.70, 0.275, 278, 244, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN APO FORM
3556, d5kx8A_, 0.7565, 2.96, 0.270, 285, 248, IRAK4-INHIBITOR CO-STRUCTURE
3557, d5flfE_, 0.7565, 2.89, 0.382, 258, 246, DISEASE LINKED MUTATION IN FGFR
3558, p3zu7A_, 0.7565, 3.47, 0.205, 344, 259, CRYSTAL STRUCTURE OF A DESIGNED SELECTED ANKYRIN REPEAT PROTEIN IN COMPLEX WITH THE MAP KINASE ERK2
3559, d3unzB_, 0.7565, 2.81, 0.242, 263, 244, AURORA A IN COMPLEX WITH RPM1679
3560, d3k54A_, 0.7565, 2.27, 0.343, 243, 239, STRUCTURES OF HUMAN BRUTON S TYROSINE KINASE IN ACTIVE AND INACTIVE CONFORMATIONS SUGGESTS A MECHANISM OF ACTIVATION FOR TEC FAMILY KINASES.
3561, d3unzA_, 0.7564, 2.81, 0.242, 263, 244, AURORA A IN COMPLEX WITH RPM1679
3562, d3rkbA_, 0.7564, 3.13, 0.224, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR RC-2-73
3563, d2henA1, 0.7564, 2.92, 0.296, 258, 247, CRYSTAL STRUCTURE OF THE EPHB2 RECEPTOR KINASE DOMAIN IN COMPLEX WITH ADP
3564, d2a1aB1, 0.7564, 2.72, 0.244, 266, 246, PKR KINASE DOMAIN-EIF2ALPHA COMPLEX
3565, d1buhA_, 0.7564, 2.70, 0.218, 287, 243, CRYSTAL STRUCTURE OF THE HUMAN CDK2 KINASE COMPLEX WITH CELL CYCLE-REGULATORY PROTEIN CKSHS1
3566, d5mqvC_, 0.7563, 3.33, 0.211, 288, 261, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
3567, d5c01B_, 0.7563, 2.79, 0.228, 260, 246, CRYSTAL STRUCTURE OF KINASE
3568, d3pxyA_, 0.7563, 3.00, 0.228, 294, 250, CDK2 IN COMPLEX WITH INHIBITOR JWS648
3569, d3ii5B_, 0.7563, 2.91, 0.270, 257, 248, THE COMPLEX OF WILD-TYPE B-RAF WITH PYRAZOLO PYRIMIDINE INHIBITOR
3570, d2qo2A_, 0.7563, 3.14, 0.313, 282, 249, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION DEPHOSPHORYLATED APO STRUCTURE
3571, d5vuaB_, 0.7562, 2.81, 0.224, 270, 245, PIM1 KINASE IN COMPLEX WITH A BENZOFURANONE INHIBITOR
3572, d5op2A_, 0.7562, 3.33, 0.267, 263, 255, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
3573, d5di1B_, 0.7562, 3.07, 0.218, 300, 252, MAP4K4 IN COMPLEX WITH AN INHIBITOR
3574, d4ztrA_, 0.7562, 2.71, 0.230, 249, 243, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO FK1141
3575, d3nlbA_, 0.7562, 3.38, 0.258, 261, 252, NOVEL KINASE PROFILE HIGHLIGHTS THE TEMPORAL BASIS OF CONTEXT DEPENDENT CHECKPOINT PATHWAYS TO CELL DEATH
3576, d1unhB_, 0.7562, 2.74, 0.212, 276, 245, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
3577, d5tf9A_, 0.7561, 2.87, 0.251, 262, 243, CRYSTAL STRUCTURE OF WNK1 IN COMPLEX WITH MN2+AMPPNP AND WNK476
3578, d3vbwA_, 0.7561, 2.60, 0.223, 264, 242, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
3579, d1uwjB_, 0.7561, 3.16, 0.267, 263, 251, THE COMPLEX OF MUTANT V599E B-RAF AND BAY439006
3580, d5x18A_, 0.7560, 3.75, 0.161, 294, 267, CRYSTAL STRUCTURE OF CASEIN KINASE I HOMOLOG 1
3581, d5l6pA_, 0.7560, 3.06, 0.282, 274, 248, EPHB3 KINASE DOMAIN COVALENTLY BOUND TO AN IRREVERSIBLE INHIBITOR (COMPOUND 6)
3582, d2b9jA_, 0.7560, 3.13, 0.194, 337, 252, CRYSTAL STRUCTURE OF FUS3 WITH A DOCKING MOTIF FROM FAR1
3583, d1jqhA_, 0.7560, 3.37, 0.315, 291, 257, IGF-1 RECEPTOR KINASE DOMAIN
3584, d5t1tA_, 0.7559, 2.96, 0.267, 283, 247, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
3585, d5ar7A_, 0.7559, 2.70, 0.246, 278, 244, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIARYL UREA
3586, d4ae9A_, 0.7559, 3.34, 0.258, 321, 256, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT C ALPHA 2
3587, d3uytB_, 0.7559, 3.31, 0.212, 286, 259, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
3588, d3oriB_, 0.7558, 2.88, 0.232, 267, 246, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 1)
3589, d2qo7A_, 0.7558, 3.06, 0.315, 278, 248, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION DEPHOSPHORYLATED AMP-PNP BOUND
3590, d2hyyD1, 0.7558, 2.40, 0.359, 251, 237, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
3591, d4p4cA_, 0.7557, 2.95, 0.304, 266, 247, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH QUINOXALINE DERIVATIVES
3592, d2qlqB_, 0.7557, 2.09, 0.352, 248, 233, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN WITH COVALENT INHIBITOR RL3
3593, d2iztA_, 0.7557, 3.49, 0.172, 296, 262, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
3594, d2henC1, 0.7557, 2.93, 0.296, 258, 247, CRYSTAL STRUCTURE OF THE EPHB2 RECEPTOR KINASE DOMAIN IN COMPLEX WITH ADP
3595, d2b9hA_, 0.7557, 3.14, 0.194, 337, 252, CRYSTAL STRUCTURE OF FUS3 WITH A DOCKING MOTIF FROM STE7
3596, d5w4wD_, 0.7556, 3.36, 0.212, 287, 260, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
3597, d5t1sD_, 0.7556, 2.94, 0.268, 281, 246, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
3598, d5o11A_, 0.7556, 2.64, 0.218, 268, 243, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL-MOLECULE INHIBITOR
3599, d4rvtB_, 0.7556, 3.25, 0.220, 297, 254, MAP4K4 IN COMPLEX WITH A PYRIDIN-2(1H)-ONE DERIVATIVE
3600, d4l3lA_, 0.7556, 3.24, 0.214, 291, 252, CRYSTAL STRUCTURES OF HUMAN P70S6K1 KINASE DOMAIN (ZINC ANOMALOUS)
3601, d4bf2A_, 0.7556, 2.49, 0.237, 253, 240, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3602, d2ojjA_, 0.7556, 3.49, 0.217, 344, 258, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH (S)-N-(1-(3- CHLORO-4-FLUOROPHENYL)-2-HYDROXYETHYL)-4-(4-(3- CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
3603, d2brmA_, 0.7556, 3.33, 0.266, 263, 252, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
3604, d1y8yA_, 0.7556, 2.91, 0.227, 292, 247, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1 5-A]PYRIMIDINE INHIBITOR
3605, d3etaA_, 0.7555, 2.95, 0.328, 293, 247, KINASE DOMAIN OF INSULIN RECEPTOR COMPLEXED WITH A PYRROLO PYRIDINE INHIBITOR
3606, d2qg5A1, 0.7555, 3.32, 0.214, 268, 257, CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840
3607, d4l46A_, 0.7554, 3.25, 0.230, 317, 252, CRYSTAL STRUCTURES OF HUMAN P70S6K1-WT
3608, d1h0vA_, 0.7554, 2.88, 0.224, 288, 246, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 2-AMINO-6-[(R)-PYRROLIDINO-5 -YL]METHOXYPURINE
3609, d5tx5B_, 0.7553, 2.50, 0.287, 263, 240, RIP1 KINASE ( FLAG 1-294 C34A C127A C233A C240A) WITH GSK772
3610, d5nguA_, 0.7553, 3.36, 0.210, 339, 257, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
3611, d5ar4A_, 0.7553, 2.41, 0.245, 274, 241, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH SB-203580
3612, d3uytC_, 0.7553, 3.44, 0.213, 286, 263, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
3613, d3mvjB_, 0.7553, 3.23, 0.224, 320, 255, HUMAN CYCLIC AMP-DEPENDENT PROTEIN KINASE PKA INHIBITOR COMPLEX
3614, d2a19B1, 0.7553, 2.83, 0.240, 261, 246, PKR KINASE DOMAIN- EIF2ALPHA- AMP-PNP COMPLEX.
3615, d1jqhC_, 0.7553, 3.38, 0.315, 291, 257, IGF-1 RECEPTOR KINASE DOMAIN
3616, d5ukfA_, 0.7552, 3.56, 0.166, 322, 265, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO AN OXINDOLE INHIBITOR
3617, d5hieC_, 0.7552, 2.53, 0.256, 253, 242, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
3618, d5fdpA_, 0.7552, 3.45, 0.354, 285, 254, STRUCTURE OF DDR1 RECEPTOR TYROSINE KINASE IN COMPLEX WITH D2099 INHIBITOR AT 2.25 ANGSTROMS RESOLUTION.
3619, d4xj0A_, 0.7552, 3.59, 0.216, 345, 259, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR 14K
3620, d2nryD_, 0.7552, 3.13, 0.259, 282, 247, CRYSTAL STRUCTURE OF IRAK-4
3621, d1omwA3, 0.7552, 3.31, 0.182, 344, 258, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN G PROTEIN-COUPLED RECEPTOR KINASE 2 AND HETEROTRIMERIC G PROTEIN BETA 1 AND GAMMA 2 SUBUNITS
3622, d5we8B_, 0.7551, 3.04, 0.235, 272, 247, CRYSTAL STRUCTURE OF WNK1 IN COMPLEX WITH N-{(3R)-1-[(4-CHLOROPHENYL) METHYL]PYRROLIDIN-3-YL}-2-(3-METHOXYPHENYL)-N-METHYLQUINOLINE-4- CARBOXAMIDE (COMPOUND 8)
3623, d4enxA_, 0.7551, 2.72, 0.221, 266, 244, CRYSTAL STRUCTURE OF PIM-1 KINASE IN COMPLEX WITH INHIBITOR (2E5Z)-2- (2-CHLOROPHENYLIMINO)-5-(4-HYDROXY-3-NITROBENZYLIDENE)THIAZOLIDIN-4- ONE
3624, d3h0zA_, 0.7551, 2.64, 0.236, 248, 242, AURORA A IN COMPLEX WITH A BISANILINOPYRIMIDINE
3625, d4yo6D_, 0.7550, 3.11, 0.268, 285, 250, IRAK4-INHIBITOR CO-STRUCTURE
3626, d4y73A_, 0.7550, 3.13, 0.268, 289, 250, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN WITH INHIBITOR
3627, d4rj3A_, 0.7550, 2.94, 0.224, 287, 246, CDK2 WITH EGFR INHIBITOR COMPOUND 8
3628, d4enyA_, 0.7550, 2.65, 0.226, 261, 243, CRYSTAL STRUCTURE OF PIM-1 KINASE IN COMPLEX WITH (2E5Z)-2-(2- CHLOROPHENYLIMINO)-5-(4-HYDROXY-3-METHOXYBENZYLIDENE)THIAZOLIDIN-4- ONE
3629, d4aotA1, 0.7550, 2.92, 0.249, 276, 245, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 (LOK) BOUND TO GW830263A
3630, d3oriA_, 0.7550, 2.78, 0.229, 267, 245, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 1)
3631, d2pk9A_, 0.7550, 2.93, 0.222, 287, 248, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE-RESPONSIVE SIGNAL TRANSDUCTION PATHWAY
3632, d4lynA_, 0.7549, 2.91, 0.223, 287, 247, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2-WT) COMPLEX WITH (2S)-N-(5-(((5-TERT-BUTYL-13-OXAZOL-2-YL)METHYL)SULFANYL)-13- THIAZOL-2-YL)-2-PHENYLPROPANAMIDE
3633, d1i09A_, 0.7549, 3.27, 0.231, 338, 255, STRUCTURE OF GLYCOGEN SYNTHASE KINASE-3 (GSK3B)
3634, d1gngA_, 0.7549, 3.30, 0.242, 348, 256, GLYCOGEN SYNTHASE KINASE-3 BETA (GSK3) COMPLEX WITH FRATTIDE PEPTIDE
3635, d1ckiA_, 0.7549, 3.22, 0.218, 292, 257, RECOMBINANT CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317
3636, d5opbA_, 0.7548, 3.29, 0.268, 262, 254, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH INDAZOLE LRRK2 INHIBITOR
3637, d4qyhB_, 0.7548, 3.36, 0.259, 264, 251, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE GNE-783
3638, d5k75C_, 0.7547, 2.99, 0.267, 282, 247, IRAK4 IN COMPLEX WITH COMPOUND 1
3639, d4ztmC_, 0.7547, 2.81, 0.278, 282, 245, IRAK4-INHIBITOR CO-STRUCTURE
3640, d4btjA_, 0.7547, 3.45, 0.219, 292, 260, TTBK1 IN COMPLEX WITH ATP
3641, d3zhpC1, 0.7547, 3.10, 0.276, 267, 250, HUMAN MST3 (STK24) IN COMPLEX WITH MO25BETA
3642, d5k5nB_, 0.7546, 3.24, 0.240, 334, 254, CRYSTAL STRUCTURE OF GSK-3BETA COMPLEXED WITH PF-04802367 A HIGHLY SELECTIVE BRAIN-PENETRANT KINASE INHIBITOR
3643, d4qygA_, 0.7546, 3.27, 0.256, 264, 250, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE COMPOUND 14
3644, d3ormA_, 0.7546, 2.81, 0.229, 266, 245, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN D76A MUTANT
3645, d2c5yA_, 0.7546, 2.97, 0.227, 290, 247, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
3646, d4qygB_, 0.7545, 3.36, 0.259, 264, 251, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE COMPOUND 14
3647, d3nw6A_, 0.7545, 3.18, 0.310, 301, 252, CRYSTAL STRUCTURE OF INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R-WT) COMPLEX WITH A CARBON-LINKED PROLINE ISOSTERE INHIBITOR (11A)
3648, d1v0bA_, 0.7545, 2.92, 0.222, 286, 248, CRYSTAL STRUCTURE OF THE T198A MUTANT OF PFPK5
3649, d5op4A_, 0.7544, 3.12, 0.262, 259, 248, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMINOPYRIMIDINE LRRK2 INHIBITOR
3650, d6b8uA_, 0.7543, 2.89, 0.271, 253, 247, CRYSTALS STRUCTURE OF B-RAF KINASE DOMAIN IN COMPLEX WITH AN IMIDAZOPYRIDINYL BENZAMIDE INHIBITOR
3651, d5t1sB_, 0.7543, 2.82, 0.272, 282, 243, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
3652, d5oorA_, 0.7543, 3.36, 0.278, 273, 252, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH STAUROSPORINE
3653, d5acbD_, 0.7543, 3.42, 0.243, 319, 259, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
3654, d2w5aA1, 0.7543, 3.12, 0.234, 259, 248, HUMAN NEK2 KINASE ADP-BOUND
3655, d1ywnA_, 0.7543, 3.26, 0.331, 279, 248, VEGFR2 IN COMPLEX WITH A NOVEL 4-AMINO-FURO[23-D]PYRIMIDINE
3656, d6bruA_, 0.7542, 3.59, 0.151, 322, 265, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A (S)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
3657, d5d10A_, 0.7542, 2.09, 0.329, 248, 234, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL236
3658, d4rmzA_, 0.7542, 3.14, 0.260, 284, 250, CRYSTAL STRUCTURE OF IRAK-4
3659, d4bcqA1, 0.7542, 2.86, 0.209, 289, 249, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
3660, d3f69A_, 0.7542, 2.81, 0.228, 270, 246, CRYSTAL STRUCTURE OF THE MYCOBACTERIUM TUBERCULOSIS PKNB MUTANT KINASE DOMAIN IN COMPLEX WITH KT5720
3661, d2w5bA1, 0.7542, 2.83, 0.236, 263, 246, HUMAN NEK2 KINASE ATPGAMMAS-BOUND
3662, d5o12A_, 0.7541, 2.57, 0.228, 264, 241, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL-MOLECULE INHIBITOR
3663, d4knbD_, 0.7541, 2.58, 0.359, 247, 237, C-MET IN COMPLEX WITH OSI LIGAND
3664, d4iq6A_, 0.7541, 3.22, 0.232, 324, 254, GSK-3BETA WITH INHIBITOR 6-CHLORO-N-CYCLOHEXYL-4-(1H-PYRROLO[23- B]PYRIDIN-3-YL)PYRIDIN-2-AMINE
3665, d4cqeB_, 0.7541, 2.49, 0.260, 248, 242, B-RAF KINASE V600E MUTANT IN COMPLEX WITH  A DIARYLTHIAZOLE B-RAF INHIBITOR
3666, d3qc4B1, 0.7540, 2.86, 0.227, 268, 247, PDK1 IN COMPLEX WITH DFG-OUT INHIBITOR XXX
3667, d2hz0B_, 0.7540, 2.17, 0.346, 243, 234, ABL KINASE DOMAIN IN COMPLEX WITH NVP-AEG082
3668, d4lg4C_, 0.7539, 3.19, 0.230, 288, 252, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
3669, d4fv1A_, 0.7539, 3.47, 0.218, 342, 257, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK4
3670, d4btmB_, 0.7539, 3.37, 0.201, 293, 259, TTBK1 IN COMPLEX WITH INHIBITOR
3671, d3pj8A1, 0.7539, 2.97, 0.226, 287, 248, STRUCTURE OF CDK2 IN COMPLEX WITH A PYRAZOLO[43-D]PYRIMIDINE BIOISOSTERE OF ROSCOVITINE.
3672, d2c30A_, 0.7539, 3.56, 0.190, 289, 258, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 6
3673, d1h0uA_, 0.7539, 2.90, 0.224, 291, 246,  
3674, d5ct7B_, 0.7538, 2.67, 0.253, 254, 245, BRAF IN COMPLEX WITH RAF265
3675, d4btmA_, 0.7538, 3.40, 0.208, 292, 259, TTBK1 IN COMPLEX WITH INHIBITOR
3676, p3vugA_, 0.7538, 3.37, 0.198, 356, 257, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M2 IN MAP KINASE JNK1
3677, d3dtcA_, 0.7538, 2.14, 0.355, 245, 234, CRYSTAL STRUCTURE OF MIXED-LINEAGE KINASE MLK1 COMPLEXED WITH COMPOUND 16
3678, d3c7qA_, 0.7538, 3.19, 0.331, 286, 248, STRUCTURE OF VEGFR2 KINASE DOMAIN IN COMPLEX WITH BIBF1120
3679, d5k75D_, 0.7537, 2.96, 0.272, 280, 246, IRAK4 IN COMPLEX WITH COMPOUND 1
3680, d5hieB_, 0.7537, 2.91, 0.270, 259, 248, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
3681, d5c01A_, 0.7537, 2.77, 0.229, 258, 245, CRYSTAL STRUCTURE OF KINASE
3682, p3teiA_, 0.7537, 3.12, 0.211, 339, 251, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
3683, d5vubB_, 0.7536, 2.82, 0.230, 269, 244, PIM1 KINASE IN COMPLEX WITH A BENZOFURANONE INHIBITOR
3684, d5oq6A_, 0.7536, 3.26, 0.273, 257, 249, STRUCTURE OF CHK1 12-PT. MUTANT COMPLEX WITH AMINOPYRIMIDO- BENZODIAZEPINONE LRRK2 INHIBITOR
3685, d5opvA_, 0.7536, 3.19, 0.261, 261, 249, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIDINE LRRK2 INHIBITOR
3686, d4u41B_, 0.7536, 3.13, 0.218, 297, 252, MAP4K4 BOUND TO INHIBITOR COMPOUND 1
3687, d4oboB_, 0.7536, 3.07, 0.219, 297, 251, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 22) 6-(3-CHLOROPHENYL) QUINAZOLIN-4-AMINE
3688, d2qodA_, 0.7536, 3.13, 0.315, 274, 248, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y602F MUTANT
3689, d4l3jA_, 0.7535, 3.31, 0.218, 291, 252, CRYSTAL STRUCTURES OF HUMAN P70S6K1 KINASE DOMAIN
3690, d3w55A_, 0.7535, 3.07, 0.217, 335, 249, THE STRUCTURE OF ERK2 IN COMPLEX WITH FR148083
3691, d2v0dA_, 0.7535, 2.98, 0.223, 292, 247, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
3692, d2ojiA_, 0.7535, 3.51, 0.217, 344, 258, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-BENZYL-4-(4-(3- CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
3693, d2j4zB_, 0.7535, 3.09, 0.242, 269, 248, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-680626
3694, d2e14A_, 0.7535, 3.07, 0.217, 335, 249,  
3695, d4ez7A1, 0.7534, 2.93, 0.202, 298, 247, CDK2 IN COMPLEX WITH STAUROSPORINE AND 2 MOLECULES OF 8-ANILINO-1- NAPHTHALENE SULFONIC ACID
3696, d3o71A_, 0.7534, 3.35, 0.215, 340, 256, CRYSTAL STRUCTURE OF ERK2/DCC PEPTIDE COMPLEX
3697, d2uzoA_, 0.7534, 2.90, 0.227, 290, 247, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
3698, d2qvsE_, 0.7534, 3.17, 0.228, 323, 254, CRYSTAL STRUCTURE OF TYPE IIA HOLOENZYME OF CAMP-DEPENDENT PROTEIN KINASE
3699, p5nzzE_, 0.7533, 3.12, 0.208, 343, 250, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
3700, d4qyeA_, 0.7533, 3.37, 0.267, 271, 251, CHK1 KINASE DOMAIN IN COMPLEX WITH DIARYLPYRAZINE COMPOUND 1
3701, d4fv3A_, 0.7533, 3.49, 0.218, 346, 257, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK6
3702, d5oq8A_, 0.7532, 3.28, 0.261, 261, 253, STRUCTURE OF CHK1 12-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
3703, d4rvmA_, 0.7532, 3.38, 0.267, 264, 251, CHK1 KINASE DOMAIN WITH DIAZACARBAZOLE COMPOUND 19
3704, d2qoiA_, 0.7532, 3.14, 0.315, 274, 248, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F:Y602F DOUBLE MUTANT
3705, d1pxlA_, 0.7532, 2.94, 0.228, 290, 246, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR [4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]- (4-TRIFLUOROMETHYL-PHENYL)-AMINE
3706, d1jqhB_, 0.7532, 3.42, 0.315, 287, 257, IGF-1 RECEPTOR KINASE DOMAIN
3707, d4qpaB_, 0.7531, 3.43, 0.210, 345, 257, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 7-(1-BENZYL-1H-PYRAZOL-4- YL)-2-(PYRIDIN-4-YL)-5H-PYRROLO[23-B]PYRAZINE
3708, d2brgA_, 0.7531, 3.25, 0.261, 257, 249, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
3709, d5kx8D_, 0.7530, 3.14, 0.258, 283, 248, IRAK4-INHIBITOR CO-STRUCTURE
3710, d4qyhA_, 0.7530, 3.29, 0.260, 264, 250, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE GNE-783
3711, d4ficB_, 0.7530, 2.04, 0.351, 245, 231, KINASE DOMAIN OF CSRC IN COMPLEX WITH A HINGE REGION-BINDING FRAGMENT
3712, p3vukA_, 0.7530, 3.38, 0.198, 355, 257, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M5 IN MAP KINASE JNK1
3713, d3h0zC_, 0.7530, 2.58, 0.237, 246, 240, AURORA A IN COMPLEX WITH A BISANILINOPYRIMIDINE
3714, d4ftiA_, 0.7529, 3.41, 0.263, 270, 251, CRYSTAL STRUCTURE OF THE CHK1
3715, p3vudA_, 0.7529, 3.31, 0.195, 355, 256, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M1 IN MAP KINASE JNK1
3716, d5hieA_, 0.7528, 2.93, 0.263, 258, 247, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
3717, d4fg8B_, 0.7528, 2.58, 0.242, 268, 240, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-315 IN COMPLEX WITH ATP
3718, d4aotB1, 0.7528, 3.01, 0.251, 277, 247, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 (LOK) BOUND TO GW830263A
3719, d1cm8B_, 0.7528, 3.09, 0.188, 327, 250, PHOSPHORYLATED MAP KINASE P38-GAMMA
3720, d1cm8A_, 0.7528, 3.09, 0.188, 327, 250, PHOSPHORYLATED MAP KINASE P38-GAMMA
3721, p6g9hA_, 0.7527, 3.40, 0.219, 343, 256, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
3722, d5vdkA_, 0.7527, 2.96, 0.207, 260, 246, CRYSTAL STRUCTURE OF HUMAN WEE2 KINASE DOMAIN IN COMPLEX WITH MK1775
3723, d3oz6B_, 0.7527, 2.92, 0.230, 341, 248, CRYSTAL STRUCTURE OF MAPK FROM CRYPTOSPORIDIUM PARVUM CGD2_1960
3724, d3lfnA_, 0.7527, 2.84, 0.229, 285, 245, CRYSTAL STRUCTURE OF CDK2 WITH SAR57 AN AMINOINDAZOLE TYPE INHIBITOR
3725, d2qq7B_, 0.7527, 1.86, 0.348, 244, 230, CRYSTAL STRUCTURE OF DRUG RESISTANT SRC KINASE DOMAIN WITH IRREVERSIBLE INHIBITOR
3726, d2c69A_, 0.7527, 2.99, 0.223, 292, 247, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
3727, d5oq7B_, 0.7526, 3.13, 0.277, 256, 249, STRUCTURE OF CHK1 8-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
3728, d5d9kB_, 0.7526, 3.07, 0.200, 280, 250, RSK2 N-TERMINAL KINASE IN COMPLEX WITH BI-D1870
3729, d4ztnB_, 0.7526, 2.81, 0.272, 282, 243, IRAK4-INHIBITOR CO-STRUCTURE
3730, d4usfA1, 0.7526, 3.07, 0.258, 275, 248, HUMAN SLK WITH SB-440719
3731, d4qp1A_, 0.7526, 3.36, 0.207, 342, 256, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
3732, d4obqB_, 0.7526, 2.98, 0.220, 293, 250, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 31) N-[3-(4- AMINOQUINAZOLIN-6-YL)-5-FLUOROPHENYL]-2-(PYRROLIDIN-1-YL)ACETAMIDE
3733, p3vuhA_, 0.7526, 3.31, 0.195, 355, 256, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M3 IN MAP KINASE JNK1
3734, d3uytA_, 0.7526, 3.33, 0.219, 287, 260, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
3735, d2c6oA_, 0.7526, 2.94, 0.227, 290, 247, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
3736, d2c3lA_, 0.7526, 3.38, 0.267, 265, 251, IDENTIFICATION OF A BURIED POCKET FOR POTENT AND SELECTIVE INHIBITION OF CHK1: PREDICTION AND VERIFICATION
3737, d1wzyA_, 0.7526, 3.49, 0.213, 350, 258, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A PYRAZOLOPYRIDAZINE DERIVATIVE
3738, d5vucB_, 0.7525, 2.84, 0.221, 269, 244, PIM1 KINASE IN COMPLEX WITH A BENZOFURANONE INHIBITOR
3739, d5l4qB_, 0.7525, 3.02, 0.212, 287, 245, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE 1 (AAK1) IN COMPLEX WITH LKB1 (AAK1 DUAL INHIBITOR)
3740, d4yc6E_, 0.7525, 2.98, 0.211, 285, 247, CDK1/CKS1
3741, d5ih5A_, 0.7524, 3.33, 0.224, 286, 259, HUMAN CASEIN KINASE 1 ISOFORM DELTA (KINASE DOMAIN) IN COMPLEX WITH EPIBLASTIN A
3742, d3zhpD_, 0.7524, 3.06, 0.277, 264, 249, HUMAN MST3 (STK24) IN COMPLEX WITH MO25BETA
3743, d3ot3A_, 0.7524, 3.28, 0.260, 259, 250, X-RAY CRYSTAL STRUCTURE OF COMPOUND 22K BOUND TO HUMAN CHK1 KINASE DOMAIN
3744, d2qooA_, 0.7524, 3.14, 0.310, 273, 248, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F:Y602F:Y742F TRIPLE MUTANT
3745, d2qofA_, 0.7524, 3.15, 0.315, 280, 248, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F MUTANT
3746, p6g91A_, 0.7523, 3.32, 0.199, 344, 256, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
3747, d4joaA_, 0.7523, 2.37, 0.309, 250, 236, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 7-AZAINDOLE BASED INHIBITOR
3748, d2oj9A_, 0.7523, 3.22, 0.317, 295, 252, STRUCTURE OF IGF-1R KINASE DOMAIN COMPLEXED WITH A BENZIMIDAZOLE INHIBITOR
3749, d1ob3A_, 0.7523, 2.94, 0.223, 277, 247, STRUCTURE OF P. FALCIPARUM PFPK5
3750, d5k00A_, 0.7522, 2.75, 0.279, 311, 244, MELK IN COMPLEX WITH NVS-MELK5
3751, d5w84A_, 0.7521, 2.98, 0.269, 279, 245, CRYSTAL STRUCTURE OF IRAK-4 WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 4)
3752, d4rvkA_, 0.7521, 3.49, 0.269, 264, 253, CHK1 KINASE DOMAIN WITH DIAZACARBAZOLE COMPOUND 8: N-[3-(6-CYANO-9H- PYRROLO[23-B:54-C ]DIPYRIDIN-3-YL)PHENYL]ACETAMIDE
3753, d4fv2A_, 0.7521, 3.51, 0.218, 344, 257, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK5
3754, d3u9nA_, 0.7521, 3.21, 0.269, 257, 249, X-RAY CRYSTAL STRUCTURE OF COMPOUND 1 BOUND TO HUMAN CHK1 KINASE DOMAIN
3755, d3op5A_, 0.7521, 3.57, 0.163, 320, 264, HUMAN VACCINIA-RELATED KINASE 1
3756, d2r3oA_, 0.7521, 2.88, 0.229, 289, 245, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
3757, d2io6A_, 0.7521, 2.69, 0.212, 252, 241, WEE1 KINASE COMPLEXED WITH INHIBITOR PD330961
3758, d2bdwA_, 0.7521, 3.66, 0.245, 309, 261, CRYSTAL STRUCTURE OF THE AUTO-INHIBITED KINASE DOMAIN OF CALCIUM/CALMODULIN ACTIVATED KINASE II
3759, d1j3hA_, 0.7521, 3.24, 0.228, 329, 254, CRYSTAL STRUCTURE OF APOENZYME CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT
3760, d4fsrA_, 0.7520, 3.27, 0.261, 269, 249, CRYSTAL STRUCTURE OF THE CHK1
3761, d1pxkA_, 0.7520, 2.99, 0.228, 290, 246, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR N-[4-(24-DIMETHYL-THIAZOL-5-YL)PYRIMIDIN-2-YL]- N -HYDROXYIMINOFORMAMIDE
3762, d4nt4A1, 0.7519, 3.50, 0.171, 299, 263, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF GILGAMESH ISOFORM I FROM DROSOPHILA MELANOGASTER
3763, d4fkuA_, 0.7519, 3.10, 0.225, 293, 249, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
3764, d3zzwA_, 0.7519, 3.10, 0.270, 269, 248, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF ROR2
3765, d4kbkC_, 0.7518, 3.29, 0.209, 280, 258, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
3766, d4h58C_, 0.7518, 3.03, 0.253, 272, 249, BRAF IN COMPLEX WITH COMPOUND 3
3767, d3pxzA1, 0.7518, 3.15, 0.214, 298, 248, CDK2 TERNARY COMPLEX WITH JWS648 AND ANS
3768, d2c68A_, 0.7518, 2.96, 0.223, 290, 247, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
3769, d4ft9A_, 0.7517, 3.38, 0.260, 270, 250, CRYSTAL STRUCTURE OF THE CHK1
3770, d3e3pA_, 0.7517, 3.01, 0.180, 337, 250, GLYCOGEN SYNTHASE KINASE FROM LEISHMANIA MAJOR
3771, d1tvoA_, 0.7517, 3.44, 0.218, 350, 257, THE STRUCTURE OF ERK2 IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
3772, d5lcjA_, 0.7516, 3.33, 0.199, 345, 256, IN-GEL ACTIVITY-BASED PROTEIN PROFILING OF A CLICKABLE COVALENT ERK 1/2 INHIBITOR
3773, d5ih6A_, 0.7516, 3.35, 0.224, 286, 259, HUMAN CASEIN KINASE 1 ISOFORM DELTA (KINASE DOMAIN) IN COMPLEX WITH EPIBLASTIN A DERIVATIVE
3774, d3umwA_, 0.7516, 2.85, 0.221, 264, 244, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH INHIBITOR (Z)-2-[(1H- INDAZOL-3-YL)METHYLENE]-6-METHOXY-7-(PIPERAZIN-1-YLMETHYL)BENZOFURAN- 3(2H)-ONE
3775, d3lfsA_, 0.7516, 2.97, 0.228, 290, 246, CRYSTAL STRUCTURE OF CDK2 WITH SAR37 AN AMINOINDAZOLE TYPE INHIBITOR
3776, d3lfqA_, 0.7516, 2.95, 0.229, 289, 245, CRYSTAL STRUCTURE OF CDK2 WITH SAR60 AN AMINOINDAZOLE TYPE INHIBITOR
3777, d3e3pB_, 0.7516, 3.02, 0.180, 337, 250, GLYCOGEN SYNTHASE KINASE FROM LEISHMANIA MAJOR
3778, d2nryC_, 0.7516, 3.08, 0.261, 280, 245, CRYSTAL STRUCTURE OF IRAK-4
3779, d1gz8A_, 0.7516, 2.93, 0.224, 290, 246, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 2-AMINO-6-(3 -METHYL-2 -OXO)BUTOXYPURINE
3780, d1e1xA_, 0.7516, 2.89, 0.224, 290, 245, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU6027
3781, d4s33A_, 0.7515, 3.44, 0.206, 347, 257, ERK2 R65S MUTANT COMPLEXED WITH AMP-PNP
3782, d4l43A_, 0.7515, 3.38, 0.231, 316, 251, CRYSTAL STRUCTURES OF HUMAN P70S6K1-T389A (FORM I)
3783, d4ibmB_, 0.7515, 3.04, 0.317, 294, 249, CRYSTAL STRUCTURE OF INSULIN RECEPTOR KINASE DOMAIN IN COMPLEX WITH AN INHIBITOR IRFIN-1
3784, d4ft3A_, 0.7515, 3.12, 0.263, 269, 247, CRYSTAL STRUCTURE OF THE CHK1
3785, d4erkA_, 0.7515, 3.52, 0.217, 350, 258, THE COMPLEX STRUCTURE OF THE MAP KINASE ERK2/OLOMOUCINE
3786, p3vuiA_, 0.7515, 3.34, 0.195, 355, 256, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M2 IN MAP KINASE JNK1
3787, d3uysD_, 0.7515, 3.31, 0.209, 284, 258, CRYSTAL STRUCTURE OF APO HUMAN CK1D
3788, d5oneA_, 0.7514, 3.00, 0.241, 257, 245, CRYSTAL STRUCTURE OF AURORA-A IN COMPLEX WITH FMF-03-145-1 (COMPOUND 2)
3789, d3vw6B_, 0.7514, 2.54, 0.237, 253, 240, CRYSTAL STRUCTURE OF HUMAN APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) WITH IMIDAZOPYRIDINE INHIBITOR
3790, d3oroA_, 0.7514, 2.97, 0.228, 272, 246, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 4)
3791, d3nw7A_, 0.7514, 3.14, 0.312, 297, 250, CRYSTAL STRUCTURE OF INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R-WT) COMPLEX WITH A CARBON-LINKED PROLINE ISOSTERE INHIBITOR (34)
3792, d1wccA_, 0.7514, 2.78, 0.225, 283, 244, SCREENING FOR FRAGMENT BINDING BY X-RAY CRYSTALLOGRAPHY
3793, d1b38A_, 0.7514, 2.90, 0.224, 290, 245, HUMAN CYCLIN-DEPENDENT KINASE 2
3794, d4l45A_, 0.7513, 3.35, 0.227, 317, 251, CRYSTAL STRUCTURES OF HUMAN P70S6K1-T389E
3795, d4ztlC_, 0.7512, 3.17, 0.259, 282, 247, IRAK4-INHIBITOR CO-STRUCTURE
3796, d4bf2B_, 0.7512, 2.46, 0.238, 252, 239, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3797, d3zonA_, 0.7512, 2.85, 0.237, 261, 245, HUMAN TYK2 PSEUDOKINASE DOMAIN BOUND TO A KINASE INHIBITOR
3798, d3pa4A_, 0.7512, 3.28, 0.257, 257, 249, X-RAY CRYSTAL STRUCTURE OF COMPOUND 2A BOUND TO HUMAN CHK1 KINASE DOMAIN
3799, d2hy0A_, 0.7512, 3.42, 0.271, 272, 251, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 22
3800, d2c6kA_, 0.7512, 2.96, 0.223, 292, 247, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
3801, p6g9mA_, 0.7511, 3.52, 0.214, 341, 257, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
3802, d4fsnA_, 0.7511, 3.46, 0.262, 270, 252, CRYSTAL STRUCTURE OF THE CHK1
3803, p3v3vA_, 0.7511, 3.29, 0.196, 351, 255, STRUCTURAL AND FUNCTIONAL ANALYSIS OF QUERCETAGETIN A NATURAL JNK1 INHIBITOR
3804, d3p9jA_, 0.7511, 2.80, 0.243, 249, 243, AURORA A KINASE DOMAIN WITH PHTHALAZINONE PYRAZOLE INHIBITOR
3805, d3erkA_, 0.7511, 3.47, 0.210, 350, 257, THE COMPLEX STRUCTURE OF THE MAP KINASE ERK2/SB220025
3806, d2izuA_, 0.7511, 3.54, 0.160, 297, 262, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
3807, d1q3dA_, 0.7511, 3.36, 0.230, 339, 256, GSK-3 BETA COMPLEXED WITH STAUROSPORINE
3808, p5nzzG_, 0.7510, 3.25, 0.207, 342, 251, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
3809, d5uoxB_, 0.7509, 2.60, 0.237, 252, 241, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
3810, d3dxnA_, 0.7509, 3.11, 0.275, 258, 247, CRYSTAL STRUCTURE OF THE CALCIUM-DEPENDENT KINASE FROM TOXOPLASMA GONDII 541.M00134 KINASE DOMAIN.
3811, d4hokM_, 0.7508, 3.63, 0.220, 291, 264, CRYSTAL STRUCTURE OF APO CK1E
3812, d4ft7A_, 0.7508, 3.38, 0.264, 270, 250, CRYSTAL STRUCTURE OF THE CHK1
3813, d3pa3A_, 0.7508, 3.35, 0.272, 259, 250, X-RAY CRYSTAL STRUCTURE OF COMPOUND 70 BOUND TO HUMAN CHK1 KINASE DOMAIN
3814, d3oz6A_, 0.7508, 3.17, 0.206, 343, 252, CRYSTAL STRUCTURE OF MAPK FROM CRYPTOSPORIDIUM PARVUM CGD2_1960
3815, d2b9fA_, 0.7508, 3.34, 0.217, 337, 253, CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED FUS3
3816, d5oq7A_, 0.7507, 3.25, 0.279, 259, 251, STRUCTURE OF CHK1 8-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
3817, p5nzzF_, 0.7507, 3.12, 0.201, 341, 249, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
3818, d2qg5D1, 0.7507, 3.35, 0.223, 267, 256, CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840
3819, d1nvsA_, 0.7507, 3.41, 0.267, 264, 251, THE COMPLEX STRUCTURE OF CHECKPOINT KINASE CHK1/SB218078
3820, d4yc6C_, 0.7506, 3.01, 0.211, 285, 247, CDK1/CKS1
3821, d4qyfA_, 0.7506, 3.34, 0.260, 269, 250, CHK1 KINASE DOMAIN IN COMPLEX WITH AMINOPYRAZINE COMPOUND 13
3822, d1w8cA_, 0.7506, 2.94, 0.224, 290, 246, CO-CRYSTAL STRUCTURE OF 6-CYCLOHEXYLMETHOXY-8-ISOPROPYL-9H- PURIN-2-YLAMINE AND MONOMERIC CDK2
3823, d1v0pA_, 0.7506, 2.93, 0.220, 277, 246, STRUCTURE OF P. FALCIPARUM PFPK5-PURVALANOL B LIGAND COMPLEX
3824, d1ol6A_, 0.7506, 2.58, 0.233, 245, 240, STRUCTURE OF UNPHOSPHORYLATED D274N MUTANT OF AURORA-A
3825, d5mqvA_, 0.7505, 3.33, 0.216, 286, 259, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
3826, d4yc6A_, 0.7505, 3.01, 0.211, 285, 247, CDK1/CKS1
3827, d3tkiA_, 0.7505, 3.44, 0.270, 272, 252, CRYSTAL STRUCTURE OF CHK1 IN COMPLEX WITH INHIBITOR S25
3828, d3q96A_, 0.7505, 2.88, 0.268, 253, 246, B-RAF KINASE DOMAIN IN COMPLEX WITH A TETRAHYDRONAPHTHALENE INHIBITOR
3829, d3pxfA1, 0.7505, 3.14, 0.214, 298, 248, CDK2 IN COMPLEX WITH TWO MOLECULES OF 8-ANILINO-1-NAPHTHALENE SULFONATE
3830, d3comB_, 0.7505, 3.16, 0.236, 279, 254, CRYSTAL STRUCTURE OF MST1 KINASE
3831, d2ofvB2, 0.7505, 2.08, 0.355, 243, 231, CRYSTAL STRUCTURE OF AMINOQUINAZOLINE 1 BOUND TO LCK
3832, d5opsA_, 0.7504, 3.16, 0.266, 258, 248, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIDINE LRRK2 INHIBITOR
3833, d4xs2C_, 0.7504, 3.03, 0.264, 281, 246, IRAK4-INHIBITOR CO-STRUCTURE
3834, d3pj3A_, 0.7504, 2.13, 0.316, 240, 234, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 2-METHYL-5-[(E)- (3-PHENYL-ACRYLOYL)AMINO]-N-(2-PHENYL-3H-IMIDAZO[45-B]PYRIDIN-6-YL)- BENZAMIDE
3835, d4yp8D_, 0.7503, 3.17, 0.272, 285, 250, IRAK4-INHIBITOR CO-STRUCTURE
3836, d4tw9B_, 0.7503, 3.44, 0.212, 289, 260, DIFLUORO-DIOXOLO-BENZOIMIDAZOL-BENZAMIDES AS POTENT INHIBITORS OF CK1DELTA AND EPSILON WITH NANOMOLAR INHIBITORY ACTIVITY ON CANCER CELL PROLIFERATION
3837, d4fsuA_, 0.7503, 3.38, 0.264, 260, 250, CRYSTAL STRUCTURE OF THE CHK1
3838, d4ek5A_, 0.7503, 2.97, 0.229, 289, 245, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
3839, d2r3rA_, 0.7502, 2.90, 0.229, 290, 245, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
3840, d1b39A_, 0.7502, 2.91, 0.224, 290, 245, HUMAN CYCLIN-DEPENDENT KINASE 2 PHOSPHORYLATED ON THR 160
3841, d5mqvF_, 0.7501, 3.39, 0.215, 286, 260, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
3842, d5k76B_, 0.7501, 2.86, 0.275, 281, 244, IRAK4 IN COMPLEX WITH COMPOUND 28
3843, d5ih4A_, 0.7501, 3.37, 0.224, 286, 259, HUMAN CASEIN KINASE 1 ISOFORM DELTA APO (KINASE DOMAIN)
3844, d4s32A_, 0.7501, 3.46, 0.206, 346, 257, CRYSTAL STRUCTURE OF ERK2 AMP-PNP COMPLEX
3845, d3w16A_, 0.7501, 2.79, 0.239, 249, 243, STRUCTURE OF AURORA KINASE A COMPLEXED TO PYRAZOLE-AMINOQUINOLINE INHIBITOR III
3846, d3uliA_, 0.7501, 2.96, 0.232, 286, 246, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) BOUND TO AZABENZIMIDAZOLE DERIVATIVE
3847, d5valB_, 0.7500, 2.78, 0.261, 254, 245, BRAF IN COMPLEX WITH N-(3-(TERT-BUTYL)PHENYL)-4-METHYL-3-(6- MORPHOLINOPYRIMIDIN-4-YL)BENZAMIDE
3848, d4s34A_, 0.7500, 3.35, 0.191, 343, 256, ERK2 (I84A) IN COMPLEX WITH AMP-PNP
3849, d4ek4A_, 0.7500, 2.97, 0.224, 287, 245, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
3850, d3vapA_, 0.7500, 2.85, 0.247, 249, 243, SYNTHESIS AND SAR STUDIES OF IMIDAZO-[12-A]-PYRAZINE AURORA KINASE INHIBITORS WITH IMPROVED OFF TARGET KINASE SELECTIVITY
3851, d3d2kA_, 0.7500, 2.65, 0.243, 245, 239, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240- >ARG MET302->LEU) IN COMPLEX WITH [7-(2-{2-[3-(3-CHLORO- PHENYL)-UREIDO]-THIAZOL-5-YL}-ETHYLAMINO)-PYRAZOLO[43- D]PYRIMIDIN-1-YL]-ACETIC ACID
3852, d1fotA_, 0.7500, 3.17, 0.234, 299, 252, STRUCTURE OF THE UNLIGANDED CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT FROM SACCHAROMYCES CEREVISIAE
3853, d5l4qA_, 0.7499, 2.71, 0.211, 293, 242, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE 1 (AAK1) IN COMPLEX WITH LKB1 (AAK1 DUAL INHIBITOR)
3854, d4xp2A_, 0.7499, 3.47, 0.206, 337, 257, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
3855, d4u45B_, 0.7499, 3.04, 0.220, 295, 250, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 25)
3856, d4eqmE_, 0.7499, 2.94, 0.232, 268, 246, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
3857, d5jt2C1, 0.7498, 2.42, 0.280, 247, 239, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-BISAMIDE
3858, d5d9kA_, 0.7498, 3.08, 0.201, 280, 249, RSK2 N-TERMINAL KINASE IN COMPLEX WITH BI-D1870
3859, d4rmzB_, 0.7498, 3.17, 0.258, 282, 248, CRYSTAL STRUCTURE OF IRAK-4
3860, d4j8mA_, 0.7498, 3.04, 0.239, 265, 247, AURORA A IN COMPLEX WITH CD532
3861, d4eqmF_, 0.7498, 2.94, 0.232, 268, 246, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
3862, d3idpA_, 0.7498, 3.05, 0.270, 255, 248, B-RAF V600E KINASE DOMAIN IN COMPLEX WITH AN AMINOISOQUINOLINE INHIBITOR
3863, d2hwpA_, 0.7498, 1.84, 0.328, 245, 229, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH COVALENT INHIBITOR PD168393
3864, d1golA_, 0.7498, 3.46, 0.198, 357, 257, COORDINATES OF RAT MAP KINASE ERK2 WITH AN ARGININE MUTATION AT POSITION 52
3865, p6g9dA_, 0.7497, 3.39, 0.211, 345, 256, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
3866, d5uitA_, 0.7497, 2.87, 0.278, 284, 245, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 14
3867, d5d10B_, 0.7497, 1.98, 0.342, 247, 231, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL236
3868, d4ztlA_, 0.7497, 3.06, 0.260, 280, 246, IRAK4-INHIBITOR CO-STRUCTURE
3869, d4yfiC_, 0.7497, 2.76, 0.232, 269, 241, TNNI3K COMPLEXED WITH INHIBITOR 1
3870, d4eqmD_, 0.7497, 2.93, 0.232, 268, 246, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
3871, d3iggA_, 0.7497, 2.93, 0.229, 290, 245, NOVEL CDK-5 INHIBITORS - CRYSTAL STRUCTURE OF INHIBITOR EFQ WITH CDK-2
3872, d2hogA_, 0.7497, 3.44, 0.267, 272, 251, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 20
3873, d1y91A_, 0.7497, 2.94, 0.230, 286, 244, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1 5-A]PYRIMIDINE INHIBITOR
3874, d5ci6B_, 0.7496, 2.99, 0.218, 350, 248, CRYSTAL STRUCTURE OF ARABIDOPSIS THALIANA MPK6
3875, d4fuxA_, 0.7496, 3.30, 0.200, 342, 255, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E75
3876, d3qquA_, 0.7496, 3.11, 0.312, 285, 250, COCRYSTAL STRUCTURE OF UNPHOSPHORYLATED IGF WITH PYRIMIDINE 8
3877, d3ns9A_, 0.7496, 2.96, 0.229, 289, 245, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH INHIBITOR BS-194
3878, d3bizA_, 0.7496, 2.74, 0.202, 250, 242, WEE1 KINASE COMPLEX WITH INHIBITOR PD331618
3879, d2ofvA2, 0.7496, 2.31, 0.355, 243, 234, CRYSTAL STRUCTURE OF AMINOQUINAZOLINE 1 BOUND TO LCK
3880, d5iexA_, 0.7495, 2.99, 0.235, 285, 247, CRYSTAL STRUCTURE OF (RS)-S-{4-[(5-BROMO-4-{[(2R3R)-2-HYDROXY-1- METHYLPROPYL]OXY}- PYRIMIDIN-2-YL)AMINO]PHENYL}-S- CYCLOPROPYLSULFOXIMIDE BOUND TO CDK2
3881, d4ek3A_, 0.7495, 2.99, 0.229, 287, 245, CRYSTAL STRUCTURE OF APO CDK2
3882, d3oriD_, 0.7495, 2.91, 0.220, 267, 245, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 1)
3883, d1v0oA_, 0.7495, 2.87, 0.206, 276, 243, STRUCTURE OF P. FALCIPARUM PFPK5-INDIRUBIN-5-SULPHONATE LIGAND COMPLEX
3884, d4zsjA_, 0.7494, 3.52, 0.213, 344, 258, MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR
3885, d4xrlA_, 0.7494, 3.42, 0.207, 337, 256, CRYSTAL STRUCTURE AT ROOM TEMPERATURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
3886, d4dbnB_, 0.7494, 2.88, 0.252, 263, 246, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN B-RAF WITH A [1 3]THIAZOLO[54-B]PYRIDINE DERIVATIVE
3887, d2qlqA_, 0.7494, 1.92, 0.345, 245, 229, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN WITH COVALENT INHIBITOR RL3
3888, d2c6mA_, 0.7494, 2.99, 0.223, 290, 247, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
3889, d1nvqA_, 0.7494, 3.44, 0.267, 264, 251, THE COMPLEX STRUCTURE OF CHECKPOINT KINASE CHK1/UCN-01
3890, p4ux9A_, 0.7493, 3.24, 0.194, 343, 253, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
3891, d2x8iA_, 0.7493, 3.31, 0.256, 261, 250, DISCOVERY OF A NOVEL CLASS OF TRIAZOLONES AS CHECKPOINT KINASE INHIBITORS - HIT TO LEAD EXPLORATION
3892, d2b52A_, 0.7493, 2.77, 0.214, 283, 243, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DPH- 042562
3893, d1nvrA_, 0.7492, 3.43, 0.271, 264, 251, THE COMPLEX STRUCTURE OF CHECKPOINT KINASE CHK1/STAUROSPORINE
3894, d1f5qA_, 0.7492, 3.19, 0.210, 296, 252, CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO HUMAN CYCLIN DEPENDENT KINASE 2
3895, d4wovA_, 0.7491, 2.76, 0.250, 258, 244, CRYSTAL STRUCTURE OF TYROSINE KINASE 2 JH2 (PSEUDO KINASE DOMAIN) COMPLEXED WITH BMS-066 AKA 2-METHOXY-N-({6-[3-METHYL-7-(METHYLAMINO)- 35810-TETRAAZATRICYCLO[7.3.0.0 6]DODECA-1(9)2(6)4711-PENTAEN- 11-YL]PYRIDIN-2-YL}METHY L)ACETAMIDE
3896, d4ithA_, 0.7491, 2.14, 0.279, 247, 233, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-1 ANALOG
3897, d2z7rA_, 0.7491, 2.56, 0.217, 265, 240, CRYSTAL STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF HUMAN RSK1 BOUND TO STAUROSPORINE
3898, d5wdyA_, 0.7490, 2.78, 0.241, 260, 241, CRYSTAL STRUCTURE OF WNK1 IN COMPLEX WITH 1-CYCLOHEXYL-N-({6-FLUORO-1- [2-(3-METHOXYPHENYL)PYRIDIN-4-YL]-1H-INDOL-3-YL}METHYL)METHANAMINE (COMPOUND 6)
3899, d5k7gC_, 0.7490, 3.15, 0.263, 283, 247, IRAK4 IN COMPLEX WITH AZ3862
3900, d5c9cA_, 0.7490, 2.87, 0.269, 254, 245, CRYSTAL STRUCTURE OF BRAF(V600E) IN COMPLEX WITH LY3009120 COMPND
3901, d4fkvA_, 0.7490, 2.78, 0.226, 282, 243, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
3902, d4fkqA_, 0.7490, 2.82, 0.230, 283, 244, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
3903, d3pyyA1, 0.7490, 2.52, 0.359, 251, 237, DISCOVERY AND CHARACTERIZATION OF A CELL-PERMEABLE SMALL-MOLECULE C- ABL KINASE ACTIVATOR THAT BINDS TO THE MYRISTOYL BINDING SITE
3904, d3oriC_, 0.7490, 2.93, 0.220, 267, 245, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 1)
3905, d3c9wA2, 0.7490, 3.08, 0.211, 335, 247, CRYSTAL STRUCTURE OF ERK-2 WITH HYPOTHEMYCIN COVALENTLY BOUND
3906, d2vtlA_, 0.7490, 2.92, 0.229, 290, 245, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
3907, d5k7gD_, 0.7489, 3.18, 0.259, 283, 247, IRAK4 IN COMPLEX WITH AZ3862
3908, d5hieD_, 0.7489, 2.61, 0.256, 253, 242, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
3909, d4g6oA_, 0.7489, 3.33, 0.205, 339, 254, CRYSTAL STRUCTURE OF THE ERK2
3910, d4fszA_, 0.7489, 3.27, 0.254, 268, 248, CRYSTAL STRUCTURE OF THE CHK1
3911, d3umxA_, 0.7489, 2.80, 0.227, 261, 242, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH INHIBITOR (Z)-2-[(1H- INDOL-3-YL)METHYLENE]-7-(AZEPAN-1-YLMETHYL)-6-HYDROXYBENZOFURAN- 3(2H)-ONE
3912, d5w85B_, 0.7488, 2.78, 0.280, 279, 243, CRYSTAL STRUCTURE OF IRAK-4 WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 9)
3913, d5o23A_, 0.7488, 3.32, 0.230, 269, 252, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED APO STATE
3914, d3is5F1, 0.7488, 2.97, 0.243, 259, 247, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
3915, d2r3iA_, 0.7488, 3.02, 0.228, 289, 246, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
3916, p6gdmA_, 0.7487, 3.46, 0.223, 341, 256, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
3917, d4yfiA_, 0.7487, 2.73, 0.229, 268, 240, TNNI3K COMPLEXED WITH INHIBITOR 1
3918, d4iz7A_, 0.7487, 3.24, 0.209, 344, 253, STRUCTURE OF NON-PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
3919, d2weiA1, 0.7487, 3.31, 0.231, 269, 251, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE IN COMPLEX WITH 3- MB-PP1
3920, d1h0wA_, 0.7487, 2.84, 0.225, 283, 244, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 2-AMINO-6-[CYCLOHEX-3-ENYL]METHOXYPURINE
3921, p6ge0A_, 0.7486, 3.47, 0.211, 343, 256, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
3922, d5uiuB_, 0.7486, 3.15, 0.266, 287, 248, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 30
3923, d4y73D_, 0.7486, 3.25, 0.268, 288, 250, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN WITH INHIBITOR
3924, d4ntsA_, 0.7486, 3.27, 0.224, 341, 254, APO STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE
3925, d4mygB_, 0.7486, 3.37, 0.196, 335, 255, MAPK13 ACTIVE FORM
3926, d4kaoA_, 0.7486, 3.09, 0.368, 252, 247, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 1-(5-TERT- BUTYL-2-P-TOLYL-2H-PYRAZOL-3-YL)-3-(4-PYRIDIN-3- YL-PHENYL)-UREA
3927, d3sqqA_, 0.7486, 2.84, 0.209, 288, 244, CDK2 IN COMPLEX WITH INHIBITOR RC-3-96
3928, d3py3A1, 0.7486, 3.49, 0.202, 352, 257, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38ALPHA MAP KINASE
3929, d3r7iA_, 0.7485, 2.91, 0.225, 282, 244, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-74
3930, d2vtrA_, 0.7485, 3.02, 0.228, 290, 246, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
3931, d2r3pA_, 0.7485, 2.93, 0.224, 289, 245, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
3932, d1oirA_, 0.7485, 2.95, 0.221, 286, 244, IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION
3933, d5dlsA_, 0.7484, 3.33, 0.253, 257, 249, IDENTIFICATION OF NOVEL IN VIVO ACTIVE CHK1 INHIBITORS UTILIZING STRUCTURE GUIDED DRUG DESIGN
3934, d4aaaA1, 0.7484, 3.09, 0.225, 290, 249, CRYSTAL STRUCTURE OF THE HUMAN CDKL2 KINASE DOMAIN
3935, d4obqA_, 0.7483, 2.72, 0.244, 275, 242, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 31) N-[3-(4- AMINOQUINAZOLIN-6-YL)-5-FLUOROPHENYL]-2-(PYRROLIDIN-1-YL)ACETAMIDE
3936, d4l42A_, 0.7483, 3.32, 0.222, 299, 252, CRYSTAL STRUCTURES OF HUMAN P70S6K1-PIF
3937, d3c9wB2, 0.7483, 3.21, 0.222, 335, 248, CRYSTAL STRUCTURE OF ERK-2 WITH HYPOTHEMYCIN COVALENTLY BOUND
3938, d5mqvD_, 0.7482, 3.46, 0.226, 287, 261, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
3939, d4y73B_, 0.7482, 3.09, 0.271, 289, 247, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN WITH INHIBITOR
3940, d4hniA_, 0.7482, 3.33, 0.230, 284, 257, CRYSTAL STRUCTURE OF CK1E IN COMPLEX WITH PF4800567
3941, d4fklA_, 0.7482, 2.94, 0.224, 290, 245, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
3942, d2z7lA_, 0.7482, 3.38, 0.200, 329, 255, UNPHOSPHORYLATED MITOGEN ACTIVATED PROTEIN KINASE ERK2 IN COMPLEX WITH (4-{[5-CARBAMOYL-4-(3-METHYLANILINO)PYRIMIDIN 2-YL]AMINO}PHENYL)ACETIC ACID
3943, d2r3hA_, 0.7482, 2.89, 0.230, 289, 244, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
3944, p6g92A_, 0.7481, 3.60, 0.217, 343, 258, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
3945, d5ih9A_, 0.7481, 2.66, 0.278, 308, 241, MELK IN COMPLEX WITH NVS-MELK8A
3946, d4zy5B_, 0.7481, 3.36, 0.227, 287, 255, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 17
3947, d4kspB_, 0.7481, 2.89, 0.265, 256, 245, CRYSTAL STRUCTURE OF HUMAN B-RAF BOUND TO A DFG-OUT INHIBITOR TAK-632
3948, d3ma3A_, 0.7481, 2.66, 0.237, 266, 241, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND A NAPHTHO-DIFURAN LIGAND
3949, d2r3fA_, 0.7481, 2.94, 0.229, 290, 245, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
3950, p5oatF_, 0.7480, 3.43, 0.190, 359, 258, PINK1 STRUCTURE
3951, d2ds1A_, 0.7480, 2.96, 0.233, 290, 245, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
3952, d5lckA_, 0.7479, 3.36, 0.200, 345, 255, A CLICKABLE COVALENT ERK 1/2 INHIBITOR
3953, d5cwzC_, 0.7479, 2.62, 0.237, 271, 240, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE
3954, d4zzoA_, 0.7479, 3.34, 0.200, 339, 255, HUMAN ERK2 IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR
3955, d4b0gA_, 0.7479, 2.70, 0.228, 247, 241, COMPLEX OF AURORA-A BOUND TO AN IMIDAZOPYRIDINE-BASED INHIBITOR
3956, d1erkA_, 0.7479, 3.50, 0.206, 357, 257, STRUCTURE OF SIGNAL-REGULATED KINASE
3957, p6g8xA_, 0.7478, 3.47, 0.202, 338, 258, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
3958, d5nhfA_, 0.7478, 3.45, 0.211, 339, 256, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
3959, d4lggB_, 0.7478, 2.24, 0.349, 245, 232, STRUCTURE OF 3MB-PP1 BOUND TO ANALOG-SENSITIVE SRC KINASE
3960, d3pyyB1, 0.7478, 2.06, 0.359, 244, 231, DISCOVERY AND CHARACTERIZATION OF A CELL-PERMEABLE SMALL-MOLECULE C- ABL KINASE ACTIVATOR THAT BINDS TO THE MYRISTOYL BINDING SITE
3961, d3py1A1, 0.7478, 2.94, 0.206, 298, 247, CDK2 TERNARY COMPLEX WITH SU9516 AND ANS
3962, d2c6lA_, 0.7478, 2.98, 0.224, 291, 246, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
3963, d2c6iA_, 0.7478, 3.03, 0.227, 292, 247, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
3964, d2c6dA_, 0.7478, 2.99, 0.242, 254, 244, AURORA A KINASE ACTIVATED MUTANT (T287D) IN COMPLEX WITH ADPNP
3965, d3we4A_, 0.7477, 3.25, 0.224, 286, 250, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PYRIMIDINE DERIVATIVE PF-4708671 2-{[4-(5-ETHYLPYRIMIDIN-4-YL)PIPERAZIN-1- YL]METHYL}-5-(TRIFLUOROMETHYL)-1H-BENZIMIDAZOLE
3966, d3my0K_, 0.7477, 3.20, 0.245, 261, 249, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3967, p6cpwA_, 0.7476, 3.35, 0.209, 328, 253, DISCOVERY OF 3(S)-THIOMETHYL PYRROLIDINE ERK INHIBITORS FOR ONCOLOGY 
3968, d4yc6G_, 0.7476, 3.07, 0.211, 285, 247, CDK1/CKS1
3969, d2fysB_, 0.7476, 3.13, 0.203, 338, 251, CRYSTAL STRUCTURE OF ERK2 COMPLEX WITH KIM PEPTIDE DERIVED FROM MKP3
3970, d5ih8A_, 0.7475, 2.68, 0.279, 306, 240, MELK IN COMPLEX WITH NVS-MELK1
3971, d4zsgA_, 0.7475, 3.55, 0.208, 347, 259, MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR
3972, d4xp3A_, 0.7475, 3.50, 0.198, 339, 257, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
3973, d3lokB_, 0.7475, 1.82, 0.355, 242, 228, DRUG RESISTANT CSRC KINASE DOMAIN IN COMPLEX WITH COVALENT INHIBITOR PD168393
3974, d1pxmA_, 0.7475, 3.00, 0.228, 290, 246, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 3-[4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2- YLAMINO]-PHENOL
3975, d4s31A_, 0.7474, 3.49, 0.206, 347, 257, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 1 WTERK2 AT 1.45A
3976, d3qrjB1, 0.7474, 2.56, 0.363, 252, 237, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN T315I MUTANT IN COMPLEX WITH DCC-2036
3977, d2vtmA_, 0.7474, 3.04, 0.228, 290, 246, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
3978, d2hwoB_, 0.7474, 1.83, 0.338, 242, 228, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH COVALENT INHIBITOR
3979, d3r8mA_, 0.7473, 2.94, 0.224, 286, 246, CDK2 IN COMPLEX WITH INHIBITOR L3-3
3980, d3qquB_, 0.7473, 3.30, 0.306, 288, 252, COCRYSTAL STRUCTURE OF UNPHOSPHORYLATED IGF WITH PYRIMIDINE 8
3981, d5umoA_, 0.7472, 3.41, 0.203, 347, 256, STRUCTURE OF EXTRACELLULAR SIGNAL-REGULATED KINASE
3982, d3op5B_, 0.7472, 3.58, 0.152, 319, 263, HUMAN VACCINIA-RELATED KINASE 1
3983, d2w1hA_, 0.7472, 2.90, 0.229, 283, 245, FRAGMENT-BASED DISCOVERY OF THE PYRAZOL-4-YL UREA (AT9283) A MULTI-TARGETED KINASE INHIBITOR WITH POTENT AURORA KINASE ACTIVITY
3984, d4fkiA_, 0.7471, 2.81, 0.227, 287, 242, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
3985, d3zfyA_, 0.7471, 2.95, 0.289, 260, 242, CRYSTAL STRUCTURE OF EPHB3
3986, d5fdxB_, 0.7470, 3.04, 0.371, 274, 245, STRUCTURE OF DDR1 RECEPTOR TYROSINE KINASE IN COMPLEX WITH D2164 INHIBITOR AT 2.65 ANGSTROMS RESOLUTION.
3987, p6g9nA_, 0.7469, 3.51, 0.219, 344, 256, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
3988, d1ckiB_, 0.7469, 3.46, 0.208, 286, 259, RECOMBINANT CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317
3989, d5mqvB_, 0.7468, 3.48, 0.226, 287, 261, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
3990, d5ieyA_, 0.7468, 2.98, 0.228, 286, 246, CRYSTAL STRUCTURE OF A CDK INHIBITOR BOUND TO CDK2
3991, d4ztqA_, 0.7468, 2.75, 0.237, 247, 241, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO FK932
3992, p4ux9C_, 0.7468, 3.14, 0.197, 333, 249, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
3993, d4fc0B_, 0.7468, 2.99, 0.264, 263, 246, CRYSTAL STRUCTURE OF HUMAN KINASE DOMAIN OF B-RAF WITH A DFG-OUT INHIBITOR
3994, d3wf7A_, 0.7468, 3.40, 0.247, 288, 251, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PURINE DERIVATIVE 1-(9H-PURIN-6-YL)-N-[3-(TRIFLUOROMETHYL)PHENYL]PIPERIDINE- 4-CARBOXAMIDE
3995, d2c6eA_, 0.7468, 2.97, 0.241, 251, 245, AURORA A KINASE ACTIVATED MUTANT (T287D) IN COMPLEX WITH A 5-AMINOPYRIMIDINYL QUINAZOLINE INHIBITOR
3996, d5t1tB_, 0.7467, 2.90, 0.273, 280, 242, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
3997, d5mhqA1, 0.7467, 2.95, 0.221, 288, 244, CCT068127 IN COMPLEX WITH CDK2
3998, d3dakD_, 0.7467, 3.28, 0.235, 284, 247, CRYSTAL STRUCTURE OF DOMAIN-SWAPPED OSR1 KINASE DOMAIN
3999, d4kbaB_, 0.7466, 3.45, 0.224, 285, 259, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
4000, d3r63A_, 0.7466, 3.43, 0.203, 347, 256, STRUCTURE OF ERK2 (SPE) MUTANT (S246E)
4001, d2vtoA_, 0.7466, 2.87, 0.230, 283, 243, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
4002, d5mqvE_, 0.7465, 3.48, 0.222, 287, 261, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
4003, d5eykA_, 0.7465, 3.08, 0.188, 263, 250, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH BI 847325
4004, d4kb8B_, 0.7465, 3.46, 0.216, 285, 259, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
4005, p4h3pD_, 0.7465, 3.27, 0.224, 338, 250, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
4006, d3my0X_, 0.7465, 3.18, 0.255, 257, 247, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4007, d2bvaB_, 0.7465, 3.02, 0.198, 274, 247, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4
4008, d1h01A_, 0.7465, 2.97, 0.225, 286, 244, CDK2 IN COMPLEX WITH A DISUBSTITUTED 2 4-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
4009, d5v19A_, 0.7464, 2.43, 0.236, 250, 237, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
4010, d5d9hA_, 0.7464, 3.31, 0.239, 290, 247, CRYSTAL STRUCTURE OF SPAK (STK39) DIMER IN THE BASAL ACTIVITY STATE
4011, d5byyA_, 0.7464, 3.36, 0.213, 338, 254, ERK5 IN COMPLEX WITH SMALL MOLECULE
4012, d4xneA_, 0.7464, 3.33, 0.200, 344, 255, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
4013, d3h10B_, 0.7464, 3.14, 0.242, 267, 248, AURORA A INHIBITOR COMPLEX
4014, d2wmrA_, 0.7464, 3.20, 0.264, 254, 246, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4015, d2jfmA_, 0.7464, 3.02, 0.205, 287, 244, CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE (UNLIGANDED FORM)
4016, d5w85A_, 0.7463, 3.02, 0.270, 278, 244, CRYSTAL STRUCTURE OF IRAK-4 WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 9)
4017, d4zznA_, 0.7463, 3.44, 0.207, 338, 256, HUMAN ERK2 IN COMPLEX WITH AN INHIBITOR
4018, d4hniB_, 0.7463, 3.38, 0.233, 284, 257, CRYSTAL STRUCTURE OF CK1E IN COMPLEX WITH PF4800567
4019, d4byjA_, 0.7463, 2.72, 0.225, 246, 240, AURORA A KINASE BOUND TO A HIGHLY SELECTIVE IMIDAZOPYRIDINE INHIBITOR
4020, d3wblA_, 0.7463, 2.89, 0.225, 283, 244, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH PYRAZOLOPYRIMIDINE INHIBITOR
4021, d2j51A_, 0.7463, 2.95, 0.210, 288, 243, CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE BOUND TO 5- AMINO-3-((4-(AMINOSULFONYL)PHENYL)AMINO)-N-(26- DIFLUOROPHENYL)-1H-124-TRIAZOLE-1-CARBOTHIOAMIDE
4022, d4ztmB_, 0.7462, 2.87, 0.270, 280, 241, IRAK4-INHIBITOR CO-STRUCTURE
4023, d4g6nA_, 0.7462, 3.46, 0.207, 341, 256, CRYSTAL STRUCTURE OF THE ERK2
4024, d5uiuA_, 0.7461, 3.25, 0.265, 286, 249, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 30
4025, d4ftuA_, 0.7461, 3.46, 0.271, 270, 251, CRYSTAL STRUCTURE OF THE CHK1
4026, d3ag9A_, 0.7461, 3.30, 0.217, 323, 254, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1012
4027, d2qhnA_, 0.7461, 3.30, 0.259, 268, 247, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 1A
4028, d1h07A_, 0.7461, 2.82, 0.222, 285, 243, CDK2 IN COMPLEX WITH A DISUBSTITUTED 4 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
4029, d4yffD_, 0.7460, 2.78, 0.242, 257, 240, TNNI3K COMPLEXED WITH INHIBITOR 2
4030, d3h10A_, 0.7460, 3.16, 0.242, 268, 248, AURORA A INHIBITOR COMPLEX
4031, d3fz1A_, 0.7460, 2.87, 0.230, 284, 243, CRYSTAL STRUCTURE OF A BENZTHIOPHENE INHIBITOR BOUND TO HUMAN CYCLIN-DEPENDENT KINASE-2 (CDK-2)
4032, d2jflA_, 0.7460, 3.05, 0.209, 286, 244, CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE ( DIPHOSPHORYLATED FORM) BOUND TO 5- AMINO-3-((4-( AMINOSULFONYL)PHENYL)AMINO)-N-(26- DIFLUOROPHENYL)-1H-12 4-TRIAZOLE-1-CARBOTHIOAMIDE
4033, d1e1vA_, 0.7460, 2.96, 0.224, 290, 245, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU2058
4034, d5c9cB_, 0.7459, 2.94, 0.273, 251, 245, CRYSTAL STRUCTURE OF BRAF(V600E) IN COMPLEX WITH LY3009120 COMPND
4035, d4obpB_, 0.7459, 3.03, 0.218, 290, 248, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 29) 6-(2-FLUOROPYRIDIN-4- YL)PYRIDO[32-D]PYRIMIDIN-4-AMINE
4036, d2qhmA_, 0.7459, 3.28, 0.259, 268, 247, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 2A
4037, d1ckpA_, 0.7459, 2.80, 0.228, 279, 241, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR PURVALANOL B
4038, d5k75B_, 0.7458, 2.79, 0.273, 274, 242, IRAK4 IN COMPLEX WITH COMPOUND 1
4039, d4s2zA_, 0.7458, 3.45, 0.207, 346, 256, ERK2 INTRINSICALLY ACTIVE MUTANT R65S
4040, d4lg4B_, 0.7458, 2.95, 0.235, 284, 243, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
4041, d4btkA_, 0.7458, 3.30, 0.184, 287, 256, TTBK1 IN COMPLEX WITH INHIBITOR
4042, d3qywA_, 0.7458, 3.53, 0.202, 340, 257, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
4043, d1v0oB_, 0.7458, 2.83, 0.219, 274, 242, STRUCTURE OF P. FALCIPARUM PFPK5-INDIRUBIN-5-SULPHONATE LIGAND COMPLEX
4044, d5jq5A_, 0.7457, 2.95, 0.230, 287, 243, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH INHIBITOR ICEC0942
4045, d4rzvB1, 0.7457, 2.71, 0.269, 254, 242, CRYSTAL STRUCTURE OF THE BRAF (R509H) KINASE DOMAIN MONOMER BOUND TO VEMURAFENIB
4046, d4jikA_, 0.7457, 3.21, 0.260, 256, 246, X-RAY CRYSTAL STRUCTURE OF COMPOUND 22A (R)-2-(4-CHLOROPHENYL)-8- (PIPERIDIN-3-YLAMINO)IMIDAZO[12-C]PYRIMIDINE-5-CARBOXAMIDE BOUND TO HUMAN CHK1 KINASE DOMAIN
4047, d2fumD_, 0.7457, 2.76, 0.219, 258, 242, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
4048, d1sykA_, 0.7457, 3.35, 0.220, 348, 254, CRYSTAL STRUCTURE OF E230Q MUTANT OF CAMP-DEPENDENT PROTEIN KINASE REVEALS UNEXPECTED APOENZYME CONFORMATION
4049, d4ae6B_, 0.7456, 3.30, 0.221, 321, 253, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT CALPHA 2
4050, d2iwiB_, 0.7456, 2.65, 0.226, 249, 239, CRYSTAL STRUCTURE OF THE HUMAN PIM2 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU1
4051, d5k72A_, 0.7455, 2.70, 0.279, 277, 240, IRAK4 IN COMPLEX WITH COMPOUND 21
4052, d4zzmA_, 0.7455, 3.40, 0.200, 344, 255, HUMAN ERK2 IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR
4053, d4zjiA_, 0.7455, 3.16, 0.211, 278, 251, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
4054, d4ft0A_, 0.7455, 3.41, 0.264, 266, 250, CRYSTAL STRUCTURE OF THE CHK1
4055, d3r7uA_, 0.7455, 2.96, 0.230, 282, 244, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-75
4056, d1sykB_, 0.7455, 3.34, 0.209, 323, 254, CRYSTAL STRUCTURE OF E230Q MUTANT OF CAMP-DEPENDENT PROTEIN KINASE REVEALS UNEXPECTED APOENZYME CONFORMATION
4057, d5k4iA_, 0.7454, 3.29, 0.216, 336, 250, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH COMPOUND 22
4058, d4nfnA_, 0.7454, 3.51, 0.197, 293, 259, HUMAN TAU TUBULIN KINASE 1 (TTBK1) COMPLEXED WITH 3-({5-[(4-AMINO-4- METHYLPIPERIDIN-1-YL)METHYL]PYRROLO[21-F][124]TRIAZIN-4-YL}AMINO)- 5-BROMOPHENOL
4059, d4hokW_, 0.7454, 3.63, 0.215, 289, 261, CRYSTAL STRUCTURE OF APO CK1E
4060, d5tf9B_, 0.7453, 3.07, 0.255, 266, 243, CRYSTAL STRUCTURE OF WNK1 IN COMPLEX WITH MN2+AMPPNP AND WNK476
4061, d5ievA_, 0.7453, 2.95, 0.229, 284, 245, CRYSTAL STRUCTURE OF BAY 1000394 (RONICICLIB) BOUND TO CDK2
4062, d2r0uA_, 0.7453, 3.35, 0.258, 269, 248, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 54
4063, d4zy4B_, 0.7452, 3.31, 0.232, 292, 254, CRYSTAL STRUCTURE OF P21 ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 4
4064, d4u3zA_, 0.7452, 3.07, 0.230, 282, 248, APO MAP4K4 T181E PHOSPHOMIMETIC MUTANT
4065, d4fkoA_, 0.7452, 2.93, 0.218, 291, 243, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
4066, d1fvtA_, 0.7452, 2.97, 0.230, 282, 244, THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH AN OXINDOLE INHIBITOR
4067, d5byzA_, 0.7451, 3.55, 0.223, 348, 256, ERK5 IN COMPLEX WITH SMALL MOLECULE
4068, d4zjiB_, 0.7450, 3.13, 0.223, 276, 251, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
4069, p4ux9B_, 0.7450, 3.09, 0.194, 327, 247, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
4070, d4gt3A_, 0.7450, 3.60, 0.218, 347, 257, ATP-BOUND FORM OF THE ERK2 KINASE
4071, d4fkrA_, 0.7450, 2.86, 0.230, 282, 243, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
4072, d3q96B_, 0.7450, 2.99, 0.268, 262, 246, B-RAF KINASE DOMAIN IN COMPLEX WITH A TETRAHYDRONAPHTHALENE INHIBITOR
4073, d2c47D1, 0.7450, 3.33, 0.163, 289, 257, STRUCTURE OF CASEIN KINASE 1 GAMMA 2
4074, d6bu6B_, 0.7449, 3.59, 0.162, 307, 260, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
4075, d4lg4A_, 0.7449, 3.23, 0.231, 289, 251, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
4076, d4kbkA_, 0.7449, 3.38, 0.218, 283, 257, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
4077, d4au8B_, 0.7449, 2.79, 0.205, 277, 244, CRYSTAL STRUCTURE OF COMPOUND 4A IN COMPLEX WITH CDK5 SHOWING AN UNUSUAL BINDING MODE TO THE HINGE REGION VIA A WATER MOLECULE
4078, d3w8qA_, 0.7449, 3.30, 0.187, 318, 251, STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1)
4079, d5d9hB_, 0.7448, 3.33, 0.239, 293, 247, CRYSTAL STRUCTURE OF SPAK (STK39) DIMER IN THE BASAL ACTIVITY STATE
4080, d4tn6B_, 0.7448, 3.44, 0.212, 285, 259, CK1D IN COMPLEX WITH INHIBITOR
4081, d4hokE_, 0.7448, 3.66, 0.214, 291, 262, CRYSTAL STRUCTURE OF APO CK1E
4082, d3o50B_, 0.7448, 2.83, 0.232, 249, 241, CRYSTAL STRUCTURE OF BENZAMIDE 9 BOUND TO AURORAA
4083, d2wqnA_, 0.7448, 2.88, 0.261, 259, 245, STRUCTURE OF ADP-BOUND HUMAN NEK7
4084, d2uv2A1, 0.7448, 2.99, 0.207, 286, 242, CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE BOUND TO 4-(4-( 5-CYCLOPROPYL-1H-PYRAZOL-3-YLAMINO)-QUINAZOLIN-2-YLAMINO)- PHENYL)-ACETONITRILE
4085, d5ko1A_, 0.7447, 2.96, 0.218, 265, 248, PSEUDOKINASE DOMAIN OF MLKL BOUND TO COMPOUND 4.
4086, d4m67A_, 0.7447, 2.83, 0.220, 264, 246, CRYSTAL STRUCTURE OF THE HUMAN MLKL KINASE-LIKE DOMAIN
4087, d3nw5A_, 0.7447, 3.46, 0.320, 302, 253, CRYSTAL STRUCTURE OF INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R-WT) COMPLEX WITH A CARBON-LINKED PROLINE ISOSTERE INHIBITOR (11B)
4088, d4yffA_, 0.7446, 2.92, 0.240, 264, 242, TNNI3K COMPLEXED WITH INHIBITOR 2
4089, d4u3zB_, 0.7446, 3.14, 0.220, 294, 250, APO MAP4K4 T181E PHOSPHOMIMETIC MUTANT
4090, d4s30A_, 0.7446, 3.52, 0.206, 342, 257, ERK2 INTRINSICALLY ACTIVE MUTANT (I84A)
4091, d3s2pA_, 0.7446, 2.81, 0.232, 279, 241, CRYSTAL STRUCTURE OF CDK2 WITH A 2-AMINOPYRIMIDINE COMPOUND
4092, d3i60A_, 0.7446, 3.06, 0.216, 335, 245, CRYSTAL STRUCTURE OF ERK2 BOUND TO (S)-4-(2-(2-CHLOROPHENYLAMINO)-5- METHYLPYRIMIDIN-4-YL)-N-(2-HYDROXY-1-PHENYLETHYL)-1H-PYRROLE-2- CARBOXAMIDE
4093, d2r64A_, 0.7446, 2.81, 0.228, 279, 241, CRYSTAL STRUCTURE OF A 3-AMINOINDAZOLE COMPOUND WITH CDK2
4094, d5v24A_, 0.7445, 2.54, 0.239, 249, 238, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
4095, d4hnfA_, 0.7445, 3.62, 0.213, 289, 263, CRYSTAL STRUCTURE OF CK1D IN COMPLEX WITH PF4800567
4096, d4aguC_, 0.7445, 2.92, 0.221, 278, 244, CRYSTAL STRUCTURE OF THE HUMAN CDKL1 KINASE DOMAIN
4097, d3i81A_, 0.7445, 3.24, 0.308, 296, 250, CRYSTAL STRUCTURE OF INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R-WT) COMPLEX WITH BMS-754807 [1-(4-((5-CYCLOPROPYL- 1H-PYRAZOL-3-YL)AMINO)PYRROLO[21-F][124]TRIAZIN-2-YL)-N- (6-FLUORO-3-PYRIDINYL)-2-METHYL-L-PROLINAMIDE]
4098, d1pmeA_, 0.7445, 3.37, 0.209, 333, 254, STRUCTURE OF PENTA MUTANT HUMAN ERK2 MAP KINASE COMPLEXED WITH A SPECIFIC INHIBITOR OF HUMAN P38 MAP KINASE
4099, p5oo0A_, 0.7444, 2.99, 0.224, 288, 245, CDK2(WT) COVALENT ADDUCT WITH D28 AT C177
4100, d4wovB_, 0.7444, 2.84, 0.243, 256, 243, CRYSTAL STRUCTURE OF TYROSINE KINASE 2 JH2 (PSEUDO KINASE DOMAIN) COMPLEXED WITH BMS-066 AKA 2-METHOXY-N-({6-[3-METHYL-7-(METHYLAMINO)- 35810-TETRAAZATRICYCLO[7.3.0.0 6]DODECA-1(9)2(6)4711-PENTAEN- 11-YL]PYRIDIN-2-YL}METHY L)ACETAMIDE
4101, d4lggA_, 0.7444, 1.91, 0.351, 241, 228, STRUCTURE OF 3MB-PP1 BOUND TO ANALOG-SENSITIVE SRC KINASE
4102, d4d2rA_, 0.7444, 3.21, 0.312, 300, 250, HUMAN IGF IN COMPLEX WITH A DYRK1B INHIBITOR
4103, d4iz7C_, 0.7443, 3.26, 0.211, 340, 251, STRUCTURE OF NON-PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
4104, d3zzwB_, 0.7443, 2.94, 0.281, 265, 242, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF ROR2
4105, d3idpB_, 0.7443, 3.05, 0.272, 256, 246, B-RAF V600E KINASE DOMAIN IN COMPLEX WITH AN AMINOISOQUINOLINE INHIBITOR
4106, d3f9nA_, 0.7443, 3.19, 0.261, 253, 245, CRYSTAL STRUCTURE OF CHK1 KINASE IN COMPLEX WITH INHIBITOR 38
4107, d2brhA_, 0.7443, 3.40, 0.269, 257, 249, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
4108, d5ukfC_, 0.7442, 3.54, 0.161, 317, 261, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO AN OXINDOLE INHIBITOR
4109, d4xs2B_, 0.7442, 3.00, 0.266, 278, 241, IRAK4-INHIBITOR CO-STRUCTURE
4110, d4hokU_, 0.7442, 3.59, 0.215, 289, 261, CRYSTAL STRUCTURE OF APO CK1E
4111, d4fsyA_, 0.7442, 3.39, 0.254, 267, 248, CRYSTAL STRUCTURE OF THE CHK1
4112, d5uisB_, 0.7440, 2.94, 0.260, 274, 242, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 12
4113, d4nfmA_, 0.7440, 3.51, 0.197, 293, 259, HUMAN TAU TUBULIN KINASE 1 (TTBK1)
4114, d2ja0A_, 0.7440, 3.00, 0.207, 285, 242,  
4115, d4fkgA_, 0.7439, 2.81, 0.232, 286, 241, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
4116, d4d4rA_, 0.7439, 2.90, 0.363, 251, 245, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4117, d2w06A_, 0.7439, 2.89, 0.230, 282, 243, STRUCTURE OF CDK2 IN COMPLEX WITH AN IMIDAZOLYL PYRIMIDINE COMPOUND 5C
4118, d2qolA_, 0.7438, 3.22, 0.317, 271, 246, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596:Y602:S768G TRIPLE MUTANT
4119, d2f49A_, 0.7438, 3.38, 0.222, 335, 252, CRYSTAL STRUCTURE OF FUS3 IN COMPLEX WITH A STE5 PEPTIDE
4120, p5nzzH_, 0.7437, 3.23, 0.197, 335, 249, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
4121, d5ajqB_, 0.7437, 2.85, 0.237, 267, 241, HUMAN LOK (STK10) IN COMPLEX WITH BOSUTINIB
4122, d4xp0A_, 0.7437, 3.46, 0.204, 336, 255, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
4123, d5ew9A_, 0.7436, 3.17, 0.231, 257, 247, CRYSTAL STRUCTURE OF AURORA A KINASE DOMAIN BOUND TO MK-5108
4124, d4uzhA1, 0.7436, 2.89, 0.241, 250, 241, SAR156497 AN EXQUISITELY SELECTIVE INHIBITOR OF AURORA KINASES
4125, d5uvfA_, 0.7435, 3.52, 0.158, 317, 260, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO BI- D1870
4126, d4ae9B_, 0.7435, 3.36, 0.221, 321, 253, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT C ALPHA 2
4127, d2ydjA_, 0.7435, 3.19, 0.265, 252, 245, DISCOVERY OF CHECKPOINT KINASE INHIBITOR AZD7762 BY STRUCTURE BASED DESIGN AND OPTIMIZATION OF THIOPHENE CARBOXAMIDE UREAS
4128, d5k4jA1, 0.7434, 2.85, 0.231, 281, 242, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH COMPOUND 22
4129, d5larA_, 0.7433, 3.59, 0.205, 350, 258, CRYSTAL STRUCTURE OF P38 ALPHA MAPK14 IN COMPLEX WITH VPC00628
4130, d4yffB_, 0.7433, 2.95, 0.240, 264, 242, TNNI3K COMPLEXED WITH INHIBITOR 2
4131, d4u3yA_, 0.7433, 3.49, 0.216, 295, 255, APO MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4)
4132, d4lghA_, 0.7433, 1.90, 0.342, 243, 228, CRYSTAL STRUCTURE OF 1NM-PP1 BOUND TO ANALOG-SENSITIVE SRC KINASE
4133, d3w10A_, 0.7433, 2.93, 0.224, 263, 245, AURORA KINASE A COMPLEXED TO PYRAZOLE AMINOQUINOLINE I
4134, d2wtvD_, 0.7433, 3.16, 0.239, 262, 247, AURORA-A INHIBITOR STRUCTURE
4135, d6b16B_, 0.7432, 3.27, 0.222, 281, 252, P21-ACTIVATED KINASE 1 IN COMPLEX WITH A 4-AZAINDOLE INHIBITOR
4136, d5x18B_, 0.7432, 3.95, 0.157, 294, 267, CRYSTAL STRUCTURE OF CASEIN KINASE I HOMOLOG 1
4137, d5valA_, 0.7432, 2.81, 0.263, 254, 243, BRAF IN COMPLEX WITH N-(3-(TERT-BUTYL)PHENYL)-4-METHYL-3-(6- MORPHOLINOPYRIMIDIN-4-YL)BENZAMIDE
4138, d5fp6A_, 0.7432, 2.82, 0.218, 278, 243, STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH SMALL-MOLECULE LIGAND 3-(47-DICHLORO-1H-INDOL-3-YL)PROP-2-YN-1-OL (AT17833) IN AN ALTERNATE BINDING SITE.
4139, d4qp3A_, 0.7432, 3.39, 0.218, 339, 252, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH (S)-2-((9H-PURIN-6-YL) AMINO)-3-PHENYLPROPAN-1-OL
4140, d4eqmB_, 0.7432, 3.17, 0.235, 269, 247, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
4141, d3qtrA_, 0.7432, 3.00, 0.213, 282, 244, CDK2 IN COMPLEX WITH INHIBITOR RC-1-148
4142, d3comA_, 0.7432, 3.07, 0.243, 264, 247, CRYSTAL STRUCTURE OF MST1 KINASE
4143, d1ke8A_, 0.7432, 2.98, 0.230, 282, 244, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 4-{[(2-OXO- 12-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]AMINO}-N-(13- THIAZOL-2-YL)BENZENESULFONAMIDE
4144, d4ftcA_, 0.7431, 3.34, 0.264, 266, 246, CRYSTAL STRUCTURE OF THE CHK1
4145, d4aguA_, 0.7431, 2.89, 0.214, 277, 243, CRYSTAL STRUCTURE OF THE HUMAN CDKL1 KINASE DOMAIN
4146, d3dakC_, 0.7431, 3.19, 0.237, 281, 245, CRYSTAL STRUCTURE OF DOMAIN-SWAPPED OSR1 KINASE DOMAIN
4147, d2r3gA_, 0.7431, 2.89, 0.223, 287, 242, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
4148, d5es1A_, 0.7430, 3.02, 0.275, 304, 244, CRYSTAL STRUCTURE OF MICROTUBULE AFFINITY-REGULATING KINASE 4 CATALYTIC DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE INHIBITOR
4149, d2wmvA_, 0.7430, 3.06, 0.263, 251, 243, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4150, d2vv9A_, 0.7430, 2.77, 0.224, 279, 241, CDK2 IN COMPLEX WITH AN IMIDAZOLE PIPERAZINE
4151, d2wtvA_, 0.7429, 3.17, 0.239, 262, 247, AURORA-A INHIBITOR STRUCTURE
4152, d2w5hA1, 0.7429, 2.91, 0.239, 257, 243, HUMAN NEK2 KINASE APO
4153, d2f9gA_, 0.7429, 3.17, 0.219, 332, 247, CRYSTAL STRUCTURE OF FUS3 PHOSPHORYLATED ON TYR182
4154, d2c6eB_, 0.7429, 2.78, 0.233, 246, 240, AURORA A KINASE ACTIVATED MUTANT (T287D) IN COMPLEX WITH A 5-AMINOPYRIMIDINYL QUINAZOLINE INHIBITOR
4155, d4zjjA_, 0.7428, 3.12, 0.199, 280, 251, PAK1 IN COMPLEX WITH (S)-N-(TERT-BUTYL)-3-((2-CHLORO-5-ETHYL-8-FLUORO- DIBENZODIAZEPIN-11-YL)AMINO)PYRROLIDINE-1-CARBOXAMIDE
4156, d3le6A_, 0.7428, 2.99, 0.230, 283, 243, THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH A PYRAZOLOBENZODIAZEPINE INHIBITOR
4157, d2vtsA_, 0.7428, 2.90, 0.231, 282, 242, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
4158, d2j50B_, 0.7428, 2.88, 0.240, 249, 242, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-739358
4159, d2j50A_, 0.7428, 2.88, 0.240, 249, 242, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-739358
4160, d4zslA_, 0.7427, 3.48, 0.216, 341, 255, MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR
4161, d4yffC_, 0.7427, 2.78, 0.243, 258, 239, TNNI3K COMPLEXED WITH INHIBITOR 2
4162, d4tthB_, 0.7427, 2.68, 0.200, 256, 240, CRYSTAL STRUCTURE OF A CDK6/VCYCLIN COMPLEX WITH INHIBITOR BOUND
4163, d4fv6A_, 0.7427, 2.99, 0.209, 332, 244, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E57
4164, d4fg8A_, 0.7427, 2.46, 0.234, 263, 235, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-315 IN COMPLEX WITH ATP
4165, d1jsvA_, 0.7427, 2.90, 0.223, 287, 242, THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4-[(6-AMINO-4-PYRIMIDINYL) AMINO]BENZENESULFONAMIDE
4166, p6g9jA_, 0.7426, 3.46, 0.217, 347, 254, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
4167, d6bp0A_, 0.7426, 3.55, 0.162, 317, 260, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO (R)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
4168, d3rprA_, 0.7425, 2.99, 0.225, 282, 244, CDK2 IN COMPLEX WITH INHIBITOR RC-2-49
4169, d3r9oA_, 0.7425, 2.97, 0.230, 282, 244, CDK2 IN COMPLEX WITH INHIBITOR RC-2-143
4170, d3ma6B_, 0.7425, 3.18, 0.254, 266, 248, CRYSTAL STRUCTURE OF KINASE DOMAIN OF TGCDPK1 IN PRESENCE OF 3BRB-PP1
4171, d3dakB_, 0.7425, 3.40, 0.243, 278, 247, CRYSTAL STRUCTURE OF DOMAIN-SWAPPED OSR1 KINASE DOMAIN
4172, d2wtvB_, 0.7425, 3.02, 0.241, 261, 245, AURORA-A INHIBITOR STRUCTURE
4173, d4yfiB_, 0.7424, 2.91, 0.241, 262, 241, TNNI3K COMPLEXED WITH INHIBITOR 1
4174, d4wo5A1, 0.7424, 2.70, 0.266, 250, 241, CRYSTAL STRUCTURE OF A BRAF KINASE DOMAIN MONOMER
4175, d4qp8A_, 0.7424, 3.22, 0.216, 335, 250, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-7- (PYRIDIN-3-YL)-5H-PYRROLO[23-B]PYRAZINE
4176, d4fkpA_, 0.7424, 2.85, 0.228, 279, 241, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
4177, d2wtvC_, 0.7424, 3.02, 0.241, 261, 245, AURORA-A INHIBITOR STRUCTURE
4178, d2fa2A_, 0.7424, 3.37, 0.218, 333, 252, CRYSTAL STRUCTURE OF FUS3 WITHOUT A PEPTIDE FROM STE5
4179, d5uvfB_, 0.7423, 3.53, 0.158, 316, 260, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO BI- D1870
4180, d4jjrB_, 0.7423, 3.36, 0.191, 283, 256, A P21 CRYSTAL FORM OF MAMMALIAN CASEIN KINASE 1 DELTA
4181, d4ft5A_, 0.7423, 3.26, 0.261, 265, 245, CRYSTAL STRUCTURE OF THE CHK1
4182, d4eqmA_, 0.7423, 3.16, 0.235, 269, 247, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
4183, d3mj1A1, 0.7423, 1.63, 0.330, 226, 224, X-RAY CRYSTAL STRUCTURE OF ITK COMPLEXED WITH INHIBITOR RO5191614
4184, d3lauA1, 0.7423, 2.97, 0.240, 250, 242, CRYSTAL STRUCTURE OF AURORA2 KINASE IN COMPLEX WITH A GSK3BETA INHIBITOR
4185, d2w17A_, 0.7423, 2.82, 0.220, 278, 241, CDK2 IN COMPLEX WITH THE IMIDAZOLE PYRIMIDINE AMIDE COMPOUND (S)-8B
4186, d4ek8A_, 0.7422, 2.86, 0.232, 280, 241, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
4187, d3qtsA_, 0.7422, 2.99, 0.225, 282, 244, CDK2 IN COMPLEX WITH INHIBITOR RC-2-12
4188, d2qg5B1, 0.7422, 3.43, 0.203, 275, 256, CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840
4189, d5ihaA_, 0.7421, 2.57, 0.287, 303, 237, MELK IN COMPLEX WITH NVS-MELK8F
4190, d4yomB1, 0.7421, 3.08, 0.246, 320, 248, STRUCTURE OF SAD KINASE
4191, d4qp7B_, 0.7421, 3.14, 0.209, 335, 249, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-5H- PYRROLO[23-B]PYRAZINE
4192, d4fkjA_, 0.7421, 2.77, 0.229, 278, 240, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
4193, d4bgqA_, 0.7421, 2.85, 0.230, 276, 244, CRYSTAL STRUCTURE OF THE HUMAN CDKL5 KINASE DOMAIN
4194, d3sw7A_, 0.7421, 2.73, 0.217, 278, 240, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
4195, d2j9mA_, 0.7421, 2.60, 0.228, 275, 237, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH MACROCYCLIC AMINOPYRIMIDINE
4196, d2c47B_, 0.7421, 3.33, 0.164, 289, 256, STRUCTURE OF CASEIN KINASE 1 GAMMA 2
4197, d4hokI_, 0.7420, 3.64, 0.218, 291, 262, CRYSTAL STRUCTURE OF APO CK1E
4198, d3tkhA_, 0.7420, 3.44, 0.270, 269, 248, CRYSTAL STRUCTURE OF CHK1 IN COMPLEX WITH INHIBITOR S01
4199, d1ke5A_, 0.7420, 2.93, 0.230, 281, 243, CDK2 COMPLEXED WITH N-METHYL-4-{[(2-OXO-12-DIHYDRO-3H- INDOL-3-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDE
4200, d5deyB_, 0.7419, 3.35, 0.226, 281, 252, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND G-5555
4201, d5aniA_, 0.7419, 2.84, 0.228, 280, 241, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 6-CHLORO-7H- PURINE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
4202, d4qp6A_, 0.7419, 3.33, 0.207, 339, 251, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 5H-PYRROLO[23-B]PYRAZINE
4203, d4fg7A_, 0.7419, 2.74, 0.255, 250, 239, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-293 IN COMPLEX WITH ATP
4204, d3qyzA_, 0.7419, 3.55, 0.207, 339, 256, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
4205, d1ke7A_, 0.7419, 2.94, 0.230, 281, 243, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[(22- DIOXIDO-13-DIHYDRO-2-BENZOTHIEN-5-YL)AMINO]METHYLENE}-5- (13-OXAZOL-5-YL)-13-DIHYDRO-2H-INDOL-2-ONE
4206, d3cohB_, 0.7418, 2.86, 0.237, 247, 241, CRYSTAL STRUCTURE OF AURORA-A IN COMPLEX WITH A PENTACYCLIC INHIBITOR
4207, d2oidD_, 0.7418, 2.71, 0.286, 274, 238, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN COMPLEXED WITH AMPPNP
4208, d1di8A_, 0.7418, 2.98, 0.230, 283, 244, THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4-[3-HYDROXYANILINO]-67-DIMETHOXYQUINAZOLINE
4209, d4kb8C_, 0.7417, 3.27, 0.217, 277, 254, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
4210, d4fttA_, 0.7417, 3.32, 0.260, 266, 246, CRYSTAL STRUCTURE OF THE CHK1
4211, d5fxsA1, 0.7416, 3.41, 0.321, 307, 252, IGFR-1R COMPLEX WITH A PYRIMIDINE INHIBITOR.
4212, d3cohA_, 0.7416, 2.86, 0.237, 247, 241, CRYSTAL STRUCTURE OF AURORA-A IN COMPLEX WITH A PENTACYCLIC INHIBITOR
4213, d4p41B_, 0.7415, 2.69, 0.200, 256, 240,  
4214, d4au8A1, 0.7415, 2.71, 0.216, 274, 241, CRYSTAL STRUCTURE OF COMPOUND 4A IN COMPLEX WITH CDK5 SHOWING AN UNUSUAL BINDING MODE TO THE HINGE REGION VIA A WATER MOLECULE
4215, d4aguB_, 0.7415, 2.70, 0.217, 276, 240, CRYSTAL STRUCTURE OF THE HUMAN CDKL1 KINASE DOMAIN
4216, d3qrjA1, 0.7415, 2.26, 0.364, 246, 231, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN T315I MUTANT IN COMPLEX WITH DCC-2036
4217, d2wqmA_, 0.7415, 2.80, 0.247, 258, 243, STRUCTURE OF APO HUMAN NEK7
4218, d2vtiA_, 0.7415, 2.90, 0.227, 280, 242, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
4219, d2r3mA_, 0.7415, 2.74, 0.229, 278, 240, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
4220, d4n4sA_, 0.7414, 3.25, 0.194, 342, 253, A DOUBLE MUTANT RAT ERK2 IN COMPLEX WITH A PYRAZOLO[34-D]PYRIMIDINE INHIBITOR
4221, d4kbaC_, 0.7414, 3.32, 0.220, 277, 255, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
4222, d4eqmC_, 0.7414, 3.09, 0.236, 269, 246, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
4223, d2r3nA_, 0.7414, 2.64, 0.218, 275, 238, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
4224, d3rahA_, 0.7413, 3.01, 0.225, 282, 244, CDK2 IN COMPLEX WITH INHIBITOR RC-2-22
4225, d2ym6A_, 0.7413, 3.15, 0.262, 253, 244, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4226, d2r3qA_, 0.7413, 3.01, 0.226, 286, 243, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
4227, d1h08A_, 0.7413, 2.87, 0.231, 283, 242, CDK2 IN COMPLEX WITH A DISUBSTITUTED 2 4-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
4228, d4fsmA_, 0.7412, 3.37, 0.260, 265, 246, CRYSTAL STRUCTURE OF THE CHK1
4229, d3uysA_, 0.7412, 3.36, 0.216, 281, 255, CRYSTAL STRUCTURE OF APO HUMAN CK1D
4230, d3r9nA_, 0.7412, 3.01, 0.230, 282, 244, CDK2 IN COMPLEX WITH INHIBITOR RC-2-21
4231, d3dakA_, 0.7412, 3.29, 0.236, 279, 246, CRYSTAL STRUCTURE OF DOMAIN-SWAPPED OSR1 KINASE DOMAIN
4232, d3dajA_, 0.7412, 2.84, 0.237, 245, 240, CRYSTAL STRUCTURE OF AURORA A COMPLEXED WITH AN INHIBITOR DISCOVERED THROUGH SITE-DIRECTED DYNAMIC TETHERING
4233, d5uiqB_, 0.7410, 2.98, 0.273, 272, 242, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 9
4234, p5lw1B_, 0.7410, 3.27, 0.183, 355, 251, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_232_11_D12 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
4235, d5horA_, 0.7410, 2.20, 0.355, 247, 228, CRYSTAL STRUCTURE OF C-MET-M1250T IN COMPLEX WITH SAR125844.
4236, d4qp2A_, 0.7410, 3.34, 0.207, 336, 251, CRYSTAL STRUCTURE OF ERKS IN COMPLEX WITH 5-CHLOROBENZO[D]OXAZOL-2- AMINE
4237, d2w9zB_, 0.7410, 3.02, 0.208, 287, 245, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
4238, d4zy6B_, 0.7409, 3.39, 0.223, 280, 251, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 29
4239, d4fktA_, 0.7409, 2.77, 0.233, 278, 240, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
4240, d2c47A_, 0.7409, 3.30, 0.161, 288, 255, STRUCTURE OF CASEIN KINASE 1 GAMMA 2
4241, d6btwA_, 0.7408, 3.58, 0.162, 317, 260, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PHENYL-PTERIDINONE INHIBITOR
4242, d4hokO_, 0.7408, 3.65, 0.215, 290, 261, CRYSTAL STRUCTURE OF APO CK1E
4243, d4ftjA_, 0.7408, 3.42, 0.274, 266, 248, CRYSTAL STRUCTURE OF THE CHK1
4244, d2xeyA_, 0.7408, 3.16, 0.258, 252, 244, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4245, d2uznA_, 0.7408, 2.90, 0.232, 279, 241, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
4246, d4rvlA_, 0.7407, 3.25, 0.261, 258, 245, CHK1 KINASE DOMAIN WITH DIAZACARBAZOLE COMPOUND 7: 3-(2- HYDROXYPHENYL)-9H-PYRROLO[23-B:54-C ]DIPYRIDINE-6-CARBONITRILE
4247, d4fkwA_, 0.7407, 2.85, 0.227, 280, 242, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
4248, d3zfmA_, 0.7407, 2.68, 0.290, 248, 238, CRYSTAL STRUCTURE OF EPHB2
4249, d3o50A_, 0.7407, 2.76, 0.234, 246, 239, CRYSTAL STRUCTURE OF BENZAMIDE 9 BOUND TO AURORAA
4250, d2vtpA_, 0.7407, 2.91, 0.227, 281, 242, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
4251, d4xozA_, 0.7406, 3.50, 0.211, 341, 256, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
4252, d4hokS_, 0.7406, 3.62, 0.215, 286, 260, CRYSTAL STRUCTURE OF APO CK1E
4253, d4gsbA_, 0.7406, 3.38, 0.213, 343, 253, MONOCLINIC CRYSTAL FORM OF THE APO-ERK2
4254, d4fv8A_, 0.7406, 3.02, 0.205, 333, 244, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E63
4255, d1muoA_, 0.7406, 3.14, 0.238, 251, 244, CRYSTAL STRUCTURE OF AURORA-2 AN ONCOGENIC SERINE- THREONINE KINASE
4256, d4zjjB_, 0.7405, 3.08, 0.193, 277, 249, PAK1 IN COMPLEX WITH (S)-N-(TERT-BUTYL)-3-((2-CHLORO-5-ETHYL-8-FLUORO- DIBENZODIAZEPIN-11-YL)AMINO)PYRROLIDINE-1-CARBOXAMIDE
4257, d3h10D_, 0.7405, 3.02, 0.246, 255, 244, AURORA A INHIBITOR COMPLEX
4258, d5k7gA_, 0.7404, 3.09, 0.264, 277, 242, IRAK4 IN COMPLEX WITH AZ3862
4259, d4jjrA_, 0.7404, 3.20, 0.222, 284, 252, A P21 CRYSTAL FORM OF MAMMALIAN CASEIN KINASE 1 DELTA
4260, d4ftqA_, 0.7404, 3.16, 0.259, 254, 243, CRYSTAL STRUCTURE OF THE CHK1
4261, d4kbkD_, 0.7403, 3.36, 0.216, 281, 255, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
4262, d4ftaA_, 0.7403, 3.25, 0.262, 264, 244, CRYSTAL STRUCTURE OF THE CHK1
4263, d3gc0A_, 0.7403, 3.05, 0.222, 278, 243, STRUCTURE OF THE CMGC CDK KINASE FROM GIARDIA LAMBLIA IN COMPLEX WITH AMP
4264, d4xrjA_, 0.7402, 3.50, 0.211, 344, 256, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
4265, d4hgtA_, 0.7402, 3.37, 0.227, 283, 256, CRYSTAL STRUCTURE OF CK1D WITH COMPOUND 13
4266, d1ke6A_, 0.7402, 2.79, 0.232, 280, 241, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH N-METHYL-{4- [2-(7-OXO-67-DIHYDRO-8H-[13]THIAZOLO[54-E]INDOL-8- YLIDENE)HYDRAZINO]PHENYL}METHANESULFONAMIDE
4267, d4fv0A_, 0.7401, 3.49, 0.208, 341, 255, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK3
4268, d3ig7A_, 0.7401, 2.74, 0.234, 278, 239, NOVEL CDK-5 INHIBITORS - CRYSTAL STRUCTURE OF INHIBITOR EFP WITH CDK-2
4269, d2fumC_, 0.7401, 2.68, 0.222, 254, 239, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
4270, d1szmB_, 0.7401, 3.37, 0.221, 320, 253, DUAL BINDING MODE OF BISINDOLYLMALEIMIDE 2 TO PROTEIN KINASE A (PKA)
4271, d1ke9A_, 0.7401, 2.86, 0.231, 281, 242, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[4- ({[AMINO(IMINO)METHYL]AMINOSULFONYL)ANILINO]METHYLENE}-2- OXO-23-DIHYDRO-1H-INDOLE
4272, d5uisA_, 0.7400, 2.87, 0.276, 269, 239, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 12
4273, d5imeB_, 0.7400, 3.18, 0.231, 280, 247, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 (PAK1) IN COMPLEX WITH COMPOUND 9
4274, d3is5B1, 0.7400, 3.08, 0.241, 255, 245, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
4275, d2oidB_, 0.7400, 2.84, 0.287, 272, 240, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN COMPLEXED WITH AMPPNP
4276, d2f49B_, 0.7400, 3.43, 0.218, 337, 252, CRYSTAL STRUCTURE OF FUS3 IN COMPLEX WITH A STE5 PEPTIDE
4277, d3zfyB_, 0.7399, 2.74, 0.291, 255, 237, CRYSTAL STRUCTURE OF EPHB3
4278, d4yp8B_, 0.7398, 2.87, 0.271, 278, 240, IRAK4-INHIBITOR CO-STRUCTURE
4279, d4qtaA_, 0.7398, 3.19, 0.223, 335, 247, STRUCTURE OF HUMAN ERK2 IN COMPLEX WITH SCH772984 REVEALING A NOVEL INHIBITOR-INDUCED BINDING POCKET
4280, d4hgtB_, 0.7398, 3.20, 0.218, 280, 252, CRYSTAL STRUCTURE OF CK1D WITH COMPOUND 13
4281, d3en7B_, 0.7398, 1.69, 0.344, 237, 224, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH S1 A MULTITARGETED KINASE INHIBITOR
4282, d6bruD_, 0.7397, 3.55, 0.155, 311, 258, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A (S)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
4283, d4kb8D_, 0.7397, 3.34, 0.209, 278, 254, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
4284, d4ftrA_, 0.7397, 3.41, 0.266, 258, 248, CRYSTAL STRUCTURE OF THE CHK1
4285, d2r3kA_, 0.7397, 2.76, 0.229, 277, 240, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
4286, d2a4lA_, 0.7397, 3.01, 0.227, 286, 242, HUMAN CYCLIN-DEPENDENT KINASE 2 IN COMPLEX WITH ROSCOVITINE
4287, d6bp0C_, 0.7396, 3.54, 0.154, 315, 259, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO (R)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
4288, d4yfiD_, 0.7396, 2.91, 0.237, 261, 240, TNNI3K COMPLEXED WITH INHIBITOR 1
4289, d4fv4A_, 0.7396, 2.91, 0.211, 329, 242, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK7
4290, d4fg9B_, 0.7396, 2.52, 0.242, 279, 236, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-320 IN COMPLEX WITH ATP
4291, d2hwpB_, 0.7396, 1.75, 0.329, 239, 225, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH COVALENT INHIBITOR PD168393
4292, d6bp0D_, 0.7394, 3.59, 0.155, 311, 258, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO (R)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
4293, d4n0sA_, 0.7394, 3.52, 0.212, 348, 255, COMPLEX OF ERK2 WITH CAFFEIC ACID
4294, d4m68A_, 0.7394, 3.18, 0.240, 268, 250, CRYSTAL STRUCTURE OF THE MOUSE MLKL KINASE-LIKE DOMAIN
4295, d3wf9A_, 0.7394, 3.32, 0.220, 287, 250, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A QUINOLINE DERIVATIVE 1-OXO-1-[(4-SULFAMOYLPHENYL)AMINO]PROPAN-2-YL-2-METHYL-1 234-TETRAHYDROACRIDINE-9-CARBOXYLATE
4296, d2vwiD_, 0.7394, 3.19, 0.238, 284, 244, STRUCTURE OF THE OSR1 KINASE A HYPERTENSION DRUG TARGET
4297, d5uorA_, 0.7393, 2.71, 0.239, 249, 238, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
4298, d4x7qB_, 0.7393, 2.39, 0.230, 243, 235, PIM2 KINASE IN COMPLEX WITH COMPOUND 1S
4299, d6bu6C_, 0.7392, 3.54, 0.154, 315, 259, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
4300, d3zduA_, 0.7392, 3.09, 0.208, 297, 245, CRYSTAL STRUCTURE OF THE HUMAN CDKL3 KINASE DOMAIN
4301, d3pxqA1, 0.7392, 2.99, 0.225, 294, 244, CDK2 IN COMPLEX WITH 3 MOLECULES OF 8-ANILINO-1-NAPHTHALENE SULFONATE
4302, d3wf8A_, 0.7391, 3.32, 0.220, 287, 250, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A QUINOLINE DERIVATIVE 2-OXO-2-[(4-SULFAMOYLPHENYL)AMINO]ETHYL 78910- TETRAHYDRO-6H-CYCLOHEPTA[B]QUINOLINE-11-CARBOXYLATE
4303, d5k72D_, 0.7390, 2.99, 0.266, 276, 241, IRAK4 IN COMPLEX WITH COMPOUND 21
4304, d5ihcA_, 0.7390, 2.74, 0.276, 305, 239, MELK IN COMPLEX WITH NVS-MELK12B
4305, d4qp4B_, 0.7390, 3.30, 0.216, 335, 250, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
4306, d4fswA_, 0.7390, 3.32, 0.261, 265, 245, CRYSTAL STRUCTURE OF THE CHK1
4307, d2ydjB_, 0.7389, 3.21, 0.266, 251, 244, DISCOVERY OF CHECKPOINT KINASE INHIBITOR AZD7762 BY STRUCTURE BASED DESIGN AND OPTIMIZATION OF THIOPHENE CARBOXAMIDE UREAS
4308, d4gh2A_, 0.7388, 3.28, 0.266, 266, 244, CRYSTAL STRUCTURE OF THE CHK1
4309, d4bzdA_, 0.7388, 2.80, 0.217, 277, 240, STRUCTURE OF CDK2 IN COMPLEX WITH A BENZIMIDAZOPYRIMIDINE
4310, d3rmfA_, 0.7388, 2.78, 0.217, 278, 240, CDK2 IN COMPLEX WITH INHIBITOR RC-2-33
4311, d4ek6A_, 0.7387, 2.78, 0.234, 278, 239, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
4312, d3op5C_, 0.7387, 3.51, 0.155, 308, 258, HUMAN VACCINIA-RELATED KINASE 1
4313, d1vzoA_, 0.7386, 3.26, 0.221, 319, 249, THE STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF MSK1 REVEALS A NOVEL AUTOINHIBITORY CONFORMATION FOR A DUAL KINASE PROTEIN
4314, d6bruC_, 0.7385, 3.55, 0.154, 315, 259, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A (S)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
4315, d4nj3A_, 0.7385, 3.00, 0.237, 277, 241, MODULATING THE INTERACTION BETWEEN CDK2 AND CYCLIN A WITH A QUINOLINE- BASED INHIBITOR
4316, d1w0xC_, 0.7385, 2.92, 0.231, 280, 242, CRYSTAL STRUCTURE OF HUMAN CDK2 IN COMPLEX WITH THE INHIBITOR OLOMOUCINE.
4317, d5bujA_, 0.7384, 3.01, 0.222, 331, 243, ERK2 COMPLEXED WITH A N-H TETRAHYDROAZAINDAZOLE
4318, d3kmuA_, 0.7384, 2.85, 0.274, 253, 241, CRYSTAL STRUCTURE OF THE ILK/ALPHA-PARVIN CORE COMPLEX (APO)
4319, d4o6eA_, 0.7383, 3.17, 0.211, 328, 246, DISCOVERY OF 5678-TETRAHYDROPYRIDO[34-D]PYRIMIDINE INHIBITORS OF ERK2
4320, d4hokK_, 0.7383, 3.71, 0.215, 290, 261, CRYSTAL STRUCTURE OF APO CK1E
4321, d4fksA_, 0.7383, 2.74, 0.230, 275, 239, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
4322, d2r3jA_, 0.7383, 2.77, 0.229, 278, 240, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
4323, d5uiqD_, 0.7382, 2.94, 0.285, 271, 239, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 9
4324, p5lw1E_, 0.7382, 3.30, 0.183, 355, 251, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_232_11_D12 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
4325, d4u9aA_, 0.7382, 2.68, 0.275, 272, 236, SULPHUR ANOMALOUS CRYSTAL STRUCTURE OF ASYMMETRIC IRAK4 DIMER
4326, d4b99A_, 0.7382, 3.36, 0.214, 335, 252, CRYSTAL STRUCTURE OF MAPK7 (ERK5) WITH INHIBITOR
4327, d3sa0A_, 0.7382, 3.47, 0.201, 354, 254, COMPLEX OF ERK2 WITH NORATHYRIOL
4328, d2xf0A_, 0.7382, 3.14, 0.259, 251, 243, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4329, d4p90A_, 0.7380, 2.86, 0.211, 272, 242, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN PAK1 IN COMPLEX WITH COMPOUND 15
4330, d3jvrA_, 0.7380, 3.30, 0.265, 258, 245, CHARACTERIZATION OF THE CHK1 ALLOSTERIC INHIBITOR BINDING SITE
4331, d2btsA_, 0.7380, 2.60, 0.229, 274, 236, STRUCTURE OF CDK2 COMPLEXED WITH PNU-230032
4332, d2bhhA_, 0.7380, 2.60, 0.229, 274, 236, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 4-HYDROXYPIPERINDINESULFONYL-INDIRUBINE
4333, d1dm2A_, 0.7380, 2.60, 0.220, 274, 236, HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR HYMENIALDISINE
4334, d5k72C_, 0.7379, 3.10, 0.264, 277, 242, IRAK4 IN COMPLEX WITH COMPOUND 21
4335, d4u97A_, 0.7379, 2.67, 0.280, 272, 236, CRYSTAL STRUCTURE OF ASYMMETRIC IRAK4 DIMER
4336, d3ezvA_, 0.7378, 2.77, 0.226, 277, 239, CDK-2 WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
4337, d4uynA_, 0.7377, 3.00, 0.243, 249, 243, SAR156497 AN EXQUISITELY SELECTIVE INHIBITOR OF AURORA KINASES
4338, d3en6B_, 0.7377, 1.79, 0.344, 239, 224, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP102 A MULTITARGETED KINASE INHIBITOR
4339, d2vthA_, 0.7377, 2.86, 0.233, 278, 240, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN
4340, d2vtaA_, 0.7377, 2.86, 0.233, 278, 240, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
4341, p5lw1H_, 0.7376, 3.32, 0.183, 355, 251, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_232_11_D12 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
4342, d1h00A_, 0.7376, 2.82, 0.233, 278, 240, CDK2 IN COMPLEX WITH A DISUBSTITUTED 4 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
4343, d4feqA_, 0.7375, 1.68, 0.332, 224, 223, INHIBITOR BOUND STRUCTURE OF THE KINASE DOMAIN OF THE MURINE RECEPTOR TYROSINE KINASE TYRO3 (SKY)
4344, d2w05A_, 0.7375, 2.82, 0.226, 276, 239, STRUCTURE OF CDK2 IN COMPLEX WITH AN IMIDAZOLYL PYRIMIDINE COMPOUND 5B
4345, p5o7iA_, 0.7374, 3.57, 0.212, 340, 255, ERK5 IN COMPLEX WITH A PYRROLE INHIBITOR 
4346, d5uirB_, 0.7372, 2.83, 0.287, 273, 240, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 11
4347, d5dbxA_, 0.7372, 3.06, 0.252, 284, 242, CRYSTAL STRUCTURE OF MURINE SPAK(T243D) IN COMPLEX WITH AMPPNP
4348, d4u42B_, 0.7372, 2.72, 0.230, 265, 239, MAP4K4 T181E MUTANT BOUND TO INHIBITOR COMPOUND 1
4349, d4yo6B_, 0.7371, 2.82, 0.273, 277, 238, IRAK4-INHIBITOR CO-STRUCTURE
4350, d6bp0B_, 0.7369, 3.56, 0.160, 304, 257, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO (R)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
4351, d4ftkA_, 0.7369, 3.26, 0.259, 263, 243, CRYSTAL STRUCTURE OF THE CHK1
4352, d2pmiC_, 0.7369, 2.84, 0.211, 285, 242, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE- RESPONSIVE SIGNAL TRANSDUCTION PATHWAY WITH BOUND ATP-GAMMA-S
4353, d5kx8B_, 0.7368, 2.88, 0.272, 278, 239, IRAK4-INHIBITOR CO-STRUCTURE
4354, d4fsqA_, 0.7368, 3.25, 0.267, 263, 243, CRYSTAL STRUCTURE OF THE CHK1
4355, d4acmA_, 0.7368, 2.76, 0.230, 277, 239, CDK2 IN COMPLEX WITH 3-AMINO-6-(4-{[2-(DIMETHYLAMINO)ETHYL] SULFAMOYL}-PHENYL)-N-PYRIDIN-3-YLPYRAZINE-2-CARBOXAMIDE
4356, d3s1hA_, 0.7368, 2.78, 0.218, 277, 239, CDK2 IN COMPLEX WITH INHIBITOR RC-2-39
4357, d1vyzA_, 0.7368, 2.91, 0.225, 279, 240, STRUCTURE OF CDK2 COMPLEXED WITH PNU-181227
4358, d5eakA_, 0.7367, 3.32, 0.283, 305, 247, OPTIMIZATION OF MICROTUBULE AFFINITY REGULATING KINASE (MARK) INHIBITORS WITH IMPROVED PHYSICAL PROPERTIES
4359, d5dewB_, 0.7367, 3.33, 0.219, 281, 251, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND 5
4360, d5andA_, 0.7367, 2.74, 0.235, 273, 238, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 2-IMIDAZOL-1-YL-1H- BENZIMIDAZOLE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
4361, d3p86B_, 0.7367, 2.30, 0.306, 239, 232, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN MUTANT D676N IN COMPLEX WITH STAUROSPORINE
4362, d6btwC_, 0.7366, 3.57, 0.154, 315, 259, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PHENYL-PTERIDINONE INHIBITOR
4363, d2vwiC_, 0.7366, 3.11, 0.232, 270, 241, STRUCTURE OF THE OSR1 KINASE A HYPERTENSION DRUG TARGET
4364, d2oicC_, 0.7366, 2.89, 0.269, 277, 238, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN COMPLEXED WITH STAUROSPORINE
4365, d3rzbA_, 0.7365, 3.08, 0.225, 282, 244, CDK2 IN COMPLEX WITH INHIBITOR RC-2-23
4366, d3qquD_, 0.7362, 3.34, 0.312, 292, 250, COCRYSTAL STRUCTURE OF UNPHOSPHORYLATED IGF WITH PYRIMIDINE 8
4367, d2cmwA_, 0.7362, 3.53, 0.171, 294, 257, STRUCTURE OF HUMAN CASEIN KINASE 1 GAMMA-1 IN COMPLEX WITH 2-(2-HYDROXYETHYLAMINO)-6-(3-CHLOROANILINO)-9- ISOPROPYLPURINE (CASP TARGET)
4368, d1f5qC_, 0.7362, 3.42, 0.212, 288, 250, CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO HUMAN CYCLIN DEPENDENT KINASE 2
4369, d6b8uB_, 0.7361, 2.68, 0.268, 248, 239, CRYSTALS STRUCTURE OF B-RAF KINASE DOMAIN IN COMPLEX WITH AN IMIDAZOPYRIDINYL BENZAMIDE INHIBITOR
4370, d5o1vA_, 0.7361, 3.24, 0.235, 278, 243, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED APO STATE (A-LOOP SWAPPED)
4371, d4zxtA_, 0.7361, 3.49, 0.209, 348, 254, COMPLEX OF ERK2 WITH CATECHOL
4372, d5fxqA1, 0.7360, 3.42, 0.320, 301, 250, IGFR-1R COMPLEX WITH A PYRIMIDINE INHIBITOR.
4373, d4fv9A_, 0.7360, 3.00, 0.215, 331, 242, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E71
4374, d3rakA_, 0.7360, 2.79, 0.218, 277, 239, CDK2 IN COMPLEX WITH INHIBITOR RC-2-32
4375, d2xkdA1, 0.7360, 2.51, 0.225, 243, 236, STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 12
4376, d3v6sA_, 0.7359, 3.31, 0.183, 349, 252, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
4377, d3qquC_, 0.7359, 3.48, 0.323, 293, 251, COCRYSTAL STRUCTURE OF UNPHOSPHORYLATED IGF WITH PYRIMIDINE 8
4378, d3orpA_, 0.7358, 3.29, 0.224, 274, 245, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 5)
4379, d3en5A_, 0.7357, 1.92, 0.338, 238, 225, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP494 A MULTITARGETED KINASE INHIBITOR
4380, d2iwiA_, 0.7357, 2.62, 0.233, 244, 236, CRYSTAL STRUCTURE OF THE HUMAN PIM2 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU1
4381, d5bveA_, 0.7355, 2.96, 0.212, 330, 241, TETRAHYDROPYRROLO-DIAZEPENONES AS INHIBITORS OF ERK2 KINASE
4382, d5bvdA_, 0.7355, 2.97, 0.216, 330, 241, TETRAHYDROPYRROLO-DIAZEPENONES AS INHIBITORS OF ERK2 KINASE
4383, d2x81A_, 0.7355, 2.76, 0.236, 242, 237, STRUCTURE OF AURORA A IN COMPLEX WITH MLN8054
4384, d2c47C_, 0.7355, 3.30, 0.162, 282, 253, STRUCTURE OF CASEIN KINASE 1 GAMMA 2
4385, d5uiqA_, 0.7354, 2.86, 0.277, 268, 238, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 9
4386, d2bheA_, 0.7354, 2.64, 0.220, 274, 236, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 5-BROMO-INDIRUBINE
4387, d5uirA_, 0.7353, 3.10, 0.273, 270, 242, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 11
4388, d4fstA_, 0.7353, 3.20, 0.256, 253, 242, CRYSTAL STRUCTURE OF THE CHK1
4389, d4fg9A_, 0.7353, 2.64, 0.246, 278, 236, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-320 IN COMPLEX WITH ATP
4390, d3pa5A_, 0.7353, 3.29, 0.262, 255, 244, X-RAY CRYSTAL STRUCTURE OF COMPOUND 1 BOUND TO HUMAN CHK1 KINASE DOMAIN
4391, d5anoA_, 0.7352, 2.82, 0.234, 277, 239, CRYSTAL STRUCTURE OF CDK2 PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
4392, d4ftlA_, 0.7352, 3.28, 0.259, 263, 243, CRYSTAL STRUCTURE OF THE CHK1
4393, d3is5A1, 0.7351, 3.06, 0.250, 254, 244, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
4394, d2vtjA_, 0.7351, 2.72, 0.231, 276, 238, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
4395, d3wf6A_, 0.7350, 3.12, 0.247, 277, 243, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE DERIVATIVE 4-[4-(1H-INDOL-3-YL)-36- DIHYDROPYRIDIN-1(2H)-YL]-1H-PYRAZOLO[34-D]PYRIMIDINE
4396, d3sw4A_, 0.7350, 2.85, 0.233, 279, 240, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
4397, d2wmtA_, 0.7350, 3.06, 0.258, 248, 240, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4398, d3orkA1, 0.7349, 3.12, 0.222, 272, 243, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 2)
4399, d4ftnA_, 0.7348, 3.21, 0.260, 253, 242, CRYSTAL STRUCTURE OF THE CHK1
4400, d2xezA_, 0.7348, 3.11, 0.257, 249, 241, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4401, d2w99B_, 0.7348, 3.55, 0.206, 291, 252, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
4402, d2rioA_, 0.7348, 2.70, 0.235, 396, 238, STRUCTURE OF THE DUAL ENZYME IRE1 REVEALS THE BASIS FOR CATALYSIS AND REGULATION OF NON-CONVENTIONAL SPLICING
4403, d1giiA_, 0.7348, 2.84, 0.237, 279, 240, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
4404, d5k76A_, 0.7347, 2.75, 0.283, 270, 237, IRAK4 IN COMPLEX WITH COMPOUND 28
4405, d4rzvA1, 0.7347, 2.45, 0.289, 245, 235, CRYSTAL STRUCTURE OF THE BRAF (R509H) KINASE DOMAIN MONOMER BOUND TO VEMURAFENIB
4406, d4gvaA_, 0.7347, 3.59, 0.207, 345, 256, ADP-BOUND FORM OF THE ERK2 KINASE
4407, d4hokQ_, 0.7346, 3.68, 0.212, 290, 260, CRYSTAL STRUCTURE OF APO CK1E
4408, d1aq1A_, 0.7346, 2.78, 0.227, 277, 238, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR STAUROSPORINE
4409, d4hokA_, 0.7345, 3.71, 0.215, 290, 261, CRYSTAL STRUCTURE OF APO CK1E
4410, d5tkdB_, 0.7344, 2.64, 0.236, 247, 237, CRYSTAL STRUCTURE OF TYROSINE KINASE 2 JH2 (PSEUDO KINASE DOMAIN) COMPLEXED WITH 6-[(35-DIMETHYLPHE NYL)AMINO]-8- (METHYLAMINO) IMIDAZO[12-B]PYRIDAZINE-3-CARBO XAMIDE
4411, d2fa2B_, 0.7344, 3.50, 0.222, 332, 252, CRYSTAL STRUCTURE OF FUS3 WITHOUT A PEPTIDE FROM STE5
4412, d5fxrA1, 0.7343, 3.49, 0.323, 299, 251, IGFR-1R COMPLEX WITH A PYRIMIDINE INHIBITOR.
4413, d6btwD_, 0.7342, 3.64, 0.152, 307, 257, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PHENYL-PTERIDINONE INHIBITOR
4414, d4ftmA_, 0.7342, 3.29, 0.263, 263, 243, CRYSTAL STRUCTURE OF THE CHK1
4415, d3i5zA_, 0.7340, 3.03, 0.215, 331, 242, CRYSTAL STRUCTURE OF ERK2 BOUND TO (S)-N-(2-HYDROXY-1-PHENYLETHYL)-4- (5-METHYL-2-(PHENYLAMINO)PYRIMIDIN-4-YL)-1H-PYRROLE-2-CARBOXAMIDE
4416, d2r3lA_, 0.7340, 2.73, 0.231, 275, 238, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
4417, p4looA_, 0.7339, 3.43, 0.198, 349, 253, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (MONOCLINIC CRYSTAL FORM)
4418, d2wmxA_, 0.7337, 3.10, 0.262, 248, 240, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4419, d4useA_, 0.7336, 3.41, 0.243, 286, 247, HUMAN STK10 (LOK) WITH SB-633825
4420, d3jvsA_, 0.7336, 3.30, 0.263, 256, 243, CHARACTERIZATION OF THE CHK1 ALLOSTERIC INHIBITOR BINDING SITE
4421, d5w5jB_, 0.7335, 2.39, 0.250, 257, 232, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES
4422, d4lg4E_, 0.7335, 3.08, 0.239, 275, 243, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
4423, d3rpyA_, 0.7335, 2.82, 0.230, 277, 239, CDK2 IN COMPLEX WITH INHIBITOR RC-2-40
4424, d3gbzA_, 0.7335, 2.94, 0.225, 274, 240, STRUCTURE OF THE CMGC CDK KINASE FROM GIARDIA LAMBLIA
4425, d3bqrA1, 0.7335, 2.97, 0.220, 273, 241, CRYSTAL STRUCTURE OF HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3) IN COMPLEX WITH AN IMIDAZO-PYRIDAZINE LIGAND
4426, d2rioB_, 0.7334, 2.68, 0.236, 395, 237, STRUCTURE OF THE DUAL ENZYME IRE1 REVEALS THE BASIS FOR CATALYSIS AND REGULATION OF NON-CONVENTIONAL SPLICING
4427, d5bueA_, 0.7333, 3.18, 0.212, 329, 245, ERK2 COMPLEXED WITH N-BENZYLPYRIDONE TETRAHYDROAZAINDAZOLE
4428, p4lopD_, 0.7333, 3.52, 0.197, 351, 254, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
4429, d4fv5A_, 0.7333, 3.04, 0.211, 330, 242, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK9
4430, d3v6rA_, 0.7331, 3.39, 0.183, 349, 252, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
4431, p5ax3A_, 0.7330, 3.72, 0.230, 329, 252, CRYSTAL STRUCTURE OF ERK2 COMPLEXED WITH ALLOSTERIC AND ATP- COMPETITIVE INHIBITORS.
4432, d2jboA_, 0.7330, 2.88, 0.219, 295, 242, PROTEIN KINASE MK2 IN COMPLEX WITH AN INHIBITOR (CRYSTAL FORM-1 SOAKING)
4433, d1wbwA_, 0.7330, 3.50, 0.213, 351, 253, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
4434, d5k75A_, 0.7329, 2.63, 0.281, 271, 235, IRAK4 IN COMPLEX WITH COMPOUND 1
4435, d1ungB_, 0.7329, 2.60, 0.208, 268, 236, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
4436, d3ralA_, 0.7328, 2.83, 0.218, 277, 239, CDK2 IN COMPLEX WITH INHIBITOR RC-2-34
4437, d4bbmA1, 0.7326, 3.42, 0.236, 306, 250, CRYSTAL STRUCTURE OF THE HUMAN CDKL2 KINASE DOMAIN WITH BOUND TCS 2312
4438, d3my0J_, 0.7326, 2.70, 0.264, 252, 235, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4439, d4o0tB_, 0.7325, 3.38, 0.220, 280, 250, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
4440, d2ym5A_, 0.7324, 3.10, 0.258, 248, 240, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4441, d3ot8A_, 0.7323, 3.24, 0.269, 251, 242, X-RAY CRYSTAL STRUCTURE OF COMPOUND 17R BOUND TO HUMAN CHK1 KINASE DOMAIN
4442, d3fpqA_, 0.7323, 3.29, 0.245, 262, 245, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF WNK1
4443, d5o1vB_, 0.7322, 3.01, 0.246, 270, 240, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED APO STATE (A-LOOP SWAPPED)
4444, d5jq8A_, 0.7322, 2.92, 0.234, 278, 239, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH INHIBITOR ICEC0943
4445, d3dfaA1, 0.7322, 3.25, 0.251, 262, 247, CRYSTAL STRUCTURE OF KINASE DOMAIN OF CALCIUM-DEPENDENT PROTEIN KINASE CGD3_920 FROM CRYPTOSPORIDIUM PARVUM
4446, d2vtnA_, 0.7322, 2.68, 0.220, 274, 236, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
4447, d4w4vA_, 0.7321, 3.39, 0.179, 342, 252, JNK2/3 IN COMPLEX WITH 3-(4-{[(2-CHLOROPHENYL)CARBAMOYL]AMINO}-1H- PYRAZOL-1-YL)-N-(2-METHYLPYRIDIN-4-YL)BENZAMIDE
4448, d4aa4A_, 0.7320, 3.57, 0.202, 347, 252, P38ALPHA MAP KINASE BOUND TO CMPD 22
4449, d2vtqA_, 0.7320, 2.80, 0.228, 274, 237, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
4450, d5m53A1, 0.7319, 2.55, 0.234, 248, 235, NEK2 BOUND TO ARYLAMINOPURINE INHIBITOR 11
4451, d2b55A_, 0.7319, 2.80, 0.218, 276, 238, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH INDENOPYRAXOLE DIN-101312
4452, d1h06A_, 0.7319, 2.87, 0.226, 277, 239,  
4453, d4kbaD_, 0.7318, 3.42, 0.213, 274, 253, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
4454, d4hokG_, 0.7318, 3.75, 0.215, 290, 261, CRYSTAL STRUCTURE OF APO CK1E
4455, d3d7zA_, 0.7318, 3.55, 0.213, 348, 253, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIPHENYL AMIDE INHIBITOR
4456, d5dbxB_, 0.7317, 2.91, 0.255, 282, 239, CRYSTAL STRUCTURE OF MURINE SPAK(T243D) IN COMPLEX WITH AMPPNP
4457, d5up3B_, 0.7316, 2.41, 0.250, 243, 232, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
4458, d4w4yA_, 0.7316, 3.42, 0.178, 350, 253, JNK2/3 IN COMPLEX WITH 3-(4-{[(4-METHYLPHENYL)CARBAMOYL]AMINO}-1H- PYRAZOL-1-YL)-N-(2-METHYLPYRIDIN-4-YL)BENZAMIDE
4459, d3uysB_, 0.7315, 3.36, 0.210, 279, 252, CRYSTAL STRUCTURE OF APO HUMAN CK1D
4460, d2xkfA1, 0.7315, 2.51, 0.226, 242, 235, STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 2
4461, d2o8yB_, 0.7315, 2.74, 0.288, 266, 236, APO IRAK4 KINASE DOMAIN
4462, d2btrA_, 0.7315, 2.73, 0.229, 275, 236, STRUCTURE OF CDK2 COMPLEXED WITH PNU-198873
4463, d4w4xA_, 0.7314, 3.42, 0.182, 342, 253, JNK2/3 IN COMPLEX WITH 3-(4-{[(4-FLUOROPHENYL)CARBAMOYL]AMINO}-1H- PYRAZOL-1-YL)-N-(2-METHYLPYRIDIN-4-YL)BENZAMIDE
4464, d3en6A_, 0.7314, 1.81, 0.336, 236, 223, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP102 A MULTITARGETED KINASE INHIBITOR
4465, d5uvfC_, 0.7311, 3.58, 0.157, 301, 255, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO BI- D1870
4466, d1g5sA_, 0.7311, 2.78, 0.219, 275, 237, CRYSTAL STRUCTURE OF HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH THE INHIBITOR H717
4467, p4btfA2, 0.7310, 3.10, 0.239, 297, 247, STRUCTURE OF MLKL
4468, d4f0gA1, 0.7308, 3.01, 0.257, 260, 241, CRYSTAL STRUCTURE OF THE ROCO4 KINASE DOMAIN FROM D. DISCOIDEUM
4469, d4bghA_, 0.7307, 2.74, 0.232, 275, 237, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH PAN-CDK INHIBITOR
4470, d2vwiB_, 0.7307, 3.03, 0.235, 264, 238, STRUCTURE OF THE OSR1 KINASE A HYPERTENSION DRUG TARGET
4471, d5k7iA_, 0.7306, 2.85, 0.275, 272, 236, IRAK4 IN COMPLEX WITH AZ3864
4472, d1gihA_, 0.7306, 2.80, 0.231, 276, 238, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
4473, p4lopC_, 0.7305, 3.40, 0.194, 341, 252, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
4474, d3wzuA_, 0.7305, 2.82, 0.201, 270, 239, THE STRUCTURE OF MAP2K7 IN COMPLEX WITH 5Z-7-OXOZEAENOL
4475, d4o0rB_, 0.7303, 3.19, 0.232, 282, 246, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
4476, d3is5C1, 0.7303, 3.13, 0.246, 254, 244, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
4477, d2wmwA_, 0.7302, 3.16, 0.262, 247, 240, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4478, d6eimB_, 0.7301, 3.25, 0.232, 295, 246, HUMAN STK10 BOUND TO GW683134A
4479, d5wdyB_, 0.7301, 2.84, 0.246, 259, 236, CRYSTAL STRUCTURE OF WNK1 IN COMPLEX WITH 1-CYCLOHEXYL-N-({6-FLUORO-1- [2-(3-METHOXYPHENYL)PYRIDIN-4-YL]-1H-INDOL-3-YL}METHYL)METHANAMINE (COMPOUND 6)
4480, d4izaC_, 0.7301, 3.27, 0.211, 335, 247, STRUCTURE OF DUALLY PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
4481, d4b8lA_, 0.7301, 2.92, 0.218, 249, 239, AURORA B KINASE P353G MUTANT
4482, d4aacA_, 0.7301, 3.44, 0.204, 350, 250, P38ALPHA MAP KINASE BOUND TO CMPD 29
4483, d3wf5A_, 0.7301, 3.11, 0.248, 277, 242, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE DERIVATIVE 4-[4-(1H-BENZIMIDAZOL-2-YL)PIPERIDIN-1- YL]-1H-PYRAZOLO[34-D]PYRIMIDINE
4484, d3g51A_, 0.7301, 3.03, 0.237, 280, 241, STRUCTURAL DIVERSITY OF THE ACTIVE CONFORMATION OF THE N- TERMINAL KINASE DOMAIN OF P90 RIBOSOMAL S6 KINASE 2
4485, d5l8jA_, 0.7300, 2.96, 0.223, 253, 242, AURORA-A KINASE DOMAIN IN COMPLEX WITH VNAR-D01 S93R
4486, d1v1kA_, 0.7300, 2.89, 0.226, 277, 239, CDK2 IN COMPLEX WITH A DISUBSTITUTED 4 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
4487, d4kbcB_, 0.7299, 3.34, 0.222, 277, 252, CK1D IN COMPLEX WITH {4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDIN-2- YL}METHANOL INHIBITOR
4488, d3e7oA_, 0.7299, 3.60, 0.195, 342, 256, CRYSTAL STRUCTURE OF JNK2
4489, p4lopA_, 0.7298, 3.51, 0.197, 351, 254, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
4490, d3e92A_, 0.7297, 3.50, 0.198, 348, 252, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIARYL AMIDE INHIBITOR
4491, d3kc3A_, 0.7296, 2.67, 0.218, 288, 239, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4492, d3efwB_, 0.7296, 2.70, 0.244, 242, 234, STRUCTURE OF AURORAA WITH PYRIDYL-PYRIMIDINE UREA INHIBITOR
4493, d5ankA_, 0.7295, 2.78, 0.234, 273, 235, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 246-TRIOXO-1- PHENYL-HEXAHYDROPYRIMIDINE-5-CARBOXAMIDE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
4494, d4fuyA_, 0.7295, 3.36, 0.217, 329, 249, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK2
4495, d2o8yA_, 0.7295, 2.80, 0.300, 269, 237, APO IRAK4 KINASE DOMAIN
4496, d3gc9B_, 0.7294, 3.25, 0.206, 339, 247, THE STRUCTURE OF P38BETA C119S C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE INHIBITOR
4497, d2ym7A_, 0.7294, 3.16, 0.267, 248, 240, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4498, d5o2bA1, 0.7293, 3.05, 0.243, 268, 239, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A DIPHOSPHORYLATED STATE AND IN A COMPLEX WITH THE INHIBITOR PP-121
4499, d5mrbA1, 0.7292, 3.07, 0.193, 259, 244, CRYSTAL STRUCTURE OF HUMAN MPS1 (TTK) IN COMPLEX WITH CPD-5
4500, d5k7gB_, 0.7292, 3.02, 0.272, 275, 239, IRAK4 IN COMPLEX WITH AZ3862
4501, d2bvaA_, 0.7292, 3.20, 0.192, 272, 245, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4
4502, d4ewqA_, 0.7291, 3.60, 0.198, 346, 253, HUMAN P38 ALPHA MAPK IN COMPLEX WITH A PYRIDAZINE BASED INHIBITOR
4503, d4c3pA_, 0.7290, 3.25, 0.225, 264, 244, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) BOUND TO TPX2 AND AMPPCP
4504, d2ym3A_, 0.7290, 3.09, 0.264, 247, 239, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4505, d1di9A_, 0.7290, 3.64, 0.202, 348, 252, THE STRUCTURE OF P38 MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH 4-[3-METHYLSULFANYLANILINO]-67- DIMETHOXYQUINAZOLINE
4506, d1p2aA_, 0.7288, 2.62, 0.218, 271, 234, THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH A TRISUBSTITUTED NAPHTHOSTYRIL INHIBITOR
4507, p4lopB_, 0.7287, 3.48, 0.194, 350, 252, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
4508, d4ftoA_, 0.7286, 3.27, 0.266, 252, 241, CRYSTAL STRUCTURE OF THE CHK1
4509, d5nttA1, 0.7285, 3.43, 0.197, 268, 249, CRYSTAL STRUCTURE OF HUMAN MPS1 (TTK) C604Y MUTANT IN COMPLEX WITH NMS-P715
4510, d1oukA_, 0.7285, 3.67, 0.209, 348, 253, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A PYRIDINYLIMIDAZOLE INHIBITOR
4511, d3w18B_, 0.7284, 2.60, 0.244, 236, 234, STRUCTURE OF AURORA KINASE A COMPLEXED TO BENZOIMIDAZOLE-INDAZOLE INHIBITOR XIII
4512, d3w18A_, 0.7284, 2.53, 0.229, 234, 231, STRUCTURE OF AURORA KINASE A COMPLEXED TO BENZOIMIDAZOLE-INDAZOLE INHIBITOR XIII
4513, d3gc8B_, 0.7284, 3.41, 0.206, 346, 248, THE STRUCTURE OF P38BETA C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE
4514, d2wmuA_, 0.7284, 3.07, 0.261, 246, 238, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4515, d2w96B_, 0.7284, 2.97, 0.187, 267, 241, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
4516, d3kc3E_, 0.7283, 2.67, 0.223, 287, 238, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4517, d3ezrA_, 0.7283, 2.70, 0.221, 273, 235, CDK-2 WITH INDAZOLE INHIBITOR 17 BOUND AT ITS ACTIVE SITE
4518, d5k7iB_, 0.7282, 2.94, 0.274, 271, 237, IRAK4 IN COMPLEX WITH AZ3864
4519, d3bx5A_, 0.7282, 3.47, 0.217, 338, 249, P38 ALPHA MAP KINASE COMPLEXED WITH BMS-640994
4520, d2z7sA_, 0.7282, 2.55, 0.223, 256, 233, CRYSTAL STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF HUMAN RSK1 BOUND TO PURVALNOL A
4521, d5eakB_, 0.7281, 3.15, 0.285, 300, 242, OPTIMIZATION OF MICROTUBULE AFFINITY REGULATING KINASE (MARK) INHIBITORS WITH IMPROVED PHYSICAL PROPERTIES
4522, d2vu3A_, 0.7281, 2.85, 0.216, 285, 236, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
4523, d4kkeA_, 0.7280, 3.36, 0.168, 354, 250, THE CRYSTAL STRUCTURE OF AMP-BOUND JNK3
4524, d5n87A1, 0.7279, 3.17, 0.188, 252, 245, TTK KINASE DOMAIN IN COMPLEX WITH NTRC 0066-0
4525, d5ci6A_, 0.7279, 2.96, 0.212, 335, 240, CRYSTAL STRUCTURE OF ARABIDOPSIS THALIANA MPK6
4526, d5awmA_, 0.7279, 3.28, 0.173, 345, 249, THE CRYSTAL STRUCTURE OF JNK FROM DROSOPHILA MELANOGASTER REVEALS AN EVOLUTIONARILY CONSERVED TOPOLOGY WITH THAT OF MAMMALIAN JNK PROTEINS.
4527, d3op5D_, 0.7276, 3.60, 0.153, 302, 255, HUMAN VACCINIA-RELATED KINASE 1
4528, d3ma6A_, 0.7276, 3.48, 0.263, 267, 251, CRYSTAL STRUCTURE OF KINASE DOMAIN OF TGCDPK1 IN PRESENCE OF 3BRB-PP1
4529, d3f61A_, 0.7276, 3.26, 0.214, 271, 243, CRYSTAL STRUCTURE OF M. TUBERCULOSIS PKNB LEU33ASP/VAL222ASP DOUBLE MUTANT IN COMPLEX WITH ADP
4530, d3gc8A_, 0.7275, 3.69, 0.213, 347, 253, THE STRUCTURE OF P38BETA C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE
4531, d2w9fB_, 0.7275, 2.97, 0.183, 261, 240, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
4532, d3itzA1, 0.7274, 3.59, 0.209, 353, 254, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A PYRAZOLOPYRIDAZINE INHIBITOR
4533, d3h0zB_, 0.7274, 2.69, 0.236, 240, 233, AURORA A IN COMPLEX WITH A BISANILINOPYRIMIDINE
4534, d2qkrA1, 0.7274, 2.73, 0.220, 269, 236, CRYPTOSPORIDIUM PARVUM CYCLIN-DEPENDENT KINASE CGD5_2510 WITH INDIRUBIN 3 -MONOXIME BOUND
4535, d4hokC_, 0.7273, 3.81, 0.214, 289, 262, CRYSTAL STRUCTURE OF APO CK1E
4536, d2jc6A_, 0.7273, 2.91, 0.248, 278, 238, CRYSTAL STRUCTURE OF HUMAN CALMODULIN-DEPENDENT PROTEIN KINASE 1D
4537, d2ozaB_, 0.7272, 3.40, 0.205, 340, 249, STRUCTURE OF P38ALPHA COMPLEX
4538, d6bruB_, 0.7271, 3.55, 0.154, 301, 254, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A (S)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
4539, d2ac3A1, 0.7271, 3.30, 0.203, 275, 246, STRUCTURE OF HUMAN MNK2 KINASE DOMAIN
4540, d4bc6A_, 0.7269, 3.41, 0.232, 285, 246, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 BOUND TO NOVEL BOSUTINIB ISOFORM 1 PREVIOUSLY THOUGHT TO BE BOSUTINIB
4541, d3kc3F_, 0.7269, 2.75, 0.226, 293, 239, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4542, d2duvA_, 0.7269, 2.69, 0.231, 272, 234, STRUCTURE OF CDK2 WITH A 3-HYDROXYCHROMONES
4543, d1urwA_, 0.7269, 2.87, 0.232, 274, 237, CDK2 IN COMPLEX WITH AN IMIDAZO[12-B]PYRIDAZINE
4544, d5ehlA1, 0.7268, 3.25, 0.191, 254, 246, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
4545, p5xyyA_, 0.7267, 3.73, 0.213, 350, 253, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A TRIAZOL INHIBITOR
4546, d4nifD_, 0.7267, 2.91, 0.208, 313, 240, HETERODIMERIC STRUCTURE OF ERK2 AND RSK1
4547, d4aa5A_, 0.7265, 3.49, 0.201, 340, 249, P38ALPHA MAP KINASE BOUND TO CMPD 33
4548, d3g33A_, 0.7265, 2.90, 0.183, 291, 240, CRYSTAL STRUCTURE OF CDK4/CYCLIN D3
4549, d3ckwA_, 0.7265, 2.78, 0.268, 255, 235, CRYSTAL STRUCTURE OF STERILE 20-LIKE KINASE 3 (MST3 STK24)
4550, d5uisC_, 0.7264, 2.76, 0.281, 270, 235, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 12
4551, d3dt1A2, 0.7264, 3.64, 0.198, 352, 253, P38 COMPLEXED WITH A QUINAZOLINE INHIBITOR
4552, d2vttA_, 0.7262, 2.73, 0.218, 272, 234, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
4553, p4loqD_, 0.7261, 3.52, 0.194, 351, 252, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
4554, d3a62A_, 0.7261, 2.86, 0.235, 263, 238, CRYSTAL STRUCTURE OF PHOSPHORYLATED P70S6K1
4555, d3ds6D_, 0.7260, 3.67, 0.205, 349, 254, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
4556, d3ctqA_, 0.7260, 3.30, 0.212, 336, 245, STRUCTURE OF MAP KINASE P38 IN COMPLEX WITH A 1-O-TOLYL-12 3-TRIAZOLE-4-CARBOXAMIDE
4557, d5bvfA_, 0.7258, 2.98, 0.214, 327, 238, TETRAHYDROPYRROLO-DIAZEPENONES AS INHIBITORS OF ERK2 KINASE
4558, d1zy5A1, 0.7257, 3.33, 0.235, 269, 247, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: R794G HYPERACTIVATING MUTANT COMPLEXED WITH AMPPNP.
4559, d1oitA_, 0.7257, 2.78, 0.226, 273, 235, IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION
4560, d6btwB_, 0.7256, 3.58, 0.154, 301, 254, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PHENYL-PTERIDINONE INHIBITOR
4561, d4un0D_, 0.7256, 3.13, 0.266, 276, 244, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
4562, d3ortA_, 0.7256, 3.15, 0.225, 271, 240, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 6)
4563, d2zb1A_, 0.7256, 3.43, 0.201, 345, 249, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH BIPHENYL AMIDE INHIBITOR
4564, d4nifA_, 0.7255, 2.93, 0.208, 313, 240, HETERODIMERIC STRUCTURE OF ERK2 AND RSK1
4565, d4ztlB_, 0.7254, 3.05, 0.280, 269, 236, IRAK4-INHIBITOR CO-STRUCTURE
4566, d2wtkF1, 0.7254, 2.85, 0.262, 250, 237, STRUCTURE OF THE HETEROTRIMERIC LKB1-STRADALPHA-MO25ALPHA COMPLEX
4567, d1ouyA_, 0.7254, 3.75, 0.213, 350, 253, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A DIHYDROPYRIDO- PYRIMIDINE INHIBITOR
4568, d2fvdA_, 0.7253, 2.88, 0.213, 284, 235, CYCLIN DEPENDENT KINASE 2 (CDK2) WITH DIAMINOPYRIMIDINE INHIBITOR
4569, d3kc3B_, 0.7252, 2.66, 0.224, 290, 237, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4570, d2pmiA_, 0.7251, 2.92, 0.212, 284, 240, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE- RESPONSIVE SIGNAL TRANSDUCTION PATHWAY WITH BOUND ATP-GAMMA-S
4571, d4wo5B1, 0.7250, 2.38, 0.273, 241, 231, CRYSTAL STRUCTURE OF A BRAF KINASE DOMAIN MONOMER
4572, d5tkdA_, 0.7249, 2.70, 0.238, 248, 235, CRYSTAL STRUCTURE OF TYROSINE KINASE 2 JH2 (PSEUDO KINASE DOMAIN) COMPLEXED WITH 6-[(35-DIMETHYLPHE NYL)AMINO]-8- (METHYLAMINO) IMIDAZO[12-B]PYRIDAZINE-3-CARBO XAMIDE
4573, d5ap7A1, 0.7249, 3.02, 0.186, 253, 242, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4574, p4loqC_, 0.7249, 3.51, 0.190, 337, 252, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
4575, d5kbqB_, 0.7248, 3.33, 0.220, 273, 246, PAK1 IN COMPLEX WITH BIS-ANILINO PYRIMIDINE INHIBITOR
4576, d4kkgA_, 0.7248, 3.42, 0.180, 353, 250, CRYSTAL STRUCTURE OF APO AND AMP-BOUND JNK3
4577, d2ym8A_, 0.7247, 3.14, 0.268, 246, 239, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4578, p4loqB_, 0.7246, 3.45, 0.195, 351, 251, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
4579, p4loqA_, 0.7246, 3.49, 0.194, 352, 252, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
4580, d4lg4F_, 0.7246, 3.06, 0.237, 276, 241, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
4581, d3mvlA_, 0.7246, 3.43, 0.206, 339, 247, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7K
4582, d3hmpA_, 0.7245, 3.17, 0.197, 258, 244, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH A QUINAZOLIN LIGAND COMPOUND 4
4583, d2wzjB_, 0.7245, 2.94, 0.282, 310, 241, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
4584, d2lgcA1, 0.7245, 3.65, 0.210, 353, 252, JOINT NMR AND X-RAY REFINEMENT REVEALS THE STRUCTURE OF A NOVEL DIBENZO[AD]CYCLOHEPTENONE INHIBITOR/P38 MAP KINASE COMPLEX IN SOLUTION
4585, d4m69B_, 0.7244, 3.29, 0.229, 264, 249, CRYSTAL STRUCTURE OF THE MOUSE RIP3-MLKL COMPLEX
4586, d4y46A_, 0.7243, 3.39, 0.164, 340, 250, PYRIDOPYRIMIDINONE DERIVATIVES AS POTENT AND SELECTIVE C-JUN N- TERMINAL KINASE (JNK) INHIBITORS
4587, d3g33C_, 0.7243, 3.28, 0.216, 291, 245, CRYSTAL STRUCTURE OF CDK4/CYCLIN D3
4588, d2zb0A_, 0.7243, 3.66, 0.202, 349, 252, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH BIPHENYL AMIDE INHIBITOR
4589, d1zz2A_, 0.7243, 3.41, 0.220, 337, 246, TWO CLASSES OF P38ALPHA MAP KINASE INHIBITORS HAVING A COMMON DIPHENYLETHER CORE BUT EXHIBITING DIVERGENT BINDING MODES
4590, d4qtdA_, 0.7242, 3.46, 0.184, 355, 250, STRUCTURE OF HUMAN JNK1 IN COMPLEX WITH SCH772984 AND THE AMPPNP- HYDROLYSED TRIPHOSPHATE REVEALING THE SECOND TYPE-I BINDING MODE
4591, d1wboA_, 0.7242, 3.75, 0.202, 351, 253, FRAGMENT BASED P38 INHIBITORS
4592, d5na0A1, 0.7241, 3.10, 0.185, 250, 243, TTK KINASE DOMAIN IN COMPLEX WITH A PEG-LINKED PYRIMIDO-INDOLIZINE
4593, d4x7hA_, 0.7241, 3.19, 0.225, 256, 240, CO-CRYSTAL STRUCTURE OF PERK BOUND TO N-{5-[(67-DIMETHOXYQUINOLIN-4- YL)OXY]PYRIDIN-2-YL}-1-METHYL-3-OXO-2-PHENYL-5-(PYRIDIN-4-YL)-23- DIHYDRO-1H-PYRAZOLE-4-CARBOXAMIDE INHIBITOR
4594, d1r78A_, 0.7241, 2.75, 0.217, 273, 235, CDK2 COMPLEX WITH A 4-ALKYNYL OXINDOLE INHIBITOR
4595, d4xoyA_, 0.7240, 3.35, 0.211, 326, 246, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
4596, d3kc3I_, 0.7240, 2.73, 0.227, 295, 238, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4597, d3kc3L_, 0.7239, 2.69, 0.219, 291, 237, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4598, d3gc9A_, 0.7239, 3.59, 0.212, 335, 250, THE STRUCTURE OF P38BETA C119S C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE INHIBITOR
4599, d1m7qA_, 0.7239, 3.66, 0.210, 348, 252, CRYSTAL STRUCTURE OF P38 MAP KINASE IN COMPLEX WITH A DIHYDROQUINAZOLINONE INHIBITOR
4600, d5jt2D1, 0.7238, 2.13, 0.305, 232, 226, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-BISAMIDE
4601, d2qnjB1, 0.7236, 3.13, 0.273, 321, 245, KINASE AND UBIQUITIN-ASSOCIATED DOMAINS OF MARK3/PAR-1
4602, d3mptA_, 0.7235, 3.58, 0.191, 347, 251, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A PYRROLE-2- CARBOXAMIDE INHIBITOR
4603, d3ds6A_, 0.7235, 3.57, 0.202, 343, 253, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
4604, d2x9eA_, 0.7235, 3.10, 0.189, 253, 243, HUMAN MPS1 IN COMPLEX WITH NMS-P715
4605, d2wzjC_, 0.7235, 2.94, 0.282, 310, 241, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
4606, d2bmcB_, 0.7235, 3.07, 0.238, 258, 239, AURORA-2 T287D T288D COMPLEXED WITH PHA-680632
4607, d3ds6C_, 0.7234, 3.66, 0.202, 349, 253, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
4608, d2xk4A1, 0.7234, 2.74, 0.215, 244, 237, STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 17
4609, d1w82A_, 0.7234, 3.71, 0.211, 351, 251, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
4610, d2y4pC_, 0.7233, 3.00, 0.232, 264, 237, DIMERIC STRUCTURE OF DAPK-1 CATALYTIC DOMAIN
4611, d1zycD1, 0.7232, 3.33, 0.220, 254, 246, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: WILD- TYPE IN APO FORM.
4612, d5y8uA_, 0.7231, 2.85, 0.200, 267, 235, CRYSTAL STRUCTURE OF THE C276S MUTANT OF MAP2K7
4613, d4i5hA_, 0.7231, 3.27, 0.206, 335, 243, CRYSTAL STRUCTURE OF A DOUBLE MUTANT RAT ERK2 COMPLEXED WITH A TYPE II QUINAZOLINE INHIBITOR
4614, d2xnnA1, 0.7231, 2.70, 0.229, 243, 236, STRUCTURE OF NEK2 BOUND TO CCT242430
4615, d4d1xA_, 0.7230, 2.80, 0.234, 274, 235, CDK2 IN COMPLEX WITH LUCIFERIN
4616, d3wi6F_, 0.7228, 2.54, 0.235, 283, 234, CRYSTAL STRUCTURE OF MAPKAP KINASE-2 (MK2) IN COMPLEX WITH NON- SELECTIVE INHIBITOR
4617, d3mvlB_, 0.7228, 3.41, 0.190, 339, 247, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7K
4618, d2wzjF_, 0.7228, 2.96, 0.282, 310, 241, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
4619, d5ho6A_, 0.7227, 2.02, 0.353, 240, 221, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH CMPD.
4620, d4zjiD_, 0.7227, 3.38, 0.198, 280, 247, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
4621, d4xv9A1, 0.7227, 2.53, 0.267, 244, 232, B-RAF KINASE DOMAIN IN COMPLEX WITH PLX5568
4622, d3gfeA_, 0.7227, 3.69, 0.209, 352, 253, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A PYRAZOLOPYRIDINONE INHIBITOR
4623, d1ua2A_, 0.7227, 3.03, 0.233, 286, 236, CRYSTAL STRUCTURE OF HUMAN CDK7
4624, d5n84A1, 0.7226, 3.17, 0.193, 253, 244, TTK KINASE DOMAIN IN COMPLEX WITH MPS-BAY2B
4625, d5ap0A1, 0.7226, 3.14, 0.185, 250, 243, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4626, d3wi6E_, 0.7226, 2.54, 0.231, 283, 234, CRYSTAL STRUCTURE OF MAPKAP KINASE-2 (MK2) IN COMPLEX WITH NON- SELECTIVE INHIBITOR
4627, d3wi6D_, 0.7226, 2.54, 0.235, 282, 234, CRYSTAL STRUCTURE OF MAPKAP KINASE-2 (MK2) IN COMPLEX WITH NON- SELECTIVE INHIBITOR
4628, d2xnpA1, 0.7226, 2.82, 0.214, 245, 238, STRUCTURE OF NEK2 BOUND TO CCT244858
4629, d4bi0A1, 0.7225, 3.18, 0.185, 251, 243, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
4630, d3wi6C_, 0.7225, 2.54, 0.235, 283, 234, CRYSTAL STRUCTURE OF MAPKAP KINASE-2 (MK2) IN COMPLEX WITH NON- SELECTIVE INHIBITOR
4631, d1yqjA2, 0.7225, 3.58, 0.194, 351, 252, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH A SELECTIVE PYRIDAZINE INHIBITOR
4632, d5hniX_, 0.7224, 2.54, 0.354, 245, 226, CRYSTAL STRUCTURE OF CMET WT WITH COMPOUND 3
4633, d5a6nA1, 0.7224, 2.89, 0.223, 270, 238, CRYSTAL STRUCTURE OF HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3) IN COMPLEX WITH COMPOUND 2
4634, d3q4zB_, 0.7224, 3.20, 0.212, 279, 245, STRUCTURE OF UNPHOSPHORYLATED PAK1 KINASE DOMAIN
4635, d2xk8A1, 0.7224, 2.45, 0.221, 238, 231, STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 15
4636, d1yojA_, 0.7224, 1.79, 0.341, 233, 220, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN
4637, d4x7nA_, 0.7223, 3.15, 0.212, 259, 240, CO-CRYSTAL STRUCTURE OF PERK BOUND TO 4-[2-AMINO-4-METHYL-3-(2- METHYLQUINOLIN-6-YL)BENZOYL]-1-METHYL-25-DIPHENYL-12-DIHYDRO-3H- PYRAZOL-3-ONE INHIBITOR
4638, d4w4wA_, 0.7223, 3.46, 0.176, 349, 250, JNK2/3 IN COMPLEX WITH N-(2-METHYLPYRIDIN-4-YL)-3-{4- [(PHENYLCARBAMOYL)AMINO]-1H-PYRAZOL-1-YL}BENZAMIDE
4639, d4afeA1, 0.7223, 2.86, 0.223, 245, 238, NEK2 BOUND TO HYBRID COMPOUND 21
4640, d2wzjD_, 0.7223, 2.97, 0.282, 313, 241, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
4641, d2wmqA_, 0.7223, 3.22, 0.273, 246, 238, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4642, d4x7kA_, 0.7222, 3.12, 0.218, 260, 239, CO-CRYSTAL STRUCTURE OF PERK BOUND TO 4-{2-AMINO-3-[5-FLUORO-2- (METHYLAMINO)QUINAZOLIN-6-YL]-4-METHYLBENZOYL}-1-METHYL-25-DIPHENYL- 12-DIHYDRO-3H-PYRAZOL-3-ONE INHIBITOR
4643, d4o2zA1, 0.7222, 3.29, 0.201, 357, 244, CRYSTAL STRUCTURE OF MPK3 FROM LEISHMANIA DONOVANI LDBPK_100540 IN THE PRESENCE OF NVP-BBT594
4644, d3nnwA_, 0.7222, 3.75, 0.211, 349, 251, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH DP802
4645, d3kc3J_, 0.7222, 2.65, 0.220, 288, 236, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4646, d2bmcD_, 0.7222, 3.10, 0.239, 256, 238, AURORA-2 T287D T288D COMPLEXED WITH PHA-680632
4647, d4zjiC_, 0.7221, 3.45, 0.211, 281, 247, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
4648, d3wi6B_, 0.7221, 2.56, 0.235, 283, 234, CRYSTAL STRUCTURE OF MAPKAP KINASE-2 (MK2) IN COMPLEX WITH NON- SELECTIVE INHIBITOR
4649, d2ym4A_, 0.7221, 3.39, 0.270, 251, 241, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4650, d2jc6C_, 0.7221, 2.95, 0.249, 277, 237, CRYSTAL STRUCTURE OF HUMAN CALMODULIN-DEPENDENT PROTEIN KINASE 1D
4651, d3dj6A_, 0.7220, 2.98, 0.239, 252, 238, CRYSTAL STRUCTURE OF THE MOUSE AURORA-A CATALYTIC DOMAIN (ASN186->GLY LYS240->ARG MET302->LEU) IN COMPLEX WITH COMPOUND 823.
4652, d2z7qA_, 0.7220, 2.64, 0.224, 255, 232, CRYSTAL STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF HUMAN RSK-1 BOUND TO AMP-PCP
4653, d1blxA_, 0.7220, 3.44, 0.177, 305, 248, P19INK4D/CDK6 COMPLEX
4654, d5b2kA_, 0.7219, 2.74, 0.204, 264, 235, A CRUCIAL ROLE OF CYS218 IN THE STABILIZATION OF AN UNPRECEDENTED AUTO-INHIBITION FORM OF MAP2K7
4655, d4fgbA_, 0.7219, 3.28, 0.210, 282, 248, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I APO FORM
4656, d4d9tA_, 0.7219, 3.10, 0.211, 299, 242, RSK2 C-TERMINAL KINASE DOMAIN WITH INHIBITOR (E)-METHYL 3-(4-AMINO-7- (3-HYDROXYPROPYL)-5-P-TOLYL-7H-PYRROLO[23-D]PYRIMIDIN-6-YL)-2- CYANOACRYLATE
4657, d3u8wA_, 0.7219, 3.69, 0.202, 349, 253, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A TRIAZOLOPYRIDAZINONE INHIBITOR
4658, d3nwwA_, 0.7219, 3.54, 0.214, 339, 248, P38 ALPHA KINASE COMPLEXED WITH A 2-AMINOTHIAZOL-5-YL-PYRIMIDINE BASED INHIBITOR
4659, d3ds6B_, 0.7219, 3.55, 0.202, 343, 252, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
4660, d2wqeA_, 0.7219, 2.91, 0.247, 241, 235, STRUCTURE OF S155R AURORA-A SOMATIC MUTANT
4661, d1zy4A1, 0.7219, 3.30, 0.236, 269, 246, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: R794G HYPERACTIVATING MUTANT IN APO FORM.
4662, d1lezA_, 0.7219, 3.65, 0.200, 343, 250, CRYSTAL STRUCTURE OF MAP KINASE P38 COMPLEXED TO THE DOCKING SITE ON ITS ACTIVATOR MKK3B
4663, d5uvfD_, 0.7218, 3.52, 0.155, 296, 251, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO BI- D1870
4664, d3rinA_, 0.7218, 3.76, 0.213, 349, 254, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
4665, d3fmhA_, 0.7218, 3.70, 0.195, 347, 251, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24-DIFLUORO-PHENOXY)- 8-METHYL-2-((R)-1-METHYL-2-TETRAZOL-2-YL-ETHYLAMINO)-8H-PYRIDO[23- D]PYRIMIDIN-7-ONE
4666, d2bmcE_, 0.7218, 3.12, 0.239, 256, 238, AURORA-2 T287D T288D COMPLEXED WITH PHA-680632
4667, d1w84A_, 0.7217, 3.67, 0.198, 351, 252, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
4668, d1pmvA_, 0.7217, 3.41, 0.169, 347, 248, THE STRUCTURE OF JNK3 IN COMPLEX WITH A DIHYDROANTHRAPYRAZOLE INHIBITOR
4669, d4y5hA_, 0.7216, 3.44, 0.164, 349, 250, PYRIDOPYRIMIDINONE DERIVATIVES AS POTENT AND SELECTIVE C-JUN N- TERMINAL KINASE (JNK) INHIBITORS
4670, d4x7lA_, 0.7216, 3.14, 0.218, 260, 239, CO-CRYSTAL STRUCTURE OF PERK BOUND TO 4-{2-AMINO-4-METHYL-3-[2- (METHYLAMINO)-13-BENZOTHIAZOL-6-YL]BENZOYL}-1-METHYL-25-DIPHENYL-1 2-DIHYDRO-3H-PYRAZOL-3-ONE INHIBITOR
4671, d3wi6A_, 0.7216, 2.65, 0.238, 282, 235, CRYSTAL STRUCTURE OF MAPKAP KINASE-2 (MK2) IN COMPLEX WITH NON- SELECTIVE INHIBITOR
4672, d2zazA_, 0.7215, 3.61, 0.212, 345, 250, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH 4-ANILINO QUINOLINE INHIBITOR
4673, d2balA_, 0.7215, 3.47, 0.191, 337, 246, P38ALPHA MAP KINASE BOUND TO PYRAZOLOAMINE
4674, d5ljjA1, 0.7214, 3.25, 0.205, 260, 244, CRYSTAL STRUCTURE OF HUMAN MPS1 (TTK) IN COMPLEX WITH REVERSINE
4675, d4o6lB_, 0.7214, 3.28, 0.184, 256, 244, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 401498 (N- [(1R)-1-(2-CHLOROPHENYL)PROPYL]-3-{4-[(1-METHYLPIPERIDIN-4-YL) OXY]PHENYL}-1H-INDAZOLE-5-CARBOXAMIDE)
4676, d3orlA_, 0.7214, 3.19, 0.229, 268, 240, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 3)
4677, d3efwA_, 0.7214, 2.70, 0.236, 240, 233, STRUCTURE OF AURORAA WITH PYRIDYL-PYRIMIDINE UREA INHIBITOR
4678, p4e3cF1, 0.7213, 3.42, 0.224, 290, 250, X-RAY CRYSTAL STRUCTURE OF HUMAN IKK2 IN AN ACTIVE CONFORMATION
4679, d4bi1A1, 0.7213, 3.14, 0.186, 249, 242, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
4680, d2zdtA_, 0.7213, 3.42, 0.173, 342, 248, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH AN ISOQUINOLONE INHIBITOR
4681, d1gijA_, 0.7213, 2.79, 0.234, 273, 235, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
4682, d3g9nA_, 0.7212, 3.45, 0.177, 346, 249, JNK3 BOUND TO (Z)-1-((6-FLUORO-4H-BENZO[D][13]DIOXIN-8-YL)METHYL)-3- (HYDROXYIMINO)-4-PHENYLINDOLIN-2-ONE
4683, d1lewA_, 0.7212, 3.62, 0.202, 341, 248, CRYSTAL STRUCTURE OF MAP KINASE P38 COMPLEXED TO THE DOCKING SITE ON ITS NUCLEAR SUBSTRATE MEF2A
4684, d4cjyD_, 0.7211, 3.04, 0.266, 272, 241,  
4685, d4zegA_, 0.7210, 3.11, 0.185, 260, 243, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE INHIBITOR
4686, d2pzyA_, 0.7210, 2.92, 0.230, 291, 239, STRUCTURE OF MK2 COMPLEXED WITH COMPOUND 76
4687, d1ua2C_, 0.7210, 2.87, 0.218, 286, 234, CRYSTAL STRUCTURE OF HUMAN CDK7
4688, d3mvmA_, 0.7209, 3.46, 0.190, 335, 247, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7V
4689, d3dj5A_, 0.7209, 3.00, 0.239, 252, 238, CRYSTAL STRUCTURE OF THE MOUSE AURORA-A CATALYTIC DOMAIN (ASN186->GLY LYS240->ARG MET302->LEU) IN COMPLEX WITH COMPOUND 290.
4690, d1ua2D_, 0.7209, 2.77, 0.219, 286, 233, CRYSTAL STRUCTURE OF HUMAN CDK7
4691, d3zxtA_, 0.7208, 2.87, 0.244, 249, 234, DIMERIC STRUCTURE OF DAPK-1 CATALYTIC DOMAIN IN COMPLEX WITH AMPPCP-MG
4692, d3iphA_, 0.7208, 3.57, 0.189, 345, 249, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH A BIPHENYLAMIDE INHIBITOR
4693, d3flyA_, 0.7206, 3.72, 0.195, 347, 251, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24- DIFLUORO-PHENOXY)-2-ISOPROPYLAMINO-8-METHYL-8H-PYRIDO[23- D]PYRIMIDIN-7-ONE
4694, d3dbqA_, 0.7206, 3.31, 0.191, 259, 246, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN
4695, d4u9aB_, 0.7205, 2.72, 0.283, 270, 230, SULPHUR ANOMALOUS CRYSTAL STRUCTURE OF ASYMMETRIC IRAK4 DIMER
4696, d4pwnA_, 0.7205, 2.82, 0.261, 245, 234, CRYSTAL STRUCTURE OF ACTIVE WNK1 KINASE
4697, d4c4fA1, 0.7205, 3.19, 0.181, 250, 243, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
4698, d3flsA_, 0.7205, 3.58, 0.194, 343, 248, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24- DIFLUORO-PHENOXY)-2-((R)-2-METHANESULFONYL-1-METHYL- ETHYLAMINO)-8-METHYL-8H-PYRIDO[23-D]PYRIMIDIN-7-ONE
4699, d3fknA_, 0.7205, 3.67, 0.199, 346, 251, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO7125
4700, d1wbtA_, 0.7205, 3.68, 0.212, 351, 250, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
4701, d4u97B_, 0.7204, 2.71, 0.283, 270, 230, CRYSTAL STRUCTURE OF ASYMMETRIC IRAK4 DIMER
4702, d2xnmA1, 0.7204, 2.91, 0.244, 250, 238, STRUCTURE OF NEK2 BOUND TO CCT
4703, d5hniY_, 0.7203, 2.50, 0.347, 245, 225, CRYSTAL STRUCTURE OF CMET WT WITH COMPOUND 3
4704, d4bi2A1, 0.7203, 3.10, 0.186, 250, 242, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
4705, d1zzlA_, 0.7203, 3.81, 0.197, 351, 254, CRYSTAL STRUCTURE OF P38 WITH TRIAZOLOPYRIDINE
4706, d3o0gB_, 0.7202, 2.67, 0.219, 264, 233, CRYSTAL STRUCTURE OF CDK5:P25 IN COMPLEX WITH AN ATP ANALOGUE
4707, d2bmcA_, 0.7202, 3.05, 0.241, 256, 237, AURORA-2 T287D T288D COMPLEXED WITH PHA-680632
4708, d4maoA_, 0.7201, 3.26, 0.213, 298, 244, RSK2 T493M C-TERMINAL KINASE DOMAIN IN COMPLEX WITH RMM58
4709, d5kbrA_, 0.7200, 2.73, 0.227, 259, 233, PAK1 IN COMPLEX WITH 7-AZAINDOLE INHIBITOR
4710, d5ar8A_, 0.7200, 2.46, 0.263, 255, 228, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIPHENYLSULFONAMIDE
4711, d4x7jA_, 0.7200, 3.12, 0.218, 257, 238, CO-CRYSTAL STRUCTURE OF PERK WITH 2-AMINO-N-[4-METHOXY-3- (TRIFLUOROMETHYL)PHENYL]-4-METHYL-3-[2-(METHYLAMINO)QUINAZOLIN-6- YL]BENZAMIDE INHIBITOR
4712, d4kkhA_, 0.7200, 3.70, 0.166, 351, 253, THE CRYSTAL STRUCTURE OF INHIBITOR-BOUND JNK3
4713, d2yixA_, 0.7200, 3.83, 0.209, 351, 254, TRIAZOLOPYRIDINE INHIBITORS OF P38
4714, d2xnoA1, 0.7200, 2.82, 0.225, 243, 236, STRUCTURE OF NEK2 BOUND TO CCT243779
4715, d2onlB1, 0.7200, 3.61, 0.198, 339, 248, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
4716, d6eimA_, 0.7199, 3.18, 0.218, 286, 239, HUMAN STK10 BOUND TO GW683134A
4717, d4kinD_, 0.7199, 3.53, 0.201, 339, 249, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
4718, d3zxtC_, 0.7199, 2.91, 0.231, 259, 234, DIMERIC STRUCTURE OF DAPK-1 CATALYTIC DOMAIN IN COMPLEX WITH AMPPCP-MG
4719, d3uytD_, 0.7199, 3.13, 0.221, 268, 244, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
4720, d2wzjA_, 0.7199, 3.00, 0.278, 310, 241, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
4721, d5knjB_, 0.7198, 2.99, 0.216, 259, 241, PSEUDOKINASE DOMAIN OF MLKL BOUND TO COMPOUND 1.
4722, d5ehyA1, 0.7198, 3.17, 0.189, 251, 243, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
4723, d4d9uA_, 0.7198, 3.46, 0.219, 307, 247, RSK2 C-TERMINAL KINASE DOMAIN (E)-TERT-BUTYL 3-(4-AMINO-7-(3- HYDROXYPROPYL)-5-P-TOLYL-7H-PYRROLO[23-D]PYRIMIDIN-6-YL)-2- CYANOACRYLATE
4724, d1jnkA_, 0.7198, 3.43, 0.181, 346, 248, THE C-JUN N-TERMINAL KINASE (JNK3S) COMPLEXED WITH MGAMP-PNP
4725, d1a06A_, 0.7198, 2.69, 0.251, 279, 235, CALMODULIN-DEPENDENT PROTEIN KINASE FROM RAT
4726, d5k72B_, 0.7197, 2.82, 0.280, 267, 232, IRAK4 IN COMPLEX WITH COMPOUND 21
4727, d4cvaA1, 0.7197, 3.31, 0.193, 250, 244, MPS1 KINASE WITH 3-AMINOPYRIDIN-2-ONE INHIBITORS
4728, d3hmoA_, 0.7197, 3.25, 0.193, 257, 244, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH THE INHIBITOR STAUROSPORINE
4729, d2zduA_, 0.7197, 3.39, 0.179, 330, 246, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH AN ISOQUINOLONE INHIBITOR
4730, d2okrA_, 0.7197, 3.63, 0.198, 339, 248, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
4731, d1r3cA_, 0.7197, 3.81, 0.202, 349, 252, THE STRUCTURE OF P38ALPHA C162S MUTANT
4732, d2hw7A1, 0.7196, 3.22, 0.186, 269, 242, CRYSTAL STRUCTURE OF MNK2-D228G IN COMPLEX WITH STAUROSPORINE
4733, d1pmuA_, 0.7196, 3.33, 0.169, 342, 249, THE CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH A PHENANTROLINE INHIBITOR
4734, d4a4xA1, 0.7195, 2.90, 0.223, 245, 238, NEK2-EDE BOUND TO CCT248662
4735, d3a2cF_, 0.7195, 2.98, 0.227, 287, 238, CRYSTAL STRUCTURE OF A PYRAZOLOPYRIMIDINE INHIBITOR COMPLEX BOUND TO MAPKAP KINASE-2 (MK2)
4736, d2zmcA_, 0.7195, 3.48, 0.190, 260, 247, CRYSTAL STRUCTURE OF HUMAN MITOTIC CHECKPOINT KINASE MPS1 CATALYTIC DOMAIN APO FORM
4737, d2wzjE_, 0.7195, 2.99, 0.282, 310, 241, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
4738, d2rg6A_, 0.7195, 3.44, 0.192, 335, 245, PHENYLALANINE PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 11J
4739, d5n9sA1, 0.7194, 3.27, 0.205, 256, 244, TTK KINASE DOMAIN IN COMPLEX WITH BAY 1161909
4740, d5n93A1, 0.7194, 3.19, 0.193, 256, 243, TTK KINASE DOMAIN IN COMPLEX WITH TC-MPS1-12
4741, d4fk3A1, 0.7194, 2.54, 0.268, 238, 231, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX3203
4742, d2cn5A1, 0.7194, 2.99, 0.269, 281, 234, CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH ADP
4743, d1zycC1, 0.7194, 3.46, 0.226, 269, 248, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: WILD- TYPE IN APO FORM.
4744, d3nnuA_, 0.7193, 3.73, 0.216, 348, 250, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH DP1376
4745, d5etcA_, 0.7192, 3.71, 0.207, 355, 251, STRUCTURE OF INACTIVE MAPK14 WITH ORDERED ACTIVATION LOOP
4746, d4kinB_, 0.7192, 3.65, 0.192, 341, 250, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
4747, d3vquA_, 0.7192, 3.18, 0.189, 258, 243, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 4- [(4-AMINO-5-CYANO-6-ETHOXYPYRIDIN-2- YL)AMINO]BENZAMIDE
4748, d3pzeA_, 0.7192, 3.56, 0.181, 347, 248, JNK1 IN COMPLEX WITH INHIBITOR
4749, d1bl6A_, 0.7192, 3.75, 0.198, 351, 252, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB216995
4750, d4kb8A_, 0.7191, 3.13, 0.218, 265, 243, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
4751, d3fmmA_, 0.7191, 3.67, 0.199, 346, 251, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO6226
4752, d2xk3A1, 0.7191, 2.54, 0.220, 239, 232, STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 35
4753, d2bmcC_, 0.7191, 3.25, 0.242, 257, 240, AURORA-2 T287D T288D COMPLEXED WITH PHA-680632
4754, d3flzA_, 0.7190, 3.67, 0.200, 347, 250, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 8-METHYL-6-PHENOXY-2- (TETRAHYDRO-PYRAN-4-YLAMINO)-8H-PYRIDO[23-D]PYRIMIDIN-7-ONE
4755, d3cgfA_, 0.7190, 3.45, 0.177, 346, 248, IRAK-4 INHIBITORS (PART II)- A STRUCTURE BASED ASSESSMENT OF IMIDAZO[12 A]PYRIDINE BINDING
4756, d2r0iB_, 0.7190, 3.15, 0.287, 300, 240, CRYSTAL STRUCTURE OF A KINASE MARK2/PAR-1 MUTANT
4757, d4zloB_, 0.7188, 2.82, 0.225, 263, 236, SERINE/THREONINE-PROTEIN KINASE PAK1 COMPLEXED WITH A DIBENZODIAZEPINE: IDENTIFICATION OF AN ALLOSTERIC SITE ON PAK1
4758, d3g90X_, 0.7188, 3.41, 0.178, 345, 247, JNK-3 BOUND TO (Z)-5-FLUORO-1-((6-FLUORO-4H-BENZO[D][13]DIOXIN-8-YL) METHYL)-3-(HYDROXYIMINO)INDOLIN-2-ONE
4759, d2wajA_, 0.7188, 3.41, 0.165, 348, 248, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH A 1-ARYL-34- DIHYDROISOQUINOLINE INHIBITOR
4760, d4m7iA1, 0.7187, 2.93, 0.227, 246, 238, CRYSTAL STRUCTURE OF GSK6157 BOUND TO PERK (R587-R1092 DELETE A660- T867) AT 2.34A RESOLUTION
4761, d4jg8A_, 0.7187, 3.37, 0.216, 300, 245, STRUCTURE OF RSK2 T493M CTD MUTANT BOUND TO 2-CYANO-N-(1-HYDROXY-2- METHYLPROPAN-2-YL)-3-(3-(345-TRIMETHOXYPHENYL)-1H-INDAZOL-5-YL) ACRYLAMIDE
4762, p4e3cC1, 0.7187, 3.57, 0.221, 290, 253, X-RAY CRYSTAL STRUCTURE OF HUMAN IKK2 IN AN ACTIVE CONFORMATION
4763, d2x7fE_, 0.7187, 2.54, 0.248, 251, 230, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
4764, d3zyaA1, 0.7185, 3.46, 0.198, 341, 247, HUMAN P38 MAP KINASE IN COMPLEX WITH 2-AMINO-PHENYLAMINO- DIBENZOSUBERONE
4765, d2pzyD_, 0.7185, 2.83, 0.232, 288, 237, STRUCTURE OF MK2 COMPLEXED WITH COMPOUND 76
4766, d4ka3A_, 0.7184, 3.54, 0.199, 340, 246, STRUCTURE OF MAP KINASE IN COMPLEX WITH A DOCKING PEPTIDE
4767, d3kc3H_, 0.7184, 2.81, 0.219, 290, 237, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4768, d5n7vA1, 0.7183, 3.25, 0.197, 257, 244, TTK KINASE DOMAIN IN COMPLEX WITH MPI-0479605
4769, d5mz3A_, 0.7183, 3.73, 0.212, 350, 250, P38 ALPHA MUTANT C162S IN COMPLEX WITH CMPD2 [N-(4-METHYL-3-(4455- TETRAMETHYL-132-DIOXABOROLAN-2-YL)PHENYL)-3-(TRIFLUOROMETHYL) BENZAMIDE]
4770, d5ehoA1, 0.7183, 3.05, 0.195, 255, 241, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
4771, d4kipB_, 0.7183, 3.61, 0.197, 338, 249, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 2-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-13-THIAZOLE-5-CARBOXAMIDE
4772, d4fk3B1, 0.7183, 2.77, 0.286, 241, 234, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX3203
4773, d4l7fA1, 0.7181, 3.62, 0.193, 343, 249, CO-CRYSTAL STRUCTURE OF JNK1 AND AX13587
4774, d3wyxA_, 0.7181, 3.27, 0.197, 258, 244, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 6- ((3-(CYANOMETHOXY)-4-(1-METHYL-1H-PYRAZOL-4-YL)PHENYL)AMINO)-2- (CYCLOHEXYLAMINO)NICOTINONITRILE
4775, d3hmnA_, 0.7181, 3.24, 0.189, 255, 244, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH ATP
4776, d1w7hA_, 0.7181, 3.79, 0.198, 351, 253, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
4777, d3fkoA_, 0.7180, 3.59, 0.209, 343, 249, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO3668
4778, d4m8tA_, 0.7179, 3.36, 0.212, 303, 245, RSK2 T493M C-TERMINAL KINASE DOMAIN IN COMPLEX WITH 3-(3-(1H-PYRAZOL- 4-YL)PHENYL)-2-CYANOACRYLAMIDE
4779, d4zloA_, 0.7178, 3.34, 0.204, 277, 245, SERINE/THREONINE-PROTEIN KINASE PAK1 COMPLEXED WITH A DIBENZODIAZEPINE: IDENTIFICATION OF AN ALLOSTERIC SITE ON PAK1
4780, d3eljA_, 0.7178, 3.45, 0.182, 347, 247, JNK1 COMPLEXED WITH A BIS-ANILINO-PYRROLOPYRIMIDINE INHIBITOR.
4781, d5fd2B_, 0.7177, 2.29, 0.278, 234, 227, B-RAF WILD-TYPE KINASE DOMAIN IN COMPLEX WITH A PURINYLPYRIDINYLAMINO- BASED INHIBITOR
4782, d4awiA_, 0.7177, 3.59, 0.189, 352, 249, HUMAN JNK1ALPHA KINASE WITH 4-PHENYL-7-AZAINDOLE IKK2 INHIBITOR.
4783, d3bv3A_, 0.7177, 3.55, 0.204, 338, 245, MORPHOLINO PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 2
4784, d2zmdA_, 0.7177, 3.42, 0.187, 259, 246, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN T686A MUTANT IN COMPLEX WITH SP600125 INHIBITOR
4785, d2onlA1, 0.7176, 3.59, 0.198, 338, 247, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
4786, d5ei6A1, 0.7175, 3.31, 0.197, 261, 244, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
4787, d3fmeA1, 0.7175, 3.18, 0.249, 267, 241, CRYSTAL STRUCTURE OF HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (MEK6) ACTIVATED MUTANT (S207D T211D)
4788, d5ap4A1, 0.7174, 3.26, 0.185, 253, 243, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4789, d3nnvA_, 0.7174, 3.75, 0.212, 348, 250, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH DP437
4790, d4bhzA1, 0.7173, 3.07, 0.187, 248, 240, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
4791, d3fe3B_, 0.7173, 3.26, 0.278, 317, 245, CRYSTAL STRUCTURE OF THE KINASE MARK3/PAR-1: T211A-S215A DOUBLE MUTANT
4792, d4af3A_, 0.7172, 3.05, 0.220, 253, 236, HUMAN AURORA B KINASE IN COMPLEX WITH INCENP AND VX-680
4793, d3ocgA_, 0.7172, 3.50, 0.196, 336, 245, P38 ALPHA KINASE COMPLEXED WITH A 5-AMINO-PYRAZOLE BASED INHIBITOR
4794, d4jg7A_, 0.7171, 3.47, 0.203, 307, 246, STRUCTURE OF RSK2 CTD BOUND TO 3-(3-(1H-PYRROLO[23-B]PYRIDINE-3- CARBONYL)PHENYL)-2-CYANOACRYLAMIDE
4795, d4g31A1, 0.7171, 2.95, 0.227, 247, 238, CRYSTAL STRUCTURE OF GSK6414 BOUND TO PERK (R587-R1092 DELETE A660- T867) AT 2.28 A RESOLUTION
4796, d3zz2A_, 0.7171, 3.37, 0.236, 281, 242,  
4797, d3kc3K_, 0.7171, 2.63, 0.222, 280, 234, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4798, d3flwA_, 0.7171, 3.72, 0.196, 345, 250, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH PAMAPIMOD
4799, d3fklA_, 0.7171, 3.74, 0.192, 344, 250, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO9552
4800, d3s3iA_, 0.7170, 3.88, 0.213, 349, 253, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
4801, d1zycB1, 0.7170, 3.34, 0.238, 252, 244, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: WILD- TYPE IN APO FORM.
4802, d1w83A_, 0.7170, 3.76, 0.212, 351, 250, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
4803, d5o2bB_, 0.7169, 2.93, 0.260, 257, 235, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A DIPHOSPHORYLATED STATE AND IN A COMPLEX WITH THE INHIBITOR PP-121
4804, d5nadA1, 0.7169, 3.30, 0.193, 253, 243, TTK KINASE DOMAIN IN COMPLEX WITH BAY 1217389
4805, d4kiqA_, 0.7169, 3.57, 0.201, 338, 249, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
4806, d3kq7A_, 0.7169, 3.76, 0.216, 348, 250, STRUCTURE OF HUMAN P38ALPHA WITH N-[4-METHYL-3-(6-{[2-(1- METHYLPYRROLIDIN-2-YL)ETHYL]AMINO}PYRIDINE-3-AMIDO)PHENYL]- 2-(MORPHOLIN-4-YL)PYRIDINE-4-CARBOXAMIDE
4807, d2p33A_, 0.7167, 3.46, 0.169, 332, 248, SYNTHESIS AND SAR OF AMINOPYRIMIDINES AS NOVEL C-JUN N- TERMINAL KINASE (JNK) INHIBITORS
4808, d5lohB_, 0.7166, 2.70, 0.225, 250, 231, KINASE DOMAIN OF HUMAN GREATWALL
4809, d3cgoA_, 0.7166, 3.48, 0.177, 332, 248, IRAK-4 INHIBITORS (PART II)- A STRUCTURE BASED ASSESSMENT OF IMIDAZO[12 A]PYRIDINE BINDING
4810, d3cekA1, 0.7166, 3.28, 0.180, 252, 244, CRYSTAL STRUCTURE OF HUMAN DUAL SPECIFICITY PROTEIN KINASE (TTK)
4811, d1wbvA_, 0.7166, 3.72, 0.212, 351, 250, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
4812, d5ap1A1, 0.7165, 3.33, 0.196, 264, 245, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4813, d4c3pD_, 0.7165, 3.25, 0.220, 260, 241, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) BOUND TO TPX2 AND AMPPCP
4814, p3vumA_, 0.7164, 3.44, 0.211, 347, 246, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M7 IN MAP KINASE JNK1
4815, d3kc3G_, 0.7164, 2.69, 0.221, 276, 235, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4816, d3fpqB_, 0.7164, 3.54, 0.250, 263, 248, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF WNK1
4817, d2r0iA_, 0.7164, 3.17, 0.296, 300, 240, CRYSTAL STRUCTURE OF A KINASE MARK2/PAR-1 MUTANT
4818, d3txoA_, 0.7162, 3.10, 0.258, 317, 236, PKC ETA KINASE IN COMPLEX WITH A NAPHTHYRIDINE
4819, d3hllA_, 0.7162, 3.51, 0.199, 337, 246, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH PH-797804
4820, d3flnC_, 0.7162, 3.43, 0.199, 343, 246, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH R1487
4821, d3p7aA_, 0.7161, 3.42, 0.210, 332, 243, P38 INHIBITOR-BOUND
4822, d1bl7A_, 0.7161, 3.76, 0.199, 351, 251, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB220025
4823, d5ap3A1, 0.7160, 3.13, 0.191, 250, 241, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4824, d4n4sB_, 0.7160, 3.57, 0.192, 337, 250, A DOUBLE MUTANT RAT ERK2 IN COMPLEX WITH A PYRAZOLO[34-D]PYRIMIDINE INHIBITOR
4825, d4a9tA1, 0.7160, 2.95, 0.254, 288, 232, CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH BENZIMIDAZOLE CARBOXAMIDE INHIBITOR
4826, d2wmsA_, 0.7160, 3.13, 0.268, 243, 235, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4827, d2qnjA1, 0.7160, 3.23, 0.262, 317, 244, KINASE AND UBIQUITIN-ASSOCIATED DOMAINS OF MARK3/PAR-1
4828, p5o90A_, 0.7159, 3.58, 0.198, 330, 248, CRYSTAL STRUCTURE OF A P38ALPHA T185G MUTANT IN COMPLEX WITH TAB1 PEPTIDE.
4829, d3bv2A_, 0.7159, 3.64, 0.207, 337, 246, MORPHOLINO PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 30
4830, d2hakF_, 0.7159, 3.36, 0.273, 318, 245, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
4831, d5etiA1, 0.7158, 3.78, 0.191, 352, 251, STRUCTURE OF DEAD KINASE MAPK14
4832, d5ei2A_, 0.7158, 3.14, 0.202, 256, 242, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
4833, d5angA_, 0.7158, 2.71, 0.225, 268, 231, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 7-HYDROXY-4-( MORPHOLINOMETHYL)CHROMEN-2-ONE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
4834, d4c4eA1, 0.7158, 3.18, 0.191, 253, 241, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
4835, d2i6lB_, 0.7157, 2.94, 0.231, 269, 234, CRYSTAL STRUCTURE OF HUMAN MITOGEN ACTIVATED PROTEIN KINASE 6 (MAPK6)
4836, d1pyeA_, 0.7157, 2.63, 0.223, 266, 229, CRYSTAL STRUCTURE OF CDK2 WITH INHIBITOR
4837, d1a9uA_, 0.7157, 3.77, 0.195, 351, 251, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB203580
4838, d2xkeA1, 0.7156, 2.40, 0.232, 235, 228, STRUCTURE OF NEK2 BOUND TO AMINIPYRAZINE COMPOUND 5
4839, d1oveA_, 0.7156, 3.84, 0.209, 349, 254, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A DIHYDROQUINOLINONE
4840, d3rocA_, 0.7155, 3.61, 0.202, 337, 247, CRYSTAL STRUCTURE OF HUMAN P38 ALPHA COMPLEXED WITH A PYRIMIDINONE COMPOUND
4841, d3o8uA_, 0.7155, 3.52, 0.199, 332, 246, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
4842, d3kc3C_, 0.7155, 2.57, 0.228, 281, 232, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4843, d1jsuA_, 0.7155, 3.16, 0.204, 285, 240, P27(KIP1)/CYCLIN A/CDK2 COMPLEX
4844, d3gfwA1, 0.7154, 3.11, 0.191, 249, 241, CRYSTAL STRUCTURE OF HUMAN DUAL SPECIFICITY PROTEIN KINASE (TTK) IN COMPLEX WITH A PYROLO-PYRIDIN LIGAND
4845, d3db8A_, 0.7154, 3.01, 0.252, 261, 234, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH COMPOUND 041
4846, d2j7tA_, 0.7154, 3.46, 0.236, 285, 242, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 BOUND TO SU11274
4847, d5lohA_, 0.7153, 2.56, 0.223, 248, 229, KINASE DOMAIN OF HUMAN GREATWALL
4848, d3wyyA_, 0.7152, 3.19, 0.202, 258, 242, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH (E)- 3-(4-((6-(((3S5S7S)-ADAMANTAN-1-YL)AMINO)-4-AMINO-5-CYANOPYRIDIN-2- YL)AMINO)-2-(CYANOMETHOXY)PHENYL)-N-(2-METHOXYETHYL)ACRYLAMIDE
4849, p3vulA_, 0.7152, 3.49, 0.207, 344, 246, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M1 IN MAP KINASE JNK1
4850, d2j90A1, 0.7151, 2.85, 0.223, 259, 233, CRYSTAL STRUCTURE OF HUMAN ZIP KINASE IN COMPLEX WITH A TETRACYCLIC PYRIDONE INHIBITOR (PYRIDONE 6)
4851, d3e93A_, 0.7150, 3.65, 0.210, 346, 248, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIARYL AMIDE INHIBITOR
4852, d2xrwA1, 0.7150, 3.44, 0.197, 346, 244, LINEAR BINDING MOTIFS FOR JNK AND FOR CALCINEURIN ANTAGONISTICALLY CONTROL THE NUCLEAR SHUTTLING OF NFAT4
4853, d2pzyC_, 0.7149, 3.00, 0.222, 307, 239, STRUCTURE OF MK2 COMPLEXED WITH COMPOUND 76
4854, d3v6rB_, 0.7148, 3.51, 0.189, 346, 249, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
4855, d1bmkA_, 0.7148, 3.83, 0.198, 351, 252, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB218655
4856, d4kinC_, 0.7147, 3.75, 0.205, 338, 249, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
4857, d4cv9A1, 0.7147, 3.22, 0.186, 250, 242, MPS1 KINASE WITH 3-AMINOPYRIDIN-2-ONE INHIBITORS
4858, d3flqA_, 0.7147, 3.71, 0.209, 345, 249, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24- DIFLUORO-PHENOXY)-2-((S)-2-METHANESULFONYL-1-METHYL- ETHYLAMINO)-8-METHYL-8H-PYRIDO[23-D]PYRIMIDIN
4859, d2xkcA1, 0.7147, 2.49, 0.223, 236, 229, STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 14
4860, d2p4iB_, 0.7147, 2.25, 0.363, 258, 223, EVOLUTION OF A HIGHLY SELECTIVE AND POTENT 2-(PYRIDIN-2-YL)- 135-TRIAZINE TIE-2 KINASE INHIBITOR
4861, d2okrD_, 0.7147, 3.66, 0.207, 339, 246, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
4862, d1p38A_, 0.7147, 3.81, 0.195, 351, 251, THE STRUCTURE OF THE MAP KINASE P38 AT 2.1 ANGSTOMS RESOLUTION
4863, d1g3nE_, 0.7147, 3.39, 0.218, 293, 243, STRUCTURE OF A P18(INK4C)-CDK6-K-CYCLIN TERNARY COMPLEX
4864, d3dbdA_, 0.7145, 3.03, 0.252, 261, 234, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH COMPOUND 094
4865, d4jt3A_, 0.7144, 3.44, 0.189, 254, 244, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 400740
4866, d2bmcF_, 0.7144, 3.12, 0.249, 257, 237, AURORA-2 T287D T288D COMPLEXED WITH PHA-680632
4867, p3lhjA_, 0.7143, 3.77, 0.196, 341, 250, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A PYRAZOLOPYRIDINONE INHIBITOR.
4868, d2xk9A_, 0.7143, 2.95, 0.272, 284, 232, STRUCTURAL ANALYSIS OF CHECKPOINT KINASE 2 (CHK2) IN COMPLEX WITH INHIBITOR PV1533
4869, d1r39A_, 0.7143, 3.53, 0.198, 345, 247, THE STRUCTURE OF P38ALPHA
4870, d5a6oA_, 0.7142, 2.88, 0.204, 265, 235, CRYSTAL STRUCTURE OF THE APO FORM OF THE UNPHOSPHORYLATED HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3)
4871, d3zxtB_, 0.7142, 3.04, 0.222, 253, 234, DIMERIC STRUCTURE OF DAPK-1 CATALYTIC DOMAIN IN COMPLEX WITH AMPPCP-MG
4872, d2xm9A_, 0.7142, 2.96, 0.254, 287, 232, STRUCTURE OF A SMALL MOLECULE INHIBITOR WITH THE KINASE DOMAIN OF CHK2
4873, d1wbnA_, 0.7142, 3.79, 0.212, 351, 250, FRAGMENT BASED P38 INHIBITORS
4874, d5hnvA1, 0.7141, 3.00, 0.179, 278, 235, CRYSTAL STRUCTURE OF PPKA
4875, d4kiqD_, 0.7141, 3.54, 0.191, 338, 246, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
4876, d2wqoA1, 0.7141, 2.38, 0.229, 234, 227, STRUCTURE OF NEK2 BOUND TO THE AMINOPYRIDINE CCT241950
4877, d2y4pA_, 0.7140, 2.81, 0.229, 251, 231, DIMERIC STRUCTURE OF DAPK-1 CATALYTIC DOMAIN
4878, d2o0uA_, 0.7140, 3.52, 0.165, 331, 248, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH N-{3-CYANO-6-[3-(1- PIPERIDINYL)PROPANOYL]-4567-TETRAHYDROTHIENO[23-C]PYRIDIN-2-YL}- 1-NAPHTHALENECARBOXAMIDE
4879, d3hl7A_, 0.7139, 3.48, 0.200, 336, 245, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH SD-0006
4880, d1ywrA_, 0.7139, 3.68, 0.214, 338, 248, CRYSTAL STRUCTURE ANALYSIS OF INACTIVE P38 KINASE DOMAIN IN COMPLEX WITH A MONOCYCLIC PYRAZOLONE INHIBITOR
4881, d4dfyE_, 0.7137, 3.27, 0.234, 312, 244, CRYSTAL STRUCTURE OF R194A MUTANT OF CAMP-DEPENDENT PROTEIN KINASE WITH UNPHOSPHORYLATED ACTIVATION LOOP
4882, d3fmkA_, 0.7137, 3.73, 0.192, 346, 250, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24-DIFLUORO-PHENOXY)- 8-METHYL-2-((S)-1-METHYL-2-TETRAZOL-2-YL-ETHYLAMINO)-8H-PYRIDO[23- D]PYRIMIDIN-7-ONE
4883, d1g3nA_, 0.7137, 3.41, 0.222, 293, 243, STRUCTURE OF A P18(INK4C)-CDK6-K-CYCLIN TERNARY COMPLEX
4884, d4c4gA1, 0.7136, 3.09, 0.183, 247, 240, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
4885, d3mvmB_, 0.7136, 3.42, 0.193, 332, 243, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7V
4886, d2xbjA_, 0.7136, 2.96, 0.254, 286, 232, CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR
4887, d2pzyB_, 0.7136, 2.65, 0.232, 283, 233, STRUCTURE OF MK2 COMPLEXED WITH COMPOUND 76
4888, d4fa2A_, 0.7135, 3.65, 0.206, 339, 247, HUMAN P38 ALPHA MITOGEN-ACTIVATED KINASE IN COMPLEX WITH SB239063
4889, d4c4iA1, 0.7135, 3.26, 0.186, 250, 242, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
4890, d3da6A_, 0.7134, 3.36, 0.171, 328, 245, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH N-(3-METHYL- 4-(3-(2-(METHYLAMINO)PYRIMIDIN-4-YL)PYRIDIN-2-YLOXY) NAPHTHALEN-1-YL)-1H-BENZO[D]IMIDAZOL-2-AMINE
4891, d2qr8A_, 0.7133, 3.39, 0.213, 298, 244, 2.0A X-RAY STRUCTURE OF C-TERMINAL KINASE DOMAIN OF P90 RIBOSOMAL S6 KINASE 2 (RSK2)
4892, d4eh2A_, 0.7132, 3.58, 0.200, 337, 245, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F1 AND RL87
4893, d2w7xA_, 0.7132, 2.96, 0.267, 285, 232, CELLULAR INHIBITION OF CHECKPOINT KINASE 2 AND POTENTIATION OF CYTOTOXIC DRUGS BY NOVEL CHK2 INHIBITOR PV1019
4894, d2ghmA_, 0.7132, 3.66, 0.211, 336, 247, MUTATED MAP KINASE P38 (MUS MUSCULUS) IN COMPLEX WITH INHBITOR PG-895449
4895, d4kipA_, 0.7131, 3.63, 0.198, 337, 248, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 2-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-13-THIAZOLE-5-CARBOXAMIDE
4896, d4cv8A1, 0.7131, 3.11, 0.192, 252, 240, MPS1 KINASE WITH 3-AMINOPYRIDIN-2-ONE INHIBITORS
4897, d3fv8A_, 0.7131, 3.38, 0.188, 331, 245, JNK3 BOUND TO PIPERAZINE AMIDE INHIBITOR SR2774.
4898, p2xs0A_, 0.7131, 3.28, 0.185, 346, 243, LINEAR BINDING MOTIFS FOR JNK AND FOR CALCINEURIN ANTAGONISTICALLY CONTROL THE NUCLEAR SHUTTLING OF NFAT4
4899, d2oidC_, 0.7131, 2.98, 0.299, 256, 231, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN COMPLEXED WITH AMPPNP
4900, d2yitA_, 0.7130, 3.10, 0.269, 286, 234, STRUCTURAL ANALYSIS OF CHECKPOINT KINASE 2 IN COMPLEX WITH PV1162 A NOVEL INHIBITOR
4901, d5ap6A1, 0.7129, 3.24, 0.193, 259, 243, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4902, d4tyhB_, 0.7129, 3.47, 0.208, 335, 245, TERNARY COMPLEX OF P38 AND MK2 WITH A P38 INHIBITOR
4903, d4kbaA_, 0.7129, 3.14, 0.220, 263, 241, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
4904, d4g34A1, 0.7129, 3.03, 0.239, 247, 238, CRYSTAL STRUCTURE OF GSK6924 BOUND TO PERK (R587-R1092 DELETE A660- T867) AT 2.70 A RESOLUTION
4905, p4whzA_, 0.7128, 3.46, 0.174, 342, 247, DESIGN AND SYNTHESIS OF HIGHLY POTENT AND ISOFORM SELECTIVE JNK3 INHIBITORS: SAR STUDIES ON AMINOPYRAZOLE DERIVATIVES
4906, d2yirA_, 0.7128, 3.09, 0.274, 286, 234, STRUCTURAL ANALYSIS OF CHECKPOINT KINASE 2 IN COMPLEX WITH INHIBITOR PV1352
4907, d2ycfA_, 0.7128, 3.03, 0.270, 286, 233, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 2 IN COMPLEX WITH INHIBITOR PV1531
4908, d2gfsA_, 0.7128, 3.67, 0.205, 344, 249, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO3201195
4909, d4bdiA1, 0.7127, 3.01, 0.255, 289, 231, FRAGMENT-BASED SCREENING IDENTIFIES A NEW AREA FOR INHIBITOR BINDING TO CHECKPOINT KINASE 2 (CHK2)
4910, p3hdmA_, 0.7127, 3.46, 0.205, 285, 244, CRYSTAL STRUCTURE OF SERUM AND GLUCOCORTICOID-REGULATED KINASE 1 IN COMPLEX WITH COMPOUND 1
4911, d3fmjA_, 0.7127, 3.69, 0.206, 344, 248, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 4-(5-METHYL-3-PHENYL- ISOXAZOL-4-YL)-PYRIMIDIN-2-YLAMINE
4912, d3hecA_, 0.7126, 3.32, 0.200, 329, 240, P38 IN COMPLEX WITH IMATINIB
4913, p5etaB_, 0.7125, 3.60, 0.199, 335, 246, STRUCTURE OF MAPK14 WITH BOUND THE KIM DOMAIN OF THE TOXOPLASMA PROTEIN GRA24
4914, d4zthA_, 0.7125, 3.72, 0.206, 339, 248, STRUCTURE OF HUMAN P38AMAPK-ARYLPYRIDAZINYLPYRIDINE FRAGMENT COMPLEX USED IN INHIBITOR DISCOVERY
4915, d4xv3A1, 0.7125, 2.37, 0.286, 232, 227, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX7922
4916, d4kiqB_, 0.7125, 3.55, 0.195, 338, 246, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
4917, d3kf7A_, 0.7125, 3.63, 0.194, 337, 247, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH A TRIAZOLOPYRIMIDINE COMPOUND
4918, d3fl4A_, 0.7125, 3.43, 0.209, 339, 244, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO5634
4919, d2pk9C_, 0.7125, 2.63, 0.222, 266, 230, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE-RESPONSIVE SIGNAL TRANSDUCTION PATHWAY
4920, d3w1fA_, 0.7124, 3.31, 0.193, 259, 244, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 5-(5- ETHOXY-6-(1-METHYL-1H-PYRAZOL-4-YL)-1H-INDAZOL-3-YL)-2- METHYLBENZENESULFONAMIDE
4921, d1zmwA_, 0.7124, 3.14, 0.276, 302, 239, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: T208A/S212A INACTIVE DOUBLE MUTANT
4922, d3ptgA_, 0.7123, 3.29, 0.202, 340, 242, DESIGN AND SYNTHESIS OF A NOVEL ORALLY EFFICACIOUS TRI-SUBSTITUTED THIOPHENE BASED JNK INHIBITOR
4923, d1zyjA_, 0.7123, 3.52, 0.200, 331, 245, HUMAN P38 MAP KINASE IN COMPLEX WITH INHIBITOR 1A
4924, d1ny3A_, 0.7123, 2.63, 0.247, 277, 231, CRYSTAL STRUCTURE OF ADP BOUND TO MAP KAP KINASE 2
4925, p4d28C_, 0.7122, 3.45, 0.221, 279, 244, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.11 AT5G35410
4926, d2rg5A_, 0.7122, 3.51, 0.205, 333, 244, PHENYLALANINE PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 11B
4927, d3gp0A1, 0.7121, 3.60, 0.205, 332, 244, CRYSTAL STRUCTURE OF HUMAN MITOGEN ACTIVATED PROTEIN KINASE 11 (P38 BETA) IN COMPLEX WITH NILOTINIB
4928, d2ycqA_, 0.7121, 3.03, 0.275, 285, 233, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 2 IN COMPLEX WITH INHIBITOR PV1115
4929, d5a6nB1, 0.7120, 3.00, 0.208, 265, 236, CRYSTAL STRUCTURE OF HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3) IN COMPLEX WITH COMPOUND 2
4930, d4eh7A_, 0.7120, 3.62, 0.192, 337, 245, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F6 AND RL87
4931, d1v0bB_, 0.7120, 2.87, 0.233, 261, 232, CRYSTAL STRUCTURE OF THE T198A MUTANT OF PFPK5
4932, d3p78A_, 0.7119, 3.44, 0.206, 332, 243, P38 INHIBITOR-BOUND
4933, d1zmwB_, 0.7119, 3.23, 0.283, 302, 240, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: T208A/S212A INACTIVE DOUBLE MUTANT
4934, d5tbeA_, 0.7118, 3.59, 0.195, 332, 246, HUMAN P38ALPHA MAP KINASE IN COMPLEX WITH DIBENZOSUBERONE COMPOUND 2
4935, d4kiqC_, 0.7117, 3.67, 0.189, 338, 249, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
4936, d4f9yA_, 0.7117, 3.83, 0.201, 339, 249, HUMAN P38 ALPHA MAPK IN COMPLEX WITH A NOVEL AND SELECTIVE SMALL MOLECULE INHIBITOR
4937, d3p4kA_, 0.7117, 3.56, 0.204, 338, 245, THE THIRD CONFORMATION OF P38A MAP KINASE OBSERVED IN PHOSPHORYLATED P38A AND IN SOLUTION
4938, d4js8A_, 0.7116, 3.30, 0.193, 259, 243, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 401348
4939, d2oo8X_, 0.7116, 2.44, 0.368, 259, 223, SYNTHESIS STRUCTURAL ANALYSIS AND SAR STUDIES OF TRIAZINE DERIVATIVES AS POTENT SELECTIVE TIE-2 INHIBITORS
4940, p5yj9D_, 0.7115, 3.35, 0.191, 333, 241, CRYSTAL STRUCTURE OF TRIBOLIUM CASTANEUM PINK1 KINASE DOMAIN IN COMPLEX WITH AMP-PNP 
4941, d4yr8E_, 0.7115, 3.29, 0.178, 317, 242, CRYSTAL STRUCTURE OF JNK IN COMPLEX WITH A REGULATOR PROTEIN
4942, d3ttiA_, 0.7115, 3.53, 0.178, 341, 247, CRYSTAL STRUCTURE OF JNK3 COMPLEXED WITH CC-930 AN ORALLY ACTIVE ANTI-FIBROTIC JNK INHIBITOR
4943, d3fe3A_, 0.7115, 3.32, 0.278, 317, 245, CRYSTAL STRUCTURE OF THE KINASE MARK3/PAR-1: T211A-S215A DOUBLE MUTANT
4944, d1zydB1, 0.7115, 3.23, 0.228, 251, 241, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: WILD- TYPE COMPLEXED WITH ATP.
4945, d4jg6A_, 0.7114, 3.33, 0.207, 302, 242, RSK2 CTD BOUND TO 2-CYANO-3-(1H-INDAZOL-5-YL)ACRYLAMIDE
4946, d4equB_, 0.7114, 3.15, 0.242, 282, 236, HUMAN STK-10 (LOK) KINASE DOMAIN IN DFG-OUT CONFORMATION WITH INHIBITOR DSA-7
4947, d2pkjA_, 0.7114, 3.37, 0.198, 332, 242,  
4948, d2javA1, 0.7114, 3.05, 0.245, 245, 237, HUMAN KINASE WITH PYRROLE-INDOLINONE LIGAND
4949, d1zmuB_, 0.7114, 3.03, 0.284, 296, 236, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: WILD TYPE
4950, d1ua2B_, 0.7114, 3.44, 0.234, 286, 239, CRYSTAL STRUCTURE OF HUMAN CDK7
4951, d5owrA_, 0.7113, 3.45, 0.241, 282, 241, HUMAN STK10 BOUND TO DASATINIB
4952, d3p7cA_, 0.7113, 3.59, 0.203, 332, 246, P38 INHIBITOR-BOUND
4953, d3mh0A_, 0.7113, 3.45, 0.198, 332, 243, MUTAGENESIS OF P38 MAP KINASE ESHTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
4954, d3hv4A_, 0.7113, 3.75, 0.206, 339, 247, HUMAN P38 MAP KINASE IN COMPLEX WITH RL51
4955, d4xv1B1, 0.7111, 2.46, 0.281, 233, 228, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX7904
4956, d4ehvA_, 0.7111, 3.72, 0.206, 337, 247, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F10 AND RL87
4957, d2xk7A1, 0.7111, 2.62, 0.221, 238, 231, STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 23
4958, d4ynzB1, 0.7110, 3.48, 0.263, 316, 247, STRUCTURE OF THE N-TERMINAL DOMAIN OF SAD
4959, d4othA_, 0.7110, 2.94, 0.280, 305, 232, CRYSTAL STRUCTURE OF PRK1 CATALYTIC DOMAIN IN COMPLEX WITH RO-31-8220
4960, d4c4jA1, 0.7110, 3.30, 0.189, 258, 243, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
4961, d4a9uA1, 0.7110, 2.97, 0.247, 286, 231, CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH BENZIMIDAZOLE CARBOXAMIDE INHIBITOR
4962, d3wzkA_, 0.7110, 3.33, 0.185, 258, 243, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH N- CYCLOPROPYL-4-(8-((THIOPHEN-2-YLMETHYL)AMINO)IMIDAZO[12-A]PYRAZIN-3- YL)BENZAMIDE
4963, d3kvxA_, 0.7110, 3.36, 0.180, 327, 244, JNK3 BOUND TO AMINOPYRIMIDINE INHIBITOR SR-3562
4964, d1pmnA_, 0.7109, 3.72, 0.176, 344, 250, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH AN IMIDAZOLE- PYRIMIDINE INHIBITOR
4965, d2wtiA_, 0.7108, 2.99, 0.247, 286, 231, CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR
4966, d4f9wA_, 0.7107, 3.67, 0.211, 336, 247, HUMAN P38ALPHA MAPK IN COMPLEX WITH A NOVEL AND SELECTIVE SMALL MOLECULE INHIBITOR
4967, d3p5kA_, 0.7106, 3.59, 0.203, 332, 246, P38 INHIBITOR-BOUND
4968, d2ok1A_, 0.7106, 3.38, 0.178, 333, 242, CRYSTAL STRUCTURE OF JNK3 BOUND TO N-BENZYL-4-(4-(3- CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
4969, d1wfcA_, 0.7106, 3.63, 0.203, 340, 246, STRUCTURE OF APO UNPHOSPHORYLATED P38 MITOGEN ACTIVATED PROTEIN KINASE P38 (P38 MAP KINASE) THE MAMMALIAN HOMOLOGUE OF THE YEAST HOG1 PROTEIN
4970, d1gzoA_, 0.7106, 3.13, 0.247, 271, 235, STRUCTURE OF PROTEIN KINASE B UNPHOSPHORYLATED
4971, d3nnxA_, 0.7105, 3.64, 0.214, 336, 243, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38 ALPHA IN COMPLEX WITH DP802
4972, d2j90B_, 0.7105, 2.74, 0.222, 262, 230, CRYSTAL STRUCTURE OF HUMAN ZIP KINASE IN COMPLEX WITH A TETRACYCLIC PYRIDONE INHIBITOR (PYRIDONE 6)
4973, d5a14A_, 0.7104, 3.21, 0.218, 284, 239, HUMAN CDK2 WITH TYPE II INHIBITOR
4974, d4xv1A1, 0.7104, 2.48, 0.294, 228, 228, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX7904
4975, d3p7bA_, 0.7104, 3.54, 0.205, 332, 244, P38 INHIBITOR-BOUND
4976, d2ycrA_, 0.7103, 2.93, 0.270, 282, 230, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 2 IN COMPLEX WITH INHIBITOR PV976
4977, d1zydA1, 0.7103, 3.54, 0.232, 268, 246, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: WILD- TYPE COMPLEXED WITH ATP.
4978, d4yr8A_, 0.7102, 3.26, 0.187, 320, 241, CRYSTAL STRUCTURE OF JNK IN COMPLEX WITH A REGULATOR PROTEIN
4979, d3is5E1, 0.7101, 2.94, 0.253, 243, 233, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
4980, d3o8tA_, 0.7100, 3.49, 0.202, 332, 243, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG-MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
4981, d3ttjA_, 0.7099, 3.64, 0.169, 333, 248, CRYSTAL STRUCTURE OF JNK3 COMPLEXED WITH CC-359 A JNK INHIBITOR FOR THE PREVENTION OF ISCHEMIA-REPERFUSION INJURY
4982, d2gtnA_, 0.7099, 3.63, 0.196, 337, 245, MUTATED MAP KINASE P38 (MUS MUSCULUS) IN COMPLEX WITH INHBITOR PG-951717
4983, d1wbsA_, 0.7099, 4.21, 0.216, 351, 255, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
4984, d4bdgA1, 0.7098, 2.96, 0.270, 285, 230, FRAGMENT-BASED SCREENING IDENTIFIES A NEW AREA FOR INHIBITOR BINDING TO CHECKPOINT KINASE 2 (CHK2)
4985, d3c5uA_, 0.7098, 3.60, 0.198, 338, 247, P38 ALPHA MAP KINASE COMPLEXED WITH A BENZOTHIAZOLE BASED INHIBITOR
4986, d2oidA_, 0.7098, 2.73, 0.311, 263, 228, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN COMPLEXED WITH AMPPNP
4987, d4o6lA_, 0.7097, 3.19, 0.196, 257, 240, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 401498 (N- [(1R)-1-(2-CHLOROPHENYL)PROPYL]-3-{4-[(1-METHYLPIPERIDIN-4-YL) OXY]PHENYL}-1H-INDAZOLE-5-CARBOXAMIDE)
4988, d5b2lA_, 0.7096, 3.65, 0.204, 288, 250, A CRUCIAL ROLE OF CYS218 IN THE STABILIZATION OF AN UNPRECEDENTED AUTO-INHIBITION FORM OF MAP2K7
4989, d2wtjA1, 0.7096, 3.01, 0.247, 286, 231, CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR
4990, d5ap5A1, 0.7095, 3.07, 0.188, 248, 239, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4991, d3gi3A_, 0.7095, 3.37, 0.200, 330, 240, CRYSTAL STRUCTURE OF A N-PHENYL-N -NAPHTHYLUREA ANALOG IN COMPLEX WITH P38 MAP KINASE
4992, d3d83A_, 0.7095, 3.71, 0.206, 347, 247, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIPHENYL AMIDE INHIBITOR
4993, d3p79A_, 0.7094, 3.55, 0.205, 332, 244, P38 INHIBITOR-BOUND
4994, d1oz1A_, 0.7093, 3.77, 0.218, 344, 248, P38 MITOGEN-ACTIVATED KINASE IN COMPLEX WITH 4-AZAINDOLE INHIBITOR
4995, d3gcuA_, 0.7092, 3.79, 0.206, 339, 247, HUMAN P38 MAP KINASE IN COMPLEX WITH RL48
4996, d2wtcA_, 0.7092, 2.95, 0.248, 284, 230, CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR
4997, d2wtdA_, 0.7091, 2.95, 0.248, 285, 230, CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR
4998, d4bdfA1, 0.7090, 2.92, 0.271, 284, 229, FRAGMENT-BASED SCREENING IDENTIFIES A NEW AREA FOR INHIBITOR BINDING TO CHECKPOINT KINASE 2 (CHK2)
4999, d3mpaA_, 0.7090, 3.43, 0.198, 331, 242, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
5000, d3hp2A_, 0.7090, 3.67, 0.191, 341, 246, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH A PYRIDINONE COMPOUND
